{"title": "PDF", "author": "PDF", "url": "www.gpoh.de/kinderkrebsinfo/content/e1662/e2163/e11236/e13253/2003_kpoh_midterm_report_ger.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "BMBF COMPETENCE NETWORKS \nMidterm Report\nand\nFollow-up Proposal\nof the Competence Network \nPediatric Oncology and Hematology \nContents Page\nSection 1: Speaker's Midterm Report 1 Section 2: Cover Page to list the Research Projects 47 \nSection 3: Midterm Report of Running Projects and  \n Application for Continued Funding 48\nSection 4: New Project -  \n Application for the Second Funding Period 1871Section 1 \nSpeaker\u2019s Midterm Report \nTitle Page \nNetwork title : Competence Network \n  Pediatric Oncology and Hematology\nPeriod covered by this report : 01.07.1999\u201331.03.2002\nName of network speaker : Prof. Dr. med. Dr. h.c. G\u00fcnter Henze\nInstitution : Klinik f\u00fcr P\u00e4diatrie mit Schwerpunkt \n  Onkologie und H\u00e4matologie \n  Charit\u00e9 Campus Virchow-Klinikum \n  Medizinische Fakult\u00e4t der  \n  Humboldt-Universit\u00e4t zu Berlin\nAddress : Augustenburger Platz 1 \n  13353 Berlin\nPhone : +49 (0) 30 \u2013 45 05 \u2013 66 03 2\nFax : +49 (0) 30 \u2013 45 05 \u2013 66 90 6\nE-mail : guenter.henze@charite.de (personal) \n  sprecher@kompetenznetz\u2013 \n  paed\u2013onkologie.de (administrative)\nNetwork homepage :    http://www.kompetenznetz\u2013 \n  paed\u2013onkologie.de/Speaker\u2019s Midterm Report Section 1 \n2Part A \u2013 Research Results \n1 Publications\na) How many network-related English papers have been published in re-\nviewed journals during the funding period or are momentarily  in press? \nb) How many of the publications listed in a) involved at least three network \npartners from different universities or non-university research institu-tions?\nc) How many of the publications listed in b) have an international partner? \nAttach full citation in the annex and mark those referring to  \nquestions b) and c). \n2 Patents\na) Are patents planned or applied for within your network? \nno, not intended  \nyes,\nnumber of patents in preparation number of patents applied for\nnumber of accepted patents \nb) How many of the patents listed in a) involved at least three network \npartners from different universities or non-university research institu-tions?\nAttach a full list of all patents applied for or accepted in the annex. 30\n0\n086\n24\n21Speaker\u2019s Midterm Report Section 1 \n33 Describe the scientific highlights of the network so far .\nDuring the first funding period, the scientific highlights of this competence net-\nwork were the following:  \nOrganizational\n\u0083 The inauguration of a comprehensive system for the networking of pre-\nexisting and newly created research and health care structures.\n\u0083 The introduction, training, and efficacy assessment of assistants for clinical \nresearch and quality control (Forschungs- und Studienassistenten) in the 27 largest Pediatric Oncology institutions throughout Germany (cf. project A) \n\u0083 The first-time nation-wide employment of a common patient identification \ncode (\u201ePID\u201d) available for trial participating institutions over a legally secure public internet system for data exchange in clinical trials (cf. B/2) \n\u0083 The deployment of a common computer application for therapy and documen-\ntation (including the nation-wide harmonized coding of diagnoses and proce-dures according to international and national classifications, cf. B/1 and A) \n\u0083 The development of a common tumor tissue bank (commencing with embryo-\nnal tumors, extending to other entities, cf. G) \n\u0083 The commencement of the measurement of the health-related quality of life in \ntwo frequent malignancies (cf. I), including a newly built-up network of psy-chosocial and medical care providers\n\u0083 The nation-wide registration of second malignancies and the start of associ-\nated epidemiological studies (cf. K) \n\u0083 The establishment of prolific co-operations on MRD (studies on the minimal \nresidual disease, cf. F) and the consolidation of Germany\u2019s leading position in this field\n\u0083 The establishment of co-operations on apoptosis and drug resistance, includ-\ning the development of novel methods (cf. D)  \n\u0083 The start of a internet presentation of the network and the scientific society \n(GPOH) with their respective personal and institutional members, aiming at public visibility and making internal co-working easier (cf. B/2 and A)\n\u0083 The initiation of a registry of studies employing immuno- and gene therapy in \nPediatric Oncology in Germany (cf. H) \nSpecific, single project related \n\u0083 Newly identified molecular changes and prognostic factors (cf. project G): \nA characteristic gene expression profile in embryonal tumors (ref. G/26), A new, two entity genetic concept in medulloblastomas (refs. G/6, G/8), c-myc as a prognostic marker in medulloblastoma (ref. G/7), telomerase as an important prognostic marker in neuroblastoma (ref. G/13), Gam 1q as an important prognostic marker in Wilm\u2019s tumors (ref. G/28).\n\u0083 The development of a new flow cytometry method for detection of mitochon-\ndrial cytochrome c release, a major apoptosis signaling molecule (patents ap-plied for) and the revelation that chemotherapy in vivo predominantly induces apoptosis in an immature sub-population of leukemia cells identified by the progenitor marker CD34 (cf. D)Speaker\u2019s Midterm Report Section 1 \n4Part B \u2013 Network Organization and Management \n4 a) Which instruments were implemented to assure the quality and efficiency \nof the collaboration within the network? \nassessment of the progress of projects\njoint measures for scientific/methodological quality assurance  joint measures for quality assurance of medical care mechanisms for the management of conflicts between network membersmechanisms for the controlling of finances questionings concerning satisfaction of network members and external cli-\nents with the network \nmechanisms for the acceptance of new projects within the network \nmechanisms for the dismissal of unsuccessful projects other instruments, please list \n-----------------------------------------------------------------------------------\nb) List eventually newly accepted projects and/or dismissed projects \nAccepted :\nTOPP \u2013 Telemedizin in der onkologischen p\u00e4diatrischen Palliativmedizin, by \nDr. B. Zernikow,University\u2019s Children Hospital, M\u00fcnster (cf. section 4, project T) \nProject G \u2013 Application \u201eCollection of malignant germ cell tumor tissue samples, an \nextension to the tumor bank for neuroblastomas and rare tumors,\u201c by Prof. G\u00f6bel, Dr. Schneider, University Children's Hospital, D\u00fcsseldorf (cf. section 3, project G) Speaker\u2019s Midterm Report Section 1 \n5c)  Describe each of the instruments and mechanisms used in your network \nso far, report the results achieved and problems with the handling of the instruments. Describe the proposed activities for the second funding pe-riod.\nAssessment of the progress of projects \nA structured form for the cumulative documentation of a project\u2019s progress and\nchanges has been developed in early 2000 and since has been gradually adopted \nby the project leaders. The competence network has entirely been modeled withMS Project software in late 2000, including changes in the projects\u2019 status. How-ever, these instruments have not yet been used at all times. During status meet-ings and using questionnaires, several projects have repeatedly assessed their status as reported in the corresponding sections of this midterm report.  \nThe project leaders have reported the progress to the \u201eErweiterte Leitgruppe\u201d, and \nadjustments were discussed, if necessary, in order to achieve the projected aims or to focus on specific aspects that turned out to be particularly important. Deci-sions were made mostly unanimously or by the majority of votes within the \u201eEr-weiterte Leitgruppe\u201d or within the group of project leaders.\nJoint measures for scientific/methodological quality assurance \nVarious pre-existing measures for quality assurance were refined or newly defined \nrelated to the specific needs of the project:\nThe \u201ebasic data set\u201d is the one common basis of all clinical trials and most re-\nsearch projects. It is used for storing and exchanging data related to patients, dis-eases, and treatments. Although its inauguration precedes this competence net-work, a major revision of the basic data set (version 2.0) has recently been achieved by network personnel and by the society\u2019s experts. Both constitute a so-called \u201eJoint Standardization Group\u201d which will continuously adapt the basic data set to future needs. Before the network\u2019s support, only minor revisions were done discontinuously and were not made publicly available.  \nProjects D (Drug resistance), F (MRD) and H (Gene- and immunotherapy) have \neach succeeded with regard to inter-group methodological quality assurance (e.g., quantitative PCR, flow cytometry, apoptosis assays), as reported in their corre-sponding sections of this midterm report.  \nThe annual workshops of the scientific collaborators from various clinical trial of-\nfices were concerned with the standardization of electronic data bases, of proce-dures for survival analysis, of inter-trial harmonization, and with the adoption of the GCP guidelines, where applicable. It was decided that all newly planned clinical trials should be in agreement with GCP rules.  \nThe newly founded tumor tissue bank constitutes a joint instrument for quality as-\nsurance, of both patient samples processing and of transparent usage for scientific research (ref. section 3 of project G). The latter is most important because the pro-cedures agreed upon (\u201eStatutes\u201d, ref. annex) preclude that the precious patients\u2019 samples are exclusively exploited by individuals. Instead, the tumor bank\u2019s opera-tors re-distribute samples to scientifically approved projects.\n           \u2026  Speaker\u2019s Midterm Report Section 1 \n6The quality assurance of medial procedures and of laboratory techniques has \nbeen promoted as the main topic during special workshops, which were conducted either by the network or collaboratively by the network and the scientific society (GPOH).\nA special education program for the network\u2019s assistants in clinical research and \nquality control (Forschungs- und Studienassistenten, FSA) has been devised and successfully put into practice. This includes common training meetings, training on site, standardized site visits, and performance tests on and off site. A special pro-gram for the certification of the FSA is presently under development.  \nThe network tried to rapidly and liberally communicate results and various pieces \nof information including own surveys, reviews of external information sources, pro-tocols of our meetings, and own presentations and speeches. For this purpose, mainly our internet web pages and circular letters were used.\nJoint measures for quality assurance of medical care \nFor the quality assurance of medical care, clinical trials are of utmost importance. \n23 such trials are conducted in German Pediatric Oncology (ref. to annex for a complete list and details). In contrast to other countries, inclusion rates are ex-traordinarily high (estimate, 95%). In addition, the proportion of regular study sub-jects (as compared with surveillance subjects) among included patients is high (average, 92%) because of rather strict adherence to the prescribed diagnostics and treatment and because of the control and interventions exercised by trial office staff. By means of close contact between trial offices and participating trial centers, patients are followed closely and medical problems or errors can be detected and tackled. It can be incurred from external sources (ref. annex) that Pediatric Oncol-ogy trials reduce early mortality, morbidity, and overall costs and that they increase survival rates and health-related quality of life.  \nIt is of note that no single clinical trial or trial office has been supported directly with \nnetwork resources, based on reviewers\u2019 recommendation for the first funding pe-riod. The extent to which the clinical trials improve medical care in German Pediat-ric Oncology can hardly quantified because the trials already constitute a dis-persed, but comprehensive quality assurance structure that has been developed over the past 30 years and ist working successfully.\nHowever, the network is supporting trial offices by a central service group which is \ncalled the \u201estudy support\u201d (ref. section 3, project A). The aims of this group include reducing redundant work load in trial offices, standardizing workflow, and harmo-nizing trial details.\nParallel to and in context and ccoperation with network activities, European educa-\ntion guidelines for physicians in Pediatric Oncology and Hematology were co-authored and have been put into practice in Germany since 2001. The recognition of this education program (\u201eArzt/\u00c4rztin f\u00fcr Kinder- und Jugendmedizin, Schwer-punkt P\u00e4diatrische Onkologie und H\u00e4matologie\u201d) by the German Medical Council (\u201eBundes\u00e4rztekammer\u201d) has been assented but will be formally completed not be-fore 2003.\nMedical guidelines are to be described according to a question below (part E).             \u2026  Speaker\u2019s Midterm Report Section 1 \n7Recommendations and guidelines for daily care\nSpecific recommendations for daily care have been set up and have been made \navailable with the help of the network. These are intended to be used during rou-tine daily care by physicians working in this field of medicine. Presently, they entail guidelines for the supportive care, for the emergency treatment of cytostatic drug paravasation, vaccination recommendations, and other topics which are continu-ously worked-up or completed.  \nFollow-up guidelines are largely the results of the network\u2019s project I (Late effects \nand quality of life). These are published as easily usable single-page sheets in-tended for both scheduling and documenting individual patient information.\nMechanisms for the management of conflicts between network members \nConflicts have been openly discussed with the project leaders and/or within the \n\u201eErweiterte Leitgruppe\u201d. In general, agreement could be achieved. If a broader ba-sis was necessary to achieve specific goals, a task force was instituted (e.g., pro-ject B/1). In part, conflicting issues discussed between members of the \u201eErweiterte Leitgruppe\u201d and external experts. So far, there was no need to install persistent mechanisms for conflict resolution.\nMechanisms for the controlling of finances \nFinancial responsibility rests with the various autonomous project leaders of this\nnetwork, who in turn mostly rely on their respective institutions\u2019 administrative and financial controlling. In order to render resources and results more transparentamong network members, some information on job costs and other costs were obtained as part of the project progress documentation (see above). Although such information was incomplete, almost all changes of projects\u2019 plans and re-sources were communicated to the coordination and management group.\nAs project A comprises about one half of the entire network\u2019s funding, its finances \nwere controlled by about monthly reviewing balances. Vacant positions were ac-tively sought to be occupied. Usage of travel resources was restricted by initially agreed upon network rules. Resources for new sub-projects (e.g., public relation activities, evaluation proceedings) were covered by resource re-allocation in ac-cordance with DLR/PT. Project A\u2019s expenditures in 2000 were sampled, checked, and identified correct by a consulting agency (Ernst & Young) on behalf of the Charit\u00e9 Innenrevision (the voluminous report is available from Ms Schensick, Charit\u00e9, phone +49 (0) 30 \u2013 45 05 \u2013 57 20 21 on request.)\nQuestionings concerning satisfaction of network \nmembers and external clients with the network \nComprehensive questionings were developed and carried out by the coordination \nand management group together with two commercial partners of project A, WIAD (Wissenschaftliches Institut der \u00c4rzte Deutschland e.V., Scientific institute of the German physicians) and Prognos AG (a consulting agency). These partners and the external evaluation measures were newly introduced by the end of 2001, when funding according to a scientific grant application was obtained from the DLR/PT.  \nThe questionings covered amongst other topics the satisfaction with changes and \nproblems perceived, and the details of local, structural, and procedural characteris-Speaker\u2019s Midterm Report Section 1 \n8tics of the collaboration within German Pediatric Oncology. These questionings \nwere carried out at base-line in December, 1999, and for comparison in an ex-tended fashion in January, 2002. Independently from network member status, leaders of the 54 largest Pediatric Oncology institutions, 35 Pediatric Oncology trial offices or reference laboratories, and 65 assistants (FSA or documentation staff) were questioned with 4 to 6 page questionnaires.\nIn a nutshell, preliminary results of the latest questioning (2002) on the status of \nnetworking within Pediatric Oncology since the competence networks's start were (a) 55% of central institutions experienced a substantial improvement of data and documentation quality; 89% noticed the largest effect on the completeness of data; 70% reported to be well informed about the competence network; 80% expect further improvements to be delivered;  (b)  70% of 32 participating hospitals feel comprehensively informed on network activities; 25% report improvements on information exchange and general  communication with regard to clinical trials; but workload reduction by the assistants for clinical research and quality control (FSA) is only moderate; (c) on the other hand, 90% of the FSA report to greatly unburden other staff  members; 70% are more than weekly communicating with trial offices   (also please refer to project A for more details.).\nMechanisms for the acceptance of new projects within the network \nPutative new projects were identified by network members and asked to hand in a \nproject draft, including motives for joining the network. During the first funding pe-riod, no new project was accepted, but two new projects were identified, one of which is proposed for funding during the second funding period (ref. section 4 of this midterm report).\nMechanisms for the dismissal of unsuccessful projects \nMechanisms for the dismissal of unsuccessful or non-compliant projects were \nagreed upon in the network\u2019s by-laws. The \u201eErweiterte Leitgruppe\u201d (advisory board, project leaders, experts from the medical society) and the \u201eTask force\u201d (see above) decided on project B/1 to be endangered for discontinuation of funding if specified criteria were not to be met in 2002.\nProposed activities for the second funding period \nIn order to maintain and extend both quality and efficiency of the network, the fol-\nlowing measures are proposed:\nTo strengthen the activities to extend the process of networking, i.e., improve ex-\nchange of data between hospitals, research laboratories, reference laboratories, registries and trial offices by using the tools and structures created during the first funding period:   the assistants in clinical research and quality control (FSA), \u201eStudy support\u201d group, PID, DOSPO, internet information services, the revised \u201ebasic data set\u201d etc.\nAll relevant information should be made available not only to already existing net-\nwork partners, but also to medical laymen, private practitioners, parents and pa-tients in suitable form (vertical networking).  Speaker\u2019s Midterm Report Section 1 \n9Part B \u2013 Network Organization and Management \n5 a) Which organizational support and services for network partners are pro-\nvided by the network1?\norganization of scientific and network meetings \nproviding information about the state of the projects for the network partners\nbrokerage of general information\nproviding information about the availability of devices and materials among \nthe partner institutions \narrangement of joint purchases of devices, licenses etc. \nset up, maintenance of, and user support for material banks \nset up, maintenance of, and user support for data banks \nset up, maintenance of, and user support for information and knowledge \nservices\n providing advice on the requirements concerning: \nethicsbiometryhuman genome and gene technology clinical pharmacology patentsfunding and legal requirements others\nset up and maintenance of reference centers \nco-ordination of clinical studies \n                                           \n1 By any of the network partnersSpeaker\u2019s Midterm Report Section 1 \n10Part B \u2013 Network Organization and Management \nproviding advice for media presentation\nother services and support, please list:  PID service, DRG support \nb) Describe each of the services which have been installed and which ex-\npert advice and support is provided in your network so far, and describe the proposed activities for the second funding period.\nOrganization of scientific and network meetings\nThe following regular meetings are organized with resources of the network \n(content competence, preparation, support on site, travel expenses partly; proto-cols published on the internet sites):  \n\u0083 Semi-annual scientific meeting of network members (about sixty participants, \nmain topics: discussion of interim results and further proceedings, inter-project transparency checks, inspection of project leaders' steering mechanisms and results)\n\u0083 Annual status meeting of the GPOH (so-called \u201eStrukturtagung\u201c, about seventy\nparticipants, main topics: agreements on long-term aims, perspectives and measures to take with regard to clinical trials, lectures on generally important issues such as legal requirements, ethics, funding, and trial reporting)\n\u0083 Project meetings (multiple, five to 35 participants, at least annually; main top-\nics: working group sessions, agreements on standardized procedures, involv-ing external project partners, training on the project)\n\u0083 Meetings of all medical documentarists in Pediatric Oncology and Hematology\nwere initiated as a consequence of the interest in the very close guidance of the assistants in clinical research and quality control (FSA) \n\u0083 Annual meetings of clinical trial offices\u2019 staff (about thirty participants, main \ntopics: common data problems; exchange of solutions; promotion of GCP-adoption; harmonization of documentation; procedures, recalls)\nBrokerage of general information, \nProviding information about the state of the projects for the network partners\nInformation can be obtained by regular meetings (as described above), by con-\nventional circular letters, by email distribution lists and by searching or browsing th internet sites (as described below, part B, question 6 b in section 1).\nSet up, maintenance of, and user support for data banks\n\u0083 An internet data bank for electronic slide exchange has been built up and fed \nsince 2000 (project A). Until now, four clinical trials\u2019 offices have contributed more than 80 slides (MS PowerPoint format) with recent general and special \ninformation. These key reference slides shall be used for medical education such as lectures.Speaker\u2019s Midterm Report Section 1 \n11\u0083 A generic data bank for the administration of laboratory samples has been de-\nveloped in the year 2000 (project A). Since, it is being continuously used in \nHannover, M\u00fcnster and Freiburg laboratories (projects E and F). The data bank is freely available to network members.  \n\u0083 A special data bank for the administration of laboratory samples has been set \nup for the use with the embryonal tumors\u2019 bank. It has been developed in co-operation with a commercial IT-firm (cf. project G). \nAccordingly, the data bank \nis freely available to network members (Oracle license required). \nSet up, maintenance of, and user support for material banks\nSetting up a new material bank was part of project G\u2019s strategic concept to foster \nresearch. The expected delivery of patients\u2019 samples was repeatedly compared with their actual numbers. In order to improve the input, the cooperation with hos-pitals and especially with pathologists was intensified on a broad basis.\nA new material bank is being built up for leukemic cells in collaboration with trials \non ALL, AML, relapsed ALL and project F.  \nA special data bank has been set up and is maintained to support the ALL im-\nmunophenotyping reference laboratory since the year 2000.\nProviding information about the availability of devices \nand materials among the partner institutions\nInformation on the availability of materials, devices or drugswere communicated \nvia the described services (question B.6).\nSet up, maintenance of, and user support for information and knowledge services\nKnowledge services are being built up. The design of content structure and layout \nhas been completed for the incorporation into our new internet information portal on children\u2019s cancer (www.kinderkrebsinfo.de).  \nProviding advice on the requirements concerning biometry\nBiometry counseling has been offered cautiously to planned and running clinical \ntrials (project A).\nProviding advice on the requirements concerning \nhuman genome and gene technology\nComprehensive information on general requirements, legal issues and administra-\ntive procedures for obtaining a production license in Germany has been compiled by project H as a result of its experience with the official bodies. Project H freely supplies this compilation and offers consulting services to researchers in this field. \nSet up and maintenance of reference centers\nA system of laboratory reference centers has been set up for investigating sus-\npected myeolodysplastic syndromes (project E) and for investigating minimal re-sidual disease (project F). Both laboratories receive several hundred samples peryear. Most patients are examined repeatedly to assess the time course of changes. From the number of samples and of cooperating hospitals, these refer-ence laboratories are well established and process literally every patient\u2019s sam-p l e s .             \u2026  Speaker\u2019s Midterm Report Section 1 \n12Maintenance of laboratory reference centers was realized by supporting them as \npart of research-related cooperations. Modest fiancial and personnel support should facilitate the establishment of networking structures. Support was given the immunophenotyping laboratory (project A), the cytogenetic laboratory and the mo-lecular genetic laboratory (project F) \nCo-ordination of clinical studies\nTo improve and to unburden clinical trial offices (\u201eclinical studies\u201d) are the two \nprime goals of a special working group of project A (\u201eStudienunterst\u00fctzung\u201d).However, the clinical trial offices are autonomous and liable to the respective funding organization only. Thus, the harmonization of clinical studies, that is, the propagation of the best legal, ethical, medical, and administrative practice of how to perform studies, is expected to change clinical studies in the long run only. Still, this central \u201eStudy support\u201d group promotes the use of the basic data set (cf. an-nex), of the revised common toxicity criteria, of GCP adoption, usage of the \u201eMasterprotokoll\u201c (Deutsche Krebsgesellschaft) and of stringent data management practices in every clinical study.  \nThe assistants in clinical research and quality control (FSA) coordinate clinical \nstudies at their respective place of action/hospital. As stated in the initial agree-ment on the services the FSA have to perfom, they are \u201emembers of the hospital\u2018s multi disciplinary scientific team\u201d. The FSA\u2019s prime tasks are to prepare realizing, to locally coordinate and to practically carry out clinical trials in participating hospi-tals. (Approved clinical trials encompass exclusively the multi center cooperative GPOH trials, which have elsewhere been scientifically reviewed, funded and ethi-cally approved.) FSA are bound to support the physician who is responsible for the respective trial (\u201ePr\u00fcfarzt\u201d) by scheduling examinations, by collecting and dis-tributing patients\u2019 samples and by documenting the relevant data.\nProviding advice for media presentation\nTemplates for media presentation have on a few occasions been prepared and \nhave been used by project leaders e.g. for status lectures and posters. The press conference has been prepared by advising the participants on how to prepare the topics and speeches. A preceding audition was organized which turned out to be very helpful: redundant slides were omitted, speech duration was controlled and communicating with the journalists was anticipated.  \nOther services installed\nWith the help of the competence network, the following services were initiated and \nare working in practice:\n\u0083An electronic, unique patient identification service is accessible via the internet \nto provide a pseudonymous 8 digit number for the reliable identification of vari-ous patient data (e.g. blood and tumor samples, paper sheets, etc. \u201ePID-Dienst\u201d, project B/2).\n\u0083\nAn electronic certificate service provides file based certificates to individuals for \nuse in their internet browsers with which access-limited information can then be obtained (project B/2). Likewise, certificates for secure email communica-tion are obtainable (\u201ePGP\u201d, projects A and B/2). The use of these certificates is well accepted by the scientific community.  Speaker\u2019s Midterm Report Section 1 \n13\u0083 A working group on the classification of diagnoses and procedures in Pediatric \nOncology and Hematology has been founded together with the GPOH. This group published in 2001 a booklet with recommendations for the classification according to the ICD 10 and OPS301, which are very important to the forth-coming diagnosis related groups system of health care financing. In addition, this group stated current and anticipated problems of Pediatric On-cology to legal bodies such as the Deutsche Krebsgesellschaft and the Deutsche Krankenhausgesellschaft.\nActivities for the second funding period: services, expert advice\nand support for network organization and management\nThe aims of the activities are to further strengthen the networking of experts, work-\ning groups, trial offices and hospitals and to manage the cooperation of the net-work members accordingly.\nFor this purpose, activities started during the first funding period will be continued. \nThe contributions of the FSA to the performance of clinical trials have to be con-tinued. For the second funding period, the education has to achieve a formal com-pletion by certification and possibly a legal recognition (project A). The supported reference laboratories have to tailor investigations and to continue with standardiz-ing the respective methods (projects E and F).  \nThe internet knowledge services that have been prepared in concept are to be put \ninto pratice (information portal on children\u2019s cancer). The use of the PID and cer-tificate services has to be promoted to include all reference laboratories and clini-cal trial offices. Corresponding data security policies have to be implemented andput into practice.Speaker\u2019s Midterm Report Section 1 \n14Part B \u2013 Network Organization and Management \n6 a) Which IT-techniques are used for networking? \nnetwork web-site \ninformation server  \nnetwork mailing-address  IT-support for clinical studies (remote data entry or other)  electronic access to databanks\npatient databanks gene databanksother databanks, please list________________________\nother IT-techniques \nb) Describe each of the strategies used for networking so far and problems \nwith the handling of the techniques. Describe the proposed activities for \nthe second funding period .\nThe strategies used for networking are intended to enhance communication be-\ntween network members, personally meeting partners, creating corporate attitudestowards the promotion of general network aims, increasing the specialization and clustering of scientific competence as well as pushing for delegation of subtasks and partition of responsibilities with junior scientists.  \nThese strategies are intended to bring about trusting, demand-oriented co-working \nand to reduce possible limitations. Technically, we use for networking\n\u0083 conventional circular letters,  \n\u0083 email distribution lists for various network and GPOH groups. A discussion list \nfor interested individuals (forum@gpoh.de) is moderated but not restricted to formal involvement with the network or society,  \n\u0083 several linked, searchable, and browsable internet sites.\nAmong the IT techniques, email correspondence has shown to be suitable to the \naims mentioned and it has extensively been used by this network. On the basis of the network\u2019s recommendations and offerings on the use of PGP, it is also possi-ble to use emails for trustful and personal communication.  Speaker\u2019s Midterm Report Section 1 \n15Networking was also supported to a significant extent by employing internet web \nsites. The top most site (www.kompetenznetz-paed-onkologie.de) includes gen-eral descriptions of every project. Individual projects\u2019 internet sites can then be reached by following hyperlinks. Several cross-links exist from and to the GPOH internet site (www.gpoh.de).  \nHowever, these linked, but dispersed internet sites resulted in unexpected prob-\nlems. Many users complained of difficulties navigating and finding information. Different authentication procedures were confusing. Most important, a number of requests received were directed to the GPOH clinical trials. Users requested to get an in-depth insight into these 23 trials, which should entail ways to review the \ntrial protocol and recent results onlline. Only very few requests addressed patient information, which until now has not been covered by the network.\nThese problems may have arisen from the initiation of a comprehensive internet \npresentation only after the network has started. However, plans for IT networking support will be part of the proposed activities for the second funding period, includ-ing professionally producing and presenting scientist\u2019s and layman\u2019s information.  \nIT-support for clinical studies (remote data entry or other), patient databanks\nThe mainstay of this network\u2019s IT-support for clinical studies is DOSPO, the elec-\ntronic documentation system for Pediatric Oncology. It is technically and finan-cially supported comprehensively by project B/1, with logistic support by project A. Politically, it is recently supported by the DOSPO task force, and the \u201eErweiterte Leitgruppe\u201d. DOSPO is a multiple user data bank with forms corresponding to the usual documentation procedures in Pediatric Oncology. The program is vastly ad-vantageous over paper documentation because it features comprehensive chemo-therapy planning, diagnosis and procedures coding, toxicity documentation, statis-tical analysis and data exchange.  \nThus, DOSPO constitutes IT-support for performing clinical studies in participating \nhospitals. However, compatibility problems and requirements for intranet data ex-change are not yet met, but improvements are perceivable recently.\nElectronic access to databanks \nEletronic access to data banks has not been requested by network members and \nthus is not provided by this network, partly because most members have access to restricted facilities through their respective university network, e.g. to the Coch-rane library or special information retrieval services.\nOther IT-techniques\nSome of the network\u2019s research projects employ special IT-techniques for re-\nsearch. Neuronal networks (project G) and gene analysis (project H) were devel-oped in conjunction with local experts in such data analysis.\nThe purpose of the unique patient identification service (PID, project B/2) is to \nsupport networking by labeling patients\u2019 samples and written or electronic data with a PID code that is suitable for matching records, but prohibits exposing any personal data. This technique supports both clinical trial offices, reference labora-tories, and hospitals.Speaker\u2019s Midterm Report Section 1 \n16Proposed activities for the second funding period\nThe started activities will be persued during the second funding period and the \ndeveloped techniques are to be used in continuation.\nThe network\u2019s internet sites will be completely revised. The GPOH internet site will \nbe included into our restructuring of German internet information on Pediatric On-cology and Hematology. The internet information portal (www.kinderkrebsinfo.de) will present patient, nonprofessionals and expert information that is specially writ-ten by dedicated network scientists. This information shall complement the excel-lent \u201epatient-to-patient\u201d (or healthcare provider-independent) information published in the internet by the self-help organizations. Thus, the planned knowledge or in-formation server will be realized. We also plan to achieve formal recognition of the quality of our internet contents and the coordination and management group will apply for the admission to the German afgis (Aktionsforum Gesundheitsinformationssystem of the BMBF).\nThe DOSPO system will be used in an increasing number of hospitals and com-\npatibility problems will be tackled. With regard to telemedicine networking, a switch in focus towards a central medical image storage will be evaluated togetherwith web based data capture methods for the purpose of supporting the exchange of image and clinical data within the clinical trials.Speaker\u2019s Midterm Report Section 1 \n17Part C \u2013 Added Value through Networking\n7 Cooperation within the network \nDesign a matrix of the network projects indicating all research groups actively \ninvolved in each individual research project. Include associated projects, which are funded through other funding organizations (DFG, EU, BMG, foundations, industry) and mark the respective funding organization in footnotes.\nFor the matrix, please refer to this Midterm Report\u2019s Annex, page 20. \n8 Cooperation with other networks \na)  In which of the following network-overlapping joint activities is the \nnetwork collaborating? \nTelematics Platform \nBrain-NetPublic Relations Team other fields of cooperation\nplease point out the field and the cooperating network(s): \nCooperations were initiated with the competence networks \u201e\nAcute\nand Chronic Leukemias\u201d (an epidemiological investigation together \nwith project A; project E, relapses post stem cell transplantation), \nand \u201eRare Diseases\u201d (projects A, D, E)\nExchange with the competence network \u201eMalignant Lymphomas\u201d \nhas been sought and taken up by collaborators of project A (re-\nsearch assistants for clinical trials; electronic chemotherapy sys-\ntems). \nb)  Describe the contributions of your network to the joint measures so \nfar, point out the initiatives of your network to the joint activities and the added value your network experienced from (which of) the joint ac-tivities, and describe the proposed activities for the second funding period.\nOur contributions \nThe contributions of our network to joint measures and activities were: \n\u0083 Three out of four existing working groups of the Telematics Platform and \ntheir projects were actively shaped by participants from our network (see below). Several meetings were hosted, including the first network-overlapping TMF workshop (03/2002).Speaker\u2019s Midterm Report Section 1 \n18Working group \u201eData protection and IT security\u201c (TMF): Concepts of pro ject\nB/2 were offered, were then cooperatively extended and are now under re-alization, including chip card use and interfacing with a public key infrastruc-ture.   \nWorking group \u201eIT Quality Management\u201c (TMF): Existing and evolving re-\nquirements for IT solutions were proposed and defined, resulting in a grant application (see below).  \nWorking group \u201eUrheber- und Verwertungsrecht\u201d (TMF): Items and services \nsuitable for commercialization were identified; examples out of this network served as model problems. In this context, project G developed a model contract for commisioning data bank development with mutual utilization. Moreover, the working group carried out model consultation talks about re-sults transfer during a work shop of this network\u2019s project leaders.\n\u0083 Working group \u201ePublic relations\u201d (DLR/PT): Active-creative participation, \ndelivery of presentation material for the use of others, representation of the network during public occasions.  \n\u0083 Active collaboration on the development of the \u201eMidterm Report\u201d as a tool \nfor the structured reporting and the overlapping evaluation of medical com-petence networks.\n\u0083 Relaying cases of disapproval of health care insurance payments for the \ntreatment of children and young adults with cancer to the competence net-works\u2019 speakers\u2019 speaker.\nOur initiatives \n\u0083 For the second funding period of the Telematics Plattform, three grant ap-\nplications were intiated and submitted by our network, each in cooperation with at least three other networks:   (1) \u201cData protection and IT security\u201d,   (2) \u201cPublic key infrastructure\u201d,   (3) \u201cTelemedicine Infrastructure\u201d.  \n\u0083 We conducted a workshop about the possibilities for \u201eLong-term stabiliza-\ntion of networks\u201d as part of the first symposium for competence networks (Darmstadt, 12/2001). In addition, our proposal (Prof. Friesdorf, co-investigator project A) was appreciated to transfer scientific and economic aims into a framework of a so-called \u201eEingetragene Genossenschaft\u201d (co-operative society) and its subordinated firms, respectively.\nExperienced added value \nThe competence networks have gained attention by the media through the co-\nworking on public relations. In fact, the term \u201eKompetenznetze\u201d seems to have turned into a hallmark that elicits interest into all competence networks.  \nThe existence of the experts\u2019 Telematics Platform has enabled a productive \ncooperation of previously autonomous networks by funding overlapping pro-\njects which are already based on emerging demands and experiences from the \nfirst funding period of the respective network.\n           \u2026  Speaker\u2019s Midterm Report Section 1 \n19Joint activities proposed for the second funding period\nThe networking between the partnering competence networks will be continued \nand extended. The projects within the Telematics Platform will be energeticallypersued in order to evaluate their model solutions for our network. We willshare tasks and responsibilities within the public relations team and take over the organization of coming events. Potential synergies have to be found out between the two networks\u2019 working groups on electronic systems for conduct-ing clinical trials and tailoring chemotherapy (B/1 and \u201e\nAG Telematik\u201d of the \ncompetence network \u201eMalignant Lymphomas\u201d). Speaker\u2019s Midterm Report Section 1 \n20Part C \u2013 Added Value through Networking\n9 a) Are clinical multi-center studies performed in your network? \nNo Yes  \nb) if yes, give the following numbers: \ntotal number of multi-center studies \ntotal number of network members involved \nnumber of multi-center studies which have been newly initiated \nsince the network exists \nnumber of study groups which have started substantial coopera-tion through the network \nnumber of new study groups which result from activities of the \nnetwork\nGive a list of all clinical multi-center studies performed in your network in the \nannex. Indicate:\u2013 the number of network members involved in each study ,\n\u2013the number of patients recruited in each study, \n\u2013 percentage of recruited patients compared to the planned number.\nPlease, refer to this list in the annex, page 22. \nc) Describe the activities and problems concerning clinical studies so far \nand describe the proposed activities for the second funding period. \nActivities and problems concerning clinical studies and \nproposed activities for the second funding period\nVirtually all multi-center clinical studies in Pediatric Oncology and Hematology \nare conducted under the auspices of the Society for Pediatric Oncology and Hematology (GPOH). The open 23 studies (cf. annex) cover not less than 90% of all the malignant diseases in childhood and young adulthood, including mis-takenly termed \u201ebenign\u201c brain tumors and Langerhans' cell histiocytosis. In-deed, more than 90% of patients receive diagnostic and therapeutic measures as proposed in these studies. Almost all current studies are based on preced-ing studies, the first of which were started in 1976.\n           \u2026  6\n24\n2\n6\n3Speaker\u2019s Midterm Report Section 1 \n21These sequential studies have turned the clinical trials offices and the GPOH \ninto one large virtual competence center. It is characterized by defined respon-sabilities, reporting and reviewing mechanisms, and intensive scientific ex-change.\nIt is the most important obligation of this competence network to further in-\ncrease cooperative networking and also to structurally stabilize this existing competence center. A prominent goal will thus be the creation of a continuous, sound financial support for the clinical studies, i.e. for diagnosis and treatment according to the state-of-the-art.\nAs shown, comprehensive multi-center studies (\u201eTherapieoptimierungsstudien\u201c) \nwere not to be included in this competence network. However, the network's studies reported above [9 a), 9 b), annex] are accompanying add-on studies, which are accordingly multicentric (\u201eBegleitstudie\u201c). Indeed, the studies listed are progressing from separate special funding to participating in regular clinical studies' funding such as granted by the Deutsche Krebshilfe, Deutsche Leuk\u00e4mieforschungshilfe or the Deutsche Krebsgesellschaft.\nMoreover, succeeding multi-center studies will increasingly be international \nstudies. The competence center still has to prepare for this situation. Trials and projects will have to take the internationalization process into account. Speaker\u2019s Midterm Report Section 1 \n22Part C \u2013 Added Value through Networking\n10 Are network projects performed together with international partners? \nNo Yes,  number: \nList those international network projects in the annex which involve at least\nthree network partners from different universities or non-university research institutions, identify the international groups involved.\nPlease, refer to this list in the annex, page 23. \n11 Patient documentation \nIs the network using standardized patient documentation?  \nNo Yes  \na) Has the network developed standardized procedures for patient \ndocumentation? \nNo Yes: new development Yes: further development\nb) Is the data processing IT-based? \nNo, not intended Planned  Yes, already in use \nc) Are the data collected supra-regionally and centrally analyzed?  No, not intended Planned \nYes, already in use \nd) Number of institutions documenting data   actual number: planned number: \nuniversity hospitals: non-university hospitals: private practices: 6\n* 32\n40\n0 **Speaker\u2019s Midterm Report Section 1 \n23e) Total number of documented patients compared to overall-incidence \nand \u2013prevalence (for specific diseases and regions): \nnation-wide: 92\u201395% (Annual Report, German Childhood Cancer Registry)\nf) Is it possible to describe changes in health care performance by the \npatient documentation system used in your network? \n no, not intended yes Speaker\u2019s Midterm Report Section 1 \n24Part C \u2013 Added Value through Networking\ng) Describe the activities and problems concerning standardized patient \ndocumentation so far. Describe the proposed activities for the second funding period.\nMost of patient documentation is performed by means of paper copies pro-\nduced from respective clinical trial protocol sheets. The initial report of each newly diagnosed malignancy is performed by means of carbon copy forms pro-vided by the German Childhood Cancer Registry. Thus, standardized patient documentation is used partly in the GPOH and the competence network. Stud-ies accompanying clinical trials request separate patient documentation only if the information cannot be obtained from the trials\u2019 data banks.\nStandardization of patient documentation is advanced through several ap-\nproaches. Obligatory terms and definitions were being reconciled for base data and are under harmonization for disease-specific data. Paper forms of ongoing trials were repeatedly analysed and harmonizing changes were proposed. Pa-per flow sheets were newly developped with standardized contents and ap-pearance (\u201eCheck lists\u201c, cf. annex). Medical diagnosis and procedures coding was harmonization by explicit recommendations distributed to all GPOH mem-bers. DOSPO is a container application that can host similar documentation forms for use with various clinical studies. First standard operating procedures for practically performing the documentation were developed by clinical trial offices and are presently tested in the field by the assistants in clinical research and quality control (FSA).\nAs put forward in the initial grant application and in this continuation report, IT-\nbased data documentation in hospitals participating in clinical trials shall sub-stantially be improved. Presently, patient documentation is not IT-, but paper-based. This also holds true for the 23 clinical trial offices and the German Childhood cancer registry, which keep paper files of all 30000 patients. To ac-commodate long-term archiving, we evaluate to provide a service support for scanning and digitally archiving documents in conjunction with an appropriate retrieval application.  \nHowever, data collection is performed by the clinical trial offices, which are \neach responsible throughout Germany. Some clinical trial offices are also for responsible for Swiss, Austria, Spain, or some other European hospitals. These trial offices are the most central structure units. Analyses are not centralized any further.\nThe number of institutions documenting data varies largely with the clinical tri-\nals, that is, with the disease entity, and amount to maximally 130 institutions(e.g. osteosarcoma, Ewing's tumor). The actual numbers are estimated aver-ages of the number of trial conducting hospitals.  \n* With regard to planned numbers of documenting institutions, there are no \nplans to further recruit institutions for participating in Pediatric Oncology clinical trials. (The questionnaire implies wanted increasing numbers.)   Speaker\u2019s Midterm Report Section 1 \n25Indeed, numbers of documenting institutions may decrease as a result of the \nplanned introduction of a common quality control system into these institutions, including formal certification procedures and agreements with legal partners. Such a system is presently prepared and a special working group has been installed.  \nIt is not yet known how many private practices are to be summoned for docu-\nmenting data during long-term follow-up (cf. project I). This largely depends on the acceptance in the medical community and on the pertinent advertisements of this project in relevant media. Pilot investigations are to be completed, which will help to estimate the necessary local infrastructure (cf. project A).  \nThe comparison of incidences and patients included in trials (11.E) is directed \nat the completeness of patient registration. Since the initiation of the German Childhood Cancer Registry (GCCR) in 1980, information relating to patients registered in trials is collected. This increasing registration with the GCCR was 66,7% (1980\u20131984), 74,6% (1985\u20131989), 90,5% (1990\u20131994) and is now 91,6% (1995\u20131999). However, the goal is to register 100% of patients \u2013 also those with a second malignant neoplasm \u2013 with the GCCR, for reasons of qual-ity control (of diagnosis and treatment) and of honoring (analyzing) every pa-tient\u2019s clinical course data.   Speaker\u2019s Midterm Report Section 1 \n26Part C \u2013 Added Value through Networking\n12 Material banks \nIs your network setting up material banks? \nNo            Yes \nWhich materials are collected within your network?  \nBone marrow aspirates, peripheral blood samples,\ntumor samples (embryonal and germ cell tumors), blood smears.\nIs the network using standardized documentation for materials?  \nNo Yes  \na)  Are the material data correlated with the medical patient records? \nNo Yes: new development Yes: further development\nb)  Is the data processing IT-based? \nNo, not intended Planned  Yes, already in use \nc) Are the data collected supra-regionally and centrally analyzed?  No, not intended Planned \nYes, already in use \nd) Number of institutions sending materials and documenting data   actual number: planned number: \nuniversity hospitals: non-university hospitals: private practices: \ne) Total number of documented materials: \nf) Total number of documented materials  \ncorrelated with patient data: \ng) Are the materials and the material data used as diagnostic reference \nsamples? \nNo, not intended Yes32 *\n40*\n0*\n>4200\n>4200Speaker\u2019s Midterm Report Section 1 \n27Part C \u2013 Added Value through Networking\nh)  Other use of the materials and/or the material data: \nThe patients samples (\u201ematerials\u201d) are collected for the scheduled investiga-\ntions, which are part of the various project\u2019s research question. In addition, ma-terials can be requested from some of the material banks for use with hitherto unknown, new research questions. If such a request is to be fulfilled, the mate-rial banks provide patients samples, preliminary clinical data (full data to be obtained from clinical trial offices) and the formal legitimation for material use abroad. Fulfillment of researchers\u2019 requests is decided by designated inde-pendent scientific review panels.\ni) Describe the activities and problems concerning material collection \nand documentation so far and describe the proposed activities for the second funding period.\nActivities and problems concerning material collection \nThe activities of this network\u2019s projects were both to collect samples (\u201emateri-\nals\u201d) from newly diagnosed patients (e.g., projects D, E, F and G) as well as to additionally examine previously stored samples (projects E and F). Stored samples may serve as a reference with regard to molecular markers, portion of blasts, clone diversity or else. These projects incorporated results and (some) samples into their new banks for data and samples. Presently, material banks in German Pediatric Oncology and Hematology are established and working for all patients with a\n\u0083 embryonal/rare tumor (project G),\n\u0083 myelodysplastic syndrome, Fanconi anemia, severe aplastic\nanemia, and congenital neutreupenia (project E),\n\u0083 solid tumor (Kindertumorregister Kiel, funded elsewhere),  \n\u0083 acute lymphoblastic leukemia (part of project F) or\n\u0083 acute or chronic leukemia (immunophenotyping samples, part of project A). \nThere were differences in the portion of possibly suitable and finally collected \nmaterials, as reported in the respective projects\u2019 reports. No problems were observed by projects with immediate feedback and possible benefit for deci-sions on treatment options, such as reference examinations for suspected myelodysplastic syndrome and minimal residual disease. Less compliance was experienced with regard to submission of embryonal tumor samples, which is deemed to be due to competing research activities in non-delivering university hospitals and less cooperative pathologists in non-university hospitals. These problems have been addressed and compliance has increased recently.  \n* Thus, a comprehensive coverage of institutions caring for Pediatric Oncology \nand Hematology patients has already been reached. Therefore, there are no plans to further extend the number of institutions sending material. This situa-tion is similar to the number of documenting institutions, as also explained in section C.11 g).Speaker\u2019s Midterm Report Section 1 \n28Proposed activities for the second funding period\nThe newly installed material banks will be continuing to collect samples. For the \nlong-term sustainment of material banks, financing and organizational concepts have to be developed. So far, respective ideas are to operate material banks with a portion of the clinical trial funding on a per patient base.\nThe information among scientists about the existence of the material banks will \nbe distributed in order to elicit new research projects and to demonstrate that material banks facilitate judicious and time-conserving research performance.  \nScientific exchange with other networks (e.g., the BrainNet) on various topics \nrelated to material banks will be evaluated, for instance on legal implications, procedures for re-distribution, storage optimization, maintenance and sustain-ment mechanisms.Speaker\u2019s Midterm Report Section 1 \n29Part C \u2013 Added Value through Networking\n13 a)  Which programs for the promotion of young scientists are realized by \n     the network? \nPromotion of scientific exchange \nOrganization of continuing medical education (\u201eFort- u. Weiterbildung\u201c)\n       Career development paths for young clinical scientists        Others \nb)  Describe the programs and activities realized in your network so far  \n     and describe the proposed activities for the second funding period. \nPrograms and activities \nYoung scientists were promoted by direct appointment and assignment of pro-\njects responsibilities (several network projects), by support with scholarships (completed in project H, planned in project F) and travel/meeting grants. Con-tinuing medical education is delivered during scientific meetings as presented in B.5 b). For instance, the annual GPOH meetings 2001 were rewarded 11and 9 CME points by the regionally responsible Lower Saxonia and Berlin Medical Councils, respectively.  \nPromising progress has been made towards establishing the formal education \nin Pediatric Oncology and Hematology: For the Federal Medical Council as-sembly, the proposal of a so-called \u201eSchwerpunkt P\u00e4diatrische Onkologie und H\u00e4matologie\u201d was accepted for decision in 2003. The proposal has been de-vised together with European coworkers (by U. Creutzig on behalf of the medi-cal society).  \nProposed activities for the second funding period\nSpecial scholarships will be included in the second funding period. We propose \nto fund again scholarships for special research projects. These shall be granted with the approval of scientific applications by the \u201eErweiterte Leitgruppe\u201d. \nSpeaker\u2019s Annotation to Section 1, Part C \u2013 Added Value through Networking\nAdded value was obtained through networking in more places than listed above. With regard to clinical trials, these added values correspond to the following:  \n\u0083 data banks of clinical trials are more complete and more correct, resulting  \nin a richer base for analyzing current and conceiving future clinical trials;\n\u0083 network partners increasingly work together on a trusting, demand-oriented\nbasis; resulting in overcoming abridging competition;\n\u0083 separate projects on the quality control of diverse medical and laboratory proce-\ndures are getting coordinated; leading towards the wanted comprehensive quality control systems.Speaker\u2019s Midterm Report Section 1 \n30PART D \u2013 Visibility of the Network  \n14 Has the network been presented comprehensively at scientific con-\ngresses?\nNo Yes \nAttach a list in the annex including: name, date, site, organizer of the scien-\ntific congress, topic of the network presentation, approximate number of ex-ternal participants during the network presentation, number of participating network members. \nPlease, refer to this list in the annex, page 24. \n15 a) Which public relation activities have been performed by the network \nfor which addressees/multipliers? \nGive numbers of    Addressee: \npress conferences                 Invited special and regional journalists .\npress reports     General and medical public .\nTV presentations       General public .\nradio presentations       General public .\nOthers, please list ___________________________________________\nAttach a list of all public relation activities in the annex. \nPlease, refer to this list in the annex, page 31. \nb) Do you evaluate the echo of such presentations for instance via the \ncollection of press reports (Pressespiegel)? \nNo Yes\n16 Is your network cooperating with self help groups / other lay groups? \nNo Yes \n17 Is the network offering medical information for external groups? \nNo Yes, information for patients Yes, information for doctors\n        and family members1\n19\n2\n2Speaker\u2019s Midterm Report Section 1 \n3118 Describe the activities and problems concerning the visibility of your \nnetwork so far and describe the proposed activities for the second fund-ing period. \nActivities and problems \nThe public visibility of our network has recently increased. After the first scien-\ntific results were obtained and central structures were built up, we took several steps to arouse interest into Pediatric Oncology and Hematology. The first press release reported on the creation of this network and the funded research intentions, and the second press release was directed at some facts and out-come results of national health care in Pediatric Oncology. A corresponding press conference was jointly performed by members of the medical society (GPOH) and the competence network. The media reports on our network fo-cused on the special requirements of the patient population and the compara-tively good prognosis. Some media provided the communicated explanationthat this is a result of the continuing networking.\nThe need for addressing the media evolved during the last two years. A com-\nprehensive public relations concept was designed, and in 2001, was granted 40000 \u20ac by the DLR. Acitivites related to internet presentation the information brochure, media contacts and continuous press relations will be performed to-gether with professional firms (project A). A first product is the information bro-chure on cancer in children and young adults. It features general facts on Pedi-atric Oncology, including important points such as the psychosocial implica-tions, the importance of cooperative trials and the use of non-approved drugs. Network and GPOH contact information as well as space for further information sheets are provided. It will be available for network and GPOH members in May 2002 (preliminary version in the annex).  \nTo increase the visibility among physicians and reseachers, there were several \npresentations on the network itself during scientific meetings (cf. annex). In ad-dition, the network's status and changes are repeatedly presented during the scientific meetings. A forthcoming highlight is the \u201eSecond Scientific Bi-national Israel German Conference\u201c (19.-20.11.2002), which is organized with the help of the network; project G will be one of the three main topics.\nProposed activities for the second funding period\nPublic relation activities will be continued and extended. Continuous attention \nshall be attracted to the successful health care and research in Pediatric On-cology.\nA successor information brochure has to be produced. About two more \npress conferences are planned (the measures are included in the professional partner\u2019s bid, annex page 86).\nProviding expert medical information to all afflicted individuals and interested \nparties is part of our forthcoming information services (cf. B.6 b). Short texts will be produced and published by the coordination and management group (A) from mid-2002 on. Explicit and detailed patient information will be produced with the help of a separate project (grant application in preparation).  Speaker\u2019s Midterm Report Section 1 \n32Part E \u2013 Transfer of Research Results into the Health Care System \n19 a) Are meta-analyses or systematic reviews performed by the network? \n no, not intended   \n in preparation            number:\nyes, published or in press            number:\nAttach a list of all reviews in the annex \nb) If yes, how many reviews are performed according to Cochrane crite-\nria?\nNumber:  \nMark those reviews in the list attached in the annex \nc) Is the network substantially involved in Cochrane Reviews? \nNo\nYesIf yes, give the number of network members involved as: \nformal member constant collaborator responsible for a chapter \nSpeaker\u2019s Annotation to Section 1, Part E, Question 19\nAll projects of our network are concerned with systematic data collection, analysis \nand reporting. These data enable clinical trial offices to perform systematic reviews with regard to scientific evidence for optimizations of the complex diagnostic and therapeutic strategies. However, we are presently not involved with the Cochrane Collaboration because of the complexity of Pediatric Oncology clinical trials as com-pared with regular Cochrane contents.Speaker\u2019s Midterm Report Section 1 \n33Part E \u2013 Transfer of Research Results into the Health Care System\n20 a) Are network members substantially participating in the preparation \nand/or revision of national guidelines (local and regional guidelines are excluded) for diagnosis and therapy? \nno, not intended   \nyes, please specify : \n  number:       21\n  topics:          Pediatric Oncology and Hematology\nb)  Please describe for each guideline: \n     Kind of guideline: \n step 1 (expert group) \n step 2 (formal consensus process)  step 3 \n (guidelines with all elements of systematic development: logical analysis, clinical algorithm, consensus, evidence based, decision analysis,   outcome analysis) \nnumber of persons within the network involved: \n(planned) date of publication:        ___ ________________________\nPlease, refer to page 33 in the annex for a description of the guidelines.\nMost of the guidelines are \u201estep 1 + IDA\u201d (i.e., with i nterd isciplinary a greement).\nSpeaker\u2019s annotation to the section 1, part E, question 20 b): \nThe \u201estep\u201d number is attached to a guideline by the working group of the scien-\ntific medical specialist societies in Germany (AWMF). From our point of view, requirements for classification according to step 3 are met by several of our oncology guidelines. Talks on re-classification are planned. 14Speaker\u2019s Midterm Report Section 1 \n3421 Describe which new effective therapeutic or diagnostic methods have \nbeen developed by the network \nThe following methods were developed by the network\n\u0083 MRD (minimal residual disease): The concept entails that changes of the \nindividual\u2019s leukemic cell mass over time are traced. The smaller/slower the response to treatment, the higher is the risk of an adverse event. New mo-lecular techniques permit quantification of the leukemic cell mass over about six decimal places, where previous techniques were limited to about two. MRD in acute lymphoblastic leukemia (ALL) has been introduced be-fore the network\u2019s start.   However, MRD in ALL relapses and MRD in acute myeloid leukemia is be-ing developed and introduced as part of the network into the respective clinical trials and thus into clinical practice. The importance of this diagnos-tic method is the possibility to prospectively tailor and individualize the in-tensive chemotherapy. \nAlthough this procedure might not increase cure \nrates further, it could increase the patients\u2019 quality of life because less (toxic) chemotherapy would probably suffice for cure. (Extension to non-Hodgkin lymphomas is planned. Also please refer to project F.) \n\u0083 QoL (quality of life): Comprehensive standardized diagnostics for the quality \nof life of children and young adults with ALL and with brain tumors (medul-loblastoma) were delevoped and introduced into practice. These patient groups are diametrically opposed with regard to the possible impairment of QoL by the disease as well as by the treatment. In fact, to continue treat-ment in impaired patients always necessitates considering actual and future QoL. However, these standardized QoL assessments are not yet available in all participating hospitals due to the required resources of skilled staff. (Also please refer to project I.)  Speaker\u2019s Midterm Report Section 1 \n35Part E \u2013 Transfer of Research Results into the Health Care System \n22 a)  Which instruments are used to implement clinical guidelines and new \neffective therapeutic or diagnostic methods2?\nDissemination of guidelines (printed or computer based), continuing education \nTargeting opinion leaders Redesigning care pathways and documentation sheets Inventing checklists for clinicians Audit of performance and feedback to clinicians Others, please list\n________________________________\nb)  Number of network members involved\n23 Describe each of the efforts in your network and \u2013 if possible \u2013 their im-\npact and the problems to transfer innovative research results into the health care system so far. Describe your collaboration with scientific so-cieties in this respect. Describe the proposed activities for the second funding period.\nEfforts to transfer innovative research results into the health care system \nThe principle of response to treatment as a prognostic factor has been intro-\nduced in leukemia trials. Increasingly, molecular characteristics of leukemia and tumor cells are being used to select the appropriate treatment strategy. Unnecessarily toxic regimens may be avoided by this procedure. The tools to introduce these innovative research results into practical medicine are the na-tion-wide clinical trials.  \nCollaboration with scientific societies \nThe network originates from the Society of Pediatric Oncology and Hematology \n(GPOH) and has since kept close to the society\u2019s aims, members, and projects. Collaboration with the GPOH has been productive in as much as the compe-tence network tried to shape and also to conduct projects on behalf of or in col-laboration with the GPOH.\nBeyond this, the competence network initiated unprecedented though important \nprojects (such as telemedicine, research assistants and QoL implementation) for which funding on a broad basis could hardly be achieved otherwise.\n                                           \n2The question refers to guidelines and new methods in general, not only to those developed by the \nnetwork 40Speaker\u2019s Midterm Report Section 1 \n36Three delegates of the GPOH's board are permanent members of the net-\nwork's \u201eErweiterte Leitgruppe\u201c. The most prominent common goal is to improve the clinical trials in Pediatric Oncology, both as a comprehensive system and each separately.\nProposed activities for the second funding period\nStarted activities will be continued using the potential of the improved network-\ning structures developed during the first funding period.  Speaker\u2019s Midterm Report Section 1 \n37Part F \u2013 Sustainability \n24 a) Which measures have been installed or are planned to secure the \nnetwork and its central facilities and services on the long run? \nformal alliance \nx company constituted under German law (\u201eGesellschaft b\u00fcrgerlichen \nRechts\u201c), statutes installed (\u201eSatzung\u201c)? \n planned installed \nx foundation of a registered association (\u201eeingetragener Verein\u201c) \n  planned installed \nx foundation of a limited liability company (Ltd., \u201eGmbH\u201c) \n  planned installed \nengagement of long term financiers \n(for instance for the installment of the coordinating unit and the central services) \nacquisition of scientific grants, which were provided due to the exis-\ntence of the network \nacquisition of donations to the benefit of the network (\u201eSpenden\u201c) further measures, please list: For a model description, please see below.\nb) Describe the strategy to continue the network after the BMBF grant \nended. Give the financiers, the amount, kind and period of all additional financial support obtained by the network so far. \nTogether with the GPOH, the network, has created structures such as the \nGerman Children\u2019s Cancer Registry, the Children\u2019s Tumor Registry, the Coop-erative Pediatric Stem Cell Transplant Registry, reference laboratories for im-munophenotyping, cytogenetics and molecular genetics, the central business office of the GPOH, as well as more than twenty trial offices. These institutionscontribute substantially to state-of-the-art patient care and to ascertain a high degree of quality control in diagnostic as well as therapeutic measures.\nThis system has been established with the help of sponsoring and funding or-\nganizations and has thus never caused any costs to the responsible health in-surance system. To ascertain quality control of patient care, however, is a le-gally required (financial) responsibility of the health insurance system. In order to sustain the created structures which are essential for the high quality patient care and \nresponsible for the achieved high cure rates in Germany, it is planned Speaker\u2019s Midterm Report Section 1 \n38to offer this highly effective system for quality control to the health insurance \ncompanies on a commercial basis. The expected income shall be used to fi-nance and to maintain continuously the infrastructure.  \nAdditional income for this purpose may be achieved by patents, cooperations \nwith pharmaceutical companies and selling of knowledge, e.g. on informationtechnology or laboratory methods.\nFinancial support obtained by the network so far \nSo far, additional financial support to the network was limited to state subsidies. \nThese amounted to 36 k\u20ac (project A). In addition, some projects were finan-cially supported by add-on grants obtained for own Telematics platform appli-cations. Other grants are in preparation (e.g., patient information).\nStrategies for the continuation of the network \nConsiderations for the continuation of the network are outlined above. The \nstrategy is to develop a convincing concept during the second half of 2002 and to present it to representatives of health insurance companies and responsible politicians. This could set a precedent for other medical specialist societies and networks if accepted.\nScientific aspects of clinical trials will be subject to funding as before.Basic science-oriented projects of the network have to be continued with fund-\ning by sponsoring institutions as usual. Speaker\u2019s Midterm Report Section 1 \n39Part G \u2013 Summary of the Status quo and \nProposed Activities for the Second Funding Period \nState whether the general objectives of the network, as set down in the project \nproposal, are still relevant and achievable. If not, explain why. Provide a short summary of the objectives in the first part of the funding project and those proposed for the second part. \nGeneral aims of the network were to start the process of networking between pre-\nexisting structures (clinical trials, reference laboratories, registries and hospitals) of Pediatric Oncology and Hematology in Germany and to newly install tools and in-struments for communication and transfer of data and material, thereby facilitating laboratory and clinical research with the final aim of improving prognosis and out-come in children and young adults with cancer.  \nThe competence network consists of three parts: four projects addressing general \ncoordinating and networking aspects (A, B/1, B/2 and C), four projects addressing basic science (D, E, F and G) and three projects addressing clinical research (H, I and K). The new project, telemedicine in palliative Pediatric Oncology, is related to both networking aspects and clinical support (see below).  \n(1) Projects addressing coordinating and networking aspects  \nProject A - Coordination and management group\nAims  \n\u0083 coordinating the single projects of the network \n\u0083 improving documentation and material exchange \n\u0083 providing structured support for clinical trial offices \n\u0083 establishing public relations about Pediatric Oncology \n\u0083 evaluating the network\u2019s progress  \nResults:  FSA were introduced in the 27 largest hospitals and a training program was \nset up. A working group \u201eStudy support\u201d has been established providing support in organizing clinical trials according to the needs defined by clinical trial offices. The design of an information system has been completed and the information server is being filled with information for professionals and laymen. Activities have taken place to present the network to the public at various occasions. Progress of networking in Pediatric Oncology has been documented by repeated evaluation.               \u2026  Speaker\u2019s Midterm Report Section 1 \n40During the second funding period , the started activities will be continued. It is aimed \nat completing the FSA training with a certification program. The information services will substantially be extended. Efforts are being made to establish a financial basis for the continuation of specific central structures of the network. The aim is to get the quality in Pediatric Oncology delivered by these structures financed by the health care system.\nProject B/1 Computer-based application systems (DOSPO) \nAims\n\u0083 developing a computer-based application system for Pediatric Oncology \n\u0083 supporting clinicians, clinical trial offices and other research institutions \n\u0083 developing a generic tool for study databases\n\u0083 standardizing medical terminology for Pediatric Oncology  \nResults : The development, introduction and maintenance of DOSPO are in progress. \nA revised \u201eBasic data set\u201d will be published soon.  \nDuring the second funding period , all resources of B/1 will be concentrated on the \nintroduction of DOSPO into hospitals. Thus far, this has been hampered by lack of compatibility with meanwhile installed competing patient information systems in the hospitals. Further aims are to be additionally funded by other sources.\nProject B/2 \u2013 IT security and data protection, Knowledge server \nAims\n\u0083 developing strategies and building up secure  \ncommunications between network partners\n\u0083 building up an information server framework \nResults:  In essence, both aims were achieved (parts are to be delivered by end of \n2002).\nDuring the second funding period,  external data security services (\u201eTrust center\u201d) will \nbe maintained with remaining funds from the first funding period.\nProject C - Telemedicine in Pediatric Oncology \nAims\n\u0083 promoting research and increasing the standards of care in Pediatric Oncology \nand Hematology\n\u0083 enhancing communication standards and enabling ambitious network activities in \nresearch and patient care by implementation of telemedicine            \u2026  Speaker\u2019s Midterm Report Section 1 \n41Results:  A demand profile for telemedicine in Pediatric Oncology has been gathered \nin two surveys. Several commercially available technical solutions were tested, but either not suitable to meet the requirements or too expensive. The attempt to start a broader use of telemedicine into clinical practice was hampered by the fact that a substantial part of external partners was a priori not willing to open their archives for access.\nDuring the second funding period , the previous experience will be used to switch the \nproject\u2019s focus on establishing a central server for telemedicine, for storage and ex-changing of medical images between involved cooperation partners. Already existing cooperations between M\u00fcnster, Homburg, Berlin and W\u00fcrzburg will be continued and intensified (a suitable candidate for the position in Halle could be found only sixth months ago).\nAs soon as a usable, safe and working system and configuration is achieved, partici-\npation will be offered further to interested institutions. For the nephroblastoma trial, the exchange of medical images and clinical data as a telemedicine application will be realized using a remote data entry system.\n(2) Basic science projects\nProject D \u2013 Molecular parameters of drug resistance \nAims\n\u0083 developing an acquisition system for collection of patient  \nmaterial for cellular, protein, RNA and DNA analysis \n\u0083 developing methods for measurement of apoptosis signaling  \nin primary leukemia cells \n\u0083 analyzing leukemia cell apoptosis in drug response assays \n\u0083 indentifying apoptosis gene mutations inferring drug resistance \n\u0083 analyzing apoptosis gene expression profiles for prediction of drug resistance \n\u0083 indentifying of apoptosis signaling in peripheral leukemia cells\nactivated by in vivo chemotherapy \nResults: Working cooperations on apoptosis and drug resistance were established, \nincluding comprehensive material exchange and newly developed methods for flow cytometry. It was then found out that only fresh material, but not frozen samples were suitable for analysis. Methodological expertise was transferred to project partners. A patent has been applied for (in two countries).\nDuring the second funding period, the planned investigations will be continued, partly\nwith modified approaches. In addition to patients' samples, which are to be tested in a larger set, mouse model leukemia cells will be established within in a new coopera-tion and also assessed for apoptosis and drug resistance.   \n            \u2026  Speaker\u2019s Midterm Report Section 1 \n42Project E \u2013 Preleukemic bone marrow diseases \nAims\n\u0083 characterizing preleukemic bone marrow disorders  \nby various molecular biology studies \n\u0083 screening for genetic changes in the NBS1 gene  \n\u0083 performing angiogenesis studies  \n\u0083 providing reference morphology and oncogenetic studies\nResults  Together with international partners, a novel classification of myelodysplastic \nsyndromes has been elaborated which should also help to interpret molecular biology results. These were obtained in a very large number of samples. In addition, meth-odological advances were made. Some of the initial questions could already be an-swered.\nDuring the second funding period,  the analyses will be continued and completed, and \nthe associations between laboratory results and clinical course will be elucidated in detail.\nProject F \u2013 Minimal residual disease \nAims\n\u0083 standardizing method for MRD analysis in relevant diseases\n\u0083 building up and optimizing logistics for complete coverage of patient samples\n\u0083 discovering the most suitable time points for sampling for MRD analysis  \n\u0083 investigating the time course of response in patients \n\u0083 evaluating MRD monitoring as a prognostic factor\nResults:  The cooperation on MRD studies has been established, including the stan-\ndardisation for MRD in AML. A large number of samples has been examined, accord-ing to schedule. New infrastructures at involved laboratories were established. First results to the stated aims are detailed in the report.\nGermany has a leading position in assessing the prognostic value of MRD monitoring\nin childhood malignancies. The technique is already being used in the current proto-col for frontline ALL and will be introduced in the trial for relapsed ALL on short no-tice. Therefore, the group of project leaders unanimously felt that this project wouldneed definitely more scientific support.\nDuring the second funding period,  the work will be continued. The technical support \nby the network is planned to be tailored to the evolving needs. Detailed scientific analyses of the vast body of accumulated data, introduction of new methods (in par-ticular in AML), advances in standardization and establishment of quality control and of reference laboratories have to be accomplished. As soon as MRD projects are separately funded as regular parts of clinical trials, the technical support by the net-work may be reduced.\n            \u2026  Speaker\u2019s Midterm Report Section 1 \n43Project G \u2013 Clinical importance of molecular changes in embryonal tumors \nAims \n\u0083 establishing tissue banks for embryonal and rare tumors\n\u0083 collecting all relevant and suitable tumor tissue\n\u0083 investigating the respective tumor entities for pertinent molecular changes  \n\u0083 reconsidering pathogenetic models  \n\u0083 identifying potential immune and/or gene therapy targets  \nResults:  A comprehensive tumor tissue bank system has been built up. An inde-\npendent panel of reviewers has been instituted to decide upon new applications for the redistribution of the precious patient samples to research groups. In addition, pro-\nject G's research results comprise new prognostic markers and also hints to a new \nunderstanding of some of the embryonal and rare tumors. A patent for the tissue col-lection system has been applied for.  \nDuring the second funding period,  the planned activities will be continued. Beyond \nthis, further scientific support is proposed in order to optimize tissue preparation and delivery to the tumor bank system. These issues are a major problem and not suffi-ciently covered within the project. A scientific coworker is needed for persistent activi-ties such as coordination, cooperation negotiation and hospital/pathologists informa-tion. Also, further technical assistance is necessary to conduct and prepare the planned gene screening investigations.\n(3) Projects addressing clinical research\nProject H \u2013 Immune- and gene therapy \nAims\n\u0083 establishing a registry of trials employing immune-\nand gene therapy in Pediatric Oncology in Germany \n\u0083 supporting the treatment centers concerning regulatory and legal issues \n\u0083 improving communication between the treatment centers on\nan international and national basis, improving documentation \n\u0083 creating synergies between research groups \nResults  - A survey of current trials has been performed. As part of a successful li-\ncensing process, experiences in legal issues were compiled. As stated in the Midterm Report (section 3), substantial parts of funds were reallocated to purchase DNA mi-croarrays and reagents for gene chip preparation and processing. Results of these investigations are not detailed in the report.\nDuring the second funding period,  the stated aim is to achieve \u201ea shift [ }] from es-\ntablishing network structures to using these efficiently for the advancement of pediat-\nric immune and gene therapy\u201d. Furthermore, it is stated that \u201eproject H has been offi-cially commissioned by the GPOH/KPOH to establish a quality coordination center for Speaker\u2019s Midterm Report Section 1 \n44gene chip analysis of pediatric tumors\u201d. Substantial funds are requested for materials \nand a position for a technical assistant. Details of the planned experiments are not specified.\nAmong the network\u2019s project leaders, the proposal was controversially discussed. \nThe conceptual basis for immune-/genetherapeutic approaches is still unclear. The idea of identifying target structures for such approaches is probably correct and the method of gene expression analysis is adequate. There are, however, special pro-jects funded by the BMBF in which also pediatric oncologists are involved. Thus, there is a definite interest in participating in this kind of research from various groups. \nTherefore, the majority of the project leaders did not agree with the proposed aims of \nproject H. They felt that at present, there is no publication-based expertise to decide upon a commission to establish a center for gene chip analysis of pediatric tumors. Furthermore, materials for laboratory investigations should be separately funded, e.g. within the German Human Genome Project. Instead, the activities of project H during the second funding period should be focused on coordinating the various efforts in gene expression in pediatric malignancies. This should result in creating a sound sci-entific basis for considerations on immune and gene therapy.\nProject I \u2013 Late effects, quality of life and vertical networking\nAims\n\u0083 developing, standardizing and promoting a set  \nof instruments to assess the quality of life \n\u0083 applying these instruments to two patient  \ngroups to prospectively assess HRQL \n\u0083 designing structured guidelines for follow-up  \n\u0083 developing a vertical network for follow-up integrating\nvarious levels of health care providers\nResults  \u2013 A multicentric evaluation of late effects and quality of life in patients with \nbrain tumors and ALL is underway. Cooperations between psychosocial and medical caregivers were set up.\nDuring the second funding period  the multicentric evaluation will be continued. Addi-\ntional scientific support is needed for a comprehensive analysis of the data accumu-lated during the first funding period. Standardized flow sheets to assess QoL in ongo-ing clinical trials in Pediatric Oncology will be developed as amendments to the pro-tocols. Information on pediatric cancer treatment and follow-up will be prepared for the internet presentation, for practical vertical networking among health care provid-ers and for patients and families.\nProject K \u2013 Second malignant neoplasms after childhood cancer \nAims\n\u0083 establishing a nation-wide add-on registry to the GCCR\n(German Childhood Cancer Registry) for second malignanciesSpeaker\u2019s Midterm Report Section 1 \n45\u0083 establishing a consultant board of clinical trials\u2019 principal investigators\n\u0083 preparing the intended epidemiological case-control study\n\u0083 identifying risk factors responsible for the etiology of secondary malignancies\n\u0083 improving long-term follow-up beyond childhood\nResults : Second malignancies in survivors of childhood cancer were completely as-\nsessed. Procedures for the prospective validation of suspected new cases were set-tled. The planned epidemiological case-control study has been completed in design.\nDuring the second funding period,  the planned work will be continued. Emphasis will \nbe given to systematically look for risk factors for SMN. The case-control study will be performed. Publication of the results is in progress. \nProject T \u2013 Telemedicine in palliative Pediatric Oncology \nWith the aim of vertical networking and as an add-on project related both telemedi-\ncine and medical care, palliative care of bedridden patients together with their private practitioners shall be started as a regional pilot project (TOPP).\nThe group of project leaders felt that this is a valuable and practical application of \ntelemedicine which might help to involve private practitioners more in the care of criti-cally ill patients.\nSummary \nMany of the initially described aims could already be achieved. In some projects, it \nappeared to be necessary to make amendments or to focus more closely to certain aspects because of relevant, unforeseen experiences made during the first funding period.\nWith the proposed changes, the project leaders feel that the general aims as set \ndown in the initial network proposal are still relevant and achievable.  Speaker\u2019s Midterm Report Section 1 \n46Part H \u2013 Financing of Central Activities  \nfor the Second Funding Period \nList in tabular form the expenditures of the following funding period.  \nSeparate the costs for the network and for single research projects.\nCompetence Network Pediatric Oncology and Hematology3\n  First Funding Period  Second Funding Period \n# Project Title  Grant Per- \nsonal Other \nCosts2Rest4 Re-\nquested Per- \nsonal Other \nCosts5\nA Coordination and  \nmanagement6 2751,3 2557,9 193,4 0,0 2770,1 2431,0 339,2 \nB/1 Computer-based  \napplication systems  650,1 582,2 67,9 78,7 415,6 366,4 49,2 \nB/2 Data Protection, IT-security  \nand knowledgeserver 225,9 165,7 60,2 20,2 0,0 0,0 0,0 \nC Telemedicine in  \nPediatric Oncology 743,5 538,7 213,1 119,6 396,0 385,0 13,0 \nD Apoptosis and  \ndrug resistance  459,6    370,0 308,0 52,0 \nE Preleukemic diseases  \nof the bone marrow  485,8   90,3 238,3 198,3 40,0 \nF Prognostic relevance of  \nminimal residual disease 577,6   0,0 691,5 613,1 78,4 \nG Clinical relevance of  \nmolecular changes in  \nembryonal tumors  583,2   0,0 470,0 392,0 78,0 \nH Immune- and  \ngene therapy  221,4 63,8 49,4  386,8 166,7 200,0 \nI Quality of life and  \nvertical network  284,3 133,3 132,8 4,2 266,7 261,7 25,0 \nK Second malignant \nneoplasms  238,9 232,7 6,1 0,0 198,2 194,0 4,2 \nT Telemedicine in palliative \nPediatric Oncology (new) \u2013 \u2013 \u2013 \u2013 211,2 138,0 73,2 \nSum total network 7221,6    6414,4 5454,2 950,2 \n                                           \n3  Figures are given in thousand Euros (k\u20ac). Differences may arise due to rounding.  \n4  \u201eRests\u201d: Estimated remaining funds until the end of the first funding period. Calculation: grants \nminus (real expenditures plus projected expenditures). Please note that expenditures were not \navailable for all projects due to local administration issues. The listed rests shall become part of \nthe overall finances of the competence network. Date of calculation: 31.03.2002.  \nZero rests indicate that the DLR granted an extension of the first funding period in order to syn-chronize the ends of the first funding period among the network projects. Such rests are con-\nsumed for the period extensions, at equa l costs of the first funding period.  \n5  \u201eOther costs\u201d: commissions, consumables, inve stments, travel costs and various other costs.  \n6 Network\u2019s executive, coordinator and secretaries; 17 assistants in clinical research and quality \ncontrol (FSA); \u201eStudy support\u201d group; commissioned public relations and evaluation activities;  \ntravel resources for all network meetings etc.  47Section 2 \nCover Page to list the Research Projects \nTitle Page \nNetwork title : Competenc Network \n  Pediatric Oncology and Hematology \nPeriod covered by this report  : 01.07.1999\u201331.03.2002\nList of projects covered by this report:\nNo. Grant \nNo.Project Title Scientist-in-\nchargeInstitution Page\nA 01 GI \n99 58/5 Coordination and  \nmanagement group Univ.-Prof. Dr. \nG\u00fcnter Henze Charit\u00e9 Children\u2019s \nUniversity Hospital, Berlin48\nB/1 01 GI \n99 59 Computer-based application \nsystem for Pediatric Oncol-ogy and Hematology Dr. Ulrike Kutscha Medical Informatics, \nHeidelberg 59\nB/2 01 GI \n99 67/3 Data protection, IT security \nand knowledge server  Univ.-Prof. Dr. \nKlaus Pommere-ningIMBEI, Mainz 76 \nC 01 GI \n99 60 Telemedicine in  \nPediatric Oncology  Univ.-Prof. Dr. \nNorbert Graf and Dr. Michael Pau-\nlussenChildren\u2019s University \nHospital, M\u00fcnster 83\nD 01 GI \n99 61 Molecular parameters  \nof drug resistance Dr. Karsten \nStahnke and  \nUniv.-Prof. Dr. \nKlaus-M. Debatin Children\u2019s University \nHospital, Ulm 97\nE 01 GI \n99 62 Preleukemic diseases  \nof the bone marrow  Univ.-Prof. Dr. \nCharlotte Nie-\nmeyer Children\u2019s University \nHospital, Freiburg 110\nF 01 GI \n99 63/2 Prognostic relevance of  \nminimal residual disease Univ.-Prof. Dr. \nJochen Harbott  Children\u2019s University \nHospital, Giessen 123\nG 01 GI \n99 64/5 Clinical relevance of  \nmolecular changes in  \nembryonal tumors Univ.-Prof. Dr. \nFrank Berthold Children\u2019s University \nHospital, K\u00f6ln 138\nH 01 GI \n99 65 Immune- and gene therapy\nof pediatric neoplasias Univ.-Prof. Dr. \nStephan Burdach  Children\u2019s University \nHospital, Halle (Saale) 151\nI 01 GI \n99 66 Late effects, quality of life \nand a vertical network Dr. Gabriele \nCalaminusChildren\u2019s University \nHospital, D\u00fcsseldorf 167\nK 01 GI \n99 67/3 Second malignant  \nneoplasms after  \nchildhood cancer Dr. Peter Kaatsch IMBEI, Mainz 176 \nT N/A TOPP (Telemedicine in pal-\nliative Pediatric Oncology) Dr. Boris \nZernikow Children\u2019s University \nHospital, M\u00fcnster 18748Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title : Coordination and management  \n  (Project A)  \nGrant No. : 01 GI 99 58/5 \nName of scientist-in-charge :  Prof. Dr. med. Dr. h.c. G\u00fcnter Henze \nInstitution :  Klinik f\u00fcr P\u00e4diatrie mit Schwerpunkt \n  Onkologie und H\u00e4matologie \n  Charit\u00e9 Campus Virchow-Klinikum \n  Medizinische Fakult\u00e4t der  \n  Humboldt-Universit\u00e4t zu Berlin \nAddress : Augustenburger Platz 1 \n  13353 Berlin \nPhone : +49 (0) 30 \u2013 45 05 \u2013 66 03 2 \nFax : +49 (0) 30 \u2013 45 05 \u2013 66 90 6 \nE-mail : guenter.henze@charite.de \nProject home page (if different from \nNetwork homepage) : http://www.knm-poh.charite.de/49Part A - General Statements about the Project\nA.1.Subject\nCoordination and management group (CMG, project A) of  \nthe competence network Pediatric Oncology and Hematology \nA.2. Co-Investigators\n\u0083 Prof. Dr. med. Ursula Creutzig, University Children\u2019s Hospital, M\u00fcnster;  \nNetwork executive\n\u0083 Prof. Dr. med. Wolfgang Friesdorf; head, Lehrstuhl f\u00fcr Arbeitswissenschaften \nund Produktergonomie, Technische Universit\u00e4t Berlin;  Chief executive officer, Clinical Systems Management e.G., Berlin \n\u0083 Prof. Dr. Klaus Pommerening, Institut f\u00fcr Medizinische Biometrie, Epidemiolo-\ngie und Informatik (IMBEI), Johannes-Gutenberg-Universit\u00e4t Mainz; IT coordinator competence network Pediatric Oncology and Hematology \n\u0083 Dr. rer. hort. Martin Zimmermann, University Children\u2019s Hospital, Hannover, \nbiostatistical consultant ALL-BFM, NHL-BFM and AML-BFM clinical trials; project leader \u201eStudy support\u201c\n\u0083Dr. med. Ralf Herold, Charit\u00e9, Berlin; Network coordinator \nA.3 Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4Requested Funds for the Second Funding Period* \nPlease note that the second funding period of project A starts on 01.10.2002 (to \n30.09.2004), in contrast to that of the other projects (01.01.2003 \u2013 31.12.2002). \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1 Amount1\nRequested \n2002 296,3 5,3 8,4 12,5 11,6 334,10\n2003 1209,6 16 0 50,0 77,9 1353,50\n2004 925,1 11,3 0 37,5 108,7 1082,60\n1(amounts in thousand Euro), * should correlate to funds specified in Part D 50Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe coordination and management group (CMG) is responsible for own projects \nand working as a coordinating and service unit for all partners involved in re-search in Pediatric Oncology and Hematology.  \nMajor tasks have been to coordinate and manage the various projects and the \ncooperation within the network, to organize meetings, to employ coworkers, to organize an evaluation program and to organize public presentations of the net-work including press conferences and to prepare interim reports and the Midterm Report.\nAmong the CMG's own projects, the concept of implementing the new profession \nof the assistant in clinical research and quality control (FSA) in the largest treat-ment institutions has been put into practice and has shown first promising results(cf. section 1, B.4 c). A working group \u201eStudy support\u201c was instituted to support clinical trials in data management and documentation.  \nTools for information exchange and PR have been developed and are working. \nB.2 Original aims of the project \nAims\n\u0083 coordinating and managing the structures and instruments\nof the competence network Pediatric Oncology and Hematology \n\u0083 supporting the conduct of clinical trials as instruments of both quality control \nand clinical research by establishing and improving the systematic exchange of data and material (tissue, blood, bone marrow) between treating institu-tions, trial offices and the German Childhood Cancer Registry (GCCR), to be achieved by employing additional personnel (FSA) \n\u0083 establishing a comprehensive training and certification program for the FSA \n\u0083 supporting clinical trials in respect to data management, data base design, \nharmonization of information techniques, reduction of data queries\n\u0083 building up a knowledge and information base using internet technology \n\u0083 supporting reference laboratories with respect to cell banking and networking \n\u0083 supporting a registry for pediatric stem cell transplantations\n\u0083 organizing the external evaluation of the network \n\u0083 organizing PR activities to present the network to the public \n\u0083 building up a collaboration between professionals from treating institutions, \nprivate practitioners, patients and families for vertical networking  \n\u0083 searching for options to sustain the network beyond funding.  51B.3 Scientific results \nThe major purpose of the project is coordination and management. Therefore, \nscientific results in a strict sense are limited. However, most of the described aims have been achieved or are in progress.\nHighlights are:\n\u0083 FSA have become meaningful skilled st aff members in Pediatric Oncology. \nAccording to the results of the evaluation, their work is successful and highly appreciated by the physicians and trial offices.\n\u0083 The network has been presented to the public at various occasions and has \nbeen well recognized by the audience and in the media.\n\u0083 The internet presentation is of interest and recognized. The new media for \ninformation \u2013 internet presentation and newsletter \u2013 are well appreciated, rec-ognized and used.\n\u0083 Well attended and scientifically successful meetings have been organized be-\ntween network members and/or GPOH members.  \n\u0083 Out of several potential options to reach sustainability of the network, con-\ncrete and promising ideas have been developed together with co-opted ex-perts from the \u201eInstitute for Clinical Health Care Systems\u201c e.G., Berlin.\nFurther important results of the CMG are listed all parts of section 1 of this Mid-\nterm Report.\nB.4 Publications and patents \nCreutzig U, Calaminus G. Vertikale Vernetzung in der P\u00e4diatrischen Onkologie. \nOnkologe 6: 814-188, 2000 \nHerold R, Schreiber B, Paulussen M, L\u00e4ngler A, Berthold F, Kodierempfehlungen \nf\u00fcr Diagnosen und Prozeduren in der P\u00e4diatrischen Onkologie und H\u00e4matologie, November 2001, published by the GPOH and the competence network, 60 pages \nLanger T, Henze G, Beck J.D. Basic methods and the developing structure of a \nlate effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatric Oncology 34: 348-351, 2000 \nL\u00f6ning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, Schrappe M. \nSecondary neoplasms subsequent to Berlin-Frankfurt-M\u00fcnster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radio-therapy. Blood 95: 2770-2775, 2000 \nHerold R, Henze G, Creutzig U. Kompetenznetz P\u00e4diatrische Onkologie und \nH\u00e4matologie. humboldt spektrum 4: 4-9, 1999 \nCreutzig U, J\u00fcrgens H, Henze G. Kompetenznetzwerk P\u00e4diatrische Onkologie \nund H\u00e4matologie (Editorial). Klin P\u00e4diatrie 211: 187-188, 1999 \nHerold R, Creutzig U, Henze G. Kompetenznetz P\u00e4diatrische Onkologie und \nH\u00e4matologie. InFoOnkologie 5: 292-295, 1999 52Henze G: Das Kompetenznetz P\u00e4diatrische Onkologie und H\u00e4matologie. BVM \nMedical, 2002, in press \nHerold R, Henze G, Creutzig U. Kompetenznetz P\u00e4diatrische Onkologie und \nH\u00e4matologie. In: Lebendige Wissenschaft \u2013 Medizin, alpha Verlag Lampertheim 2001\nPatents\nNone planned.\nB.5 Networking \nAll the activities of the CMG are directed at either implementing or improving \nnetworking between the structures of the network, the GPOH, external partners and interested professional and non-professional groups.53Part C \u2013 Follow-Up Proposal \nC.\n1Aims\nThe started activities will be continued according to the aims listed in B.2.\nDuring the second funding period, emphasis will be put on the following issues:  \n\u0083 developing a concrete concept to finance and to sustain the created\nnetwork structures that are essential for high quality patient care  \n\u0083 developing and cataloguing qualification criteria  \nfor certification of treatment institutions\n\u0083 developing a recognized certification program for the FSA\n\u0083 supporting efforts to harmonize the design and conduct of clinical trials\n\u0083 transporting the aims and ideas of Pediatric Oncology to the public \n\u0083 providing professional and non-professionals with a comprehensive  \nmedical information service portal on the internet  \n\u0083 realizing and intensifying vertical networking  \n\u0083 evaluating the network internally in respect to the initially proposed aims as \nwell as externally in respect to the network's lasting effects on patient care within the public health system \nC.2Methodological approach \nMethods, instruments and tools will be the same as before (for details,\nplease refer to parts B \u2013 F in section 1 of the Midterm Report).\nC.3Work plan \nThe general aims as stated in the initial project proposal are still relevant and \nachievable.  \nThe coordination and management group (CMG) will continuously provide the \nservices established and, in particular, continue to coordinate and manage the various projects and the cooperation within the network.\nMilestones of the CMG activities are detailed in the annex (page 43).  \nC.\n4Networking  \nAll the activities of the CMG are directed at either implementing or improving \nnetworking between the structures of the network, the GPOH, external partners and interested professional and non-professional groups.\nThe activities of the CMG during the second funding period will contribute to the \ngeneral goals of the competence network and of the GPOH. The structures of the network facilitate the cooperation between the various research groups. Re-dundancy will be avoided. Exchange of data and material will be supported on various levels. Especially, putting the concept of sustainability into practice will result in added value to the network members, the GPOH and patients and fami-lies. These three groups are in the same way interested in achieving a perma-nent recognition and financing of those diagnostic and therapeutic measureswhich establish the quality of care. 54Part D- Requested Funding for the Project \nD.\n1Salaries\nPositions needed\n# Position Justification Description of main tasks \n1 Network  \nexecutive  Required for running the \nnetwork\u2019s business and \nfor persuing the realiza-tion of the medical, organ-izational and scientific \nnetwork aims Leading the coordination \nand management group \nroutinely, directing running \nand new CMG subprojects\nManaging the cooperation \nbetween network projects\nProviding expert knowledge \non Pediatric Oncology\nCommunicating and equal-\nizing with the GPOH  \n2 Network  \ncoordinatorRequired for performing \nthe coordination of net-\nwork projects and for con-\nducting CMG subprojectsOrganizing and leading the \nFSA mission and employ-\nment and coordinating net-\nwork projects\nDevising and realizing con-\ncepts and contents for FSA \ntraining, certification and \nprofession establishment\nEstablishing internet-based \ninformation services  \nDevising a concept from the \nideas for sustainability of \nthe network and the quality \nsystem, starting to realize it \n3 Biomedical \ndocumentarists\n(2,5 posts; 0,5 \nadded as com-pared with first funding period; planned shift from a 1,0 post of a coworker in \u201ebasic data set\u201d implemen-tation from pro-\nject B/1)Required for the \u201eStudy \nsupport\u201d as centrally es-\ntablished for GPOH clini-\ncal trialsRetrieving overlapping \nproblems of clinical trials; \ndevising solutions with re-gard to data management for trial offices and refer-\nence laboratories  \nProviding advice on re-\nquirements relevant to trials \nsuch as biometry and GCP; evaluating and piloting the use of standard operating \nprocedures\nOrganizing and managing \ntrial office staff meetings  \nStarting to elaborate \u201etrial \nspecific data (terminology) 554 FSA monitor Required for the practical \nFSA action controlMonitoring the FSA action \nby performing site visits and \nreviewing local fulfillment of \naction requirements\nRegistering on site work-\nflows, identifying and re-\nporting problems during the practical conduct of the \nclinical trials  \nOrganizing FSA training \nmeetings, caring for FSA \nstaff\n5 Assistants in \nclinical re-\nsearch and quality control (FSA)\n(9 full time \nposts, 16 half \ntime posts*) Required to improve prac-\ntically performing clinical \ntrials in participating treatment institutions and to markedly intensify the networking between pre-existing structures (i.e., clinical trials, reference laboratories, registries \nand hospitals)  The tasks have been laid \ndown in the \u201eT\u00e4tigkeitspro-\nfil\u201d which is part of the con-tracts between the CMG and participating hospitals on the local FSA grant (cf. \nannex)\nThe tasks encompass reg-\nistering patients, organizing \ninvestigations according to the trial protocols, gathering and reporting clinical data, exchanging patient sam-ples, delivering material to the tumor banks, using electronic means such as DOSPO, informing involved coworkers about details of clinical trials and amend-ments, participate in train-ings and improving local \ntrial infrastructures.  \n6 Secretaries  \n(2 x 0,75; \nadded 0,75 taken from \nFSA posts) Required for running the \nnetwork executive\u2019s office \nand for administrating the FSA and coworkers of the \nCMGRunning the network ex-\necutive\u2019s office \nCoordinating and \nadministratively managing \nCMG staff (about 39 individuals), including applications, resource control and meeting \norganisation\n7 Scientific co-\nworker to the \nSpeaker\n(0,5 post; new) Required to enable the \nSpeaker to be present \nand take respective re-sponsiblities at various \noccasions for the network. Taking over routine obliga-\ntions in clinical care and \nmedical education from the \nSpeaker.\nThe heavy workload was \nnot anticipated for the first \nfunding period.  568 Scientific edi-\ntor\n(0,5 post;\npost was part of project B/2 during the first \nfunding period) Experienced medical co-\nworker required for the \ninformation services (internet knowledge \nserver)  Managing the contents and \nthe presentation of the \ninternet information ser-vices; generating contents and composing internet \nformat articles \nResearching topics of Pe-\ndiatric Oncology and He-\nmatology and and equaliz-ing also with the GPOH, network projects and self-\nhelp organizations\n9 Documentarist/ \nTechnical As-\nsistantRequired for the contin-\nued support to the ALL \nimmunophenotyping ref-\nerence laboratory continue managing data, \nmaterials, the data base, \nperforming exchange of lab \ndata with trials offices\n10 Student co-\nworkers (6 x \n40 hrs/month+)Required for logistics and \nsupport of the CMG co-\nworkersAccording to\nthe assignment+\n*The assignment of FSA posts to treating institutions is based on the respective numbers of patients registered with the GCCR from 01.01.1996 to 31.12.2000. Half and full posts were assigned if more than 25 and 50 patients were regis-tered, respectively. This procedure was again confirmed and agreed upon by the project leaders. Reductions in post assignments to three institutions from the first to the second funding period are due to fewer patients registered. To compensate for the administrative workload experienced during the first funding period (39 actual/former FSA), a 0,75 secretarial post is proposed for funding from the reduction of posts as stated above.\n+ The assignment of student coworkers is as follows: network executive\u2019s office \n(1), coordinator\u2019s office (1) and immunophenotyping reference laboratory (2 x 40 hrs/month). These assignments correspond to the well-established employ-ment of student coworkers during the first funding period. Additionally, one stu-dent coworker is proposed as a (so far lacking) support of the ALL-BFM cell bank, which is necessary to guaranty material exchange with several competence network projects.  \n           \u2026  57Funds needed (given in \u20ac)\n# Position Posts 2002 2003 2004 \n1* BAT Ia  1 23008,13 94657,48 72385,13 \n2 BAT Ib 1 14826,00 60492,00 46278,00 \n3 BAT Iva 2,5 30180,00 123120,00 94207,50 4* BAT Vb 1 10188,00 41340,96 31470,57 \n5 BAT Vb 17 173196,00 706656,00 540549,00 6 BAT Ivb \nBAT Vb 0,75\n0,758349,75\n7641,0034065,00\n31176,0026061,75\n23847,74\n7 BAT Ib  0,5 7413,00 30246,00 23139,00 8 BAT Ib 0,5 7413,00 30246,00 23139,00 9 BAT Vb (Ost) 0,5 4228,50 17250,00 13198,50 10 Student coworkers 6 9875,89 40358,17 30862,13 \n* The funds are to be commissioned (\u201eForschung und Entwicklung\u201d contracts).  \nD.\n2Consumables (given in \u20ac) \nTitle Justification 2002 2003 2004 \nPosition 0838, \n\u201eConsum-ables\u201dMaterials for circular letters, \ncosts for own printed matters, refill material, costs for rented appliances, e.g. for meetings  1000 4000 3000 \nPosition 0839, \n\u201eGesch\u00e4fts-bedarf\u201dNetwork executive\u2019s office costs \nincluding telephone, online, postage and service costs. 2000 6000 4000 \nPosition 0840, \n\u201eLiterature\u201dCosts of special literature not to \nobtained from the local library 1000 1000 500 \nPosition 0841, \nPR team costsCosts of overlapping PR activi-\nties as proposed by the DLR/PT and the PR team of the medical competence networks  (reference: protocol of the PR team meeting 15.12.2001). 1250 5000 3750 \nPlease note that the costs of these consumables requested for funding corre-\nspond to expenditures during the first funding period.\nD.3Investments\nSix computers are required to fulfill current requirements for data exchange, \nprogramming and information services applications associated with positions 1, 2, 3 (three individuals) and 8. Estimated costs (6 x 1400 \u20ac) total: 8400 \u20ac. 58D.\n4Other Costs (given in \u20ac) \nTravel costs\nThe costs of the travels of network\u2019s personnel and of own scientific meetings \n(such as detailed in section 1, B5, page 10) are administered and covered by travel funds which are associated with project A. These funds closely covered the needs. For the second funding period, an annual amount of 50000 \u20ac for \ntravel and meeting expenditures is again requested on behalf of the network.\nCommissions\nDuring the first period, both commissions listed below were funded by reallocat-\ning funds of project A according to an official arrangement with the DLR/PT. This was based on an approved grant application (\u201eExtern-wissenschaftliche Evaluation und Proze\u00dfbegleitung des Kompetenznetzes\u201d) that extended until 2004. Accordingly, the following commissions are proposed for continuation of funding. The commercial bids of the partners are partly included in the annex.\nTitle/Contents (Partner)  2002  2003 2004 \nNetwork public relations, information brochure re-\nlease, press conferences, media contact services and marketing; including concept refinement ac-cording to the first funding period. (drescher kon-zept grafik design, Berlin)  11600 46400 34800 \nNetwork evaluation and process management. \n(Wissenschaftliches Institut der \u00c4rzte Deutsch-lands gem. e.V., Bonn, and Prognos AG, K\u00f6ln) 0 31496 73882 59Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Computer-based application system  \n  for Pediatric and Oncology \n  Hematology (Project B/1)  \nGrant No. : 01 GI 99 59 \nName of scientist-in-charge : Dr. sc. hum. Ulrike Kutscha \nInstitution : University of Heidelberg  \n  Institute for Medical Biometry und \n  Informatics  \n  Department of Medical Informatics \nAddress : Im Neuenheimer Feld 400  \n  D-69120 Heidelberg, Germany \nPhone : +49 (0) 62 21 \u2013 56 \u2013 54 81 \nFax : +49 (0) 62 21 \u2013 56 \u2013 49 97  \nE-mail : ulrike_kutscha@med.uni-heidelberg.de  \nProject home page (if different from \nNetwork homepage) : http://dospo.uni-hd.de/60Part A - General Statements about the Project\nA.1.Subject\nThe aim of this project is to provide a computer-based application system for Pe-\ndiatric Oncology research networks that supports clinicians, trial centers and other research institutions in their routine work. The following developments are currently in progress: \n\u0083 Aim1: Development, introduction and maintenance of the Pediatric  \nOncology documentation and therapy planning system (DOSPO). \n\u0083 Aim2: Development of a terminology server for Pediatric Oncology. \n\u0083Aim3: Development of a generic tool for trial databases and\ntrial specific data entry modules for DOSPO.\nA.2. Co-Investigators\n\u0083 DOSPO Task Force, Chair: Prof. Dr. N. Graf, University Hospital,  \nDepartment of Pediatrics, Homburg/Saar \n\u0083 Medical Informatics in Pediatric Oncology Work Group, Chair: Dr. O. Basu, \nUniversity Hospital, Department of Pediatrics, Essen; Co-Chair: Dr. U. Kutscha, University of Heidelberg, Institute for Medical Biometry and Informat-ics, Department of Medical Informatics \n\u0083 Terminology Server, Prof. Dr. K. Welte, University Hospital,  \nDepartment of Pediatrics, Hannover \n\u0083 Data Protection, Knowledge Server, Prof. Dr. K. Pommerening, University of \nMainz, Institute for Medical Biometry, Epidemiology and Informatics  \n\u0083 Telemedicine, Prof. Dr. H. J\u00fcrgens, University Hospital,  \nDepartment of Pediatrics, M\u00fcnster \n\u0083 Standards committee, Chair: Dr. P. Kaatsch,\nGerman Childhood Cancer Registry, Mainz \n\u0083Several hospitals and trial centers are cooperating in tool applications,  data exchange, and standardization of terminology61A.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 181,6 10,6 3,0 12,6 0 207,8 \n2004 184,8 10,5 0 12,6 0 207,8 \n1(amounts in thousand Euro),\n * should correlate to funds specified in Part D62Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe B1 subproject is divided into three closely connected subprojects. During the \ncourse of the first subproject, a documentation system for Pediatric Oncology, DOSPO, was to be developed further and introduced in the hospitals. A consid-erable share of DOSPO's further development is taken in by the realization of a diagnosis and procedure documentation system, which is well-adapted to meet the needs of its competence network. Countless other improvements were also realized, or are currently underway. DOSPO has also been introduced to addi-tional hospitals. Organizational prerequisites were established and systematically introduced to meet the requirements of the individual hospitals. They were har-monized to the goals of the whole competence network. \nThe terminology server needed to standardize terminology within Pediatric On-\ncology has been realized, and an application system developed to maintain it. Currently, the terminology server is being filled with content. A standardization committee has been established to oversee this process. The first task of the committee was to create of a new version of the basic data set used in Pediatric Oncology. This data set has been embedded into the terminology server. Mean-while, a first study is being standardized and entered into the terminology server. Certain improvements to the terminology server are still necessary. \nA first milestone has been reached in the development of the module generator, \nwhich generates study-specific modules for DOSPO. Study-specific databases can be generated based on the standardized terminology of the terminology server. To date, a second work phase is in progress in which study-specific forms (electronic and conventional) are being created. \nThe subproject was recognized with an international award for DOSPO's excel-\nlent architectural concept.\nB.2 Original aims of the project \nAim1: Development, introduction and maintenance of the documentation and \ntherapy planning system for Pediatric Oncology (DOSPO). \nThe documentation and therapy planning system for Pediatric Oncology will be \ndeveloped further in close adherence to the needs of the participating hospitals. Beside further development, providing, or intensifying, support to the individual hospitals is also necessary. \nAim2: Development of a terminology server for Pediatric Oncology. To ensure the comparability of the data collected in the clinical trials, and to sim-\nplify documentation within the hospitals, the documentation language for therapy optimization trials of the GPOH is to be standardized. A terminology server will be developed and realized to simplify administration of the documentation language. \nAim3: Development of a generic tool for trial databases and trial specific data \nentry modules for DOSPO. 63Specific data entry modules and interfaces to the databases of the trial centers \nmust be implemented to collect trial specific data. To reduce manual effort, and to increase the accuracy of developing and updating trial-specific modules for DOSPO, we are implementing a generic software tool to automatically generate the modules. This generic tool uses the terminology server for Pediatric Oncol-ogy.\nB.3 Scientific results \nThe results of the project have been organized for presentation according to the \nproject aims. \nB.3.1 DOSPO Core System\nDevelopmental standing of DOSPO (December 2001) During the past two years, the following most important further developments \nhave been realized. \nFunctions for clinical support \n\u0083 - During the course of the project, the health policy reform 2000 was \npassed. Hereby, a DRG-oriented billing system will come into effect in 2003. It is of immense importance to the competence network that the necessary documentation is standardized and oriented towards specific specialty and medical aspects. Good documentation will become existential for hospitals. In cooperation with the hospitals in Homburg and Berlin Charit\u00e9, a module was realized for systematic, centralized collection of diagnoses and procedures, and integrated into DOSPO. DOSPO was, therefore, expanded to include a documentation component that was not initially planned for the project. How-ever, since its benefit to the competence network is rated extremely high, the development of the diagnosis and procedure documentation module was added and treated as a major project activity.  \n\u0083 The modules responsible for defining the protocol and for calculating therapy \nplans were expanded to include the possibility of randomization. Therapy branches were added, as well as presentation of the underlying calculations within the therapy schedules. \n\u0083 Defining study protocols requires a high initial effort in terms of introducing \ntherapy-planning components. To reduce these efforts, essential studies (cur-rently 8) were inputted by the DOSPO team. Currently, the entered protocols have been distributed to interested hospitals. The necessary hospital-specific modifications are being supported.  \n\u0083 Discharge letter writing / report generation was revised in cooperation with the \nhospitals in Essen and K\u00f6ln to ensure user-friendly presentation. Concur-rently, the system was adjusted to support Microsoft Word 2000. \n\u0083 -In cooperation with the hospitals in Stuttgart and Essen, DOSPO was modi-\nfied to include a module for scheduling appointments. In addition, DOSPO was fitted with a patient-centered note pad function.\nFunctions to support networking within the competence network\u0083 The newly developed GPOH-PID (person identifier), stemming from the B/2 \nsubproject, has been integrated into DOSPO. The PID can be entered and its 64validity tested.  \n\u0083 Specific functions for evaluating the frequencies of diagnoses, procedures, \nchemotherapies, toxicities, participation in trials, other more general charac-teristics, as well as length of stay were included in DOSPO. \n\u0083 The fundamental technical requirements for exporting data to the childhood \ncancer registry have been met. Currently, the interface needed to accept messages by the childhood cancer registry is currently under development. In addition, organizational tasks must be supported more extensively to actually bring the interface to operation. \nRealization of technical requirements\u0083 The installation program has been expanded to secure data during distribution \nof updates. \n\u0083 The help function has been revised completely and expanded.  \n\u0083 In order to use DOSPO within a network environment, the data base man-\nagement system was switched to a client/server-capable data base manage-ment system, Interbase.\n\u0083 Data protection mechanisms for the DOSPO databases were improved in co-\noperation with the hospital Berlin Charit\u00e9.\nRealization of organizational requirements \nDue to the immense efforts placed in bringing DOSPO to widespread routine use \nin the hospitals, several new requirements have arisen during the course of the project regarding functionality and user friendliness. The very different prerequi-sites brought by the various hospitals make clear how diverse the priorities and requirements of each are, some of which stand in competition to one another. An essential task arose from this aspect. The various requirements and priorities of the hospitals are being collected, structured, and their realization initiated in pro-jects. Strategic planning of the further development should not be the sole re-sponsibility of the subproject. Therefore, in September 2000, a steering commit-tee (DOSPO Task Force) was formed. The steering committee members are im-portant decision makers of the competence network (speakers, executives), as well as specialists of various areas (hospitals, trial centers, childhood cancer reg-istry).   (Current task force members are Prof. Dr. U. Creutzig, S. Garde (System devel-opment DOSPO), Prof. Dr. N. Graf (chair of the task force), Prof. Dr. Henze, Dr. Herold, Dr. Kaatsch, Prof. Dr. Niemeyer, Dr. Kutscha (Project leader DOSPO), Dr. Schilling, Dr. Zimmermann.)  \nStanding of the introduction (December 2001) DOSPO is running routinely in 6 hospitals. However, therapy planning functional-\nity (4 hospitals, some with individual cycles only), physician discharge letter func-tionality (3 hospitals), diagnoses and service documentation (2 hospitals), sched-uling of appointments (1 hospital) and note pad functionality (1 hospital) are not in use in all hospitals. Test installations were set up in 24 hospitals. The diagnoses and procedures documentation is receiving very positive acceptance due to its strong focus on the needs of Pediatric Oncology and its user friendliness. A pilot phase to introduce a HL7 interface is underway for three hospitals.65B.3.2 Development and establishment of a terminology server\nDevelopment of a computer-based application system for the terminology server \nA semantic data model has been designed to represent the terminology. The item \ndefinitions are concept-oriented, while each concept can possess several syn-onymous terms. Relationships between concepts can be represented. In addition, standardized and non-standardized, items can be differentiated. Also, it is possi-ble to define trial forms logically using the general items. It is possible to specify which trial item should appear in which context on which form. The semantic data model was realized as a relational database structure. This concept was kept very general to ensure portability to other specialty areas. An application system has been developed that allows building the terminology based on the semantic data model. \nStandardizing the terminology The basic data set of the GPOH was completely revised (final decision by \n01/2001). The coding tables were modified to meet the latest international stan-dards to ensure international comparability of the collected data. Ambiguities were removed from the GPOH classification. The basic data set was extended to include a glossary of definitions of the most important concepts contained. The basic data set is available to all hospitals and trial centers at http://www.dospo.uni-hd.de/mv/bds_dt.htm. \u201eStandardizing terminology in Pediat-ric Oncology \u2013 the base date set\u201c was presented for publication in the specialty journal \u201eKlinische P\u00e4diatrie\u201c during mid-01/2002. \nEntry of the terminology used in Pediatric Oncology The old and new basic data sets have been maintained in the terminology server. \nCurrently, the items of a first clinical trial (therapy trial SIOP 01-09 for Nephro-blastoma, Wilms-Tumor) are being entered, taking standardization into account across all trials. The targeted standardization of all items, across all trials, is work intensive, and will require further resources throughout 2003 and 2004.\nB.3.3 Module generator\nRequirements analysis Within the scope of requirements analyses, object-oriented business process \nanalyses were conducted in two GPOH trial centers. The trial center of the Coop-erative Soft Tissue Sarcoma Trial at the Olga Hospital, Stuttgart, Germany, was chosen as an example trial for solid tumors. The identified business processes were represented using UML use cases and specified in structured descriptions. Next, the trial center of the ALL-Relapse Trial of the Charit\u00e9, Berlin, Germany, was examined. The modeling results of the trial center examinations were com-pared systematically. The requirements analysis resulted in important knowledge about the organizational sequences and setup of the trial centers.\nDesign and development of a program to generate study databases based on the \nterminology server66An algorithm was designed and successfully realized to automatically generate \ntrial databases based on the terminology server. The business processes identi-fied in the requirements analysis were used. With the help of this algorithm, a da-tabase can be generated automatically for any trial defined in the terminology server. In combination with respective on-screen forms, the database is to be-come the primary part of the respective trial-specific DOSPO module. Currently investigations are underway to determine to what extent the generated database can also be used in trial centers. This may ease data exchange between the Pe-diatric Oncology centers and the trial centers considerably. Due to the automatic generation, terminological changes within the terminology server can be inte-grated into the respective database quickly and consistently. This is an important step toward integrating the standardized terminology into the documentation of the competence network.\nB.3.4 Consequence of the feedback of the external advisory board \nThe feedback of the external advisory board in september 2001 triggered an in-\ntensive restructuring of the current project plan in cooperation with the task force. Derived from the recommendations of the advisory board, the task force initiated precise projects focussed on essential aims of DOSPO. The first main activity is the implementation of a HL7-Interface to automatically receive patient data from the hospital patient management systems. DOSPO was modified to represent the necessary HL7 case structure. The HL7 interface has been developped. Piloting of the HL7 interface's functionality in 3 cooperating pilot institutions is currently underway. Meanwhile, the Charit\u00e9 has successfully tested the interface in a rou-tine environment.\nSecondly, comprehensive improvements of the modules protocol definition and \ntherapy planning are initiated. A product requirement specification is created in close collaboration with selected users with DOSPO experience. A prototype has been developped which illustrates the improved user interface and functionality. Additionally, the prototype demonstrates new guidelines for the future design of DOSPO user interfaces. Currently the task force is revising the product require-ment specification, which will be the base for the reimplementation of the therapy planning module.   \nB.4 Publications and patents \nKnaup P, Harkener S, Ells\u00e4sser K.-H, Haux R, Wiedemann T. On the necessity \nof systematically planning clinical tumor documentation. Meth Inform Med 2001;40, 90-98 \nKnaup P, Wiedemann T, Wolff A, Creutzig U, Haux R, Schilling FH (1999). Com-\nputer-assisted documentation and therapy planning in paediatric oncology--introduction of a nationwide solution. Klinische P\u00e4datrie 211(4), 189-91. \nMerzweiler A, Knaup P, Creutzig U, Ehlerding H, Haux R, Mludek V, Schilling FH, \nWeber R, Wiedemann T. (2000). Requirements and Design Aspects of a Data Model for a Data Dictionary in Paediatric Oncology. In: Hasman, A, Blobel, B, Dudeck, J. et al. (Hrsg.). Medical Infobahn for Europe, 696-700. \nAmsterdam: IOS \nPress.\nKnaup P, Mludek V, Wiedemann T, Bauer J, Haux R, Kim L, Schilling FH, Selle \nB. (2000). Integrating Specialized Application Systems into Hospital Information 67Systems -Obstacles and Factors for Success. In:Hasman, A, Blobel, B, Dudeck, \nJ. et al. (Hrsg.). Medical Infobahn for Europe, 890-894. Amsterdam: IOS Press. \nMerzweiler A, Knaup P, Weber R, Ehlerding H, Haux R, Wiedemann, T. (2001). \nRecording clinical data - from a general set of record items to case report forms (CRF) for clinics. In: Patel, V, Rogers, R, Haux, R. (Hrsg.). MEDINFO 2001. Pro-ceedings of the 10th World Congress on Medical Informatics, 653-657. Amster-dam: IOS. \nWeber R, Knaup P, Knietig R, Haux R, Merzweiler A, Mludek V, Schilling FH, \nWiedemann T. (2001). Object-oriented business process analysis of the Coop-erative Soft Tissue Sarcoma Trial of the German Society for Paediatric Oncology and Haematology (GPOH). In: Patel, V, Rogers, R, Haux, R. (Hrsg.). MEDINFO 2001. Proceedings of the 10th World Congress on Medical Informatics, 58-62. Amsterdam: IOS. \nKnaup P, Merzweiler A, Mludek V, Weber R, Wiedemann T. (2000). P\u00e4diatrische \nOnkologie. Rechnerunterst\u00fctzte Dokumentation und Therapieplanung. Praxis Computer - Magazin f\u00fcr moderne Technologien und Management in der Arztpra-xis (Beilage zum Deutschen \u00c4rzteblatt), 16,6/2000,34-36. \nKnaup P, Merzweiler A, Mludek V, Weber R, Wiedemann T. (2000). P\u00e4diatrische \nOnkologie. Rechnerunterst\u00fctzte Dokumentation und Therapieplanung. Deutsches \u00c4rzteblatt, 97,45,B2564-B2566. \nKnaup P, Wiedemann T, Bachert A, Creutzig U, Haux R, Schilling F. (2002). Effi-\nciency and Safety of Chemotherapy Plans for Children. CATIPO \u2013 a nationwide approach. Artificial Intelligence in Medicine, 24,229-242. \nB.5 Networking \nThe terminology server supports the standardization of the terminology. A new \nbasic data set has been created and fit to meet current international standards. The development of a diagnoses and procedures documentation module sup-ports a uniform presentation of the competence network to the outside. In the therapy planning area, the relevant study protocols, which have been created for DOSPO, are being made available to other hospitals. Hereby, a synergetic step and a contribution to quality assurance have been made.  68Part C \u2013 Follow-Up Proposal \nC.1 Aims\nThe computer-based documentation system for Pediatric Oncology (DOSPO) will \nhelp support clinicians in their daily work and documentation needs. A wide-spread use of DOSPO in hospitals will have a standardizing and quality assur-ance effect that goes beyond the individual hospitals. The data collected in the planning and documentation system will be made available to the hospitals, trial \ncenters, and the childhood cancer registry. The central target of the B1 subpro-\nject is to fulfill this requirement within the present and upcoming funding period. \nThe following aims arise from this target:\nAim 1: Expansion of routine DOSPO operation within the hospitals.\nIn February 2002, the extended leadership met to intensively discuss the DOSPO \nproject and its further development. The extended leadership fully stands behind a continuation of the project. However, they point out that the development and evaluation of a user-friendly system for hospitals, capable of integration in stand-ing hospital information systems, requires sufficient resources. Therefore, the extended leadership resolved to concentrate with highest priority on DOSPO's clinical introduction within the upcoming funding period. Furthermore, the module generator development subproject will be postponed to prevent endangering the achievement of this aim. More importance will apparently be attached to hospital needs (therapy planning, clinical documentation, \u2026) in comparison with the first founding period. \nThe necessary measures to realize the expansion of routine DOSPO operation \nare discussed in the methodological approach (C.2).  \nAim 2: Provide the trial centers with the support needed to achieve \ncomprehensive terminological standardization of the trials.\nNext to using computer supported data exchange to network the clinics and trial \ncenters, a central task of this subproject continues to be networking the trial cen-ters by supporting the standardization of terminology.  \nAim 3: Secure DOSPO's operation and provide sufficient support to \nthe user hospitals and trial centers beyond the funding period. \nSoftware must continually be fitted to meet new requirements, for example, \nchanges in legal requirements or technical innovations. Supporting the hospitals in the introduction and operation of DOSPO, or new DOSPO functionality, will require a continuous effort. In the long run, these activities will need to be se-cured independent of temporary funding. Therefore, Aim 3 was included as a fur-ther aim of this subproject. Building long term structures to support the compe-tence network during the introduction and maintenance of the computer-supported application system requires efforts that must be covered by the up-coming funding period.69C.2 Methodological approach \nSteps to achieve Aim 1: Expansion of routine DOSPO operation within hospitals\nThe intended measures to reach widespread routine use of DOSPO are de-\nscribed in the following.\nProvision of project management support to hospitals regarding the introduction \nof DOSPO \nIn addition to the quality of a software product, the way the product is introduced \nalso has a major impact on the success of the introduction. Software introduction must be recognized as a project. Therefore, it should be conducted using the methods common to project management. These methods include producing re-quirements specifications, as well as a project plan. The latter shows the timely sequence and necessary project resources. The specified requirements describe the basic requirements of the user clinic that are important to system introduction (e.g. standing patient management and communication systems). Also, it should specify how DOSPO will be used in the hospitals (work stations, study protocol). The user clinic and the project leader, in cooperation with the established DOSPO Task Force, dismiss the specifications and the project plan. These documents are the foundation upon which the following project phases of the sys-tem introduction build, such as system installation and customization to the indi-vidual clinic environments. Examples of necessary adjustments are setting inter-face parameters, performing integration tests (in which the application system is tested within a test scenario set by the clinic), user training, and beginning routine operation. The requirements specifications and the project plan can help super-vise the progress and success of the project. The individual introduction projects are part of an overall project to comprehensively introduce DOSPO in the user hospitals.\nClose connection between the project phases development, piloting, comprehen-\nsive introduction, and routine operation \nThe path certain modules take from development to comprehensive routine use \nin the user institutions is decided in specific interwoven project phases (develop-ment, piloting, comprehensive introduction, routine operation). For this reason, primary user contacts must be designated during the development phase. These individuals closely accompany the development phase. A pilot phase in 2 or 3 user hospitals directly follows the development phase in accordance to the pro-ject plan. Following the pilot phase, a comprehensive introduction of the module is planned and realized. Herein, the introduction of the module stands in the fore-ground, not its further development. Therefore, suggestions for improvements are gathered and projected for specific update cycles. However, the introduction is largely independent of the recommendations. Beside the introduction, preliminary tasks for later system operation are underway, for example, user support, acqui-sition of new user hospitals, planning and conducting introductions in new hospi-tals. Operational tasks include the systematic and continual collection of require-ments placed upon DOSPO. Significant requirements are presented to the task force with an estimate of the efforts involved. The task force discusses the gen-erality and priority of the individual aspects and dismisses procedures for their realization, while taking the proposed efforts into account. To a certain extent, the realization of these requirements can take place parallel to the main development activities (see below).70Steps to achieve Aim 2: Provide the trial centers with the support needed to \nachieve comprehensive terminological standardization of the trials.\nTo achieve Aim 2, a continuation of the subproject responsible for the develop-\nment and establishment of the terminology server is essential.  \nThe semantic data model of the terminology server was expanded to include ref-\nerence integration components and version management for the items, as well as adjustments to the database schema. These expansions are also to be made to the functionality of the application system.  \nA pilot study will determine the necessary changes to improve the practicality of \nthe functionality of the application system. The functionality will need to be ad-justed accordingly. Simultaneously, the pilot study will evaluate how far stan-dardization of the items used in the study forms can be increased by use of the terminology server.\nIn addition, in cooperation with the standardization committee, further items (by \ntopic area) must be standardized and further trials taken up by the terminology server. This process has proven more work intense than initially planned. There-fore, a continuation of this subproject will be required beyond 2002. Medical in-formatic support will continue to be necessary throughout the second funding pe-riod.\nSteps to achieve Aim 3: Secure DOSPO's operation and provide sufficient sup-\nport to the user hospitals and trial centers beyond the funding period.\nTo ensure the utilization of DOSPO, as well as the long-term continuity of main-\ntenance and technical support to the user hospitals, a concept must be designed and realized that reflects the increasing routine use of the system. In this case, hand over to a cooperation partner, e.g. a transfer or industrial partner, is rea-sonable and should be established within the upcoming funding period. The fol-lowing aspects must be considered in this regard. The activities must be coordi-nated according to the terms of the competence network. The project leader posi-tion must be upheld within the competence network. Beside the project manage-ment tasks, the project leader is responsible for conceptional activities, quality assurance of the software, consulting, and training of the user hospitals. In case highly innovative scientific questions (e.g., an overall system evaluation) arise, cooperation should be maintained with research centers (see figure below). The lobby of the competence network should be strengthened by a higher-ranking steering committee. As shown, the functions of the project leader bridge an im-portant gap. \n           \u2026  71Steering committee \n\u201eComputer-based application \nsystems\u201c \nProject leadership \n\u201eComputer-based application \nsystems\u201c\nSystem development, \nTechnical support of user \nclinics Processing questions of \nscientific interest \nSummary\nThe upcoming funding period is dedicated to ensuring that DOSPO finds wide \nuse in the hospitals. Realization of system improvements and provision of intense introductory support to the hospitals are necessary parts of this dedication. The previous work invested in standardizing the terminology must be continued. By the end of the funding period, maintenance and technical support of DOSPO is to be handed over to a cooperation partner. By building up the cooperation during the funding period, the transfer of know-how is to be ensured.\nC.3 Work plan \nWork plan for the further development and introduction of DOSPO in hospitals\nThe DOSPO development and introduction work plan is divided into the various \nproject modules. It can be found in the appendix section (DOSPO Work Plan). The plan contains the activities required for further development and introduction of the current DOSPO core system. A detailed list of the necessary activities and their dependencies are contained in the work plan. It presents the time schedule planned from 2002 to 2004 to make the relationships among remaining tasks more transparent. Blue activities mark software development projects and pilot phases. Blue-green activities represent widespread introduction projects in hospi-tals. Green activities stand for operative tasks of the components. For example, until mid-2003 the development and piloting of the HL7-Interface is finished and their introduction in further hospitals combined with the introduction of the docu-mentation of diagnoses and procedures is underway. Furthermore, the reimple-mentation of the modules protocol definition and therapy planning is finished and they are introduced in selected pilot hospitals.  \nThe time schedule is based on the resources requested below. With the pro-\nposed personnel, the subproject will be able to complete the development and introduction of DOSPO in hospitals within the second funding period. A transition to ongoing routine operation can be achieved.72Work plan to achieve widespread terminological standardization of the studies.\nThe work plan for widespread standardization of the terminology can be found in \nthe appendix section. (Terminology Server Work Plan). \nWork Plan to ensure the routine use of DOSPO beyond the funded time period.\nIn 2003, different cooperation schemes will be developed. Possibly, a call for ten-\nders will be conducted. In cooperation with the steering committee, selection of the cooperation scheme best suited for the competence network will be selected. In 2004, the hand over of the maintenance of the application system and its users will be prepared.\nC.4 Networking  \nThe terminology server provides the prerequisite for comprehensive evaluations \nacross the clinical trials. Integration of the trials into the terminology server, while simultaneously providing standardization, enables finding answers to medically relevant questions beyond the bounds of a single trial. In this area, medical in-formatics research directly provides important methods for medical research. Since other competence networks also see the need for a terminology server, the following project phase also examines the usability of the terminology server for other competence networks.\nFurthermore, cooperation with other competence networks in the area of therapy \nplanning is targeted. A first contact has been achieved with the competence net-work \u201eMalignant Lymphoma\u201c, which is developing similar functionalities (e.g. therapy planning) within the scope of a development of an 'onco-work station' for adult oncology. Next to exchanging experience among work groups, an examina-tion of whether certain developments and activities can be brought together is planned to achieve a synergy effect. 73Part D- Requested Funding for the Project \nD.1 Salaries\nProject leadership\nThe project must remain under the leadership of a project leader (BAT Ib). The \nproject leader is responsible for the keeping the budget and the overall project plan. A good calculation of the resources is very important for the various project areas and subprojects. The project is a combination of system development and system introduction. The hospitals and trial centers involved must be networked. The project leader fosters contacts to the hospitals and trial centers, and supports system introduction through project management measures.  \nAnother important task of the project leader is to continue establishment of a \nmodel for cooperation between the competence network, system development, system support, as well as research. This is important to ensure the stability of the model beyond the funding phase. Also, to ensure that scientific results are transferred to practical everyday routine use in both hospitals and trial centers. \nResources and time planning: \u00bd Bat Ib 1/2003 \u2013 12/2004 System development, System introduction and routine operation\nConception and realization of the necessary modules, and their improvements, \nbelong to the area of system development. Both occur in tight cooperation with the user. Thereupon, a pilot phase within the user hospitals must take place. As presented in C.2, it will be necessary to support the users intensely during the introduction phase of DOSPO. Each introduction, in each clinic, is seen as a sub-project. Therefore, it must be accompanied by project management measures. On location customizing of the system to meet the needs of the specific clinical environment (especially, setting interface parameters and adjusting study proto-cols to the hospitals), as well as user training remain part of the system introduc-tion phase. Following a resource intensive introduction, a certain amount of effort remains for supporting everyday clinical routine operation.  \nOutstanding developments, as well as system introduction, will require the sup-\nport of 2 scientific employees by the end of 2004, in order to provide full function-ality to all of the hospitals involved.  \nResources and time planning: 2 Bat IIa  1/2003 \u2013 12/2004 System development and introduction\nDuring system development and introduction, a certain amount of well-bounded \nsubtasks arise, for example, buildup of a gateway for an interface in one of the user hospitals, or the realization of a note pad function for DOSPO. To effectively support the areas of system development and introduction, the employment of 2 assistants is sensible.\nResources and time planning: 2 scientific assistants 1/2003 \u2013 12/2004 74Standardization of Terminology\nMaintenance functionality for the terminology server and the application system \nmust be expanded. Evaluation of the terminology server must be continued, as it will help make the terminology server utilizable for other competence networks. \nResources and time planning: \u00bc Bat IIa 1/2003 \u2013 12/2004 Overall personnel requirements (in \u20ac)\n Estimated Per-\nsonnel costs \n2003\n(per Month) 2003 Estimated Per-\nsonnel costs \n2004\n(per Month) 2004\n1/2 Project \nleader5041,00 30246,00 5142,00 30852,00 \n2 Scientists \n(System devel-opment, sys-tem introduc-tion)4734,00 113616,00 4828,00 115872,00 \n\u00bc Scientist \n(Support uni-formity of ter-minology) 4734,00 14202,00 4828,00 14484,00 \n2 Scientific as-\nsistants11779,14 23558,28 11779,14 23558,28 \nAnnual sum  181622,28  184766,28 \nOverall sum    366388,56 \nD.2 Consumables\nTo professionally further the development of the system, an update of the devel-\nopment environment (Delphi and special tools) will be necessary for several workstations. The update is to take place during the year 2003. An exact listing can be found in the table below. In addition, 500 \u20ac per year will be necessary for smaller hard and software components. The handover of software operation to a cooperation partner in the year 2004 requires a calculation of 10,000 \u20ac. \nConsumables (in \u20ac) 2003 2004 \n2x Delphi 6.0 Enterprise 7669 \u2013 \n2x InfoPower 3000 Professional 823 \u2013 \n2x Orpheus 4 818 \u2013 1x Upgrade Delphi 6.0 Professional 357 \u2013 2x IBExpert 392 \u2013 Smaller SW and HW components 500 500 Handover to cooperation partner \u2013 10000 \nAnnual sum 10559 10500 \nOverall sum  2105975D.3 Investments\nThe roll out of DOSPO results in a lot of location support of the hospitals. In this \nway, the mobility requirement increases. The developers need a laptop for effi-cient support. In 2003 we want to replace one project PC, which no longer meets the increasing hardware requirements for software developing, by a laptop. The prices listed below are taken from the current recommendations posted by the Center for Information Management, Heidelberg.\nList of Annual hard and software investments exceeding 400 \u20ac (in \u20ac): \n 2003 2004 \nLaptop approx. 3000 \u2013 \nAnnual sum 3000 \u2013 \nOverall sum  3000\nD.4 Other Costs \nDue to the relevance of the project throughout the entire competence network, \nmany business trips are necessary. The present intensity of the support required by the participating hospitals shows how important presence is for a successful introduction of DOSPO. However, this requires 2 employees to be on the road for 2 days every 2 weeks. The costs of other necessary regular meetings are pre-sented in the following. The frequent business trips make the purchase of a Bahncard (140 \u20ac) sensible. The average expenses amount to 80 \u20ac for travel, 14 \u20ac pocket money for one day (18 \u20ac for two days), and 60 \u20ac for one night. The follow-ing annual calculation can be shown:\n Nr / Year Number of \nEmployees Overnight Costs \n(in \u20ac) \nLayovers Costs / Year    \nBahncard 1 4 \u2013 560 \nDOSPO task force \nmeeting6 4 \u2013 2256 \nMeeting of extended \nleadership3 1 1 474 \nMeeting  Informatics \nwork group 2 4 \u2013 752 \nMeeting with cooperat-\ning partners 4 2 1 1264 \nMeeting with other work \ngroups of competence network2 3 1 948 \nIntroduction into clinic 20 2 1 6320 \nAnnual sum    12574 \nOverall sum    2514876Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Data Protection, IT Security and \n  Knowledge Server \u2013  \n  Computer-based Application Systems  \n  (Project B/2)  \nGrant No. : 01 GI 99 67/3 \nName of scientist-in-charge : Univ.-Prof. Dr. Klaus Pommerening \nInstitution : Institut f\u00fcr Medizinische Biometrie,  \n  Epidemiologie und Informatik (IMBEI) \n  Johannes-Gutenberg-Universit\u00e4t Mainz \nAddress : D-55101 Mainz, Germany  \nPhone : +49 (0) 61 31 \u2013 17 \u2013 31 06 \nFax : +49 (0) 61 31 \u2013 17 \u2013 47 31 06 \nE-mail : pommerening@imsd.uni-mainz.de  \nProject home page (if different from \nNetwork homepage) :  http://www.kompetenznetz-paed- \n  onkologie.de/prjb/net_B.xml 77Part A - General Statements about the Project\nA.1.Subject\nPart 1: Data Protection and IT Security \nPart 2: Knowledge Server\nA.2. Co-Investigators\n\u0083 Coordination and Management Group, Prof. Dr. G. Henze, Berlin \n\u0083 Telemedicine, Prof. Dr. H. J\u00fcrgens, M\u00fcnster \n\u0083 TMF Coordination Center Fraunhofer ISST, Dr. W. Glitscher, Berlin \n\u0083 German Childhood Cancer Registry, Dr. P. Kaatsch, Mainz\nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nNone.\nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 0 0 0 0 0 0 \n2004 0 0 0 0 0 0 \n1(amounts in thousand Euro), \n * should correlate to funds specified in Part D78Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe Project B/2 consists of two parts. Part one is \u201eData Protection and IT Secu-\nrity\u201c, part two is \u201eKnowledge Server\u201c. Due to a delayed start the project is 4\u00bd months behind its schedule. The delay affects part one only, whereas part two is in time. \nIn part one we established secure communication by PGP and secure client-\nserver interaction by SSL and X.509 certificates. We worked out concepts for data protection and IT security, in particular with regard to access control on servers, access to and use of mailing lists, confidentiality of communication and integrity of information. We carried out a market analysis for a smart card based public key infrastructure and decided to delay its introduction until - at the end of 2001 - a consensus was reached in the telematics platform TMF. As an additional working package for part one, a pseudonymisation service turned out to be of fundamental importance for the network. We developed and installed this service which is in production since the beginning of 2002. \nIn part two we established a working web server that offers a considerable body \nof information as well as many mailing lists. As it turned out the workflow can be improved by transferring the knowledge server to the coordination center. This transfer will be accomplished in steps beginning with april 2002. \nThe results on IT security as well as the software for pseudonymisation will be of \nuse for the other networks of the TMF as well. \nB.2 Original aims of the project \nPart 1: The Competence Network for Pediatric Oncology and Hematology devel-\nops a comprehensive communication infrastructure. The requirements of data protection in medicine necessitate a carefully developed concept for IT security and its implementation; in particular for \n\u0083 confidentiality of patient data and other person-related data, \n\u0083 authenticity and integrity of data and information contents, \n\u0083 access protection and access control for network services. \nThe communication channels to be protected use e-mail and client-server inter-\naction.\nPart 2: The Competence Network for Pediatric Oncology and Hematology needs \na knowledge server that \n\u0083 provides medical information such as study and treatment protocols as well as \nrecommendations for hospitals, practitioners and patients, \n\u0083 offers information for education and training, \n\u0083 hosts mailing lists and discussion groups, \n\u0083 contains results by the projects of the network.  79B.3 Scientific results \nThe projects focus is on essential elements of the infrastructure for the compe-\ntence network. The scientific innovation consists in part only in showing how to exactly specify and realize well-known general and theoretical demands. The most pretentious part of the project was the development of the pseudonymisa-tion service. Some recommendations and specification documents are accessible via the project URL. \nB.3.1. Concepts We developed policies, defined roles and formulated access rights for information \naccess and interactive web services, including telemedicine services. The essen-tial roles in the network are \u201emember of the network\u201d, \u201ephysician\u201d, \u201estudy nurse (FSA)\u201d. Access is restricted to members for some documents on the knowledge server, the server of the coordination center, and some study centers. There are special access restrictions for file upload, the pseudonymisation service, the management of mailing lists, the maintenance of the user database, and some special functions. \nB.3.2. E-mail communication We established secure e-mail communication by PGP, including means for cen-\ntrally signing and distributing public keys. In particular PGP is used for data trans-fer to the childhood cancer registry, and provides confidentiality, integrity, and authenticity of e-mail messages in a really simple and cheap way. \nB.3.3. Secure client-server interaction We developed recommendations for the setup of secure web servers, including \nthe \u201ehardening\u201c of servers that is making them secure against attacks from the internet. As a first step we used SSL-enabled servers to \n\u0083 establish cryptographically secure connections and \n\u0083 password protected access to confidential documents; due to the\nSSL connection the passwords are not exposed on the internet. \nAs a second step we introduced soft user certificates (X.509) to enable strong \nauthentication for web services. Up to now (march 2002) this is used for the pseudonymisation service. A uniform infrastructure that allows single logon to all services in the competence network is in preparation. \nWe offer a web interface for users to sign on to the access restricted services and \nget a certificate. Furthermore we set up a central user directory that supports the management of roles and rights for web services and the dynamic generation of mailing lists. A data base (postgreSQL) feeds the directory. A java frontend gives access to the data base; access is restricted to a few individuals and controlled by certificates. A distributed object approach presents the data base as a CORBA service and allows authorized access through firewalls. \nB.3.4. Smart card based public key infrastructure The implementation of a smart card based public key infrastructure (PKI) is de-\nlayed. An initial market analysis early in 2000 showed that the available PKI solu-80tions were either proprietary or had no provisions to integrate them into the exist-\ning or planned applications. There\u2019s not even a simple way to integrate the smart card PKI into existing web browsers. To get to a usable, portable, standardized open solution, we sought the close cooperation and consensus within the TMF platform. In the meantime the market situation is unchanged but, after many ef-forts, a global (TMF wide) solution is in sight and will be implemented in the com-petence network in the remaining months of 2002. \nBecause of the delay there remain some unused funds for external trust center \nservices that should be spent in the second funding period to extend the PKI as far as originally planned. \nB.3.5. Pseudonymisation (PID service) As an additional working package a pseudonymisation service turned out to be of \nfundamental importance for the network. This was realized as a web based ser-vice that gives a unique patient identifier (PID) to be used as a pseudonym. The software is highly configurable, allows several steps of pseudonymisation, and provides flexible database and record-matching schemes. The matching strategy also\n\u0083 covers cases where the input data are marked as  \nunsure and tries to give a best match, \n\u0083 tries to avoid homonym errors that are unacceptable in a treatment context, \n\u0083 minimizes synonym errors. \nThe matching algorithm and the PID generating algorithm are innovative. The \nPIDs are constructed by a new cryptographic algorithm and contain redundant information for optimal error detection and correction. \nThe PIDs are useful as pseudonymous identifiers for multicenter studies as well \nas epidemiological studies and for the childhood cancer registry. This service is in production since the beginning of 2002. \nB.3.6. Web service The web server was set up with a content management on XML basis together \nwith a search engine. The server contains a large but still incomplete quantity of information. The acceptance is quite good; we count several hundreds visits per day. A part of the information is static documents, another part, such as news or the collection of useful links, are dynamically generated from the data base. \nTo enhance the workflow and the content management the service is being trans-\nferred to the network coordination center in the second half of 2002. \nB.3.7. Mailing lists and discussion groups We established several mailing lists and discussion groups, some of them with \narchives, that are maintained in the user directory and dynamically generatedfrom there.81B.4 Publications and patents \nPommerening K. Sicherheit f\u00fcr ein medizinisches Kompetenznetz. In: Victor N et \nal (Ed.), Medical Informatics, Biostatistics and Epidemiology for Efficient Health Care and Medical Research, Urban & Vogel MMV, M\u00fcnchen: 272-275, 1999. \nPommerening K. IT-Sicherheit in medizinischen Netzen -- aktuelle Probleme und \nL\u00f6sungsans\u00e4tze. Zentralbl Gynakol 122: 658-662, 2000. \nPommerening K. Medizinische Netzwerke: Sicherheit - eine dauerhafte Aufgabe. \nDtsch Arztebl 98: A 2085-2087, 2001. \nPommerening K, Wagner M. Ein Pseudonymisierungsdienst f\u00fcr medizinische \nForschungsnetze. Informatik, Biometrie und Epidemiologie in Medizin und Biolo-gie 32: 251, 2001. \nPatents\nNone planned.\nB.5 Networking \nBoth parts of the project constitute fundamental infrastructure components for the \ncompetence network. Part one is of basic importance for communication and in-teraction with respect to data security requirements in medicine and medical re-search. The public key infrastructure enables the confidential transfer of patient data for multicentric studies and to the childhood cancer registry. The pseudo-nymisation service reduces the transfer and storage of person-related data and gives an unique - pseudonymous - patient identifier across the competence net-work, including the childhood cancer registry. \nPart two, the knowledge server, is an essential tool for horizontal and vertical \nnetworking, for cooperation and communication inside the network, and for the visibility of the network to the general public. \nPart one of the project has pilot character for the other networks under the roof of \nthe TMF; the results are being transferred to other networks.82Part C \u2013 Follow-Up Proposal \nC.1 Aims\nPart 1: Data Protection and IT Security. \nThis part is essentially finished with the first funding period. Due to the delayed \ndecision with respect to smart card technology, there are some unused funds for external services (ca EUR 18000) that should be transferred to the coordination center in the second funding period. \nPart 2: Knowledge Server. This part should be transferred to the coordination center for the second funding \nperiod.\nC.2 Methodological approach \nN/A.\nC.3 Work plan \nN/A.\nC.4 Networking  \nN/A.\nPart D- Requested Funding for the Project \nD.1 Salaries\nNone.\nD.2 Consumables\nNone.\nD.3 Investments\nNone.\nD.4 Other Costs \nNone.83Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Telemedicine in Pediatric Oncology\n  (Project C)  \nGrant No. : 01 GI 99 60 \nName of scientist-in-charge : Dr. med. Michael Paulussen (responsible)\nInstitution : Universit\u00e4t M\u00fcnster, Universit\u00e4tsklinikum, \n  Klinik und Poliklinik f\u00fcr Kinderheilkunde,\n  P\u00e4diatrische H\u00e4matologie/Onkologie \nAddress : Albert-Schweitzer-Str. 33 \n  48149 M\u00fcnster \nPhone : +49 (0) 25 1 \u2013 83 4 \u2013 77 42  \nFax : +49 (0) 25 1 \u2013 83 4 \u2013 78 28  \nE-mail : michael.paulussen@uni-muenster.de \nName of scientist-in-charge : Univ.-Prof. Dr. med. Norbert Graf \nInstitution : Universit\u00e4t des Saarlandes, Universit\u00e4ts- \n  klinik f\u00fcr Kinder- und Jugendmedizin,  \n  P\u00e4diatrische H\u00e4matologie/Onkologie  \nAddress : 66421 Homburg/Saar \nPhone : +49 (0) 68 41 \u2013 16 28 39 7/9 \nFax : +49 (0) 68 41 \u2013 16 28 30 2 \nE-mail : norbert.graf@uniklinik-saarland.de \nProject home page (if different from \nNetwork homepage) : http://medweb.uni-muenster.de/telemed/84Part A - General Statements about the Project\nA.1.Subject\nTelemedicine in Pediatric Oncology\nA.2. Co-Investigators\n\u0083 Prof. Dr. G. Henze, Humboldt-University Berlin, Charit\u00e9  \n\u0083 Prof. Dr. J. Dunst, University of Halle  \n\u0083PD Dr. J. K\u00fchl, University of W\u00fcrzburg \nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 192,5 2,5 2,5 1,5 0 198 \n2004 192,5 2,5 2,5 1,5 0 198 \n1(amounts in thousand Euro), \n * should correlate to funds specified in Part D85Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe telemedicine project of the Competence Network Pediatric Oncology was \ninstituted with the aim to evaluate the needs for and possibilities of the use of telemedicine applications in Pediatric Oncology.\nThe project has analyzed the needs of the network Pediatric Oncology institutions \nfor electronic exchange of medical information, focusing on teleradiology and tel-emicroscopy. Suitable information technology (IT) systems were identified in a market survey. System installations were undertaken in the participating institu-tions, and a test phase of the use of teleradiology systems in Pediatric Oncologywas started. The results of these tests will lead to the identification of suitable systems for the needs of Pediatric Oncology, which may then be further analyzedduring routine use in participating institutions.\nAs a first result of the projects it was noted that the IT and network facilities in the \nmajority of Pediatric Oncology and radiology institutions participating/co-operating in the Competence Network Pediatric Oncology are sufficient, but there is a lack of qualified personnel to implement and maintain telemedicine applications in every day use. Moreover, acquisition of such personnel seems difficult at present. \nA second major result relates to prerequisites for electronic exchange of radio-\nlogical data. Electronic picture archiving and communication systems (PACS) are in internal use in the majority of radiology departments involved in German Pedi-atric Oncology. Certain aspects of data exchange with other institutions, however, are regarded problematic: While most institutions are willing to accept electronic images as DICOM data from external sources, they refuse to give external clients access to the own electronic data archive. In contrast, active transmission of DI-COM data to trusted partners is generally regarded as non-problematic, provided data security and consistence and the fulfillment of legal requirements are en-sured.\nHence, as conclusion from the first phase of the telemedicine project, it is sug-\ngested that the evaluation of options for the establishment of a central electronic image clearing institution for German Pediatric Oncology should be a major new task for the second funding period of the telemedicine project of the KPOH. To this end, certain modifications to the original work program are required, as out-lined in part C below. \nB.2 Original aims of the project \nThe telemedicine project of the Competence Network Pediatric Oncology was \ninstituted with the aim to evaluate expectations, requirements and possibilities regarding a potential use of telemedicine applications in Pediatric Oncology.  \nThe primary focus was to analyze, if the use of electronic information technolo-\ngies (IT) in radiographic image based communication between Pediatric Oncol-ogy hospitals and clinical phase III trial centers of the Society of Pediatric Oncol-ogy and Hematology (Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie, GPOH) might be useful in terms of increasing data quality, data transfer speed, 86and data reproducibility, thus potentially improving the quality of treatment deci-\nsions and ultimately of patient care.\nIn case these analyses should indicate potential benefits from the use of IT tech-\nnologies in Pediatric Oncology, it was planned to define scenarios for such struc-tures, to analyze the available IT market for solutions eventually available, and to plan example implementations. \nB.3 Scientific results \nThe project strategy included the gathering of a demand profile for telemedicine \nservices within the Pediatric Oncology community and the evaluation of currently available telemedicine systems, focusing on teleradiology, with the ultimate goal of designing a set of recommendations for their actual implementation.\nIn order to objectify the demand for telemedicine services, two surveys were con-\nducted within the Pediatric Oncology and radiology communities in Germany. The first questionnaire was mailed to 54 Pediatric Oncology units participating in GPOH trials, with a return rate of 45 (83%). The response was generally positive expecting beneficial uses of teleradiology (98% for CT/MR images, 73% for pla-nar images, 61% for ultrasound) as well as telemicroscopy (82% for hematology and 59% for histology specimens). The majority of participating institutions re-ported existence of an internal data network (84%) and internet access (95%, 43% with high bandwidth). Six participants were involved in other telemedicine projects during the survey period. 70% of participants expressed interest in im-plementing a telemedicine infrastructure within the next two years. The main pre-cautions expressed concerning future implementations of telemedicine regarded data security, standardization of protocols and applications as well as the non-ambiguous identification of images used in telemedicine sessions. 43% of partici-pants expressed a willingness to make investments of at least \u20ac10.000 in local telemedicine infrastructure. \nA separate survey was conducted as a combined paper/online questionnaire \nmailed (via their corresponding Pediatric Oncology units) to 110 radiology de-partments providing diagnostic services for Pediatric Oncology units. With the survey still being in progress, at present (after six months) only 26 questionnaires (24%) have been returned or entered into the online database. Main require-ments expressed towards teleradiology systems concern data security, image quality and usability. A preliminary analysis of the results shows that 61% of the participants are operating digital imaging infrastructure with picture archiving and communication systems (PACS), using the Digital Imaging and Communication (DICOM) Standard of ACR (American College of Radiology) and NEMA (National Electrical Manufacturers Association). 66% of the participants intend to introduce teleradiology services within the next 5 years. Only 19% (5) of the participants are willing to open their image archives to external participants. With 57% of par-ticipants a far larger number of institutions are prepared to actively exchange im-ages with external participants.\nWorkflow analysis in three major GPOH multi-centre solid tumor trials (EURO-\nE.W.I.N.G. 99, COSS 96, SIOP 93-01/GPOH) showed that handling of radiology films accounted for a relevant share of the daily workload. For an average Pediat-ric Oncology study, an inflow of 2-3 new patients was registered per week. An average of 60 therapy documentation forms per week were typically received and filed. Handling of radiology films varied between 20 to 120 per week. The time 87allocated to receiving, handling, searching for and mailing out of films was given \nas 4-15 hours per week. In a typical hematological study centre (AML-BFM 98), about 30 bone marrow samples were handled per week.\nPrior to installation and evaluation of teleradiology systems, a set of basic re-\nquirements was conceived by the project participants. The requirements were mailed to providers of teleradiology systems located by means of a web search. The responders' systems were compared in a side-by-side matrix regarding the required criteria. Two systems (CHILI, KAMEDIN) were found to match the rele-vant criteria and were thus chosen for evaluation. At a later stage, the \u201eeFilm\u201c and \u201eSiemens MagicWeb\u201c systems became available and were added to the evalua-tion panel.\nThe systems cover a wide range of radiology image software functionality from \nsimple DICOM file viewers over image workstations with advanced conferencing and image manipulation features to full PACS applications with integrated image storage and routing features. The DICOM image file standard is supported by all products, but not all packages offer network connectivity using DICOM. An HL7 interface for exchange of administrative, order, or report data is not available in any of the systems evaluated. Usability is comparable between products, but the DICOM interface configuration methods varies between graphics user-interface-(GUI)-based (e.g. eFilm) and file-based (e.g. CHILI) applications. Software set-up and DICOM configuration necessary to achieve connectivity to locally existing PACS installations as well as to external data sources and/or recipients proved to be a non-trivial task requiring intimate knowledge of the local radiology network as well as a firm grasp of DICOM terminology.  \nIn conclusion, both providers and recipients of radiology images seem to be in-\nterested in the introduction of telemedicine services within the Pediatric Oncologycommunity. Analyses of ongoing clinical trials have shown that the handling of image hard-copies, reports and samples constitute a relevant share of the daily workload. Especially in solid tumor studies relying heavily on radiological imag-ing, the introduction of teleradiology services could optimize workflow and re-source usage. With local area networks, internet connections and PACS avail-able at many partner hospitals, the necessary infrastructure is largely in place. Teleradiology systems are commercially available at varying degrees of function-ality, facilitating their integration into existing imaging networks. Vendor-independent interoperability is, however, currently limited to exchange of DICOM data, as there is no standardized conferencing and collaboration protocol. Data security, data confidentiality, and image quality are main focuses of concern in electronic data exchange.\nHence, as first major result, core assumptions of the initial project proposal were \nconfirmed during the first project period: \n\u0083 A survey among Pediatric Oncology study hospitals showed a high demand \nand positive attitude towards telemedicine applications, based on the expecta-tion that such services would increase patient treatment quality while reducing costs.\n\u0083 Building largely on existing network infrastructure more than two thirds of the \nparticipants stated plans to introduce telemedicine applications within a two-year period.              \u2026  88\u0083 These results were corroborated by workflow analyses of Pediatric Oncology\nstudies that showed a high volume of radiology images being mailed between participants, the handling of which constituted a major time burden on study personnel.\n\u0083\nA survey among radiology partner institutes showed that 60% of participants \nwere already using digital imaging and archiving systems as well as in-house online image distribution.\n\u0083 An evaluation of teleradiology systems showed that systems commercially \navailable cover a broad range of functionality allowing a selection according to the individual needs of participating hospitals.  \n\u0083 As a second major result of the initial evaluation period, some relevant imple-\nmentation barriers could be identified:\n\u0083 While more than 50% of surveyed radiology institutes were willing to actively \nsend images to and retrieve them from external partners, only 19% were will-ing to open their own archives for external access.\n\u0083 Configuration and integration of teleradiology systems into imaging infrastruc-\ntures proved to be a nontrivial task requiring intimate knowledge of the DI-COM standard as well as detailed insight into local imaging data infrastruc-tures and proprietary imaging modalities.\n\u0083 Recruitment of skilled personnel meeting these requirements emerged as a \nrelevant problem at several partner locations.\n\u0083 Point-to-point communication strategies necessitate the establishment of sev-\neral individually configured connections between several imaging systems at multiple locations and from various vendors. Apart from these technical diffi-culties, the problem of trust between partners that have to provide mutual ac-cess to their archives increases disproportionately with the number of partners involved.  \nTo evaluate the benefit of telemedicine services within a prospective trial of the \nPediatric Oncology community (SIOP 93-01/GPOH and SIOP 2001/GPOH) forms were developed, asking for time aspects, for the quality of transferred imaging studies and  logistics regarding problems in transferring and viewing of imaging studies, problems in making a correct diagnosis and reporting this diagnosis to the local center. These forms are filled out for electronically transferred imaging studies as well as for hardcopies. By comparing these results , it is possible to measure the benefit of telemdicine services within a prospective trial of the Pedi-atric Oncology community. This analysis started in 2000 and is still going on.  \nUp to now, only few centers (Berlin, G\u00f6ttingen, Krefeld, M\u00fcnster, Mannheim, \nOldenburg, Z\u00fcrich) and one radiologist outside a center (Deggendorf) did send imaging studies electronically to the study center in Homburg. In all these cases an electronic exchange of these imaging studies was done between Homburg (study center for the nephroblastoma trial) and Heidelberg (radiological reference center of the nephroblastoma trial, Prof. Tr\u00f6ger, Heidelberg) and the imaging studies were discussed regarding quality of the images and the logistics of the electronical exchange using the developed forms.\nAs a preliminary result the following three aspects can be concluded: \u0083 The electronic transfer of imaging studies is much more difficult than expected \nbefore. Main problems are: firewalls, the absence of a PACS system at the lo-cal radiological institution and the refusal of local radiologists to send imaging 89studies outside of their hospital.\n\u0083 Only the transfer of the whole imaging set as DICOM files is sufficient to per-\nform a reference radiologist diagnosis. Incomplete imaging studies or imaging studies send as JPEG-files or in an other NON-DICOM format are not suffi-cient regarding quality for making a correct radiological diagnosis. \n\u0083 Without the knowledge of the clinical data, it is impossible to make a right di-\nagnosis by reference radiologists. In contrast to the transfer of hard copies -usually done by clinicians and send together with clinical data - the DICOM files are transferred by radiologists or informatics in the radiological depart-ment without any clinical data. The request for clinical data is time consuming and delays the radiological diagnosis by the reference center.\nHence, options for the establishment of a central electronic image clearing institu-\ntion for German Pediatric Oncology should be evaluated during the second fund-ing period of the telemedicine project of the KPOH. \nB.4 Publications and patents \nGraf N, Paulussen M, Huf T, Ganslandt T, Stahl J, J\u00fcrgens H. Telemedizin in der \nP\u00e4diatrischen Onkologie. Ergebnisse einer Fragebogenaktion des Kompetenz-netzes P\u00e4diatrische Onkologie. Klin. P\u00e4diatr. 214:8-19, 2002\nGanslandt T, Paulussen M, Graf N, Huf T, Prokosch HU, J\u00fcrgens H: Etablierung \neines Telemedizinnetzwerkes in der p\u00e4diatrischen H\u00e4matologie/Onkologie. In: Achim J\u00e4ckel (Hrsg): Telemedizinf\u00fchrer Deutschland, Ausgabe 2002, Medizin Forum AG, Ober-M\u00f6rlen, S. 95  \nGanslandt T, Korsching E, Prokosch HU, Herbst H, B\u00f6cker W, Senninger N, \nSpiegel HU. Telepathologie: Unausgesch\u00f6pfte Potentiale. In: Achim J\u00e4ckel (Hrsg): Telemedizinf\u00fchrer Deutschland, Ausgabe 2002, Medizin Forum AG, O-ber-M\u00f6rlen, S. 170 \nB.5 Networking \nThe telemedicine project primarily involves six participating institutions, all being \nmembers of the KPOH and the GPOH. These institutions have set up IT facilities to communicate electronic data and images among them. A test phase for practi-cal use is under way. These example installations will lead to further detail results of both advantages and barriers of electronic image exchange within the compe-tence network and form the rationale for future implementation strategies.\nAs an early result achieved during the implementation phase of these test instal-\nlations, the potential benefits of a central electronic image clearing institution and potentially resulting networking activities extending over the existing KPOH net-work have become apparent. The discussion about the implementation of such a structural concept is under way; more detailed descriptions can be found in part C.4 below. 90Part C \u2013 Follow-Up Proposal \nC.1 Aims\nThe results outlined above (see B.3) lead to the following conclusions: \n\u0083 There is a high demand for and acceptance of telemedicine services; work-\nflow analyses suggest a relevant potential for optimization.\n\u0083 Network infrastructure required for the implementation of telemedicine ser-\nvices is in place or presently being introduced at many GPOH and KPOH in-stitutions, including in-house radiology image distribution; installed systems vary to a high degree between institutions, however.  \n\u0083 Thus the approach of establishing a standardized recommendation for tele-\nmedicine system installations applied throughout the complete GPOH study community might in many cases lead to the construction of parallel infrastruc-tures. Aspects of costs as well as demands for qualified personnel might pre-sent problems in a GPOH-wide adoption of this strategy.\n\u0083 Furthermore, point-to-point communication strategies necessitate the estab-\nlishment of several individually configured connections between several imag-ing systems at multiple locations and from various vendors. Apart from these technical difficulties, the problem of trust between partners who have to pro-vide mutual access to their archives increases disproportionately with the number of partners involved.\nTo overcome such implementation barriers, the project aims need to be modified\nto look into the evaluation of a centralized imaging/telemedicine infrastructure. Such a central electronic image clearing institution will function as a central radi-ology image repository that is accessed by the participating hospitals and radiol-ogy institutions but itself has no reciprocal access to the participants' image ar-chives.\nThis multipoint-to-point paradigm provides several advantages:\n\u0083 Decrease of interface complexity: Connections need only be established be-\ntween each participant and one central server, not directly between all partici-pants (see figure below). Point-to-point teleconferences could be made possi-ble by means of a web-based teleradiology server that can be used without local installation of specialized software.  \n\u0083 Integration of existing local infrastructures avoiding the need for separate im-\nage-viewing applications: In-house distribution of images is facilitated by im-age communication systems largely already in place. Hospitals that have not yet introduced such systems can make use of the recommendations estab-lished within the project when procuring a system.\n\u0083 Reduction of trust barriers: Participating radiologists could actively send im-\nages to the central archive, and only authorized study participants would ac-tively download images from the archive. Both activities can be achieved without compromising the participants\u2019 own archives.\n\u0083 Resource optimization: A single team can be leveraged to maintain the central \nserver and support participants without the need for specially trained person-nel in every participating institution. Advances in interconnectivity will auto-matically benefit all participants.91\u0083 Added value: A central anonymised image repository would provide an enor-\nmous image database which could be used for advanced applications like ref-erence image collections, computer-based training systems, teaching pur-poses, and quality management, among others. Such projects could be real-ized either within the telemedicine project, or in co-operation with other net-work members, with partners from other networks, other members of the sci-entific community, or even commercial health care providers.\nAn established centralized electronic infrastructure could moreover facilitate the \nimplementation of other network-based applications like remote data entry (RDE) systems and could hence act as a focus for secure electronic data collection and transmission, thus representing an example of both vertical and horizontal net-working communication.\nFigure: Outline of potential KPOH central electronic image clearing institution:\nC.2 Methodological approach \nIn continuation of the original work plan, point-to-point teleradiology systems will \nbe installed at more partner locations, and network connections will be estab-lished between locations. Usage patterns, stability and usability of systems will be evaluated. Experience gathered on interoperability and configuration of DI-COM connections between PACS and teleradiology systems of different vendors will be collected in a central knowledge base and made available for future use, enabling point-to-point image communication for institutions interested in such solutions.\nThese activities will, however be less extensive than planned in the initial project \nproposal. Instead, in accordance with the results of the telemedicine evaluation achieved so far (and outlined in section B.3 above), there will be a switch in theproject focus (see also section C.1 above):\n\u0083 The implementation of a central electronic image clearing institution concept \nwill be evaluated. This will include analyses of acceptance as well as struc-tural, technical and functional prerequisites as outlined under C.3 below.92\u0083 Aspects of secure network connections crucial for the implementation of such \na structural concept will be evaluated, including a survey of security infrastruc-ture (e.g. firewalls) already in place at participating hospitals and of secure connectivity products (e.g. virtual private network software) available.\n\u0083 A remote data entry (RDE) tool will be implemented and evaluated within the \nnephroblastoma SIOP 2001/GPOH study. This will easily provide the connec-tion of clinical data with imaging studies. The implementation of a DICOM viewer in such a system facilitates the work of the reference radiologists by the possibility to get information from and to give information into only one single system. By implementation of a report function, that automatically gen-erates and sends reports, it is easy to inform the local institution that did send the imaging studies without time delay. Facilitating the electronical exchange \nof imaging studies together with clinical data on a secure basis will help to in-crease the cooperation with local radiologists and the Pediatric Radiologic Society in the telemedicine project, which is mandatory for the whole project. \n\u0083 RDE evaluation will be carried out in close cooperation with the competence \nnetwork subprojects B/1 (computer-based application systems) and B/2 (data protection and data security) as well as with Telematics platform of the medi-cal competence networks of the BMBF (TMF). Regarding the subproject B/1 and DOSPO the database of the RDE is based on the developed \u201ebasic data-base\u201c, which makes it easy to exchange data between DOSPO and the RDE system. The integration of data exchange between DOSPO and the RDE sys-tem will be a mandatory issue of the RDE. By restricting the database of the RDE to the \u201ebasic database\u201c this RDE can be transferred to other study cen-ters.\nC.3 Work plan \nThe work plan outlined below contains work packages of the further test of indi-\nvidual teleradiology systems for point-to point connections, as originally proposed in the first application for funding. These efforts will, however, be reduced in ex-tensiveness as compared to the former proposal. Instead, for reasons outlined in B.3 and C.1-C.2 above, a new major project focus will be implemented regarding the evaluation of possibilities for the implementation of a KPOH central electronic image clearing institution.\nFor time schedule of deliverables, and for responsible partners, see the table in \nthe annex. See part D.1 further below for individual allocation of tasks to deliver-ables and personnel positions.  \nC.4 Networking  \nThe discussion about the implementation of a central electronic image clearing \ninstitution is under way, delivering the potential to participate by means of elec-tronic remote data entry and image communication systems in nation-wide or even international internet based electronic image (and data) exchange services. This will open the opportunity to all network participants and eventually to other interested institutions to enter electronic images and to discuss difficult cases with participating colleagues. Eventually, an expert panel for specialist consulta-tion could be set up, e.g. involving the reference specialists of the established GPOH trial centers. Moreover, an anonymised image archive could serve teach-ing or scientific needs. Finally, the technology could be used for other purposes, e.g. remote data entry for documentation and monitoring of clinical trials in Pedi-atric Oncology, or even similar purposes in other medical disciplines. A close co-operation regarding these aspects within the competence network projects A (co-93ordination) and B/1 and B/2 (documentation system for Pediatric Oncology, \nDOSPO; data confidentiality and security) is mandatory. Networking contacts to other networks and other partners in medical care are warranted.\nSuch tools could hence be used in the implementation of several other projects of \nthe competence network, and would readily increase networking activities among the competence network partners and ultimately all KPOH and GPOH institu-tions. This would foster performance and efficacy of several existing and potential future projects, and add to rational use of resources.\nPart D- Requested Funding for the Project \nD.1 Salaries\n M\u00fcnster Homburg/\nSaarHalleBerlin / \nCharit\u00e9W\u00fcrzburg Total \n2003 55000 55000 27500 27500 27500 192500 \n2004 55000 55000 27500 27500 27500 192500 \nIndividual tasks of project personnel: \nM\u00fcnster (1 scientist, medical informatics, 55000 \u20ac per annum) \nGeneral:\n\u0083 General project co-ordination and structural conception (permanent)  \n\u0083 General project reports (annual reports, final report)\nPoint-to-point telemedicine applications:  \n\u0083 Installation of local test systems (co-operation with\nHomburg, Berlin, W\u00fcrzburg, Halle; before 12/2002)\n\u0083 Technical tests (co-operation with Homburg, Berlin,  \nW\u00fcrzburg, Halle; before 03/2003)\n\u0083 Practical tests in clinic routine (co-operation with\nHomburg, Berlin, W\u00fcrzburg, Halle; before 09/2003)\n\u0083 Feasibility report, suggestions for implementation (co-operation  \nwith Homburg, Berlin, W\u00fcrzburg, Halle; before 12/2003)\nCentral electronic image clearing institution concept:Evaluation of acceptance, organizational co-ordination: \u0083 Definition of expectations, tasks and structures for a central electronic image \nclearing institution architecture (in co-operation with Homburg, Berlin; before \n06/2003)\n\u0083 Acceptance report, suggestions for implementation (in  \nco-operation with Homburg, Berlin; before 03/2004) \nAnalysis of technical requirements for set-up and maintenance: \u0083 Survey of security infrastructure (e .g. firewalls) at participating hospitals; co-\nordination with project B2 data security (Co-operation with Berlin, Homburg; \nbefore 06/2003)94\u0083 Survey of secure connectivity products (e.g. virtual private network software) \navailable (in co-operation with Berlin, Homburg; before 06/2003) \n\u0083 Analysis of staff and financial requirements for central electronic image clear-\ning institution architecture (in co-operation with Berlin, Homburg; before \n06/2003)\n\u0083 Technical feasibility report (in co-operation with\nBerlin, Homburg; before 09/2003) \nTest installation of central electronic image clearing institution functionality  \u0083 Set-up sketch for eventual central electronic image clearing institution  \narchitecture (in co-operation with Berlin, Homburg; before 06/2003) \n\u0083 Test installation of central electronic image clearing server\n(in co-operation with Berlin, Homburg; before 06/2003) \n\u0083 Function tests (Co-operation with Homburg, Berlin,  \nW\u00fcrzburg, Halle; before 09/2004) \n\u0083 Feasibility report on central electronic image clearing institution  \nconcept (Co-operation with Homburg, Berlin; before 12/2004) \nHomburg (1 scientist, medical informatics, 55000 \u20ac per annum)\nPoint-to-point telemedicine applications:  \u0083 Installation of local test systems (co-operation with\nM\u00fcnster, Berlin, W\u00fcrzburg, Halle; before 12/2002)  \n\u0083 Technical tests (co-operation with M\u00fcnster, Berlin,  \nW\u00fcrzburg, Halle; before 03/2003)\n\u0083 Practical tests in clinic routine (co-operation with\nHomburg, Berlin, W\u00fcrzburg, Halle; before 09/2003)\nCentral electronic image clearing institution concept:Evaluation of acceptance, organizational co-ordination: \u0083 Co-ordination with project B/1 DOSPO (co-operation\nwith Berlin, M\u00fcnster; 01/2003- 03/2004)  \nTest installation of central electronic image clearing institution functionality  \u0083 Function tests (Co-operation with M\u00fcnster,\nBerlin, W\u00fcrzburg, Halle; before 09/2004)\nRemote Data Entry (RDE) for GPOH Trials  \u0083 Analysis of available RDE systems (co-operation\nwith Berlin, M\u00fcnster; before 12/2003)  \n\u0083 Test implementation of an RDE system for the SIOP 2001 / GPOH trial \n(co-operation with Berlin, M\u00fcnster; before 03/2003)\n\u0083 Establishment of DOSPO (project B) compatibility  \n(co-operation with Berlin, M\u00fcnster; before 06/2003)\n\u0083 Evaluation of the established RDE for the SIOP 2001/ GPOH  \n(co-operation with Berlin, M\u00fcnster; before 09/2003)\n\u0083 Evaluation of RDE for other GPOH trials (co-operation\nwith Berlin, M\u00fcnster; before 09/2004) \n\u0083 RDE feasibility report, suggestions for implementation  \n(co-operation with Berlin, M\u00fcnster; before 12/2004) 95Berlin (1/2 scientist, medical informatics, 55000 \u20ac per annum)\nPoint-to-point telemedicine applications:  \n\u0083 Installation of local test systems (co-operation with\nM\u00fcnster, Homburg, W\u00fcrzburg, Halle; before 12/2003)\n\u0083 Technical tests (co-operation with M\u00fcnster, Homburg,\nW\u00fcrzburg, Halle; before 03/2003)\n\u0083 Practical tests in clinic routine (co-operation with M\u00fcnster,  \nHomburg, W\u00fcrzburg, Halle; before 09/2003)\nCentral electronic image clearing institution concept:Evaluation of acceptance, organizational co-ordination: \u0083 Co-ordination with telematic-platform, and project A  \n(co-operation with M\u00fcnster, Homburg; 1/2003-3/2004) \n\u0083 Co-ordination with project B/2 \u201eData Security, Knowledge Server\u201c \n(co-operation with M\u00fcnster, Homburg; before 3/2004) \nTest installation of central electronic image clearing institution functionality  \u0083 Function tests (co-operation with M\u00fcnster, Homburg,  \nW\u00fcrzburg, Halle; before 09/2004) \nHalle (1/2 scientist, medical informatics, 27500 \u20ac per annum)\nPoint-to-point telemedicine applications:  \u0083 Installation of local test systems (co-operation with\nM\u00fcnster, Homburg, Berlin, W\u00fcrzburg; before 12/2002)  \n\u0083 Technical tests (co-operation with M\u00fcnster, Homburg,\nBerlin, W\u00fcrzburg; before 03/2003)  \n\u0083 Practical tests in clinic routine (co-operation with M\u00fcnster,  \nHomburg, Berlin, W\u00fcrzburg; before 09/2003)\nCentral electronic image clearing institution concept:Test installation of central electronic image clearing institution functionality  \u0083 Function tests (co-operation with M\u00fcnster, Homburg,  \nBerlin, W\u00fcrzburg; before 09/2004) \nW\u00fcrzburg (1/2 scientist, medical informatics, 27500 \u20ac per annum)\nPoint-to-point telemedicine applications:  \u0083 Installation of local test systems (co-operation with\nM\u00fcnster, Homburg, Berlin, Halle; before 12/2002)\n\u0083 Technical tests (co-operation with M\u00fcnster,\nHomburg, Berlin, Halle; before 03/2003)\n\u0083 Practical tests in clinic routine (co-operation with\nM\u00fcnster, Homburg, Berlin, Halle; before 09/2003)\n\u0083 Central electronic image clearing institution concept:  \n\u0083 Function tests (co-operation with M\u00fcnster, \nHomburg, Berlin, Halle; before 09/2004).96D.2 Consumables\nTo guarantee permanent availability of central electronic image clearing institu-\ntion functionality:  \n\u0083 Maintenance: hardware, software: 3000 \u20ac  \n\u0083 Backup media (streamer tapes): 1000 \u20ac  \n\u0083 Permanent storage media (DVD, CD-ROM) and other consumables: 1000 \u20ac  \nTotal: 5000 \u20ac\nD.3 Investments\n\u0083 Hardware: webserver (available from first funding period): 0 \u20ac\n\u0083 Software: webserver, RDE: 5000 \u20ac  \nTotal: 5000 \u20ac\nD.4 Other Costs \nTo help in setting-up of hardware and software, to present results on network and \nnon-network meetings, to establish co-operation between partners within the pro-ject, with other network projects, with the telematic platform, and with other net-works. Total: 3000 \u20ac97Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Molecular Parameters of\n  Drug Resistance (Project D) \nGrant No. : 01 GI 99 61 \nName of scientist-in-charge : Dr. med. Karsten Stahnke (responsible) \n  Univ.-Prof. Dr. Klaus-Michael Debatin \nInstitution : University Children\u2019s Hospital \nAddress : Prittwitzstr. 43 \nPhone : +49 (0) 73 1 \u2013 50 0 \u2013 27 71 3 \nFax :  +49 (0) 73 1 \u2013 50 0 \u2013 26 76 5 \nE-mail : karsten.stahnke@medizin.uni- \n  ulm.de \nProject home page (if different from \nNetwork homepage) : ------------------------------------------------------------------------------------------ 98Part A - General Statements about the Project\nA.1.Subject\nMolecular parameters of drug resistance\nA.2. Co-Investigators\n\u0083 Prof. Dr. W. D. Ludwig und Dr. L. Karawajew,\nRobert-R\u00f6ssle-Klinik, Charit\u00e9, Berlin \n\u0083 Prof. Dr. G. Janka-Schaub, Universit\u00e4tskinderklinik Hamburg\nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 79 23 75 3 0 180 \n2004 79 23 75 3 0 180 \n1(amounts in thousand Euro), \n * should correlate to funds specified in Part D99Part B \u2013 Results from the First Funding Period\nB.1 Summary \nProgress in the treatment of acute leukemia has been achieved by development \nof empirically designed chemotherapy protocols applying different cytostatic drugs in an optimized time course. Still, primary chemo- resistance or reemer-gence of a drug resistant leukemic clone is a major problem in the treatment of acute leukemia. It has been shown that cytotoxic drugs used in anti-cancer che-motherapy induce the physiologic program of apoptosis by activation of apoptosis signaling molecules. Functional defects in apoptosis molecules or inhibition of activation of apoptosis signaling pathways may therefore be responsible for resis-tance and treatment failure of malignant diseases. This project aims at the identi-fication of molecular parameters for prediction of treatment failure by analysis of function and expression of apoptosis molecules.  \nIn a corporation of three different laboratories in Ulm, Berlin and Hamburg, 6 sci-\nentists are working on a) standardization of material acquisition for analysis of apoptosis signaling molecules b) the establishment of a functional assays for the assessment of drug sensitivity and resistance in primary leukemia cells c) the development of new methods for the detection of activated apoptosis signaling and d) the detection of apoptosis signaling during in vivo chemotherapy. Methods have been established for standardized acquisition and storage of patient mate-rial for future analysis in expression and function assays. We have developed a drug independent assay, which tests the functional ability for activation of apop-tosis pathways in primary leukemia cells. A major focus of the project was the development of methods for measurement of activated apoptosis signaling path-ways in primary cells. A new method for flow cytometric detection of mitochon-drial cytochrome c release (patent pending) has been developed and evaluated for detection of deficient mitochondrial signaling in resistant cells. Application in primary leukemia cells demonstrated a heterogeneous pattern of mitochondrial apoptosis signaling in different leukemia samples.  \nFurther analysis will be performed on the basis of a larger set of samples. Inves-\ntigation of apoptosis induction by chemotherapy in vivo revealed that apoptosis is predominantly induced in immature CD34 positive leukemia cells, indicating dif-ferential sensitivity among leukemia subpopulations. In the second funding pe-riod, these assays capable of detecting deficient mitochondrial or caspase apop-tosis signaling on a single cell level will be performed on a large number of pa-tient samples. In addition, mutation and expression analysis of apoptosis genes will be performed by sequencing and with a c-DNA array system respectively. \nB.2 Original aims of the project \nGeneral aim: \nIdentification of molecular parameters for prediction of the individual risk for \ntreatment failure by analysis of function and expression of apoptosis molecules.  \nSpecific aims:\n1. Development of an acquisition system for collection of patient  100material for cellular-, protein-, RNA- and DNA-analysis.  \n2. Development of methods for measurement of\napoptosis signaling in primary leukemia cells.  \n3. Analysis of leukemia cell apoptosis in drug response assays. 4. Identification of apoptosis gene mutations inferring drug resistance. 5. Analysis of apoptosis gene expression profiles for\nthe prediction of drug resistance. \n6. Identification of apoptosis signaling in peripheral leukemia\ncells activated by in vivo chemotherapy.\nB.3 Scientific results \nB.3.1.\nIn a cooperative work, procedures for acquisition of patient material were tested \nand general strategy for isolation, handling, storage and shipment of patient samples established. It turned out that the average amount of patient cells is not sufficient for a separate storage of cells, RNA and DNA. Therefore, all cells ob-tained in the study laboratory are stored as viable cells in DMSO permitting fur-ther expression analysis on cellular level as well as RNA and DNA expression. In addition, it was decided to perform the analysis in sequence i.e. the material ob-tained is primarily used for cellular drug response assays until a sufficient number of samples has been obtained, in a second step expression analysis of apoptosisgenes will be performed.\nB.3.2.\nMajor focus of the project was the development of a method for the detection of \napoptosis signaling in primary leukemia cells. Bulk methods using lysates of cells turned out to be of insufficient sensitivity for the detection of apoptosis in primary cells. In addition, we found that apoptosis is predominantly induced in a subset of leukemia cells (see 6). We therefore developed flow cytometric methods for the analysis of apoptosis permitting analysis on a single cell basis. In this project, we first analyzed a method for the simultaneous detection of caspase activation and mitochondrial membrane potential developed in our group.\nWe found that mitochondrial membrane permeability transition is not a common \nfeature of apoptosis in leukemia cells, thereby limiting the applicability of MMP measurement for detection of apoptosis. Caspase activation could reliably be de-tected in cell lines by fluorogenic caspase substrates developed in our group. However, in primary leukemia cell no such activity could be detected upon induc-tion of apoptosis. In summary, this method is a reliable research tool for detection of caspase and mitochondrial activation in cell culture systems but not for analy-sis of primary leukemia cells (manuscript in preparation). Since deficient activa-tion of mitochondrial apoptosis signaling may be responsible for drug resistance, we developed another method specifically aiming at detection of mitochondrial cytochrome c release. The release of cytochrome c from mitochondria to the cy-tosol represents an early and specific step of apoptosis signaling, activating fur-ther downstream events like caspase cleavage. We developed a method for the detection of cytochrome release in intact cells by flow cytometry. Jurkat T cell leukemia cells, mitochondrial cytochrome c release could be detected in CD95 receptor, and cytotoxic drug induced apoptosis.101A good correlation was found to results obtained in conventional immunoblotting \nand fluorescence microscopy. Differential requirement for mitochondrial signaling in CD95 induced apoptosis in SKW (type I) and Jurkat (type II) was detected by the method. By simultaneous measurement of cytochrome c release and active caspase-3 in multicolor flow cytometry, we identified deficient mitochondrial apop-tosis signaling in the presence of caspase-3 activation in Jurkat cells overex-pressing Bcl-2. In addition, we found the method to be applicable for analysis of primary leukemia cells identifying heterogeneous patterns of mitochondrial signal-ing and caspase activation. This method will now be applied for analysis of a lar-ger number of primary leukemia cells in combination with the functional apoptosis response assay (see 3). The method is currently being patented.\nB.3.3.\nAnother focus of the project was the analysis of leukemia cell apoptosis in drug \nresponse assays. This part of the project aimed at the identification of apoptosis signaling pathways specifically induced by different cytostatic drugs. Since a large number of leukemia cells are stored as frozen samples in Berlin and Ham-burg, we first analyzed whether functional drug response assays could be per-formed with frozen material. Since the clinical course of the patients over the last 4 to 5 years is known, experimental data could have been directly correlated to a clinical outcome. We found that in B precursor ALL samples, apoptosis was gen-erally high, and specific drug-induced apoptosis after 12 to 16 hours incubation with cytostatic drugs could not be detected. Results also varied with time of stor-age. In summary, we found frozen samples generally not applicable for apoptosis sensitivity assays. In the second funding period, it is therefore necessary to per-form these assays with fresh material. In order to collect sufficient number of samples, the assays will be performed in all three participating laboratories in parallel (see C.2).\nWe therefore investigated fresh material obtained either at the Children\u2019s Hospital \nin Hamburg and Ulm or material sent to Berlin over night. Again in about 30 to 50% of B precursor ALL samples drug specific apoptosis could not be detected after 16 hours incubation probably due to high spontaneous apoptosis. In another subproject, we analyzed kinetics of drug-induced apoptosis in precursor B and T leukemia derived p53 proficient cell lines. We found different kinetics in different drugs, for example early induction of apoptosis by etoposide and cyclophos-phomide and late induction more than 24-48 hours for vincristin. These data are complemented by analysis of a cell cycle dependency of drug-induced apoptosis demonstrating that in some cells, apoptosis induction depends on cell cycle entry. Taken together, these data suggest that treatment of primary leukemia cells in vitro requires a 24 to 48 hours incubation, which conflicts with the high spontane-ous apoptosis of B precursor leukemia cells. In order to overcome this problem, we further divided the project into 2 parts. First, we developed an apoptosis sen-sitivity assay aiming at detection of apoptosis signaling in primary leukemia cells upon unspecific stress induction, for example staurosporine. With this approach,we overcome the problem of high spontaneous apoptosis upon prolonged in vitro cultivation. The method permits measurement of general apoptosis sensitivity and induction of caspase activation and mitochondrial apoptosis signaling. The method has been established in the study laboratory in Berlin.\nThe first results show a heterogeneous pattern of apoptosis induction in 6 primary \nALL samples analyzed until now. The method will be further applied in a large-102scale analysis of primary samples in Berlin and Hamburg after modification and \noptimization of the assay.  \nIn order to address the question of differential sensitivity towards different cy-\ntostatic drugs, we are currently working on the optimization of culture conditions by supplementation with cytokines or co-incubation with feeder cells. In addition, we will investigate whether the analysis of remaining leukemia cells after 48 hours in culture by gated acquisition permits prediction of drug sensitivity or resis-tance.\nB.3.4.\nWithin a project for analysis of apoptosis gene mutations in our group, methods \nfor bax gene mutations have been established on RT-PCR level. Methods were evaluated by analysis of bax mutations in established cell lines. Additional fund-ing is required for analysis of large number of patient samples. Funding will be applied for at the Deutsche Krebshilfe. \nB.3.5.\nAnalysis of apoptosis gene expression profiles for prediction of drug resistance. \nThe development of a cDNA chip for analysis of apoptosis gene expression has made further progress. In cooperation with a local company (Interactiva Ulm), we have developed an apoptosis gene chip consisting of 96 positions with 10 con-trols and 86 apoptosis genes. The 96 cDNAs have now been completely synthe-sized. The PCR products will now be amplified for the production of the first set of arrays. The chip has been successfully evaluated with cell lines using controls and a limited set of a major apoptosis regulators like caspase-3. \nB.3.6.\nIdentification of apoptosis signaling peripheral leukemia cells activated by in vivo \nchemotherapy. In this part project we analyzed depletion and induction of apop-tosis during the acute phase of leukemia cell reduction in patients with AML and \nALL undergoing first cycle chemotherapy. Since it has recently been shown that \nleukemia arises from immature leukemia stem cells positive for CD34, we ana-lyzed apoptosis induction in the subset of CD34 positive peripheral blood leuke-mia cells. We found expression of CD34 on leukemic blasts in 20 of 23 cases and the proportion of leukemia cells expressing CD34 varied from 0% to 85.7% and 1.5% to 74.5% in AML and ALL patients respectively. During chemotherapy, CD34+ leukemia cells were more rapidly depleted than CD34- cells. Furthermore, a significant increase in leukemia cell apoptosis ex vivo in this immature sub-population was detected during treatment, while no such increase was observed in the CD34- subpopulation. In vitro treatment of ALL and AML leukemia cells with cytostatic drugs did not constantly result in predominant induction of apop-tosis in CD34 positive leukemia cells, indicating different conditions for apoptosis induction in vivo and in vitro. CD95 expression and sensitivity on both CD34 posi-tive and negative subpopulations remained low during in vivo chemotherapy and upon in vitro drug treatment, suggesting induction of apoptosis in peripheral leu-kemia cells independent of the CD95 system. These data indicate that in vivo chemotherapy for remission induction eliminates leukemia cells by induction of apoptosis especially in an immature subpopulation of CD34+ cells. These results underline the necessity for analysis of apoptosis induction on a single cell level (manuscript in preparation). 103B.4 Publications and patents \nStrau\u00df G, Osen W, Debatin K-M. Clin. Exp. Induction of apoptosis and modula-\ntion of activation and effector function in T cells by immunosuppressive drugs. Immun. 200, In Press\nWuchter C, Ruppert V, Schrappe M, Dorken B, Ludwig WD, Karawajew L. In vitro \nsusceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of  maturation stage, responsiveness to IL-7 and early cytoreduction in vivo in childhood T-ALL. Blood 2002, In Press\nStahnke K, Fulda S, Friesen C, Strauss G, Debatin KM Activation of apoptosis \npathways in peripheral blood lymphocytes by in vivo chemotherapy Blood 2001,98:3066-7330\nHerr I, Debatin K-M . Cellular stress response and apoptosis in cancer therapy. \nBlood 2001,98: 2603-2614 \nWuchter C, Krappmann D, Cai Z, Rup-pert V, Scheidereit C, Dorken B, Ludwig \nWD, Karawajew L. In vitro susceptibility to TRAIL-induced apoptosis of acute leu-kemia cells in the context of TRAIL receptor gene ex-pression and constitutive NF-kappa B activity. Leukemia  2001,15:921-8 \nCai Z, Lin M, Wuchter C, Ruppert V, Dorken B, Ludwig WD, Karawajew L. Apop-\ntotic response to homoharring-tonine in human wt p53 leukemic cells is inde-pendent of reactive oxygen spe-cies generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation.  Leukemia 2001;15:567-74\nWuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, Dorken B, \nLudwig WD. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induc-tion che-motherapy and relapse rate in child-hood acute lymphoblastic leukae-mia. Br J Haematol 2000;110:154-60 \nKarawajew L, Ruppert V, Wuchter C, Kosser A, Schrappe M, Dorken B, Ludwig \nWD. Inhibition of in vitro spontaneous apop-tosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophe-notype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood 2000;96:297-306\nFulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitize for CD95 (APO-\n1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000;60:3947-56\nBeltinger C, Fulda S, Kammertoens T, Uckert W, Debatin KM. Mitochondrial am-\nplification of death signals determines thymidine kinase/ganciclovir-triggered acti-vation of apoptosis. Cancer Res 2000;60:3212-7 \nPatent applications\n\u201eMethod of detecting release of substances from cell organells by means of flow \ncytometry\u201c (USA: US-09-987,206; Germany: 10155518.0; as of 13.11.2001).  104B.5 Networking \nIn the first funding period, a close collaboration between the study laboratories \nwas established. New methods were developed in basic research (Ulm) and ap-plied for patent. These methods could immediately be established in the clinical reference laboratories in Berlin and Hamburg for evaluation with primary material (transfer of know-how). Thereby, a new structure for translational research was established, which would not have been possible without the network. 105Part C \u2013 Follow-Up Proposal \nC.1 Aims\nGeneral aim:\nIdentification of molecular parameters for prediction of the individual risk for \ntreatment failure by analysis of function and expression of apoptosis molecules. Perspective: Individual risk adapted therapy and identification of molecular target structures for future development of leukemia therapy. The general aim and per-spective is still relevant and achievable. The specific aims were modified accord-ing to the results of the first funding period. \nHypotheses and Objectives:\n1. Hypothesis: The leukemia cells\u2019 constitutive capability of efficiently activating \napoptosis signaling pathways is a major prognostic factor for treatment out-come.Objective: Analysis of caspase activation and mitochondrial signaling by in vi-tro culture and conditions of factor deprivation, chemical stress and caspase inhibition.\n2. Hypothesis: Deficient activation of apoptosis signaling pathways in the pri-\nmary leukemia cells upon in vitro treatment with different drugs predicts drug resistance in vivo and identifies resistance towards a specific drug. Objective: Analysis of caspase activation in mitochondrial apoptosis signaling upon in vitro drug treatment in T-\nALL ad AML. Development of an in vitro drug \nsensitivity assay based on measurement of activated apoptosis signaling pathways for B precursor ALL. \n3. Hypothesis: Drug resistance in leukemia is caused by loss of function muta-\ntions in mitochondrial apoptosis signaling molecules.    \nObjective: Analysis of Bax mutations in drug resistant leukemia.\n4. Hypothesis: Apoptosis gene expression is a predictive parameter for drug re-\nsistance and sensitivity.   Objective: Analysis of apoptosis gene expression in correlation to clinical out-come and functional apoptosis assays.  \n5. Hypothesis: Analysis of apoptosis related functional changes in leukemia cells \nduring in vivo chemotherapy permits monitoring of drug efficacy. Objective: Detection of molecular changes during in vivo chemotherapy and development of assays for the detection of early proapoptotic changes in leu-kemia cells.\n6. Hypothesis: The risk of relapse can be assessed by analysis of drug-induced \nchanges in the stem cell compartment of leukemia cells.Objective: Analysis of SCID repopulating activity of primary leukemia samples treated with different cytostatic drugs. \n7. Structural aim: Establishment of a central database for the study laboratories \ncompatible with databases of the clinical studies.106C.2 Methodological approach \nDue to the results from the first funding period, the methodological approach is \nmodified as follows. We will establish an apoptosis sensitivity assay based on rapid induction of apoptosis by staurosporine. With this approach, it will be pos-sible to overcome the problem of high spontaneous apoptosis in primary B precursor ALL samples. Upon incubation with staurosporine, induction of apoptosis signaling pathways via caspase activation and mitochondrial cytochrome c release will be measured. The assay is currently standardized and will be applied in large scale in the second funding period. With this approach, it will be possible to characterize constitutive apoptosis resistance/sensitivity in primary leukemia cells, irrespective of drug sensitivity. The aspect of drug specific sensitivity or resistance will be further pursued by development of a long-term assay which permits analysis of drug effects in primary leukemia cells (see section B3 and C3). In order to prolong viability of leukemia samples, different culture conditions will be tested such as composition of culture media, addition of feeder cells and addition of cytokines.  \nSince frozen samples are not suitable for analysis in functional assays (see \nB.3.3), all assays have to be performed in the participating laboratories in paral-lel with fresh material. This requires additional logistical effort concerning transfer of know how and data management. In order to meet these requirements, we plan to establish a central database for experimental data, which is accessible via internet and is compatible with databases of clinical studies (see C.1.7).  \nExpression analysis will be done by RNA expression array as described in B3. In \naddition to the indicated modifications of our methodological approach, we will establish a human leukemia mouse model using the NOD/SCID system, whichwill be established in corporation with Dr. Iduna Fichtner, Max Dellbr\u00fcck Center (MDC) Berlin-Buch. With this method, we will address questions of chemosensi-tivity and resistance in the leukemia stem cell compartment.\nC.3 Work plan \n1. Objective: Analysis of caspase activation and mitochondrial signaling by in \nvitro culture and conditions of factor deprivation, chemical stress and caspase inhibition.   Primary leukemia cells sent to the study laboratories are isolated and cultured for different incubation times under conditions of a factor of deprivation (me-dium alone), induction of a chemical stress ( e.g. staurosporine) and caspase inhibition (zVad-fmk). Apoptosis is assessed by PI-annexin staining after de-fined time points, mitochondrial cytochrome c release and caspase-3 activa-tion is measured in subsets of leukemia cells by flow cytometry. Data are ana-lyzed in conventional dot blots and by algorithms on list mode data. First, chemical stress and caspase inhibition assay is standardized in the study laboratory in Berlin, in corporation with Hamburg and Ulm. A database for ex-perimental data is established. In a second step, the assay is applied in all study laboratories on freshly sent samples from the pediatric ALL and AML studies. Clinical and data from the Co\nALL and BFM studies are implemented \nin the database and analyzed together with the experimental data for prog-nostic significance. Tools for data analysis will be developed. \n2. Objective: Analysis of apoptosis signaling upon in vitro treatment with cy-\ntostatic drugs.   Based on the results of the first funding period, we are now able to perform an in vitro drug sensitivity assay with different cytostatic drugs with the endpoint 107of caspase and mitochondrial activation analysis. Samples sent to the study \nlaboratories will be cultured with a defined panel of cytostatic drugs for a de-fined time period. The method is established and is currently standardized. Analysis will be performed for T-\nALL and AML samples since these leukemias \nshow low background apoptosis facilitating detection of drug specific apop-tosis. Since the frequency of these leukemias is low in childhood, assays will be performed during the whole second funding period. Due to the high back-ground apoptosis of B-precursor leukemias, which represent the majority of childhood acute leukemias, this assay is not generally applicable for this dis-ease (see B3). Therefore, a long term assay will be developed in order to pre-serve viability of B-precursor ALL cells for a time sufficient to analyze drug ef-fects (see C2). After successful establishment, this assay will also be stan-dardized and applied in the study laboratories. \n3. Objective: Analysis of Bax mutations in drug resistant leukemia.  \nDrug resistant leukemias as defined by the clinical non-response or identified by functional assays in subproject 1 or  2 will be analyzed for Bax mutations \nand related mitochondrial apoptosis signaling molecules. This work will be performed within a broader project for analysis of apoptosis gene mutations in our group. The currently established method of Bax mutation analysis by RT-PCR will be substituted by sequencing of genomic DNA, once the genomic sequence of the Bax gene is available.\n4. Objective: Analysis of apoptosis gene expression in correlation to clinical out-\ncome and functional apoptosis assays.   In this part-project, we will apply the apoptosis gene chip developed in our \ngroup. The chip is currently produced. It will be validated in the first six months of the second funding period. Spotting and hybridization procedures will be optimized for primary samples. RNA preparation will be optimized for array analysis. Acquisition of RNA samples will be performed in the study laboratory according to the standardized RNA preparation protocol. Expres-sion analysis will be done in the chip facility in Ulm. Tools for data analysis are currently developed and have to be modified for implementation of clinical data.\n5. Objective: Analysis of apoptosis during in vivo chemotherapy.   \nWe will analyze p53 induction in leukemia cells by a flow cytometric method currently developed in our group: by this method it will be possible to detect p53 localization to the nucleus in combination with surface marker analysis. The method will be standardized in the second funding period and consecu-tively applied in the study laboratories.  In addition, we will develop methods \nfor detection of functional changes in leukemia cells applying fluorogenic sub-strates indicative for protease activation, radical oxygen production and ph-changes.\n6. Objective: Analysis of drug-induced changes in the leukemia stem cell com-\npartment.In corporation with MDC Berlin Buch, we will analyze SCID repopulating activ-ity of leukemia cells after drug treatment in vitro. Representative human transplantable leukemia cell lines will be established. Retransplantation char-acteristics upon drug treatment will be characterized. \n7. Objective: Establishment of a central data base for experimental data.   \nSince a main part of research work is performed on fresh primary samples in three different laboratories in parallel, exchange of data between the study laboratories will be important. The requirements for an IT solution are best 108met by a central database accessible via internet. All reports will be anony-\nmous and will identify patients by unique patient number UPN. Data will be reported to the central database by browser based data entry. We plan to use the browser base ProMISe Project Manager Internet Server system as the data management system of the subproject. Users are able to enter experi-mental data directly over a secure internet connection. All users have access to the same copy of the entire project, but users can download their own data for analysis. The Promise is used by other ongoing European projects. In par-ticular, the European group for blood and bone marrow transplantation (EBMT) has implemented promise as a data management system in 1999. Within the GPOH, the Pediatric Stem Cell Registry (Th. Klingebiel, Frankfurt) is currently establishing a Promise based database, which is localized at the University of Essen. In cooperation with this project (O. Basu, Essen) and the department of medical statistics section advanced data management at the Leiden University Medical Center (Ronald Brand) a solution could be set up within 9 months. The use of promise has been discussed with the Telematic platform for the planned network \u201eacquired disorders of hematopoesis in chil-dren and adults, Aplastic anemia and related disorders\u201d in the BMBF program \u201erare diseases\u201d (H. Schrezenmeier, Berlin). The design of the database is easy to perform and does not require additional personell for this project. The costs for database set up and work in the Department of Medical Statistics Leiden or Universit\u00e4t Essen can be roughly estimated at approximately 10000 \u20ac\u00a4 per year (FuE contract). Results from this developmental work could be used by other laboratories in the network.\nFor the table of Tasks and Milestones, please refer to the appendix. \nC.4 Networking  \nWithin this project, a close collaboration has been established between study \nassociated reference laboratories (Berlin and Hamburg) and basic research group (Ulm). New methods developed in basic research are immediately trans-fered to the clinical laboratories and evaluated with primary patient material (transfer of know-how). Since it turned out that shipment of frozen material is not a suitable approach for this research project, an even closer collaboration is necessary in the second funding period. The establishment of a common data-base for the study laboratories compatible to databases of clinical studies is an-other important contribution to a long-term constitution of stable structures for future research projects.  \nThrough this close collaboration, we will contribute to the networks aim of estab-\nlishment of new research structures connecting clinical and basic research. In addition, experimental data obtained from this project will be analyzed together with clinical data obtained from clinical studies in the network. The scientific pro-gress obtained by this corporation represents an added value that would not have been achieved without the network. 109Part D- Requested Funding for the Project \nD.1 Salaries\nScientist BAT IIa: The scientist is responsible for the establishment and stan-\ndardization of the functional apoptosis assay as stated in (C.3.1 and C.3.2). In addition, the scientist will be responsible for the further development of assays for detection of early functional changes associated with apoptosis as stated in C.3.5 and will be involved in analysis of apoptosis gene expression (C.3.4):2003 \u2013 56000 \u20ac, 2004 \u2013 57000 \u20ac\u00a4 \nTechnician BAT Vb1/2 for the work on the large amount of clinical samples: \n2003 \u2013 22000 \u20ac, 2004 \u2013 22000 \u20ac\u00a4 \nChange compared to the first funding period: + 1/2 BAT Vb. \nD.2 Consumables\nConsumables are required for cell culture media, monoclonal antibodies, fluoro-\ngenic substrates for flow cytometry and cytostatic drugs.  \nRequested amount: 2003 \u2013 23000 \u20ac, 2004 \u2013 23000 \u20acNo change compared to first funding period. \nD.3 Investments\nInvestment is needed for financing the employees working in Berlin and Ham-\nburg (FuE Vertrag): \nUniversity Hospital Charit\u00e9 Berlin \u2013 1 Bat Vc (Czervony, Grit) University Hospital Hamburg Eppendorf \u2013 1 BAT IV b (Biermann, Birgit) Requested amount: 2003 \u2013 75000 \u20ac, 2004 \u2013 75000 \u20ac \nD.4 Other Costs \nTravel expenses: 2003 \u2013 3000 \u20ac, 2004 \u2013 3000 \u20ac.110Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Characterisation of Pre-Leukemic  \n  Bone Marrow Disorders (Project E) \nGrant No. : 01 GI 99 62  \nName of scientist-in-charge : Univ.-Prof. Dr. med. Charlotte Niemeyer \nInstitution : Klinik IV: P\u00e4diatrische Onkologie\n  und H\u00e4matologie \n  Zentrum f\u00fcr Kinderheilkunde und  \n  Jugendmedizin \n  Universit\u00e4t Freiburg \nAddress : Mathildenstrasse 1 \n  79106 Freiburg \nPhone : +49 (0) 76 1 \u2013 27 0 \u2013 45 06 \nFax : +49 (0) 76 1 \u2013 27 0 \u2013 45 18 \nE-mail : niemeyer@kikli.ukl.uni-freiburg.de \nProject home page (if different from \nNetwork homepage) : ------------------------------------------------------------------------------------------ 111Part A - General Statements about the Project\nA.1.Subject\nCharacterisation of pre-leukemic bone marrow disorders\nA.2. Co-Investigators\n\u0083 Prof. Dr. med. Karl Welte, MHH Kinderklinik, Hannover \n\u0083 Prof. Dr. med. Christine Bender-G\u00f6tze, Dr. med. Monika F\u00fchrer,\nKinderpoliklinik der Universit\u00e4t M\u00fcnchen \n\u0083 Dr. med. W. Ebell, Charit\u00e9 Campus Virchow-Klinikum, Klinik f\u00fcr  \nAllgemeine P\u00e4diatrie und Knochenmarktransplantation, Berlin \n\u0083 Prof. Dr. rer. nat. Jochen Harbott, Zentrum f\u00fcr\nKinderheilkunde, Universit\u00e4t Giessen \n\u0083 Prof. Dr. med. R. Schneppenheim, Dr. J. Rischewski,  \nUniversit\u00e4ts-Krankenhaus Eppendorf, Kinderklinik, Hamburg \n\u0083 Dr. med. I. Baumann, Dr. rer. nat. A. Jung,\nPathologisches Institut der Universit\u00e4t Erlangen \n\u0083Prof. Dr. med. A. Schmitt-Gr\u00e4ff, PathologischesInstitut der Universit\u00e4t Freiburg\nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1 Amount1\nRequested \n2003 98,9 20,0 0 0 0 118,9 \n2004 99,4 20,0 0 0 0 119,4 \n1(amounts in thousand Euro), * should correlate to funds specified in Part D112Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe molecular genesis of hematopoietic neoplasm is complex. Different genetic \nabnormalities like defects of cell surface receptors, signal transduction pathways, transcriptions factors or regulators of cell cycle are known to play an important role. Congenital and acquired bone marrow failure disorders can serve as model systems for the study of leukemic transformation in a previously non-malignant hematopoietic system. Because bone marrow failure disorders are rare, our knowledge of the leukemogenesis in these diseases is patchy. Within this net-work, we attempt to characterize pre-leukemic disorders with a systematic and comparative approach. In cooperation with international investigators, we have developed a new classification of myelodysplasia. We performed extensive and consecutive oncogenetic studies and screened for heterozygous mutations of the Fanconi anemia genes. We analyzed the role of G-CSF receptor and RAS muta-tions. In addition, we started to investigate clonality and apoptosis. Overall, these studies have contributed to our understanding of the mechanisms of leukemic transformation.\nB.2 Original aims of the project \nFor all patients/subsets of patients with pre-leukemic disorders:\n\u0083 To evaluate bone marrow aspirates/biopsies by reference pathologists \n\u0083 To perform oncogenetic studies (FISH/banding cytogenetics)\non all bone marrow samples \n\u0083 To study clonality based on polymorphisms of the gene  \nof the androgen receptor (HUMARA) \n\u0083 To study the frequency of heterozygous states of Fanconi\nanemia among patients with pre-leukemic disorders \n\u0083 To study G-CSF receptor mutations  \n\u0083 To study the frequency and importance of activating RAS mutations \n\u0083 To demonstrate apoptosis by TUNEL assay and perform cell cycle analysis \n\u0083 To study the expression of genes involved in apoptosis\nB.3 Scientific results \nPre-leukemic bone marrow disorders are rare diseases in childhood. Official \nguidelines for diagnosis and classification of myelodysplastic syndromes (MDS) have been missing. During the last 2 years, international consensus has been achieved on the classification of pediatric MDS (Submitted: Proposal for the clas-sification of myelodysplastic diseases in children. Henrik Hasle, Charlotte Nie-meyer, Irith Baumann, John M Bennett, Judith Chessells, Gitte Kerndrup, David Head). The current proposal for classification reflects our present knowledge and concepts. It is based in part on the experience we gained by the reference evaluation of all morphological specimens of all patients with suspected pre-\nleukemic bone marrow disorder within this project.  \nDuring the first 24 months of funding about 1700 samples of bone marrow aspi-\nrates/biopsies of patients with suspected or rule-out pre-leukemic bone marrow 113disorders have been evaluated by the MDS or SAA study centers and the refer-\nence pathologists in Erlangen and Freiburg. Because myelodysplasia is not an uncommon finding in sick children, a variety of non-malignant disorders like infec-\ntious diseases, nutritional or metabolic disorders or diseases with mitochondrial de-letions have to be excluded by repeat studies and clinical observation. Eventually, \nabout 1 in 13 patients studied was diagnosed of a pre-leukemic bone marrow dis-order. Of the 114 patients known to be diagnosed of MDS during the study period (data form the Kinderkrebsregister in Mainz) 112 (98%) had at least 1 bone mar-row aspirate or biopsy evaluated by the reference pathologists. During the same period we are aware of 69 patients with congenital bone marrow failure disorders (severe congenital neutropenia, Shwachman syndrome, Fanconi anemia) who had their annual bone marrow evaluations to rule out MDS. Reference morphol-\nogy could be performed in 45 of these children (65%).  \nThe demonstration of chromosomal abnormali ties can be an important mean to di-\nagnose MDS in pre-leukemic bone marrow disorders. Monosomy 7 followed by trisomy 8 are the most common cytogenetic abnormalities. Fluorescence in situ\nhybridization (FISH) can be a rapid and effective method to screen bone marrowsamples for these numerical changes. Un til December 2001 bone marrow mono-\nnuclear cells from 116 children with MDS were analyzed using centromer-specific probes for chromosomes 7 and 8. Monosomy 7 was detected in 37% and 58% of patients with primary and secondary MDS, respectively, while trisomy 8 was noted in 9% of patients with primary MDS. For most cases follow-up samples (2-19 samples) were available to study clone size. Big clones (70-100%) generally remained stable in size. Interestingly, small clones (6-30%) could disappear spontaneously or evolve into big and stable clones. FISH results could be com-pared to standard cytogenetic investigations. Discrepant results were noted in about 10% of cases mostly involving small clones detected by FISH but not by cytogenetics. Current investigations include the use of probes for the long arm of chromosome 7 and FISH on aspirate smears. We believe that we have system-atically studied the biggest cohort of pediatric patients with pre-leukemic bone marrow disorders. Combined with clinical data these results will provide new in-\nsights in the prognostic values of chromosomal changes.\nHypoplastic MDS may be difficult to discriminate from aplastic anemia. Clonal he-\nmatopoiesis is strongly suggestive of MDS. Therefore, evidence of clonality could be an important mean to demonstrate a pre-leukemic state. Clonality studies de-pend on a clonal marker that differs between the normal and tumor cell popula-tion. The HUMARA (human androgen receptor) locus resembles such a marker but unfortunately the highly heterozygous CG rich STR is prone for the genera-tion of hairpin loop superstructures and is thus difficult to amplify in PCRs. To overcome this problem we have modified the HUMARA method (Jung et al., 2002). Consequently, the analyses worked well in about 92 % of leukemias from adult women. However, the modified method failed in most DNA-samples of girls with MDS. The standard HUMARA assay depends on the presence of at least 60 % tumor cells because the PCR is biased for the amplification of DNA contain-ing the shorter STR. To overcome this problem a new technique based on MSP-PCR (methyl specific PCR) was established. We investigated the methylation pattern of the HUMARA locus (position 46-358: accession # M27423) in healthy women by bisulfite sequencing and found a CGCG repeat (position 201-203) that is constantly either methylated or unmethylated on each of the two X-chromosomes. Based on this knowledge new primer sets were designed which take advantage of the fact that treatment of DNA by sodium bisulfite leads to deamination of deoxy-cytidine residues which are converted into deoxy-uracils. 114But in case of methylation of the deoxy-cytidin the base remains unaltered. As in \nmammals only deoxy-cytidins which are followed by a deoxy-guanosine are me-thylated the above mentioned CGCG sequence will be changed into UGUG on the one and kept as CGCG on the other X-chromosome. Based on amplification rates of primer sets ending on CGC (methylated allele) or TGT (unmethylated allele) the distribution of methylation of the template can be analyzed. This new method is currently being evaluated using cases kindly provided by Rosemary Gale, Ph.D. (UC London) for this project. Overall, this project is technically diffi-cult. It is not known whether small clones can reliably be detected. In addition, our studies, like all clonality studies, are hampered by the question of the most appropriate controls For these reasons, we decided to exclude this project from \nour follow-up proposal.\nFanconi anemia is a pre-leukemic bone marrow disorder with a risk of greater \nthan 50% to develop a clonal hematopoietic neoplasm. The risk for heterozygous individuals is not clear, epidemiological data are inconsistent. We screened a to-tal population of 187 pediatric patients suffering from 1\u00b0 or 2\u00b0 MDS and AML for mutations in the Fanconi anemia genes (FANC) to clarify the role of heterozygos-ity as possible risk factor. At least eight different complementation groups (FANCA, B, C, D1, D2, E, F, G) have been described, representing different genes. Screening FANCA, C, F and FANCG on a molecular base will allow to identify approximately 75-80% of the causative mutations. 72 PCR products have to be amplified and screened for each individual. The FANCA gene is very large and highly polymorphic, which hampers screening efforts. To allow for the planned screening program, a reliable high throughput screening procedure was needed. A Denaturing High Pressure Liquid Chromatography (DHPLC) based PCR product screening was established, using a semiautomatized setup. PCR is performed in a newly developed temperature gradient cycler setup, allowing si-multaneous amplification of all 72 PCR products from one individual. This setup allowed the identification of several potential pathogenic heterozygous sequence variations in the screened genes. One clearly pathogenic FANCC gene mutation, previously not described, was identified in a family with siblings suffering leuke-mia. A second pathogenic mutation was discovered in a neuroblastoma patient, being a sibling of a Fanconi anemia patient. A further previously described muta-tion was identified in the FANCA gene in an AML patient. Several other, previ-ously undescribed, sequence variations have been identified. They are currently under evaluation of their pathogenic role using site directed mutagenesis and ret-roviral transfection. \nAs a carrier rate of only 1/300 is to be expected, the results \nneed further evaluation, a pathogenic role especially of FANCC gene mutations is possible. The results are partially published, and have been presented on na-tional and international scientific meetings, in collaboration with the patient or-ganizations (the international \u201eFanconi Anemia Research Foundation\u201d and the national \u201eDeutsche Fanconi An\u00e4mie Hilfe\u201d). It is planned to continue and expand \nthe studies presented above in the follow-up period.\nMutations in the G-CSFR  gene have recently been reported in patients with con-\ngenital neutropenia progressing to leukemia suggesting a contribution of these mutations to the pathogenesis of leukemia arising from CN. These mutations oc-curred in a region in the cytoplasmic domain of the G-CSFR  spanning nucleo-\ntides 2340-2530. All these mutations were nonsense mutations that introduce a premature stop codon leading to the truncation of the distal carboxy-terminal do-main of the G-CSFR that is critical for maturation and growth arrest signaling. In the cases studied, G-CSFR mutations are acquired during the course of disease \nand are not responsible for the pathogenesis of CN. Within this project patients 115with cyclic (n=9), idiopathic (n=21) and congenital neutropenia (n=101) were \ntested for mutations in the G-CSFR . The G-CSFR mutation were present in 30 % \nof the CN patients, but absent in patients with cyclic or idiopathic neutropenia and patients with severe aplastic anemia (n=56) or primary leukemia (AML, CMML or ALL) (n=13). Therefore, somatic G-CSFR mutations do not seem to play a role in \nthe development of primary leukemia or MDS/AML other than in congenital neu-tropenia. The fact that G-CSFR  mutations were absent in the majority of CN pa-\ntients indicates that these mutations are not causally involved in the pathophysi-ology of severe congenital neutropenia. As 87 % of the patients with CN/MDS/leukemia were shown to harbor a G-CSFR mutation, these results \nstrongly indicate that these mutations are highly associated with the leuke-mogenesis in CN. In our follow-up proposal studies on the pathophysiology of congenital neutropenia will be excluded because these studies will be part of new \nnetwork (see B.5 networking). \nMutations resulting in a deregulated Ras pathway are among the most common \nabnormalities associated with hematologic malignancy. Activating RAS mutations \nhave been demonstrated in up to 30% of patients with MDS and AML. To esti-mate the frequency of RAS mutations in children with pre-leukemic and leukemic \nbone marrow disorders we studied DNA from granulocytes of 20 children with MDS or AML for mutational changes in N-RAS  codon 12 and K-RAS  codon 12 \nund 13. While none of the patients with refractory anemia (RA) or RA with excess of blasts was shown to have a RAS mutation at the time of diagnosis, 1 of 5 chil-\ndren with juvenile myelomonocytic leukemia (JMML) had a K-RAS  (codon 12 \nGGTo GTT) and 1 of 3 patients with myelodysplasia-related AML an N-RAS  mu-\ntation (codon 12 GGT o GAT). Both patient had rapidly progressing disease and \nrelapsed post SCT. We will have to expand these studies in the follow-up period \nand study all patients diagnosed of MDS for RAS mutations to correlate this later \nevent in leukemogenesis with clinical presentation, chromosomal abnormalities \nand patient outcome.  \nIn leukemogenesis defects in apoptosis have been postulated. As a model sys-\ntem we studied apoptosis in JMML, a disorder in which reduced apoptosis might be expected. Granulocytes from children with JMML were isolated and spontane-ous as well as Fas-mediated apoptosis was examined. While there was no differ-ence in Fas-mediated apoptosis between granulocytes from patients with JMML compared to granulocytes from healthy donors, granulocytes from patients with JMML showed a delay in spontaneous apoptosis. However, due to the rapid spontaneous apoptosis, these experiments were only feasible with granulocytes from freshly obtained blood specimens and not from shipped patient samples. Since any study of changes in apoptotic pathways on a molecular level in pre-leukemic bone marrow failure disorders would require a large sample size for sta-tistical evaluation and since a sufficient sample size cannot be obtained at any \ninstitution as a single center, these studies are currently not further pursued.\nB.4 Publications and patents \nTschan CA, Pilz C, Zeidler C, Welte K, Germeshausen M. Time course of in-\ncreasing numbers of mutations in the granulocyte colony-stimulating factor recep-tor gene in a patient with congenital neutropenia who developed leukemia. Blood 97: 1882-84, 2001. \nGermeshausen M, Ballmaier M, Schulze H, Welte K, Flohr T, Beiske K, Storm-\nMathisen I, Abrahamsen TG. Granulocyte colony-stimulating factor receptor mu-116tations in a patient with acute lymphoblastic leukemia secondary to severe con-\ngenital neutropenia. Blood 97: 829-830, 2001. \nGermeshausen M, Ballmaier M, Welte K. Implications of mutations in hematopoi-\netic growth factor receptor genes in congenital cytopenias. Ann NY Acad Sci 938: 305-21, 2001. \nJung A, Ruckert S, Frank P, Brabletz T, Kirchner T. 7-deaza-2`-deoxyguanosine \nallows PCR and sequencing from CpG islands. Mol Path 55, 55-57, 2001. \nRischewski J, Schneppenheim R. Screening strategies for a highly polymorphic \ngene: DHPLC analysis of the Fanconi anemia group A gene. J Biochem Biophys Methods 30;47:53-64, 2001. \nRischewski J, Clausen H, Leber V, Niemeyer C, Ritter J, Schindler D, Schnep-\npenheim R: A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy. Klin Padiatr 212:174-6, 2000. \nRischewski J, Schindler D, Ziegler K, Janka-Schaub G, Schneppenheim R: Dis-\ncrepancy of diagnostic hallmarks of Fanconi anemia in a patient with myelodys-plastic syndrome. Klin Padiatr. 2002, in press. \nRischewski J, Wierzbinski J., Schneppenheim R: Detektion von Sequenzvariatio-\nnen im Fanconi An\u00e4mie A Gen unter Verwendung der DHPLC. Medizinische Ge-netik 2002, Sonderband zum Fanconi An\u00e4mie Symposium in W\u00fcrzburg 2002, in press.\nHasle H, Niemeyer CM. Myelodysplastic syndrome and juvenile myelomonocytic \nleukemia in children. In: Trends in Molecular Medicine (formerly: Molecular Medi-cine Today) 2002, 2: 468-457, 2002, in press \nPatents\nNone planned. 117B.5 Networking \nWithin the competence network close scientific contact is established to project F \n\u201eMinimal Residual Disease\u201d. Because ~20% of all cases of MDS occur after ther-apy for malignant disease or aplastic anemia there is also an intensive exchange of data with project K \u201eSecond Malignancy\u201d. All cases of secondary MDS regis-tered at the Children\u2019s Cancer Registry in Mainz in project K are verified and studied in detail by investigators of this project E. For asservation of patient mate-rial (blood cells, marrow cells, DNA, RNA, slides) collected within this project data bases had to be constructed. Guidelines for handling of patient material had to be formulated. To achieve these aims there was intensive contact with the coordina-tion and management group in Berlin/Hannover (Mantelantrag, project A) and project G \u201eClinical Relevance of Molecular Changes in Embryonal Tumors\u201d.  \nCo-operations within and out-site of this network led to the participation of several \ninvestigators in the proposed new BMBF networks on rare diseases. One of these proposed networks is on congenital bone marrow failure disorders and will be coordinated by K. Welte. K. Welte and W. Ebell will transfer their research pro-\njects (severe congenital neutropenia, clinical study on Fanconi anemia) to this \nnewly proposed network. They will not apply for further funding in a follow-up pe-riod within this network of pre-leukemic bone marrow disorders. Chr. Bender-G\u00f6tze/M. F\u00fchrer will participate in a network on acquired aplastic anemia (coor-dination by H. Schrezenmeier) and transfer their research previously funded within this network to the proposed network on aplastic anemia. Although there is an intense exchange of ideas and concepts between this project E on pre-leukemic bone marrow disorders and the proposed new networks on rare dis-eases, there will be no overlap in funding of individual projects. The aims of each network are distinct and unique. \nThis project has an excellent international network. The principal investigators of \nthe different forms of per-leukemic bone marrow disorders like congenital neutro-penia, Shwachman-Diamond syndrome, Fanconi anemia, acquired aplastic ane-mia etc. are actively participating in international research groups. Consequently, there is synergy on a number of national and international levels. 118Part C \u2013 Follow-Up Proposal \nC.1 Aims\nReference morphology: Evaluation of the new childhood classification of \nMDS in childhood (I. Baumann, Erlangen; C. Niemeyer, Freiburg) \nRecently, we and others developed a new classification for childhood MDS and \nbone marrow failure disorders. The proposed classification will be evaluated pro-spectively. In addition, standard procedures and measurements of quality control will have to be developed for the reference evaluation of morphological and clini-cal data. These standards will have to be evaluated and communicated with the participating local centers. To transfer knowledge of the morphological evaluation of blood and marrow specimens and to educate pediatric hematologists on cur-rent classification schema a morphology course will be offered at the University of Freiburg (splitted in 2 work-shops \u00e0 2.5 days for 25 participants each, the 1. work-shop on 25.-27.09.2002) \nOncogenetic studies (J. Harbott, Gie\u00dfen) \n\u0083 Studies on the relevance of small FISH clones for monosomy 7 or trisomy 8 \n\u0083 Evaluation of a guided step-wise approach to oncogenetics\nin children with (suspected) MDS \nFluorescent in situ hybridization (FISH) offers a rapid method to screen for \nmonosomy 7 and trisomy 8. It also allows detecting small clones not recognizable with standard banding cytogenetics. These small clones with up to 30% of cells demonstrating monosomy 7 or trisomy 8 on FISH analysis tend to be quite un-stable in size. They can increase in number or disappear during consecutive evaluations. In these follow-up studies we want to determine which cells are clonal (FICTION = immunophenotyping and FISH analysis) and whether short term culture prior to FISH analysis will change clone size by initiating apoptosis or proliferation of defined cell lineages.\nOncogenetic studies are an important tool to establish the diagnosis of MDS. \nThey provide prognostic information and greatly influence therapy. Therefore, complete oncogenetic information with timely reporting of results is a pre-requisite for good quality patient care. Annually, the oncogenetic reference labo-ratory in Gie\u00dfen receives more than 500 samples of (suspected) MDS cases for evaluation. In this follow-up proposal we want to investigate a rational approach to oncogenetic studies in this patient population by applying a step-wise investi-gational procedure. All incoming MDS samples will be handled and stored in a standardized manner that will allow all necessary future studies. Further oncoge-netic analyses (banding cytogenetics, FISH studies for monosomy 7 or trisomy 8, PCR to detect the typical translocations in AML) will await and depend on the re-sults of the morphological reference review. By tailoring the investigations to the specific clinical diagnosis \u2013 and thereby eliminating all unnecessary investiga-tions \u2013 relevant oncogenetic information should be available for most patients within 21 days. Although theoretically simple, this approach will require intensive and structured communication between the reference centers and consent from the participating local physicians.  \n\u2026119Molecular studies: Influence of RAS, p53 and FLT3 gene mutations \nfor disease progression and relapse post stem cell transplantation \n(C. Niemeyer, Freiburg and A. Jung, Erlangen)\nA number of molecular abnormalities have been associated with poor response \nof hematopoietic neoplasm to chemotherapy in most, although not all clinical studies. We want to study some of these molecular abnormalities in patients with pre-leukemic bone marrow disorders to evaluate whether they are also predictive for relapse after SCT. Next to the ongoing studies on RAS mutations we want to evaluate p53 and FLT3 gene mutations. The importance of the Ras pathway is substantiated by the fact that RAS mutations often occur in the absence of chro-mosomal abnormalities, suggesting the involvement of a limited number of ge-netic defects in pathogenesis. In contrast to RAS, most cases of MDS with p53 mutations have complex cytogenetic abnormalities. It is unknown whether the complex karyotype is secondary to the p53 mutation, because p53 inactivation can lead to chromosomal instability. The precise role of p53 mutations in leuke-mogenesis remains unknown. Internal tandem duplication within the exons 11 and 12 of the FLT3 gene, a subclass III tyrosine kinase receptor, has been re-ported in approximately 10% of MDS cases, and is associated with a high risk of progression to AML. The latter studies will be performed in collaboration with S. Schnittger, M\u00fcnchen (Competence Network \u201eAcute and Chronic Leukemias\u201d).\nGenetic predisposition to MDS: Studies on the Fanconi anemia and \nNibrin gene (R. Schneppenheim and J. Rischewski, Hamburg) \nThe previously not described sequence variations of the FANCC and FANCA \ngenes have to be evaluated for their pathogenic role. With an expected carrier rate of 1/300 the current results on heterozygosity for FANC mutations need fur-ther evaluation to include or exclude a pathogenic role especially for FANCC gene mutations. The likely functional \u201eend-point\u201d of the Fanconi anemia protein cascade, FANCD2, seems to be closely connected to the Nibrin gene product (NBS1). Defects in Nibrin cause the Nijmegen breakage syndrome, whose pa-tients suffer an increased risk for the development of lymphatic neoplasms. The screening setup therefore was adapted to the NBS1 gene product. Heterozygos-ity as a risk factor for the development of lymphomas could be excluded, studies to exclude a possible risk of heterozygous for the development of lymphatic leu-kemias are under way. Here we propose to expand the NBS1 gene analyses to patients with pre-leukemic bone marrow disorders. Depending on upcoming re-sults the method of Denaturing High Pressure Liquid Chromatography (DHPLC) based PCR product screening can be adapted to identify sequence variations in different genes suspected of predisposing to MDS.  \nAngiogenesis in pre-leukemic marrow disorders (C. Niemeyer \nand J. R\u00f6\u00dfler, Freiburg, I. Baumann Erlangen) \nThe importance of angiogenesis, the formation of new blood vessels from exist-\ning ones, is well established in regard to growth and progression of solid tumors. Recent studies indicate that angiogenesis is also an important feature in the pathogenesis of leukemias. For example, vessel counts in bone marrow from children with acute lymphatic leukemia are higher than in bone marrow from con-trol patients (Perez-Atayde et al, 1997). Increased angiogenesis has also been reported in the bone marrow of patients with acute myeloid leukemia. Here, nor-malization of bone marrow microvessel density could be demonstrated when pa-tients achieved a complete remission after induction chemotherapy. Furthermore,leukemic blasts were found to over-express angiogenesis mediators such as 120VEGF (vascular endothelial growth factor) (Padro et al, 2000). Therefore, leuke-\nmia might be angiogenesis dependent and angiogenesis could offer a new target for therapy. We plan to determine vessel densities in bone marrow biopsies of pre-leukemic disorders. Moreover, the expression of angiogenic mediators such as VEGF and bFGF (basic fibroblast growth factor) will be examined. The major aim is to demonstrate the role of angiogenesis in the different pre-leukemic bone marrow disease compared to bone marrow of control patients. We will study an-giogenesis in all patients diagnosed of pre-leukemic disorders and correlate the results with other characteristics such as chromosomal abnormalities and clinical data. Finally, the possible role of blood vessel formation in the pathogenesis from pre-leukemic disease to leukemia could be clarified.  \nC.2 Methodological approach \n1. Reference morphology: The reference evaluation  \nwill be continued as established. \n2. Oncogenetic studies: The techniques for FISH analysis and standard banding \ncytogenetics are established. New molecular probes for gene loci on the long arm of chromosome 7 will be introduced. \n3. Molecular studies: The methods of mutational analysis (ASRA SSCP, se-\nquencing) are established. Cell lysates of mononuclear cells and granulocytes of blood and marrow of patients with pre-leukemic bone marrow are stored for DNA/RNA extraction.  \n4. Genetic predisposition to MDS: To examine the role of heterozygosity as a \nrisk factor for malignancies, DHPLC was introduced. DHPLC analysis can re-producible recognize known sequence aberrations and screen for unknown mutations of highly polymorphic genes. The method is established.  \n5. Angiogenetic studies: Bone marrow biopsies sent for reference pathology are \navailable for the study on angiogenesis. According to the International Con-sensus on the Methodology and Criteria of Evaluation of Angiogenesis (Ver-meulen et al 1996), we will perform immunohistochemical staining of endothe-lial cells in the bone marrow with a CD 31 antibody. Vessels will be counted and an individual vessel index for each bone marrow will be determined. The mediators of angiogenesis in the bone marrow will be identified by immuno-histochemistry with a VDGF and a bFGF antibody (see: J. Wilting, M. Pa-poutsi, B. Christ, K. Nicolides, C.S. von Kaisenberg, J. Borger, G.B. Stark, K. \nAlitalo, S.I. Tomarev, C. Niemeyer, J. R\u00f6ssler: The transcription factor PROC \n1 is a marker of lymphatic endothelial cells in normal and diseased tissues. Submitted). Statistical test will evaluate correlation with other disease and pa-tient characteristics .\nC.3 Work plan \nProjects 1 and 2  will be performed continuously during the study period.\nIn project 3 , DNA will have to be extracted from frozen cell lysates (2 months), for \nthe mutational analyses of RAS, p53 and FLT-3 we estimated a time frame of 3, 4 and 4 months, respectively.\nIn project 4\n, the previously unknown sequence variations were identified. They \nare currently under evaluation of their pathogenic role using site directed mutagenesis and retroviral transfection (18 months). Screening for mutational changes in the NBS1 gene product is estimated with a time frame of 12 months.\n\u2026121For project 5 it is estimated that CD31 staining will require 2 months, vessel \ncounts 1 month and statistical evaluation 1 month. The immunohistochemical studies for expression of VEGF and bFGF in the bone marrow are estimated with 4 months.\nC.4 Networking  \nThe current networking (see B.5) will be continued.122Part D- Requested Funding for the Project \nD.1 Salaries\nThe following positions are required to conduct this project: \nFreiburg : 0,5 BAT IIa. The scientist will be responsible for molecular studies on \nRAS, p53 and FLT3 mutations. He/she will also perform the studies on angio-genesis.   Costs in 2003: 28266 \u20ac, in 2004: 28692 \u20ac \nHamburg\n: 0,5 BAT IIa. The scientist will perform DHPLC based PCR product \nscreening of the NBS1 gene product and continue the current expression studies of the FANC genes.   Costs in 2003: 28266 \u20ac, in 2004: 28.692 \u20ac \nGie\u00dfen\n: 1 MTA Va/b. The MTA will perform all required cytogenetic studies. The \nfunding of only a 50% position till midterm of this project was insufficient. It re-sulted in a backload of incomplete studies and a significant delay in reporting on-cogenetic results to the local physicians.   Costs in 2003: 41364 \u20ac, in 2004: 41988 \u20ac.\nD.2 Consumables\nFreiburg : The cost of primers, sequence kits and antibodies for immunohisto-\nchemistry is estimated 7500 \u20ac per year. \nHamburg : Estimated costs for DHPLC analysis is 5000 \u20ac per year. \nGie\u00dfen : Consumables are estimated at 5000 \u20ac per year. \nErlangen : Annual cost of consumables is estimated at 2500 \u20ac.\nD.3 Investments\nThere will be no investments. \nD.4 Other Costs \nThere will be no additional costs. 123Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Prognostic relevance of minimal residual \n  disease in childhood acute leukemia  \n  and malignant lymphoma tested by  \n  quantitative polymerase chain reaction \n  (RQ-PCR) and multiparameter\n  immunophenotyping (Project F) \nGrant No. : 01 GI 99 63/2 \nName of scientist-in-charge : Univ.-Prof. Dr. Jochen Harbott \nInstitution : Oncogenetic Laboratory \n  Department of Pediatric Hematology  \n  and Oncology \nAddress : Feulgenstr. 12 \n  35385 Giessen \nPhone : +49 (0) 64 1 \u2013 99 43 42 6 \nFax : +49 (0) 64 1 \u2013 99 43 48 5 \nE-mail : jochen.harbott@paediat.med.uni- \n  giessen.de \nProject home page (if different from \nNetwork homepage) : ------------------------------------------------------------------------------------------ 124Part A - General Statements about the Project\nA.1.Subject\nPrognostic relevance of minimal residual disease in childhood acute leukemia \nand malignant lymphoma tested by quantitative polymerase chain reaction (RQ-PCR) and multiparameter immunophenotyping.  \nA.2. Co-Investigators\n\u0083 Prof. Dr. Hartmut Kabisch, Children\u2019s Univ. Hospital, Hamburg  \n(ALL, CoALL, Ig/TCR gene rearrangements)\n\u0083 Dr. Dirk Reinhardt, Children\u2019s Univ. Hospital, M\u00fcnster\n(AML, Immunophenotyping) \n\u0083 Dr. Dr. Karl Seeger, Charit\u00e9 - Virchow Klinikum, Berlin\n(ALL relapses, Ig/TCR gene rearrangements, Fusion genes) \n\u0083 Prof. Dr. Alfred Reiter, Dept. Ped. Oncology/Hematology, Gie\u00dfen  \n(Lymphoma, Fusion genes) \n\u0083 Prof. Dr. Martin Schrappe, Dept. Ped. Oncology/Hematology, Hannover  \n(ALL, ALL-BFM, Cell bank and preparations) \n\u0083 Prof. Dr. Claus R. Bartram, Department of Human Genetics, Heidelberg\n(ALL, ALL-BFM, Ig/TCR gene rearrangements) \n\u0083PD Dr. Frank Griesinger, Internal Medicine, G\u00f6ttingen  (AML, Immunophenotyping)\nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no 125A.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1 Amount1\nRequested \n2003 338,1 35 0 4,2 0 377,3 \n2004 275,0 35 0 4,2 0 314,2 \n1(amounts in thousand Euro), \n * should correlate to funds specified in Part D126Part B \u2013 Results from the First Funding Period\nB.1 Summary \nDuring the last years it could be shown by two large studies (Cav\u00e9 et al (1998) \nN.Engl.J.Med. 339,591; van Dongen et al (1998) Lancet 352,1731) that MRD is an important independent prognostic factor and can be used for therapy stratifica-tion in childhood ALL. Therefore, in Germany a MRD based multicenter therapy trial was started together with the \nAustrian BFM and the Italian AIEOP group. Up \nto now, this is the only study using MRD for stratification. For other types of ma-lignant diseases, however, the clinical relevance of MRD is not yet clear. \nBeside the MRD markers used in the mentioned studies (Ig/TCR-gene rear-\nrangements) other markers like fusion genes or immunophenotype are known to be useful for MRD detection in other malignant diseases. \nThe aim of this cooperative study is the evaluation of the most suitable marker for \nminimal residual disease in childhood acute leukemia and Non-Hodgkin\u2019s lym-phoma (NHL) and to clarify its meaning for therapy stratification and monitoring of the response to therapy. \nThe following markers are tested:\nLeukemia specific fusion genes: \n\u0083 ALL-relapses  \u2013 Seeger, Berlin\n\u0083 AML  \u2013 Harbott, Gie\u00dfen\n\u0083 NHL  \u2013 Reiter, Gie\u00dfen  \nIg/TCR gene rearrangements: \u0083 ALL-relapses  \u2013 Seeger, Berlin\n\u0083 ALL (BFM)  \u2013 Schrappe, Hannover, and Bartram, Heidelberg\n\u0083 ALL (CoALL)  \u2013 Kabisch, Hamburg  \nImmmunophenotyping:\u0083 AML  \u2013 Reinhardt, M\u00fcnster ,and Griesinger, G\u00f6ttingen\nAll results will be compared with clinical data provided by the therapy studies \nALL-BFM (Schrappe, Hannover), AML-BFM (Creutzig/Ritter, M\u00fcnster), ALL-REZ (Henze, Berlin), CoALL (Janka-Schaub, Hamburg), and ALL-NHL (Reiter, Gie\u00dfen). \nDuring the past 30 months the detection methods were established by the differ-\nent groups and more than 20.000 blood and bone marrow samples were ana-lyzed. After some difficulties with recruiting of follow up samples the compliance has increased in all subprojects. The cooperation between the subprojects works well and technical knowledge or missing samples are exchanged between the labs. Also the comparison of clinical data and laboratory results is regularly per-formed. First preliminary results were given in several oral and poster presenta-tions at national and international conferences.127B.2 Original aims of the project \n\u0083 Evaluation of a uniform system of data management and  \ntransfer between hospitals, therapy study, and laboratories \n\u0083 Standardization of MRD techniques \n\u0083 Optimizing of material recruitment at diagnosis and during follow-up \n\u0083 Evaluation of prognostic meaning of MRD in different malignancies \n\u0083 Evaluation of therapy influence to decrease and  \nincrease of the leukemic cell number \n\u0083 Evaluation of the best time points for MRD analysis\nand individual follow-up controls \n\u0083 Comparison MRD results of peripheral blood and bone marrow\n\u0083 Comparison of MRD techniques\nB.3 Scientific results \nFusion genes as MRD marker in AML\nThe aims of this project are the comparison of results gained by different meth-\nods to find the most suitable technique for each type of malignancy. Furthermore the best time points for therapy control should be evaluated.\nLeukemia specific fusion genes in AML were analyzed with RT-PCR and real \ntime quantitative (RQ-) RT-PCR. During the first phase of this project RT-PCR was used to identify the rearrangements and to use them as MRD marker. In the period from 1999 to 2001, 284 samples of children with newly diagnosed AML were successfully screened by RT-PCR for one of the fusion genes AML1/ETO, CBF\u00df/MYH11, MLL/AF9, and PML/RARa and 52 of them were found to be posi-tive for one of these rearrangements (19 %). Evaluation of follow-up samples showed different results for each of these rearrangements (PML/RARa excludedbecause of low numbers). AML1/ETO was detectable in nearly all samples at the early time points (TPs) 1 and 2 (before HAM). During the course of treatment at the TPs 3 \u2013 5 (before and after consolidation and after HD/VP) about 60 % of the children remained positive and also after HD/VP and during maintenance therapy about 37 % showed the rearrangement. For CBF\u00df/MYH11 the number of follow-up samples was much smaller. But also here a decrease of positive samples was visible from TP1 and 2 (75 and 80 %) to TP5 and later, where only 1/7 was posi-tive for the rearrangement (14%). The treatment response for MLL/AF9 positive patients was even better: The number of positive samples decreased from TP1 (50%) to TP3 (10%) and after HD/VP only 2/22 samples (8 %) remained positive. \nThe second phase of the project, the analysis by RQ-RT-PCR started in 2000 \nand was performed at 49 samples of 12 AML1/ETO positive patients. The results show a different response to treatment, with a decrease of copy numbers of 3 \u2013 4 log at TP3 and remain positive at this low level. One patient, however, showed a decrease of only 2 log, later on copy numbers increased to 440 before HD/VP and a relapse appeared after 2 months.\n           \u2026  128Leukemia associated immunophenotypes in AML (LAIP)\nThe AML-BFM 98 MRD study started in 1/2000 in order to evaluate, standardize \nand establish immunophenotyping in AML in children. In a first phase, the partici-pating laboratories in Muenster, G\u00f6ttingen, Vienna and Prague agreed on identi-cal antibody-panels and standardized procedures of sample processing, analysis and data management. The consensus panel was evaluated and adapted to 3-and 4-color flowcytometry. The complete panel was applied to each follow-up samples in order to minimize the risk of false negative results due to the loss or shift of antigens during treatment, a known phenomenon in myeloid blasts. Be-tween 1/2000 and 10/2001 in total bone marrow samples of 355 children have been analyzed. In detail a leukemia-associated immunophenotype could be de-fined in 168 of 198 (88%) protocol patients of the AML-BFM 98 study. In addition 89 observation patients of the AML-BFM study and 23 children with a relapse of \nAML were included. Samples of 65 children with ALL, CML, JMML, MDS, or solid \ntumors were measured to evaluate sensitivity and specificity of the consensus panel. In 149 of 185 protocol patients (78%) more than two follow-up samples were available. \nThree kinds of immunophenotypes could be defined. (1) Asynchronous expres-\nsion of stem cell and myeloid antigens i.e. CD34/CD117 combined with CD13/CD15 had a low specificity because precursors in regenerating or normal bone marrow expressed this pattern in 0.47% (0.1 to 1.5%). (2) The aberrant co-expression of stem cell antigens and lymphatic antigens such as CD7 or CD2 showed a median level of specificity (0.07% (0.05 to 0.19%). (3) Aberrant ex-pression of stem cell antigens combined with B-lymphatic (CD19, CD10) or NK-cell antigen (CD56) showed the best specificity. The maximal level in normal bone marrow was 0.05%. Sensitivity of different immunophenotypes was evalu-ated by diluting known leukemic blasts in regenerating bone marrow. Minimal level of sensitivity was found to be at 0.05%.\nAccording to these data highly specific immunophenotypes could be detected in \n33%, median specificity was seen in 71% and low specificity was seen in 88% of the protocol patients. \nTwo laboratories (G\u00f6ttingen/M\u00fcnster) analyzed simultaneously 17 samples of \nchildren with AML from diagnosis and during therapy. A high correlation of blast quantification could be demonstrated (correlation R\u00b2=0.98). In addition, two inde-pendent explorers quantified the raw data of 16 samples. All results correlated well (R\u00b2=0.97). \nBased on these data cut-off levels of each antigen combination for MRD diagnos-\ntics could be defined, calculated from median+2 standard deviations. By an online form MRD levels were centrally registered in a central data base, combin-ing the results of immunophenotyping, molecular MRD diagnostics, morphology and outcome. \nThe prospective study phase, started 1/2002, aims to test the impact of MRD di-\nagnostics as an independent prognostic factor in AML in children. This might fa-cilitate future treatment stratification and consequently optimize outcome.  \n           \u2026  129MRD in ALL relapse\nDuring the project phase (1999-2001), 1900 bone marrow and blood samples \nwere sent to the reference laboratory of t he relapse trials ALL-REZ BFM in Berlin. \nTwo hundred fifty one samples were drawn at relapse diagnosis and 885 follow-up samples were taken during treatment and were used for minimal residual dis-ease (MRD) assessment in children with first ALL relapse. MRD was quantified \nusing T-cell receptor and immunoglobulin gene rearrangements (TCR- J,-G, IgH, \nIg\u00b5) and fusion transcripts (TEL-AML1, BCR-ABL, MLL-rearrangements).\nIn 72 patients treated according to ALL-REZ BFM (strategic group S2), MRD was \nquantified during initial phases of therapy using TCR and Ig gene rearrangements as clonal MRD markers. In patients with MRD <10\n-3 (n=43) at day 36 (after sec-\nond therapy course), probability of event-free survival (pEFS) was 0.89; by con-trast, patients with MRD \u009510\n-3(n=29) had a pEFS of 0.46 (p=0.001). Using the \ngene expression of the TEL-AML1 fusion for quantification of MRD, patients with MRD <10\n-3 (n=20) at day 36 had a pEFS of 0.75, where as those with MRD \u009510-3\n(n=7) had a pEFS of 0.00 (p=0.034). G\nThe data suggest that in children with ALL relapse the extent of early response \ncan be used to predict long-term outcome. There is evidence that rapid molecular responders are likely to have an excellent prognosis with chemotherapy. Thus, transplant procedures carrying a high risk for morbidity and mortality may not be necessary in these children. In the BFM Study-Group it has been agreed that re-sults of MRD monitoring will be used for patient stratification in the new relapse trial ALL-REZ BFM 2002. Recently, the pilot phase of the protocol has started. \nMRD in ALL (BFM) \nThe analysis of minimal residual disease (MRD) has significant prognostic value \nfor the evaluation of early treatment response and contributes to the individualiza-tion of chemotherapy protocols. The International BFM Study Group used clone-specific immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements as MRD-PCR targets with a sensitivity of \u009410\n-4 on two follow-up time points to define \nthree risk groups: a low-risk group (LR) of 43% of patients with MRD negativity at the end of induction therapy (day 33) and before consolidation treatment (week 12) and a 5-year relapse-free survival (RFS) of 98%; a high-risk group (HR) of 15% of patients with MRD levels \u009510\n-3 at time point 2 and 5-year RFS of 16%; an \nintermediate-risk group (IR) containing the 43% remaining patients with a 5-year RFS of 76%. \nRelying on previous experience the BFM study group introduced MRD-adapted \ntreatment stratification in the current trial ALL-BFM 2000. Based on quantitative real-time PCR (RQ-PCR) analysis, junctional regions of Ig and TCR gene rear-rangements have effectively been used for the quantification of MRD in childhood ALL. LightCycler-assisted RQ-PCR in combination with SYBR Green detection proved to be an accurate, highly flexible and sensitive method for routine monitor-ing of ALL patients and until 12/2001 the remission status of more than 600 chil-dren has been analyzed. \n581 eligible patients were enrolled from Aug 99 to May 2001. Risk group assign-\nment on the basis of MRD detection was possible in the case of 453 (78%) pa-tients, with 45% stratified into the LR group, 46% into IR and 9% into the HR group. Taking into consideration additional risk group parameters (prednisone 130response, translocations 9;22 and 4;11) patients were eventually classified as LR \n(34%), IR (49%) and HR (17%), respectively. \nOn-time MRD-based stratification in large prospective trials is feasible using rapid \ncycle real-time PCR protocols in combination with very reliable logistics and high laboratory standards. \nCell bank of the ALL-BFM study\nThe basis for prospective and retrospective studies is a well organized cell bank. \nThe cell bank of the ALL-BFM study was originally founded to process and store samples for the analysis of Ig and T-cell receptor gene rearrangements in the molecular genetic laboratory in Heidelberg. In addition, material was provided for other projects from within and outside the network. \n60 to 80 bone marrow and/or blood samples per week are mailed to this labora-\ntory by all Pediatric centers cooperating in the ALL-BFM-trials. All samples have to be processed immediately during 6 days a week. All of them will be used for a morphological analysis and once or twice a week the collected material will be send to the molecular laboratory in Heidelberg for marker analysis. \nWithin this group a new project was started in 2001 dealing with MRD in high risk \npatients. In the meantime, more than 20 of these children were analyzed at sev-eral time points during first CR before transplantation. Among them five were BCR/ABL positive at diagnosis and the follow up data will be compared to theRT- and RQ-RT-PCR data gained in the molecular reference laboratory for fusion gene analysis in Gie\u00dfen. \nFurthermore the collaboration with the molecular laboratory of the German ALL \nrelapse study (ALL-REZ) was intensified: The Ig and T-cell receptor gene rear-rangements identified at diagnosis and relapse will be compared and an evalua-tion of clinical data and follow up data is planned.\nMRD in ALL (CoALL)\nOne fourth (~120 pts/year) of the German children with acute lymphoblastic leu-\nkemia (ALL) is treated according to the CoALL protocol. In parallel to the BFM study group specimens for MRD analysis were collected since 1992 at compara-ble time points. \nStandardization of MRD techniques:  \n\u0083 Identification of clone-specific (i.e. patient-specific) sequences by PCR and \nsequencing; subsequent selection of allel-specific oligonucleotides for each patient and MRD analysis. \n\u0083 Establishment of at least two individual clone specific markers utilizing the T-\ncell-receptor- JG-chain as well as the immunoglobulin heavy chain (IgH) and \nthe kappa-deleting element ( N-de).G\n\u0083 Evaluation of the WAVE technology for identification of clonal TCR rear-\nrangements. \nClonality of PCR amplified V G2-DG3 products were examined on a high resolution \nmicropellicular DNASep matrix (WAVE, transgenomic). 310 B-cell precursor ALL \n(221 C-ALL; 76 Pre-B-ALL; 13 Pro-B-ALL) were subjected to DHPLC analysis 131and subsequently classified into clonal, biclonal or negative samples. The overall \nincidence of clonality discovered by WAVE technology was 48.4% with no differ-ences between the two subgroups c-ALL and pre-B-\nALL, but with only 1 out of 13 \nclonal pro-B-ALL samples. In 66 of 150 positive cases bi- or oligoclonality was detected (44%). From these results we suggest that DHPLC analysis is a rapid and reliable tool for identification of MRD targets in large series of newly diag-nosed leukemias under standardized conditions.  \nOptimized material recruitment at diagnosis and during follow up: A mean recruitment of 2 x 10\n7 cells per specimen was achieved at the time point\nof diagnosis, whereas 1 x 107 cells were sufficient for follow up samples. \nEvaluation of therapy influence on MRD leading to the best time points for MRD \nanalysis and individual follow up:\nSurprisingly, at the end of induction therapy (after 5 weeks of therapy) of the \nCoALL study higher MRD values were observed in comparison to the ALL-BFM and other European studies. The slower clearance of leukemic cells in the initial phase might be due the lower cytotoxic potency of the three-drug induction regi-men used by the CoALL study compared to the four drug regimen employed in BFM protocol. Both protocols, however, have the identical long-term survival. It will be very interesting to identify the therapeutic element(s) with such an antileu-kemic potency in the context of the CoALL study. \nAs the MRD detection after CoALL induction therapy has low prognostic potential \nbecause high and low risk patients cannot be discriminated at the end of induc-tion therapy, we introduced an additional time point at day 43. This time point is supposed to give more prognostic information regarding MRD because it follows a therapy block with three further drugs. \nThis new time point for MRD analysis was introduced in July 2000. Until January \n2002, 130 bone marrow samples were collected and about 1 x 10\n7 cells (range \n1 x 106 to 1 x 108 cells) were stored and DNA was isolated. \nMRD investigations of CoALL patients with late response or after relapse who \nunderwent an allogeneic blood stem cell transplantation demonstrated clearly that a high MRD level before and after transplantation rises the risk of subse-quent relapse significantly. \nIn this transplantation related MRD study, information and specimens were ex-\nchanged frequently between the involved laboratories and may lead to more ef-fective therapy protocols. \nMRD in NHL\nThe t(8;14)(q24;q32), involving MYC gene (8q24) and the immunoglobulin heavy \nchain (IgH) locus (14q32), represents about 75% of all translocations in childhood Burkitt's lymphomas (BL) and B-cell ALL. Due to the great variability of the breakpoint region, a standard polymerase chain reaction (PCR) assay is not suf-ficient for the detection of this chromosomal translocation. The recently improved long-distance (LD) PCR for the detection of t(8;14)(q24;q32) allows to identify the specific breakpoint region within the MYC gene and the IgH locus. The combina-tion in different reactions of one primer specific for MYC exon II and four primers for the IgH locus, localized within the joining region (JH) and the constant regions 132(C\u00b5, CJ and CD), reveals the specific breakpoint region. Our investigations of\nBurkitt\u00b4s lymphoma cell lines and several childhood BL or B- ALL, positive for \nt(8;14)(q24;q32), showed a product ranging in size from 1 to 10 kb. The LD-PCR, however reached a sensitivity of 10\n-2only, which is not sufficient for detection of \nminimal residual disease. Therefore, we established a more sensitive nested PCR with a specific primer combination for each patient based on sequence analysis of the variant breakpoint regions. Thereby, two primers were specific for the MYC-gene close to the MYC/IgH breakpoint and one primer is located in the IgH locus, whereas another one overlapped the breakpoint of each specific breakpoint region. To establish the specification, we investigated the Burkitt lym-phoma cell line CA-46 and several pediatric BL or B-\nALL using their specific \nprimer combination for the nested PCR in comparison with lymphoma cell lines and pediatric leukemia which are negative for t(8;14)(q24;q32). Using this break-point specific nested PCR, we could detect the translocation in 1 out of 104 he-matopoietic cells lacking this translocation. In conclusion, we represent a combi-nation of LD- and nested PCR method as a specific and sensitive tool for the evaluation of minimal residual disease in patients affected by t(8;14)(q24;q32) positive lymphomas. \nB.4 Publications and patents \nEckert C, Landt O, Taube T, Seeger K, Beyermann B, Proba J, Henze G. Poten-\ntial of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2000;14:316-323 \nEckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Po-\ngodda M, Proba J, Henze G. Prognostic value of minimal residual disease in re-lapsed childhood acute lymphoblastic leukaemia. Lancet 2001;358:1239-1241 \nNakao M, Janssen JW, Bartram CR. Duplex PCR facilitates the identification of \nimmunoglobulin kappa (IGK) gene rearrangements in acute lymphoblastic leu-kemia. Leukemia 2000;14:218-219 \nNakao M, Janssen JW, Flohr T, Bartram CR. Rapid and reliable quantification of \nminimal residual disease in acute lymphoblastic leukemia using rearranged im-munoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res 2000;60:3281-3289\nSchrappe M. Workshop on minimal residual disease. Leukemia 2001;15:272 Seeger K, Buchwald D, Peter A, Taube T, von Stackelberg A, Schmitt G, Henze \nG. TEL-\nAML1 fusion in relapsed childhood acute lymphoblastic leukemia. Blood \n1999;94:374-376\nSeeger K, Buchwald D, Taube T, Peter A, von Stackelberg A, Schmitt G, \nKochling J, Henze G. TEL-AML1 positivity in relapsed B cell precursor acute lym-phoblastic leukemia in childhood. Berlin-Frankfurt-Munster Study Group. Leuke-mia 1999;13:1469-1470 \nSeeger K, Kreuzer KA, Lass U, Taube T, Buchwald D, Eckert C, Korner G, \nSchmidt CA, Henze G. Molecular quantification of response to therapy and re-mission status in TEL-AML1-positive childhood ALL by real-time reverse tran-scription polymerase chain reaction. Cancer Res 2001;61:2517-2522 133Seeger K, Taube T, Eckert C, Hanel C, Pogodda M, Henze G. Unusual T-cell \nreceptor-delta gene rearrangement patterns revealed by screening of a large se-ries of childhood acute lymphoblastic leukaemia by multiplex polymerase chain reaction. Br J Haematol 2001;113:318-322 \nSeeger K, Viehmann S, Buchwald D, Harbott J, Schrappe M, Stary J, Henze G, \nTrka J. Treatment response and residual-disease monitoring in initial and re-lapsed TEL-AML1 positive childhood ALL. Leukemia 2001;15:280-282 \nzur Stadt U, Harms DO, Schluter S, Schrappe M, Goebel U, Spaar H, Janka G, \nKabisch H. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leu-kemia 2001;15:283-285 \nzur Stadt U, Rischewski J, Schneppenheim R, Kabisch H. Denaturing HPLC for \nidentification of clonal T-cell receptor gamma rearrangements in newly diagnosed acute lymphoblastic leukemia. Clin Chem 2001;47:2003-2011\nPatents\nNone planned. \nB.5 Networking \nThe seven laboratories and the cell bank have started the cooperation with an \nexchange of methods leading to a standardization of the techniques. E.g. fusion gene MRD is performed in the laboratories in Gie\u00dfen (1, 5) (AML and lympho-mas) and Berlin (4) (ALL-Relapse), in the laboratories of Heidelberg (6b) (ALL-BFM), Hamburg (2) (ALL-CoALL), and Berlin (4) (ALL relapse) Ig/TCR-gene rear-rangements are analyzed and the immunophenotyping of AML material is done in G\u00f6ttingen (7) und M\u00fcnster (3). Common protocols were developed and adapted to the laboratories. Logistic problems had to be solved by the cell bank in Han-nover (6a) where DNA is extracted and the samples are shipped to the laboratory in Heidelberg (6b) to be proceeded. Furthermore, a transfer of data and material has started between the cooperation partners. At diagnosis of the disease and during follow-up, they all receive bone marrow and/or peripheral blood from all pediatric oncologic departments in Germany, which all together are the center of this network. Also with the hospitals a data exchange\u2013 clinical data vs. results \u2013takes place. All laboratories as well as the oncologic departments are in a close connection with the coordinating centers of the therapy studies involved in this project (ALL-BFM, Hannover, CoALL, Hamburg, AML-BFM, M\u00fcnster, ALL-REZ, Berlin, and NHL-BFM, Gie\u00dfen).  \nIn addition to the exchange within the competence network several national and \ninternational co-operations were started or joined mainly to standardize tech-niques to make all results comparable: The Group in Gie\u00dfen (1) is a member of the European Project for standardization of RQ-PCR (Taqman) funded by Europe against Cancer. The flow cytometry labs in G\u00f6ttingen (7) and M\u00fcnster (3) have joined the European Group for MRD in ALL by phenotyping (Berlin, Vienna, Pra-gue). The cell bank (6a) and the lab in Heidelberg (6b) are members of the Euro-pean MRD task force project, which initiated a standardization of Ig/TCR gene rearrangement detection some years ago. 134Part C \u2013 Follow-Up Proposal \nC.1 Aims\nDuring the first funding period, the structure of a network for sample collection \nand standardization was built up. The methods to use were discussed between the laboratories of this project or with other national and international partners. All clinical centers were informed how to send bone marrow and blood for the MRD analyses. Although the compliance of the centers has improved since the start, there is still a large number of missing samples at different time points which finally will hamper the evaluation of the data.\nThe second funding period will be used to build up a scientific network. The first \naim is to receive more follow up sample and to perform the analyses and submit the results in an adequate time to the hospital as well as the coordinating study center. In addition, more efforts are needed for an inter-laboratorial evaluation. To find the best time points for BMT during therapy a comparison of the results of different studies has to be performed (ALL-BFM vs. CoALL). The markers identified at diagnosis and at relapse can give important hints for leukemogene-sis. A comparison of the Ig/TCR marker found at diagnosis in Hamburg and Hei-delberg will be compared to those detected at relapse in Berlin. Similar studies will be performed for the AML laboratories: Comparison of positivity detected with LAIP and PCR, sensitivity of both methods, exchange of missing samples etc.\nOther evaluations will need by far more time. To determine whether a continuing \nmarker positivity at a low level for a long period has a clinical meaning or the identification of the best time points for BMT will need a longer follow-up period \nand more samples of a larger number of patients.\nIn addition to the original projects, the immunophenotyping analysis of patients \nwith ALL relapse is planned and in Hannover an intensive evaluation of high risk patients has started.\nC.2 Methodological approach \nAll methods which were initially described are established in the laboratories of \nthe project and standardized as described before (B.5.).\nDuring the past two years it became obvious that the workload caused by the \nhuge number of samples shipped to each of the cooperating laboratories is too much for one half time technician. The technicians have to prepare the samples for analyses, perform the analyses and enter patient\u2019s data and results into a computer. Furthermore, they are responsible for the transfer of material from one lab to the other. Therefore, a full time technician is needed in each of the labora-tories.\nFor the organization of the scientific network within the MRD project a scientist is \nneeded. In addition to the tasks of the coordination between labs and hospitals as well as coordinating study centers the preparation of publications including data collection and statistical analyses will be performed.  \nIt is planned to have two half post doctoral positions responsible for the ALL part \nof the network (BFM-ALL, Hannover; ALL-REZ Berlin) and another one for the AML laboratories (BFM-AML, M\u00fcnster). All three scientists should be experi-enced with all the problems of coordination of different groups, hospitals and 135therapy studies as well as evaluation of scientific, clinical and statistical data. \nExcept these three groups all others will have a full technician during the first \nfunding period (2003). Because in 2004 no new patients will enter the studies and only follow up samples will be analyzed, all groups will apply for only a half technician position with the exception of the project management where an addi-tional half position is needed as assistance for the documentations used for the final report.\nC.3 Work plan \nThe initially described work plan has not changed. All preparatory work as stan-\ndardization, mailing logistics etc. were finished during the first months. Data col-lection is still running and will proceed until the end of 2003. In 2002 a further midterm evaluation will be performed to control preliminary results, compare dif-ferent methods and markers and discuss again the problems of compliance. Dur-ing the year 2004 no further patients will be added to the project, but only follow-up studies will be performed. A final evaluation, however, concerning the prog-nostic meaning of all MRD markers (especially for the rare ones) can not be per-formed in this period, but will last for some other years. \nC.4 Networking  \nThe network structures built up so far by this project are described in B.5. In ad-\ndition, further co-operations are planned, e.g. the ALL relapse laboratory in Ber-lin is going to start immunophenotyping as well and a co-operation with the marker laboratory in Berlin (Prof. Dr. W.-D. Ludwig) is planned. The lymphoma group in Gie\u00dfen will join in an international MRD study initiated by groups in Toulouse, France and Padua, Italy. In addition, a co-operation has started be-tween this project and Project H of the competence network.\nIn general, the scientists included in the network of the MRD project will help to \nfulfill the aims of the whole competence network by creating closer, faster, more effective and long lasting connections between reference laboratories and thepediatric centers as well as the coordinating centers of the therapy studies. 136Part D- Requested Funding for the Project \nD.1 Salaries (given in \u20ac) \nProject Position 2003 2004 Total\nAML-fusion genes 1/1 TA +1/1 TA 44785 45456 \nALL (CoALL) 1/1 TA + \u00bd TA 44785 22728 \n\u00bd TA + \u00bd TA 22392 22728 AML (Immunol. /M\u00fc) \n\u00bd WA 30594 31052 \n\u00bd TA + \u00bd TA 22392 22728 ALL relapses \n\u00bd WA 30594 31052 \nLymphoma 1/1 TA + \u00bd TA 44785 22728 \n\u00bd TA + \u00bd TA 22392 22728 ALL (BFM)/ cell bank \n\u00bd WA 30594 31052 \nAML (Immunol. /G\u00f6) 1/1 TA + \u00bd TA 44785 22728 \nTotal  338098 274980 613078\nD.2 Consumables\nProject Consumables 2003 2004 Total \nAML-fusion genes 5000 5000 \nALL (CoALL) 5000 5000 \nAML (Immunol. /M\u00fc) 5000 5000 \nALL relapses 5000 5000 \nLymphoma 5000 5000 \nALL (BFM)/ cell bank 5000 5000 \nAML (Immunol. /G\u00f6) Reagents and lab ware  \n5000 5000 \nTotal  35000 35000 70000\nAs already stated in the initial grant application the amounts for consumables are \nnot sufficient to perform all analyses. The cooperating partners, however, take the chance of the project to build up a long lasting network. The above men-tioned amount of money will be needed mainly to build up the network and keep it running.\nD.3 Investments\nNone.137D.4 Other Costs \nProject Position 2003 2004 Total \nAML-fusion genes 600 600  \nALL (CoALL) 600 600  \nAML (Immunol. /M\u00fc) 600 600  \nALL relapses 600 600  \nLymphoma 600 600  \nALL (BFM) / cell bank 600 600  \nAML (Immunol. /G\u00f6) Travel costs \n600 600  \nTotal  4200 4200 8400 138Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Clinical Relevance of Molecular \n  Changes in Embryonal Tumors  \n  (Project G) \nGrant No. : 01 GI 99 64/5 \nName of scientist-in-charge : Univ.-Prof. Dr. med. Frank Berthold \nInstitution : Children\u2019s Hospital University of Cologne \nAddress : Joseph-Stelzmann-Str. 9 \n  50924 K\u00f6ln \nPhone : +49 (0) 22 1 \u2013 47 8 \u2013 43 80  \nFax :  +49 (0) 22 1 \u2013 47 8 \u2013 46 89 \nE-mail : frank.berthold@medizin.uni-koeln.de  \nProject home page (if different from \nNetwork homepage) : ------------------------------------------------------------------------------------------ 139Part A - General Statements about the Project\nA.1.Subject\nClinical relevance of molecular changes in embryonal tumors\nA.2. Co-Investigators\n\u0083 T. Pietsch ,Institute of Neuropathology, University of Bonn \n\u0083 W. Scheurlen, Children\u2019s Hospital, University of Heidelberg/Mannheim \n\u0083 M. Gessler, Biocenter, University of W\u00fcrzburg \n\u0083 H. Christiansen, Children \u2019s Hospital, University of Marburg :\nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 196 30 0 9 0 235 \n2004 196 30 0 9 0 235 \n1(amounts in thousand Euro), \n * should correlate to funds specified in Part D140Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe project G was successful in establishing three tumor banks (neuroblas-\ntoma/rare tumors; hepatoblastoma/medulloblastoma; nephroblastoma) which have been attractive to the group \u201egerm cell tumors\u201d and \u201esoft tissue sarcomas\u201d (application for joining). The tumor tissue set, the tumor box for mailing (patent application) and software programs proved to be useful. An independent board of directors provides tumor tissue for scientific use (4 applications). Although num-ber and quality of the collected tissue samples increased significantly with time, they are far from covering all trial patients. Further improvements are clearly nec-essary.\nThe proposed parameters per tumor entity have been studied in many instances \nand new molecular characteristics were developed for medulloblastoma, nephro-blastoma and neuroblastoma. Some markers and many trial patients were not investigated due to the lack of tumor tissue. Early data of neuroblastoma gene profiling (differential expression, SAGE analysis, selective expression) indicate new areas of research and give hope for specific gene and immunotherapeutic targets.\nB.2 Original aims of the project \nMolecular abnormalities have pathogenetic, diagnostic and prognostic implica-\ntions in each of the embryonal tumors. A main task at the beginning consisted of the utilization of experience of each group to synergize the efforts and pathways to be followed. Two major achievements were made: \n\u0083 Establishment of 3 separate tumor banks working with the same tumor tissue \nset, tumor box and logistics. \n\u0083 Beginning of a closer cooperation between labs and clinical trial office (data \nexchange) and of prospective molecular studies intending to cover all trial pa-tients.\nFor common and specific aims see section B.3.\nB.3 Scientific results  \nAim 1: Collection of tumor tissue \nRefer to section B.5 \u2013 Networking. \nAim 2: Definition of new molecular entities and \nAim 3: Description of pathogenetic hierarchies\nAs the referees initially pointed out, the aims 2 and 3 may be achieved only late \n\u201esince a wealth and mature body of data in necessary\u201d. However, the molecular distinction of medulloblastoma subtypes demonstrates first results (papers G/6, G/7 and G/8):\n\u0083 classical: LOH 17p, HIC-1 inactivation, c-myc-amplification,  \ntrkA p75 expression negative from \n\u0083 desmoblastic: LOH 9q22, PTOH inactivation, trkA p75 expression positive.  141Aim 4: Identification of potential targets for gene and immunotherapy\nMAGE-1, MAGE-3 and NY-ESO-1 were found to be selectively expressed in \nneuroblastoma (paper 10) and are currently used as targets in a phase 1 vacci-nation trail (peptides, peptide-pulsed dendritic cells). The results of serial analysis of gene expression (SAGE) in neuroblastoma are pending. \nAim 5: Infrastructure for quick evaluation of \nfuture molecular and cell biological parameters\nThe availability of tumor and reference tissue through the three tumor banks \nrepresents a major step to that aim. However, the number of samples, the quality and the size of the provided samples need to be improved dramatically. Small series (n=30) utilizing already prepar ed RNA and histological sections e.g. to \ncheck the use of recently reported markers ALK tyrosine kinase and Her2neu neuroblastoma were successfully performed (demonstrating no use). \nAim 6: hepatoblastoma markers LOH 11p15.5, \nwingless signaling pathway, \u00df-catenin mutations\nIn 56 patients, no prognostic information could be derived from LOH 11p15.5, \nLOH 1p, LOH 1q and \u00df-catenin mutations (paper 5), LOH 11p and 1q were more frequently, but not exclusively found in the embryonal subtype. The number of \u00df-catenin mutations was surprisingly high (54 %) and the accumulation of \u00df-catenin products even more (87%) suggesting a major role in hepatoblastoma tumori-genesis.\nAim 7: medulloblastoma/ PNET markers c-myc, LOH 17p13.1, \nLOH 17p 13.3, 16q, 9q31; PTCH mutations\nc-myc amplifications were found in 10 % (5/52) of classical medulloblastomas \nand proved to be a very powerful poor prognosis indicator. All c-mcy+ patients experienced early and treatment resistant progression. c-myc amplifications were always associated with 17q isochromosomes. A good discrimination was ob-tained by trkC expression studies (better prognosis with expression, p=0.034, n=33). New is the diagnostic use of LOH INI1/h SNFS for patients with malignant cerebral rhabdoid tumor a rare entity in children. LOH 17p, 16q, 9q could not yet be analyzed systematically due to the lack of sufficient tumor tissue. \nAim 8: nephroblastoma markers LOH 1p, 11p13, \n11p15 11q, 16q, 22q and imprinting analysis 11q15\nThe LOH screening has been standardized on a European level recently, but \ndata are not yet available. Mutation screening including SNF5/ SWI5, e-cadherin, cadherin-11 showed no tumorspecific mutations in genomic or cDNA and are fin-ished (paper 3). 1q gain by CGH appears to be a poor prognostic factor (collabo-ration with Dr. Pritchard-Jones) and will be included in further analysis. Currently 70 blastemateous nephroblastomas are investigated for allelic loss, p53 and \u00df-catenin mutations on the basis of archival paraffin embedded tissue (due to the lack of fresh tumor tissue). \nAim 9: neuroblastoma markers MYCN, LOH1p36.2, \nDNA ploidy, CD44, MRP, trkA, telomerase142The MYCN determination is essential for the treatment of neuroblastoma, since \namplification qualities for high therapy. The competence network helps to provide that service. Comparisons between two labs demonstrated discordances in 9/125 paired investigations. Detailed reanalysis could solve the discrepancies in all 9 cases. This resulted in the request for double testing of stratifying parameters (two labs, two methods).\nIn addition to deletion, the 1p imbalance was found to represent a poor prognos-\ntic factor as 1p deletion occurring in 9 % of patients (n=196). TrkA and CD44 were investigated in 320 patients, the data are currently been analyzed. \nA major progress was made assessing differential gene expression of 6567 \ngenes in 88 small, round and blue cell tumors. Utilizing artificial neuronal net-works typical profiles could be described for neuroblastoma, Ewing's, rhabdosar-coma and Burkitt's lymphoma. 15 genes were selectively expressed in neuroblas-toma including 12 unknown expressed sequence tags (EST) (paper 26).\nB.4 Publications and patents \nOtano-Joos M, Mechtersheimer G, Ohi 2, Wilgenbus KK, Scheurlen W, Lehnert \nT, Willeke F, Otto HF, Lichter P, Joos S. Detection of chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytoge-netics. Cytogenet Cell Genet 2000; 90:86-92 \nGranzow M, Popp S, Weber S, Hager HD, Boschert J, Scheurlen W, Jauch A. \nMultiplex-FISH classifies chromosome rearrangements in a child with intracranial ependymoma. Cancer Genet. Cytogenet (in press) \nSchulz S, Becker KF, Braungart E, Reichmuth C, Klamt B, Atkinson M, Gessler \nM, Hofler H. Molecular analysis of E-cadherin-11 in Wilm\u2019s tumours. J Pathol 2000; 191:162-169 \nHartmann W, Waha A, Koch A, Albrecht S, von Schweinitz D, Pietsch T. p57-\nKIP2 is not mutated in hepatoblastoma but shows increased transcriptional activ-ity - a comparative analysis of three imprinted genes p57-KIP2, IGF2 and H19. Am J Pathol 2000; 157:1393-403 \nWeber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of chromo-\nsomal imbalances in hepatoblastomas: a role for gains on 8q and 20 as predic-tors of outcome. Am J Pathol 2000; 157:571-578 \nB\u00fchren J, Christoph AHA, Buslei R, Albrecht S, Wiestler OD, Pietsch T. Expres-\nsion of the neurotrophin receptor p75-NTR in medulloblastomas is correlated to distinct histological and clinical features: Evidence for a medulloblastoma subtype derived from the external granule cell layer. J Neuropathol Exp Neurol 2000; 59:229-40\nHerms J, Neidt I, L\u00fcscher B, Sommer A, Sch\u00fcrmann P, Schr\u00f6der T, Bergmann \nM, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA. c-myc expression in medulloblastoma and its prognostic value. Int J Cancer 2000; 89:395-402. \nKoch A, Waha A, Tonn JC, S\u00f6rensen N, Berthold F, Hartmann W, Friedl W, \nReifenberger G, Wiestler OD, Pietsch T. Mutations of components of the wing-less/WNT si\ngnalin g pathwa y in sporadic primitive neuroectodermal tumors. Int J 143Cancer 2000; 93:445-9. \nKraus JA, de Millas W, S\u00f6rensen N, Herbold C, Schichor C, Tonn JC, Wiestler \nOD, von Deimling A, Pietsch T. Evidence for a tumor suppressor gene at 22q11-q12 involved in the pathogenesis of human ependymomas and distinct form hSNF5/INI1. Acta Neuropathol 2001; 102:69-74. \nS\u00f6ling A, Schurr P, Berthold F. Expression and clinical relevance on NY-ESO1, \nMAGE-1 and MAGE-3 in neuroblstoma. Anticancer Res 1999; 19:2205-09. \nM\u00fcller S, van den Boom D, Zirkel D, K\u00f6ster H, Berthold F, Schwab M, Westphal \nM, Zumkeller W. Retention of imprinting of the human apoptosis-related gene TSSC2 in human brain tumors. Hum Mol Gen 2000; 9:757-763. \nPoremba CH, Hero B, Heine B, Scheel CH, Schaefer KL, Christiansen H, Ber-\nthold F, Kneif S, Stein H, Juergens H, Boecker W, Dockhorn-Dworniczak B. Te-lomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediat Oncol 2000; 35:651-655. \nPoremba C, Scheel C, Hero B, Christiansen H, Schaefer K, Nakayama J, Ber-\nthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecu-lar an immunhistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissue. J Clin Oncol 2000; 18:2582-2592. \nLadenstein R, Ambros IM, Poetschger U, Amann G, Urban C, Fink FM, Schmitt \nK, Jones R, Slociak M, Schilling F, Ritter J, Berthold F, Gadner H Ambros PF. Prognostic significanes of DNA Di-tetraploidy in neuroblastoma. Med Pediat On-col 2001; 36:83-92. \nTheobald M, Christiansen H, Schmidt A, Malekian B, Wolkewitz N, Christiansen \nN, Brinkschmidt C, Berthold F, Lampert F. Sublocalization of putative tumor sup-pressor gene loci on chromosome arm 14q in neuroblastoma. Genes, Chromo-somes & Cancer 1999; 26:40-46. \nBown N, Cotterill S, Lastowska M, O\u00b4Neill S, Pearson ADJ, Plantaz D, Meddeb \nM, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Spelemann F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Eng J Med 1999; 340:1951-1962. \nPoremba C, Willenbring H, Hero B, Christiansen H, Sch\u00e4fer KL, Brinkschmidt C, \nJ\u00fcrgens H, B\u00f6cker W, Dockhorn-Dworniczak B. Telomerase activity distinguishes between neuroblastomas with good and poor prognostic. Ann Oncol 1999;10:1-7.\nD\u00f6tsch J, Harmjanz A, Christiansen H, H\u00e4nze J, Lampert F, Rascher W. Gene \nexpression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR. Int J Cancer 2000; 88:172-175. \nBrinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, B\u00f6cker W, \nDockhorn-Dworniczak B. Distal chromosome 17 gains in neuroblastomas de-tected by comparative genomic hybridisation (CGH) are associated with a poor clinical outcome. Med Pediat Oncol 2001; 36:11-13. \nVandesompele J, Speleman F, van Roy N, Laureys G, Brinkschmidt C, \nChristiansen H, Lampert F, Lastowska M,  Bown N, Pearson A, Nicholson JC, 144Ross F, Combaret V, Delattre O, Feuerstin BG, Plantaz D. Multicentre analysis of \npatterns of DNA gains and losses in 204 neuroblastoma tumors: How many ge-netic subgroups are there. Med Pediat Oncol 2001; 36:5-10. \nBergmann E, Wanzel M, Weber A, Shin I, Christiansen H, Eilers M. Expression of \np27Kip1 is prognostic and independent of MYCN amplification in human neuro-blastoma. Int J Cancer 2001; 95:176-183. \nD\u00f6tsch J, Repp R, Rascher W, Christiansen H. Diagnostic and scientific applica-\ntions of TaqMan real-time PCR in neuroblastomas. Expert Rev Mol Diagn 2001; 1:233-238.\nO\u00b4Neill S, Estrom L, Lastoska M, Robets P, Brodeur GM, Kees UR, Schwab M, \nBown N. MYCN Amplification and 17q in neuroblastoma: Evidence for structural association. Genes, Chromosomes & Cancer 2001, 30:87. \nBoon K, Caron HN, van Asperen R, Velantijn L, Hermus MC, van Sluis P, Roo-\nbeek I, Weis I, Voute PA, Schwab M, Versteeg R. N-myc enhance the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO Journal 2001; 20:1-11. \nSavelyeva L, Schwab M. Amplification of oncogenes revisited: From expression \nprofiling to clinical application. Cancer Letters 2001; 167:115-123. \nKhan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, \nSchwab M, Antonescu CR, Peterson C, Meltzer PS. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural net-works. Nature Medicine 2001; 7:673-679. \nBauer A, Savelyeva L, Claas A, Praml C, Berthold F, Schwab M. Smallest region \nof overlapping deletion in 1p36 human neuroblastoma: A 1-Mbp cosmid and PAC contig. . Genes, Chromosomes & Cancer 2001; 31:228-239. \nHing S, Lu YJ, Summersgill B, King-Underwood L, Nicholoson J, Grundy P, \nGrundy R, Gessler M, Shipley J, Pritchard-Jones K. Gain of 1q is associated with adverse outcome in favourable histology Wilm\u2019s tumors. Am J Pathol 2001; 158:393-8.\nPrzkora R, Meyer-Puttlitz B, Schmitt O, Berthold F, N\u00f6then M, Krauss J, Tonn \nJC, von Deimling A, Wiestler OD, Pietsch  T. Analysis of the TSC2 gene in hu-man medulloblastoma. Acta Neuropathol 2001; 102:380-4. \nDahmen RP, Koch A, Denkhaus D, Tonn JC, S\u00f6rensen N, Berthold F, Behrens J, \nBirchmeier W, Wiestler OD, Pietsch T. Deletions of AXIN1, a component of the WNT/ wingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61:7039-43.\nPatent application \nApplication for the newly developed tumor box (application number A2 101 \n31828.6, dated 25.06.2001). With the tumor box frozen and non-frozen tissue samples may safely be mailed together within one box to a central address (tu-mor bank). The tumor bank distributes the samples further to the cooperating labs.145B.5 Networking \nFour aspects contribute to added value and synergy: \n1. Establishing three tumor banks\nTumor tissue and blood/other tissue for comparison are collected systematically \nfrom \n\u0083 neuroblastoma, germ cell tumors, rare tumors (in Cologne, F. Berthold) \n\u0083 medulloblastoma/PNET and other brain tumors, \nhepatoblastoma (in Bonn, T. Pietsch) \n\u0083 nephroblastoma (in W\u00fcrzburg, M. Gessler) \nTwo applications for collecting germ cell tumors and soft tissue sarcomas were \nreceived (one approved, one still to be discussed). The Langerhans cell histiocy-tosis trial is considering to use the tumor box system and to establish an own tu-morbank.\n2. Software development\nThe data of sampled tumor and reference tissue (e.g. date of collection, site, vi-\nability) and of the investigated parameters (e.g. MYCN, 1p, 11q, 17q status) are collected in an Oracle data base (Cologne) and compared to the clinicial trial data. The tumor banks of Bonn and W\u00fcrzburg use an access data base and ob-serve a yearly exchange of data with the clinical nephro-, hepato- and medul-loblastoma trial.  \n3. Informed consent paper\nTo obtain the approval of the parents for research investigations in the tumor tis-\nsue of their child an informed consent proposal was made, approved by the Ethi-cal commission of the University of Cologne and provided to all network partici-pants via the clinical trial offices. \n4. Independent board of directors\nThe board of directors independent from the people sending tissue and running \nthe tumor banks decides which investigators outside the network may be pro-vided with samples for serial analyses. 4 formal applications have been received so far (and were approved). 146Part C \u2013 Follow-Up Proposal \nC.1 Aims\nThe objectives of the initial project are still relevant and achievable. As discussed \nin section 3, B3 several aims can be achieved not earlier than at the end of sec-ond period: \nTwo points need a change of the initial proposal:\n1. The number of collected tumor tissue is too low. Physicians of the cooperating \nhospitals \u2013 according to recent experience in particular the large and very busy Pediatric Oncology units \u2013 need to be scientifically sound informed to give the project the adequate high priority in their units. Similarly the research nurses need education about the importance and the skillful handling of tumor and non-tumor tissue. Furthermore the coordinated running of the tumor banks and the presentation of their model character require scientific experi-ence. For significant improvement of that performance a BAT IIa/Ib position is needed as suggested by the referees. \n2. The new development of an artificial neural network detecting characteristic \nneuroblastoma gene expression profiles requires further studies and gene screening in the tumor tissue of all patients. For the preparation of adequate cDNA microchips and the gene screening a \u00bd BAT Vb position is requested for the Heidelberg group, which is already a competence network member. Those data will be supplemented by SAGE results derived from progressing and regressing neuroblastomas (Cologne).\nC.2 Methodological approach \nNo change except DNA chip technology established in Prof. Schwab\u2019s laboratory \n(Heidelberg, NCI) and SAGE technique established in Cologne. \nC.3 Work plan \nAim 1: Collection of tumor tissue\na) Improvement of number and amount of tissue collection (tumor and non-tumor \nmaterial)\n\u0083 Continuous information on the high scientific priority in clinical routine 2002 \u2013\n2004\n\u0083 Continuous education of FSA 2002 \u2013 2004 \n\u0083 Mailing campaigns to pathologists, urologists, pediatric surgeons. 2002 and\n2003. Presentation of current results at their meetings. \n\u0083 Publication of results (public media) 2003 and 2004 \n\u0083 Improvement of feedback to applicants for the tumor bank material (2002 \u2013\n2004)\nb) Integration of system applicants (soft tissue tumors, Langerhans cell histiocy-\ntosis) to the tumor bank system (use of tumor box, separate tumor bank) 2002 147Aims 2 and 3: Definition of new molecular entities. \nDescription of pathogenetic hierarchies. \nThese goals are achievable after collection of many and mature data, thus at the \nend of the project 2004 (end of period) and should be continued even afterwards. \nAim 4: Identification of potential targets for gene and immune therapy\nThis goal depends very much on the earlier findings. Tumor selective markers \nneed to be investigated for the use as potential target. Close cooperation with project H (synergy). \n\u0083 First evaluation: 2003 \n\u0083 Final evaluation: 2004 (end of project) \nAim 5 Infrastructure for quick evaluation of \nfuture molecular and cell biological parameters\nThe infrastructure is set up and can be used. The only shortening is the availabil-\nity of the material (see: Aim 1) \n\u0083 2002 \n\u0083 2003 \n\u0083 2004 \nAim 6 Hepatoblastoma markers\nInvestigation of 50 tumors with all proposed markers 2004 (end of project) \nAim 7 Medulloblastoma markers\nInvestigation of 150 \u2013 200 tumors with all proposed markers \n\u0083 2004 (end of project) \nAim 8 Nephroblastoma markers\nInvestigation of 120 \u2013 140 tumors with all proposed markers \u0083 2004 (end of project) \nAim 9 Neuroblastoma markers\nInvestigation of 250 \u2013 280 tumors with all proposed markers \u0083 2004 (end of project).\nC.4 Networking  \n1. Project H (Immune- and gene therapy) \n a) supported by tumor tissue for the gene   core facility (application for second period)  b) comparison of gene expression data (neuronal network    (Heidelberg), SAGE (Cologne) and chip (Halle) data) \n            \u2026  1482. Structured joining of molecular data with clinical parameter and survival \nanalyses to define subgroups of different biological behavior.Suggestion of adapted treatment strategies. Medulloblastoma 2003  Neuroblastoma 2003  Nephroblastoma 2004  Hepatoblastoma 2004 \n3. International cooperation continued \n Wilm's tumor:  European Wilm's tumor trial, ICR (UK)  Neuroblastoma  NCI (USA)  Hepatoblastoma Karolinska institute (Sweden)  Medulloblastoma Queensland (Australia).149Part D- Requested Funding for the Project \nD.1 Salaries (given in \u20ac) \n Co-Investigators   Tumor-\nbox\nCenter\nK\u00f6ln\nK\u00f6ln Bonn Mann-\nheimW\u00fcrz-\nburgMar-\nburgHeid\nel-\nberg   \n Scientists Technicians \nYear \u00bd 1 1 \u00bd \u00bd \u00bd \u00bd Sum Total \n2003 28 42 42 21 21 21 21 196 \n2004 28 42 42 21 21 21 21 196 392\nJustification:\nPosition:\n\u0083 Technicians K\u00f6ln, Bonn, Mannheim, Marburg  \nNo change compared to application and granting for the first period and as suggested by the referees \n\u0083 Change:  \nreduction of the technician W\u00fcrzburg (from 1 to \u00bd position) as suggested by the referees. \n\u0083 New: \u00bd position of a scientist (BAT IIa/Ib) as suggested by the referees \nDuties:- Information and education of the partners in the cooperating hospitals (pediatric oncologist, neurosurgical, pediatric surgical, urological units) on the necessity to collect tumor and non tumor   tissue from all patients - Coordination of the tumor banks (running of, processing, applications for tissue requests, updating information material) - Presentation of results to the public \n\u0083 New: \u00bd position of a technician (BAT Vb) for Heidelberg  \n(Prof. Dr. M. Schwab, Heidelberg) (position from W\u00fcrzburg) Duties:- preparation of cDNA microchips for neuroblastoma according to the  artificial neuronal network data and screening of neuroblastoma patients 150D.2 Consumables (given in \u20ac) \nTumorbox: Costs for tumor tissue sets (approx. 500 per year \u00e0 11 tubes, 20 \nslides, information sheet, wrapping, shipping) and replacement of damaged sty-ropore parts. \nOther: No change compared to application/granting for first period. \n Co-Investigators   \nYearTumor-\nbox\nCenter\nK\u00f6ln\nK\u00f6ln Bonn Mann-\nheimW\u00fcrz-\nburgMar-\nburgHeid\nel-\nberg Sum Total \n2003 6 5 5 3 5 3 3 30  \n2004 6 5 5 3 5 3 3 30 60\nD.3 Investments\nNone.\nD.4 Other Costs (given in \u20ac) \nTravel: no change compared to application and granting for 1. period. \n Co-Investigators   \nYearTumor-\nbox\nCenter\nK\u00f6ln\nK\u00f6ln Bonn Mann-\nheimW\u00fcrz-\nburgMar-\nburgHeid\nel-\nberg Sum Total \n2003 3 1 1 1 1 1 1 9  \n2004 3 1 1 1 1 1 1 9 18151Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Immune and Gene Therapy of \n  Pediatric Neoplasias (Project H)  \nGrant No. : 01 GI 99 65  \nName of scientist-in-charge : Univ.-Prof. Dr. med. St. Burdach \nInstitution : Universit\u00e4tsklinik und Poliklinik f\u00fcr Kinder- \n   und Jugendmedizin,  \n   Martin-Luther-Universit\u00e4t \n  Halle-Wittenberg  \nAddress : Ernst-Grube-Str. 40 \n  06120 Halle \nPhone :  +49 (0) 34 5 \u2013 55 72 38 8 \nFax :  +49 (0) 34 5 \u2013 55 72 38 9 \nE-mail :  stefan.burdach@medizin.uni-halle.de \nProject home page (if different from \nNetwork homepage) : ------------------------------------------------------------------------------------------ 152Part A - General Statements about the Project\nA.1.Subject\nImmune and Gene Therapy of Pediatric Neoplasias\nA.2. Co-Investigators\n\u0083 G. Henze, J. K\u00f6chling, A. Borgmann, Charit\u00e9,  \nUniversity Children\u2019s Hospital, Berlin \n\u0083 D. Dilloo, U. Dirksen, H. Hanenberg, C. Hirschmann, C. Kramm, H.-J. Laws, \nT. Niehues, C. Kratz, D. Schneider, University Children\u2019s Hospital, D\u00fcsseldorf \n\u0083 R. Esser, T. Klingebiel, U. Koehl, D. Schwabe, Frankfurt \n\u0083 K. Hanewinkel, G. Hansen, U. Hattenhorst, R. H\u00fchn, C. Hutter,  \nM. Messerle, F. Meyer-Wentrup, M. Staege, A. Wawer, Halle \n\u0083 O. J. C. Hellwinkel, H. Kabisch, Hamburg  \n\u0083 F. Berthold, B. Hero, M. Jensen, M. W\u00f6lfl, K\u00f6ln \n\u0083 C. R\u00f6ssig, J. Vormoor, M\u00fcnster  \n\u0083 D. Beck, P. Lang, T\u00fcbingen \n\u0083 M. Eyrich, S. Rutkowski, P.-G. Schlegel, W\u00fcrzburg \nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 83,4 90 5 5 0 183,4 \n2004 83,4 90 5 5 0 183,4 \n1(amounts in thousand Euro), * should correlate to funds specified in Part D153Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe aim of Project H - Immune and Gene Therapy - is to improve the overall \nprognosis of pediatric neoplasias through immune and gene therapeutic strate-gies and to decrease the unwanted effects of mutagenic therapy in malignant diseases of childhood. The project is designed to create a network of experimen-tal, pharmaceutical and clinical immune and gene therapeutic research projects. Its primary purpose is to generate synergies between researchers in the devel-opment of novel treatment modalities and to help clinicians incorporate new im-mune and gene therapeutic insights into their treatment protocols promptly.\nTo this end the partners co-operating in Project H have initiated a therapy and \nresearch registry that is freely accessible on the internet. It includes 43 research projects conducted in 10 institutions and 8 clinical trials. In the controversial field of pediatric gene and immune therapy the registry has increased transparency. It serves as a reliable source of information for anyone afflicted by malignant dis-ease or interested in evolving therapies.\nTo document the current treatment practice a survey has been completed. It \nshows the heterogeneity of immune and gene therapeutic treatment practice in Germany.  \nAll immune and gene therapeutic treatment concepts face strict regulatory de-\nmands. The project has helped individual treatment centers to meet these de-mands. In the network created by Project H treatment centers could profit from each other\u2019s experiences. \nProject H has made significant advances towards the goal of analyzing the gene \nexpression profile of every malignant disease in childhood and of making the data available for the pediatric community.\nResearch scholarships granted to members of the institutions participating in Pro-\nject H have led to the implementation of new laboratory techniques and to a fur-ther extension of the competence network of pediatric immune and gene therapy. \nB.2 Original aims of the project \nThe project aims at improving the overall prognosis of malignant diseases in \nchildhood through immune and gene therapeutic strategies.\nTo achieve this ambitious aim the original proposal comprises the establishment \nof a project and study registry to document current treatment practice and to promote the implementation of general treatment standards. Furthermore, it in-cludes the initiation of monitoring programs to validate the effects of immune and gene therapeutic treatment strategies. The project wants to offer support for treatment centers in regulatory and lega l issues which will help to standardize \nimmune and gene therapy procedures and will increase safety and efficacy of these new therapeutic strategies.\nTo support the identification of new tumor-specific targets for immune and gene \ntherapy the project wants to build an efficient infrastructure for the transfer of tu-mor samples to network partner\u2019s equipped with the technology necessary for 154gene expression analysis.\nIn addition, the project aims at improving the communication between treatment \ncenters on a national and international basis to make scientific progress in the field of immune and gene therapeutic research more readily available for the benefit of all afflicted patients.\nResearch scholarships are granted to support the implementation of new tech-\nniques in the laboratories of the partners co-operating in the network.\nThe synergy of basic research and clinical application of immune and gene ther-\napy guarantees the continuous development of new treatment strategies and techniques meeting the pharmaceutical and medical demand.  \nB.3 Scientific results \nEstablishment of the Pediatric Immune and Gene Therapy Registry (PIaGen)\nA registry of German and Austrian immune and gene therapy research projects \nand clinical studies has been established. Currently 43 research projects and 8 \nclinical studies are registered. A total of 158 patients have been treated. 150 pa-tients have been treated with antibodies. 8 patients have received cellular thera-pies with wild type or gene modified cells. The registry has increased the flow of information between the treatment centers. It has begun to generate synergy ef-fects between research projects and has already decreased the number of re-dundant activities. It enables the participating centers to focus their activities and to co-operate wherever possible.\nThe project registry can be accessed online on the homepage of the competence \nnetwork. It serves as a source of information for affected patients, their families, primary care pediatricians and the public interested in gene and immune therapy. In addition to supplying information about clinical studies and research activities the project registry encompasses a collection of treatment protocols that are freely accessible to all partners in the network. \nTransfer of Tumor Samples\nTo facilitate a standardized transfer of tumor samples to centers equipped with \nthe technology for gene expression analysis Project H has written a memoran-dum to the GPOH explaining the technique and rationale of gene expression analysis of pediatric tumors and asking for support for the gene expression \nanalysis approach.\nDocumentation of Treatment Practices\nTreatment practices of the participating centers have been documented. Hetero-\ngeneity and discrepancies with regard to study design and regulatory issues have been identified. The results reflect the different historical back-ground of the treatment centers. While one institution holds a production license for the engi-neering of cellular and gene therapeutic agents, many others rely on the license of their blood bank or other institutions. There are four models for leukapheresis and processing and storage of cell products. In 38 % of all pediatric centers leu-kapheresis is performed in the Departments of Transfusion Medicine. 21 % co-operate with the Departments of Internal Medicine and 8 % have outsourced the process of leukapheresis. 33 % of the Children\u2019s Hospitals perform leukaphere-ses in their own facility. For processing and storage of cell products the situation 155is similar. 33 % of the Pediatric Centers co-operate with the Departments of \nTransfusion Medicine and 21 % with the Departments of Internal Medicine. 13 % have outsourced the processing and storage to biotech companies, while 8 % have outsourced to other Departments of Pediatrics. 25 % of the Children\u2019s Hos-pitals have their own facilities for processing and storage of cell products. Some centers have not obtained a production license. All research and clinical studies have been approved by the local ethics committees. One study of the University Children\u2019s Hospital of Halle concerning the use of IL-2 transgenic Ewing Tumor cell lines for the treatment of advanced Ewing Tumors has been approved by the\nCommission for Somatic Gene Therapy of the B\u00c4K (Federal Medical Board). \nRegulatory Procedures and Decision Making\nThe project has helped individual institutions to meet the regulatory demands for \nresearch or clinical projects. It has improved communication between the clinical centers to establish treatment algorithms and standards for immune and gene \ntherapy. Overall co-operation and communication has improved. \nResearch Scholarships\nSo far, two research scholarships have been granted to collaborators of the clini-\ncal institutions co-operating in Project H. The scholarships have allowed them to learn new techniques and to establish them in their laboratories. Furthermore, the scholarships have led to an increased knowledge transfer and to the initiation of new co-operations with partners outside of the pediatric competence network. \u20ac 40000 originally allowed for traveling expenses have been dedicated to the pur-chase of DNA-Micro-Arrays and reagents for gene chip-preparation and -\nprocessing.  \nAdvancement of the International State of the Art \nThe international state of the art in immune and gene therapy of pediatric malig-\nnant disease includes therapeutic trials conducted primarily in the US, i.e. at the laboratory of Malcolm Brenner at the University of Houston. In the US efforts are made for gene expression analysis of pediatric tumor samples using high density \narrays.  \nHowever, so far there is no American equivalent to Project H. Network structures \nare a major prerequisite for the successful planning and conduction of gene and immune therapeutic trials. For example, the register of immune and gene thera-peutic research projects and clinical trials (PIaGen) established by Project H has increased the transparency of immune and gene therapeutic research and has helped to decrease the incidence of redundant research projects. The register, which can be accessed online, also provides reliable information to patients, their families and the public. The collaborators of Project H believe that meeting the public need for reliable information in particular on the prospects of immune and gene therapy will pave the way for a broader acceptance of these innovative ap-\nproaches.\nIn addition, the network structures support the advance of tumor gene expression \nanalysis by improving the transfer of tumor samples to treatment centers equipped with the necessary technology and know-how. By establishing unique network structures Project H has already advanced the international state of art in gene and immune therapy of pediatric malignant disease and wants to continue \ndoing so. 156B.4 Publications and patents \nBader P, Stoll K, Huber S, Geiselhart A, Handgretinger R, Niemeyer C, Einsele \nH, Schlegel PG, Niethammer D, Beck J, Klingebiel T:  Characterization of line-age-specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Br J Haematol 108:761, 2000 \nBorgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, Nurnberg P, \nHenze G: Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol 17:635, 2000 \nBornhauser M, Theuser C, Soucek S, Holig K, Klingebiel T, Blau W, Fauser A, \nRunde V, Schwinger W, Rutt C, Ehninger G: Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Haematologica 85:839, 2000 \nBurdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D, Pape H, Dunst \nJ, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nurnberger W, Heyll A, Ladenstein R, Gadner H, Jurgens H, Goebel U: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Trans-plant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 11:1451, 2000 \nBurdach S, Baersch G, Hansen G: Immunogenetherapy with IL-2 or IL-7 trans-\nfected Ewing tumor cells in NOD/SCID mice. Med Ped Onc 37(3):178 2001 \nDeeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S, Ramsay N, Territo \nM, Khan SP, Pamphilon D, Leis JF, Burdach S, Anasetti C, Hackman R, Storer B, Mueller B: Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 7:208, 2001 \nFelzmann T, Buchberger M, Jechlinger M, Kircheis R, Wagner E, Gadner H: \nXenogenization by tetanus toxoid loading into lymphoblastoid cell lines and pri-mary human tumor cells mediated by polycations and liposomes. Cancer Lett 161:241, 2000 \nFelzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner \nH, Holter W: Functional maturation of dendritic cells by exposure to CD40L trans-genic tumor cells, fibroblasts or keratinocytes. Cancer Lett 168:145, 2001 \nFisch P, Moris A, Rammensee HG, Handgretinger R: Inhibitory MHC class I re-\nceptors on gammadelta T cells in tumour immunity and autoimmunity. Immunol Today 21:187, 2000 \nHattenhorst U, Glynne R, Murray R, Burdach S: Differential gene expression \nanalysis in pediatric c-ALL versus normal pre-B-cells and bone marrow DNA-microarrays. Blood 96(11):107a, 2000 \nHeinsohn S, Scholz RB, Weber B, Wittenstein B, Werner M, Delling G, Kempf-\nBielack B, Setlak P, Bielack S, Kabisch H: SV40 sequences in human osteosar-157coma of German origin. Anticancer Res 20:4539, 2000 \nKhan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, \nSchwab M, Antonescu CR, Peterson C, Meltzer PS: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural net-works. Nat Med 7:673, 2001 \nKroger N, Zabelina T, Kruger W, Renges H, Stute N, Durken M, Graf von Finken-\nstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Loliger C, Zander AR: Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplanta-tion from unrelated donors. Ann Hematol 80:209, 2001 \nKurre P, Burdach S: A potential role for leukemia inhibitory factor in the increased \nclonogenicity of human fetal progenitor cells. Blood 96:1199, 2000 \nPacker RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, \nMcComb JG, Cogen PH, Vezina G, Kapcala LP: Treatment of progressive or re-current pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 92:249, 2000  \nOttinger HD, Muller C, Schmitz N, Kubanek B, Arnold R, Ebell W, Eberhard HP, \nEhninger G, Fronz U, Goldmann S, Grosse-Wilde H, Havers W, Klingebiel T, Kolb HJ, Seeber S, Schaefer UW, Baldomero H, Gratwohl A: Transplant activities in Germany in 1998--a survey facilitated by the National Registry for Hemopoietic Stem Cell Transplantation. Ann Hematol 79:437, 2000Schilbach KE, Geiselhart A, Wessels JT, Niethammer D, Handgretinger R: Human gammadelta T lympho-cytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immu-nother 23:536, 2000 \nPacker RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, \nMcComb JG, Cogen PH, Vezina G, Kapcala LP: Treatment of progressive or re-current pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 92:249, 2000Schilbach K, Geiselhart A, Handgret-inger R: Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood 97:2917, 2001 \nPeters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F, Cornish J, \nOrtega J, Bekasi A, Souillet G, Stary J, Niethammer D: Statement of current ma-jority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 26:405, 2000Schlegel PG, Eyrich M, Bader P, Handgretinger R, Lang P, Niethammer D, Klingebiel T: OKT-3-based recondition-ing regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol 111:668, 2000 \nRischewski J, Bismarck P, Kabisch H, Janka-Schaub G, Obser T, Schneppen-\nheim R: The common deletion 657del5 in the Nibrin gene is not a major risk fac-tor for B or T cell non-Hodgkin lymphoma in a pediatric population. Leukemia 14:1528, 2000Schwinger W, Urban C, Lackner H, Kerbl R, Benesch M, Dorn-busch HJ, Sovinz P, Schauenstein K, Schumm M, Handgretinger R: Unrelated peripheral blood stem cell transplantation with 'megadoses' of purified CD34+ cells in three children with refractory severe aplastic anemia. Bone Ma\nrrow158Transplant 25:513, 2000 \nRuck P, Wichert G, Handgretinger R, Kaiserling E: Ep-CAM in malignant liver \ntumours. J Pathol 191:102, 2000 \nSchafer H, Bader P, Kaiserling E, Klingebiel T, Handgretinger R, Kanz L, Einsele \nH: Extramedullary relapses at uncommon sites after allogeneic stem cell trans-plantation. Bone Marrow Transplant 26:1133, 2000 \nSchilbach KE, Geiselhart A, Wessels J T, Niethammer D, Handgretinger R: Hu-\nman gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother 23:536, 2000 \nSchilbach K, Geiselhart A, Handgretinger R: Induction of proliferation and aug-\nmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood 97:2917, 2001 \nSchlegel PG, Eyrich M, Bader P, Handgretinger R, Lang P, Niethammer D, \nKlingebiel T: OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol 111:668, 2000 \nSchwinger W, Urban C, Lackner H, Kerbl R, Benesch M, Dornbusch HJ, Sovinz \nP, Schauenstein K, Schumm M, Handgretinger R: Unrelated peripheral blood stem cell transplantation with 'megadoses' of purified CD34+ cells in three chil-dren with refractory severe aplastic anemia. Bone Marrow Transplant 25:513, 2000\nSchwinger W, Urban C, Lackner H, Kerbl R, Benesch M, Dornbusch HJ, Sovinz \nP, Schumm M, Handgretinger R: Unrelated partially matched peripheral blood stem cell transplantation with highly purified CD34+ cells in a child with Wiskott-Aldrich syndrome. Bone Marrow Transplant 26:235, 2000 \nOther publications\nBurdach S, Braun T: Translational research in stem cell biology and cell based \ntherapy. ESPHI 2001 \u2013 XVIII Congress of the European Society for Paediatric Haematology and Immunology. Lucerne, 2001 \nBurdach S: Patentrecht: eine neue Dimension der medizinischen Ethik? Mittei-\nlungen der deutschen Patentanw\u00e4lte Januar:9,2001.\nPatents\nNone planned. \nB.5 Networking \nThe project has successfully increased horizontal knowledge transfer by intense \nnetworking between treatment centers on a national and international level. Common concepts for the clinical application of immune and gene therapy have evolved from discussions among the partners working on the project. This has led to increased transparency of treatment protocols and to the establishment of treatment standards, one of the aims of Project H.\nProject H has also emphasized the vertical knowledge transfer to patients, their \nfamilies, primary care pediatricians and the interested public by placing the regis-159try of research projects and clinical studies on the project\u2019s webpage. The co-\noperating partners of the project consider the provision of reliable information concerning immune and gene therapy of malignant disease a major added value of Project H.\nOn the basic research level networking with the BioinformaticsCenter of the Mar-\ntin-Luther-University Halle-Wittenberg and the IPK Gatersleben has been a major step towards the creation of a gene expression data base of pediatric malignan-cies. Project H has also begun to co-operate closely with Project G (embryonic tumors) and D (resistance to chemotherapy). It goes without saying that Project H is well integrated into the network of the GPOH. In particular cooperative efforts have been made with the LESS-Project of the GPOH to identify a genomic risk profile for the development of secondary malignomas.  \nOn behalf of Project H the University Children\u2019s Hospital of Halle has submitted a \nresearch proposal for a BMBF-PaedNet-Module to promote the pharmacological evaluation of immune and gene therapy of pediatric malignancies. The network-ing activities with the BMBF-project will foster further progress in the development of gene and immune therapeutic treatment strategies.\nTwo research scholarships granted to collaborators of Project H have led to the \ninitiation of new co-operations with national and international partners.  \nFinally, Project H has co-operated closely with the BMBF-Research Center Im-\nmunology Sachsen-Anhalt.  \nIn summary the added value of the project\u2019s networking activities include the in-\ncreased transparency of immune and gene therapeutic treatment options, the establishment of general therapy standards, the preparation of a gene expression database, horizontal and vertical knowledge transfer and an improved dialogue with institutions in- and outside the pediatric community.\nAs a result of the work of the first funding period Project H has been officially \ncommissioned by the GPOH/KPOH to function as a coordinating quality assur-ance facility for gene expression analysis of pediatric tumors in the second fund-ing period of the competence network. 160Part C \u2013 Follow-Up Proposal \nC.1 Aims\nThe aims set down in the initial proposal have been achieved. The goals of Pro-\nject H, in particular with respect to functional genomics, public relations, provision of information concerning regulatory and legal issues and project registry (PIaGen) are still relevant. Project H wants to shift its focus from establishing network structures to using them efficiently for the advancement of pediatric im-mune and gene therapy. Project H has been officially commissioned by the GPOH/KPOH to establish a quality coordination center for gene chip analyses of pediatric tumors. \nFunctional Genomics\nAnalysis of gene expression profiles of tumor cells using gene chip technology \nhas the advantage of generating in shortest time a huge quantity of data which is then available for further studies. In addition to the direct identification of target structures for new therapeutic (e.g. immunological) strategies it provides the pos-sibility to use gene expression profiles for the identification of risk groups and to utilize these data for prognosis. Both, the identification of new target structures and the molecular definition of risk groups are still at the beginning. It is indispen-sable for the mentioned tasks to examine a preferably high number of tumor samples. This should be organized and coordinated concomitantly to studies of the GPOH. \nToday the non-standardized preparation and processing of samples still consti-\ntutes a major problem of gene chip analysis since it complicates the comparability of data from different laboratories and the interpretation of partly contradictory results is difficult. \nA major aim of Project H is the coordination of gene expression analysis of all \npediatric malignancies reported in Germany and Austria. In the initial phase of the project great effort has been made to standardize the processing of tumor sam-ples and to create the necessary network structures.  \nThe focus of the follow-up proposal is on using the established structures for effi-\ncient tumor gene expression analysis and identification of target structures for immune and gene therapy. Data obtained with the tools of functional genomics will be made available to all participating centers. The data can then be used for the design of individual immune and gene therapies (vaccines, antibodies). A data base containing the genetic expression profiles of all screened pediatric ma-lignancies is planned in co-operation with the BioinformaticsCenter of the Martin-Luther-University Halle-Wittenberg and the IPK Gatersleben.  \nSignificant synergy will be created by establishing reference centers and by shar-\ning the resulting data. In addition, the standardized processing and analysis of tumor samples will improve quality of tumor gene expression analysis leading to more precise and targeted therapeutic strategies. \n           \u2026  161Public Relations\nThe participating centers wish to continuously increase the acceptance of im-\nmune and gene therapeutic treatment strategies in the general public as well as in the medical and legal community with educational campaigns, a national meet-ing and various public relation activities. \nProvision of Information concerning Regulatory and Legal Issues\nThere is still a significant information deficit concerning the regulatory and legal \nissues of gene therapy and immunotherapy. The project will continue to provide the necessary information to the treatment centers. The heterogeneity docu-mented in the treatment practices of the participating centers calls for standard-ized approaches to study and research planning, approval and conduction. \nProject Registry (PIaGen)\nProject H wants to maintain the registry of immune and gene therapeutic re-\nsearch projects and clinical trials (PIaGen) which has been initiated in the first funding period. Recently, a collection of immune and gene therapeutic treatment protocols has been started. A major aim of the second funding period is the documentation of the clinical effects of immune or gene therapy on all patients individually in Germany and Austria to increase the comparability of different trial designs.\nResearch Scholarships\nThe two research scholarships granted to collaborators of Project H in the first \nfunding period have led to a significant knowledge transfer on a national and in-ternational basis. The fast progress in the field of immune and gene therapy of malignant disease necessitates continuous exchange and networking of all scien-tists involved. The development not only of immune and gene therapeutic treat-ment strategies but also of monitoring techniques for their effects requires co-operation between treatment centers on a national and international level.\nHence, Project H wants to continue its successful strategy of granting research \nscholarships to support collaborating researchers in their efforts towards estab-lishing new techniques and concepts in their laboratories in the second funding period. The traveling expenses include research scholarships and have been cut significantly in comparison with the first funding period on request of the network coordinating center in favor of the Micro-Arrays and reagents for chip-preparation and -processing.\nC.2 Methodological approach \nFunctional Genomics - Implementation of a coordination center for gene chip \nanalysis\nFor analysis of gene expression profiles of pediatric tumor samples, we (i) will \nuse commercially available chips and (ii) will develop new chips with optimized design for the analysis of these samples (\u201cPedOncoChips\u201d). Our experience with the analysis of more than 400 tumor samples during the last years demonstrated that reproducibility and inter-sample-comparability is highest when sample-processing and chip-processing of all samples are performed under the same defined conditions.         \u2026 162For this reason the aim of this project is to create the basis for standardized and \nvalidated investigation and storage of expression profiles of tumor material from the area of the GPOH and the KPOH. For this end, reference centers for gene chip analysis have to be established and supported in the establishing period which can carry out study-accompanying gene expression profiling of tumor samples. At the same time, establishing standards for sample preparation is sup-posed to ensure that gene expression profiles, which result from the examination of different tumor entities, can be used for comparative investigations. In the course of the setup period, the reference centers which have to be established \nshould have the opportunity to achieve proper certificates by fulfillment of quality standards that have to be established first by the cooperating institutes. These certificates should qualify these centers as \u201egene chip reference centers\u201d for the accompaniment of clinical studies. With regard to comparative analysis of data material the introduction of these standards is absolutely essential. In addition, the conditions for gene chip experiments in the participating centers have to be optimized by the foundation of a \u201eChip Consortium\u201d that uses an appropriate quantity of chips for optimized purchase conditions. \nIn the laboratories of the Children\u2019s Cancer Research Center Halle and other cen-\nters of the KPOH the complete equipment for processing of high-density and/or spotted arrays is well established. For the development of \u201cPedOncoChips\u201d, samples from tumor banks of the KPOH will be send to these centers and will be analyzed on high density chips with complete genome information first. The data will be processed and stored on a server with access for all interested members of the competence network and the GPOH. In parallel, we will use data from the literature, from our previous experiments, and from the data obtained in this study using commercial chips for the development of a \u201cPedOncoChip\u201d. With increasing knowledge about gene expression in tumors the design of the \u201cPedOncoChip\u201d will be improved continuously.\nThe obtained information on gene expression in pediatric tumors can be used for \nexample for molecular classification of tumors or for the identification of new tar-gets for immune and gene therapeutic interventions. The surplus value of such data for the pediatric oncology is evident.  \nProvision of Information concerning Regulatory and Legal Issues\nProject H wants to continue the successful concept of making information con-\ncerning regulatory and legal issues of immune and gene therapy gathered through networking activities available for all partners co-operating in the net-work. Among others the project\u2019s experience includes writing of standard operat-ing procedures (SOPs), setting up GMP-suitable laboratories and treatment facili-ties and study design. All network partners will hence profit from the experiences made by others.\nProject Registry (PIaGen)\nProject H invites all German and Austrian treatment centers to register their re-\nsearch projects and clinical studies. The registry will continue to be available online on the homepage of the project. The project registry will be expanded to include a collection of treatment protocols and a database containing the data on the clinical course and outcome of all pediatric patients having received immune or gene therapy.\n            \u2026  163Public Relations\nThe centers co-operating in Project H want to satisfy the public need for reliable \ninformation on the options of immune and gene therapy for the treatment of pedi-atric malignant disease. The project\u2019s home page displays the state of the art of immune and gene therapeutic research in Germany and Austria. The registry of clinical studies shows the scope of clinical application of different treatment con-cepts. Project H will participate in the creation of booklets and brochures of the competence network. The dynamic field of immune and gene therapy can easily evoke unrealistic hopes and expectations in patients and their families. Project H wants to provide realistic and reliable information on the options and chances of immune and gene therapy. To this end national meetings are planned.  \nResearch Scholarships\nResearch scholarships will be granted to co-operating partners with the aim of \nestablishing new techniques necessary for the development of immune and gene therapeutic treatment strategies in their laboratories. All proposals must meet standard requirements. If necessary, the proposals will be reviewed by external experts.\nC.3 Work plan \nFunctional genomics\nIn order to establish a coordination center for gene chip analysis, we will deter-\nmine the current gene chip activities in the field of the KPOH. This investigation is supposed to register:\n1. which institutions are interested in carrying out own chip analysis, \n2. which institutions are already using this technology, 3. which institutions have the necessary technical equipment  \nat their disposal resp. which devices may be used, \n4. which technology is being used currently, 5. what was the whole amount of analyzed  \nsamples during the last 12 months, \n6. which tumors have been worked on and 7. which institutions for bio-informatics support\nthe project with how many scientists. \nOne major aim of this part of the investigation will be the identification of laborato-\nries working on the same tumor entities. This will help to avoid the accidental re-dundant analysis of the same tumor samples at different centers and will lead to optimal utilization of limited resources.\nFurthermore, in order to establish an appropriate standard of quality, it is neces-\nsary to document the protocols that have been used for the processing of the samples and to let them circulate between the participating institutions. These protocols shall give the basis of the standard that has to be agreed upon. \nMoreover, during the period of establishment of the reference centers, represen-\ntative samples, either from the hybridisation dilutions which have already been used in the particular institutions or (if possible) fresh tumor material, shall be 164sent to the coordination centers in Halle and other locations to be determined in \norder to analyze the corresponding samples again. The results of these data analysis have to be exchanged between the corresponding centers. Thus, it ought to be achieved that potentially occurring problems can be recognized and solved at an early point of time.\nGene expression data generated in participating centers will be used for the de-\nvelopment of a chip with optimized design for pediatric oncology (\u201cPedOn-coChips\u201d). Chips will be designed that contain all known oncogenes and tumor markers relevant for pediatric tumors. In addition to the detection of full-lengths wild-type RNA-species, these chips will allow detection of mutated genes (i.e. point mutations and translocation-related fusion transcripts).\nData from the literature and the results from the high density chips will be used \nfor continuous improvement of the design of the \u201cPedOncoChip\u201d. A cooperative data storage and maintenance system will be established that includes a search-able data base with gene expression profiles of all tumor samples that have been processed. This data base will be available for further studies.\n 2002 2003 2004 \nEstablishing and Coordi-\nnation of Reference Centers\nTumor sample acquisition    \nAnalysis of high-density \narrays    \n\u201ePedOncoChip\u201d Develop-\nment   \nImplementation of  \ndata server \nIn addition, Project H will provide reliable information on immune and gene ther-\napy of pediatric malignancies throughout the entire second funding period. It will participate in the creation of information brochures and booklets for patients, their families and primary care pediatricians.  \nThe collaborators of Project H see a persisting need for the provision of expertise \nto meet regulatory and legal demands on the practical application of immune and gene therapeutic treatment strategies. The centers will therefore increase the co-operative efforts in the second funding period.\nThe project registry (PIaGen) and the collection of treatment protocols will be \ncontinued.\nA database containing information on the clinical course and outcome of all pedi-\natric immune and gene therapy patients will complement the registry and will in-165crease treatment transparency. Finally, research scholarships will be granted \nthroughout the entire second funding period. \nC.4 Networking  \nNetworking in Project H will continue contributing to the overall goals of the com-\npetence network. All centers involved will join in the ambitious functional genom-ics project aiming at the implementation of quality standards for gene expression analysis of all pediatric malignancies in Germany and Austria. This can only be achieved in a joint effort of all centers involved in gene expression analysis.\nCo-operation with the GPOH-LESS study will be intensified to use the gene chip \ntechnology for identification of patients at risk of developing secondary malignan-cies.\nThe added value will consist of an increased amount of tumor samples to be ana-\nlyzed because all centers can send in their tumor material and gene expression analysis under standardized conditions. The implementation of quality standards and of requirements to be met by centers performing gene expression analysis of pediatric tumors will increase the overall quality and validity of the resulting data.  \nThe data will be stored in a gene expression data base to which all participating \ncenters will have free access. The data base will be generated in close co-operation with the BioinformaticCenter of the Martin-Luther-University Halle-Wittenberg and the IPK Gatersleben. Treatment centers and functional genomics facilities will work hand in hand. The increased amount of tumor samples avail-able for analysis and the improved quality of gene expression analysis are major added values of Project H. Efficient gene expression analysis will fasten the dis-covery of relevant tumor antigens as targets for immune and gene therapy, ulti-mately leading to new therapeutic options for afflicted patients.\nThe register of immune and gene therapeutic research projects and clinical trials \n(PIaGen) which is available online also contributes to the goals of the compe-tence network by increasing horizontal and vertical knowledge transfer. The pro-ject registry creates significant synergy by reducing redundant research and in-creasing communication between the participating centers.\nThe extension of the registry to document the clinical course of every pediatric \npatient treated with immune and gene therapy is another networking effort of Pro-ject H. It will increase the comparability of different treatment trials, which is of particular importance because the numbers of patients treated in the individual protocols is usually small. This should lead to the initiation of co-operative im-mune and gene therapy trials to allow for a thorough statistical evaluation. The registry is a central element of quality control of treatment regimens.  \nProject H will continue improving horizontal and vertical knowledge transfer con-\ncerning evolving concepts of immune and gene therapy by networking between treatment centers, patients, their families and primary care pediatricians. Project H has become a platform providing reliable information on the state of the art of immune and gene therapeutic research and clinical trials in Germany and Austria. It will keep up its efforts in this regard.\nResearch scholarships for investigators of the participating centers have led to a \ntransfer of new techniques and scientific approaches into their laboratories and to increased networking between centers on national and international basis in the first funding period. Therefore, Project H wants to continue granting research scholarships in the second funding period. 166Part D- Requested Funding for the Project \nD.1 Salaries\n1 Scientist; BAT-O IIa: 48246 \u20ac p.a.: The scientist will support the register of im-\nmune and gene therapeutic research projects and clinical studies (PIaGen). He will also co-ordinate the implementation of the gene chip analysis quality assur-ance project and the development of a \u201ePedOncoChip\u201d.\n1 Technician; BAT Vc: 35106 \u20ac p.a.: This technician will be responsible for isola-\ntion and processing of RNA from tumor samples in course of the gene chip analysis quality assurance project. \nD.2 Consumables\nMicro-Arrays and reagents for chip-preparation and -processing required for the \ngene chip analysis quality assurance project:     78500 \u20ac p.a. \nReagents for the development of the \u201ePedOncoChip\u201d:   11500 \u20ac p.a. \nIncluded are costs for commercially available chips and for the development of \nnew chips with an optimized design for the analysis of pediatric tumor samples (\u201ePedOncoChip\u201d).\nD.3 Investments\nTwo high-performance PCs for data analysis and -storage:   10000 \u20ac.  \nOne PC will be necessary for comparative data analysis in Halle. This PC will be \nused for analysis of data sets in course of standardization and quality assurance of gene chip analysis. A second PC will be necessary for the implementation of an on-line data base of gene-chip data with restricted access for members of the GPOH network. \nD.4 Other Costs \nTraveling expenses:        5000 \u20ac p.a. \nThe traveling expenses include research scholarships and have been cut signifi-\ncantly in comparison with the first funding period on request of the network coor-dinating center in favor of the Micro-Arrays and reagents for chip-preparation and -processing. The implementation of efficient quality assurance structures requires sufficient financial support for the organizing of meetings and the provision of lo-cal on-site support. 167Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Late Effects and Quality of Life [1] \n  A Vertical Network for  \n  Pediatric Oncology [2] (Project I)  \nGrant No. : 01 GI 99 66  \nName of scientist-in-charge : Dr. Gabriele Calaminus \nInstitution : Children's Hospital \n  University of D\u00fcsseldorf \nAddress : Moorenstr.5 \nPhone : +49 (0) 21 1 \u2013 81 1 \u2013 91 08  \n  +49 (0) 21 1 \u2013 81 1 \u2013 61 00  \nFax : +49 (0) 21 1 \u2013 81 1 \u2013 62 06 \nE-mail : calaminus@med.uni-duesseldorf.de \nProject home page (if different from \nNetwork homepage) : http://www.med.uni- \n  duesseldorf.de/kmnpoh-Lq/ 168Part A - General Statements about the Project\nA.1.Subject\nEvaluation of Late effects and QoL in patients with ALL and brain tumors [1] \nEstablishment of a vertical network between medical caregivers and creation and \nimplementation of disease specific standardized operating procedures for (long) term follow-up [2]\nA.2. Co-Investigators\n\u0083 J. Beck, University Children\u2019s Hospital, Erlangen [1] \n\u0083 U. Ravens-Sieberer, Robert Koch Institute, Berlin [1] \n\u0083 J. K\u00fchl, H. Ottensmeier, W\u00fcrzburg [1] \n\u0083U. Creutzig, Coordination and Management Group, Competence\nNetwork Pediatric Oncology and Hematology, Hannover [2] \nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 130,9 12,5 0 0 0 142,40 \n2004 130,9 12,5 0 0 0 142,40 \n1(amounts in thousand Euro), \n* should correlate to funds specified in Part D169Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThis project which is unique in  in Europe comprises two parts : [1] Late effects \nand Quality of Life and [2] A Vertical Network for Pediatric Oncology  \n[1] Within the first funding period an effective cooperation between 18 institutions \nwas established to estimate somatic, psychological and QoL data in newly diag-nosed ALL and brain tumors.  Compliance to the testset and to the participation in the pro\nject is satisfactory. Regarding Concerning the results it becomes clear \nthat patients with a brain tumor suffer more from impairements and negative in-fluence of  the disease and treatment than patients with leukemia . Specifically visuomotoric and concentration is a problem, whereas global intelligence is not significantly different. It becomes visible that patients groups of high risk for psy-chosozial, neuropsychological and QoL abnormalities can be defined, who there-fore need more extensive support than the others. The used instrument set was useful in most of its parts. Since a reduction of tests was planned after the first period, extensive analyses were prepared and led to a first suggestion. A prob-lem appaers in collecting and completion of somatic data, as this cannot be done by the psychologists who are the main cooperators in the project. As these data are of importance for correlation with psychosozial and QoL issues this must be improved.\n[2] Contacts between involved expert groups and professionals were established \nas well as the development of standardized recommendation for relapse diagnos-tic and follow-up for most GPOH trials. Preparations in cooperation with the coor-dination centre of the whole network and especially the LESS office (Prof. Beck) are ongoing to prepare presentations concerning disease, treatment, toxicity and long term after care for medical caregivers as well as for laymen for presentation in the network. \nFor both parts, it became visible that administrative work within the projects \nneeds more manpower because this very important part of the project is steadily increasing. Therefore financial support for an AIP Arzt im Praktikum) will be needed and applied for.\nB.2 Original aims of the project \n[1] Children with cancer suffer from disease, treatment and the consequences for \ntheir life, which can sometimes be impaired lifelong. A prospective evaluation of health status, psychological aspects and well-being has never been investigated so far, although a systematic evaluation of these areas in P.O. is lacking. There-fore, a core set of instruments should be identified for broad use within P.O. to measure these areas and adapt patients and familiy support to the results, which are collected at 4 different time points during treatment and within the follow-up. This is only possible in a multicentre setting, which is established within the pro-ject. Target groups are patients with ALL as the most common disease and pa-tients with brain tumors, who have the highest burden of disease and treatment. 170The question shall be cleared, what differences in health status, psychological \nissues and QoL between these groups are detecable and what specific problems can be defined (A). Within the first part of the project it was also aimed to validate the instruments and suggest a first reduction after two years, if possible (B) \n[2] The vertical network aims to build up structures for the exchange of informa-\ntion between caregivers and to patients and laymen. The task is also to develop standardization for relapse diagnostic and follow-up recommendations. (C, D) \nB.3 Scientific results \n1 A: Neuropsychology: (see Annex 1) Intellectual abilities (K-.ABC, K-Tim) are \nnot significantly different between leukemia and brain tumor patients. There is a difference but for both group at time point 1 and 2 Global IQ is within the normal range. For visuomotoric integration (VMI) there is also a difference but not a sig-nificant one. Speed components and concentration (D2, DL-KG and DL-KE). Brain tumor patients show impairment in these components from the beginning (tumor related?). \nQoL: (Annex 2) Children with cancer at diagnosis (E1) express negative QoL rat-\nings specifically in the domains: physical functioning (K), cognition (C) emotion (E) and autonomy (AUT). Brain tumor patients express specifically autonomy and social functioning (Fam) within the family negative. At E 2 these negative ratings are again obvious although they are little improving in most domains. Compari-sons of patients\u2019 and parents\u2019 ratings reveal a significantly more negative rating of the parents viewing their children QoL.\nComparison of psychosocial and QoL data. (Annex 3): Patients with abnormali-\nties in their psychosocial history are at risk to develop (neuro-) psychological and QoL impairment. This has to be evaluated further when different time points of evaluation can be compared. \nIn conclusion. The project generates important and unique, never reported infor-\nmation on health status and QoL. Late effect data will be available within the fol-low-up at time point 4.\n1B: On major task underlined by the reviewers of the project is the survey of the \nused instruments in terms of concurrent validity (Annex 4), practicability and rela-tion of expense and utility. Therefore, all available data sets of leukemia and \nbrain tumors were compared for correlation of tests, to find out if redundant measures are used. This is not the case. \nThrough checking of practicability, tapping as the measure of testing motor speed \nand reaction time appears to be problematic: Only old computers can be used, the software is often problematic and the test itself is reported to be not very at-tractive, as also no direct correlation can be drawn from the test between the measured values and the impairment, this instrument will not longer be recom-mended. It is free for the institutions to use it. Patients who were already tested with tapping should proceed with this to compare the different time points. In W\u00fcrzburg all patients will continue to be tapped as there the optimal setting (ex-pertise) is provided. Within the project as compensation additional parts of the VMI will be used and circulated to the cooperating institution. The FBT is a test with a high percentage of children at time point 2 who still remember the first evaluation, this influences the result. Therefore the FBT should be used at time 171point 1 and 3 and not at every time point. K-TIM: The experimental version, which \nis used in the project, bears several problems: It is not user friendly. Children with a brain tumor are often frustrated and do not want to go further. The K-TIM is not able to differentiate global IQ within lower ranges. Therefore as also stated in the literature for brain tumor patients, the Wechsler scale will be suggested for use in the second part of the project for all patients with brain tumors, already at 6 years of age. The use of the Wechsler scales will also implement a part for concentra-tion and speed which is redundant to D2/DL-KE/DL-KG, so these can be ex-changed if the Wechsler scales are used.\nQOL instruments (Annex 5): The first investigation with the MAP analysis re-\nvealed that the sensitivity and the concurrent validity between the used instru-ments is good and that the PEDQOL is a sensitive and reliable QoL measure for patients with cancer. Therefore, no changes will be done for the QoL set. As it appears that the CHQ as the parent measure is more pointing out on behavior than on well-being, the parents\u2019 form of the PEDQOL will be used in addition and circulated to the participating institution.\n2C. The preparations for presentation of information for caregivers and laymen \nabout disease and treatment as well as follow-up are still under process. An in-formation portal is already created and the contents will be added in second part of the funding period.\n2D. Within the vertical network so far the following guidelines in form of flow \nsheets are prepared or nearly finished so far: AML/ALL, germ cell tumors, Neuro-blastoma, Wilm's-Tumor, Hepatoblastoma, NHL, sarcoma, still pending are Hodgkin and brain tumors (Annex 7). \nB.4 Publications and patents \nLanger T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W. CNS late-\neffects after ALL-therapy in childhood Part III: Neuropsychological performance in long-term survivors of childhood ALL. Impairments of distractibility, attention and memory and its interferences to CNS morphology. Med Pediatr Oncol. In Press2002\nMarx M, Beck JD, Grabenbauer GG, D\u00f6rr HG. Spontaneous nocturnal growth \nhormone secretion in children after medulloblastoma therapy. Med Pediatr Oncol 36:494-496,2001.\nLanger T, Henze G, Beck JD. Basic methods and the developing structure of a \nlate effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH). Med Pediatr On-col 34:348-51,2000. \nM\u00fcller HL, Bueb K, Bartels U, Roth C, Harz K, Graf N, Korinthenberg R, Betten-\ndorf M, K\u00fchl J, Gutjahr P, S\u00f6rensen N, Calaminus G. Obesity after childhood craniopharyngioma\u2013German multicenter study on pre-operative risk factors and quality of life. Klin P\u00e4diatr. 213:244-9,2001 \nCalaminus G, Weinspach S, Teske C, G\u00f6bel U. Quality of life in children and \nadolescents with cancer. First results of an evaluation of 49 patients with the PEDQOL questionnaire. Klin P\u00e4diatr. 212:211-5,2000. 172Patents\nNone planned.\nB.5 Networking \nThe character of the project itself is a total network project as it can only be es-\ntablished and successfully promoted with a network of partners. \n1. Late effects and QoL  \nHere the cooperating institutions build up a network to require information on health status and well-being, added through the collaboration of the 3 study centers (CoALL, ALL-BFM and HIT 2000). The partners are networkingthrough the project center in D\u00fcsseldorf and the cooperation partner in Erlan-gen.   Within the project as a result for the network a core set for evaluation of late effects and QoL will be defined for broad use in P.O. \n2. Vertical Network  \nHere different groups are networked for designing standard operational pro-cedures (SOP) for relapse diagnosis and follow-up of children with cancer. Together with the coordination center of the whole network an information structure via internet will be established for distribution of information accord-ing disease, treatment and follow-up. To generate the information needed,again networks of partners have to be established (clinicians, general practi-tioners, health care system, LESS, QoL, study coordinators, experts, cancer registers).\nAs a surplus for the health care system, SOPs for most disease groups in Pediat-\nric Oncology will be available as well as  an information system for all target \ngroups of the vertical network (see point 2).  173Part C \u2013 Follow-Up Proposal \nC.1 Aims\nThe objectives of the initial project are still relevant and achievable. Several aims \ncan be achieved at the end of the second period: \nThree points need a change according to the initial proposal \n1. The collection of the somatic data in the institutions is an immanent problem. \nThese data are absolutely necessary to correlate somatic and psychosocial and QoL data. Also late effects cannot be valued which is an important part of the project. Therefore, medical students on an hourly base will be applied for to support the cooperating institutions. This system is working very efficiently in Berlin and M\u00fcnster, which are paying students for such a support from own expenses already.\n2. The administrative work within the project part [1] and part [2] has increased \nand is still further increasing. In D\u00fcsseldorf for both parts of the project only one BAT Ib/2 position is available for the whole work load. Therefore it is planned to apply for an AIP (Arzt im Praktikum) position in addition, which would be able to do part of the administration, contact the cooperating institu-tions, has the responsibility for the students and for the data collection through students for the medical data.\n3. Change in the set of instruments as recommended test set will be the use of \nthe FBT at time point 1 and 3, the extension of VMI, no more recommendation to use the tapping , a use of the Wechsler scales in patients with brain tumors and then, the abdication of D2, DL-KG, DL-KE, if the Wechsler scales are used. Therefore, all institutions will be asked to implement the HAWIK/HAWIE in their test set. The K-TIM will be continuously used in the ALL population .\nC.2 Methodological approach \nSee point 3 above. \nC.3 Work plan \nPart [1]\n\u0083 Further recruitment of patients until the end of 2002,\nfurther collection of somatic, psychosocial and QoL data \n\u0083 Improvement of feedback of medical data \n\u0083 Interim analyses of data at the end of 2002, presented at scientific meetings. \n\u0083 Publication of results (public media and scientific media) 2003 and 2004 \n\u0083 Further work on the definition of a core set.  \nPlanned definitely for the end of 2004.\nPart [2]\n\u0083 Creation and establishment of SOPs for all diseases, in term of relapse\ndiagnosis, follow-up and risk of second-malignancies (2003 and 2004) \n            \u2026  174\u0083 Establishment of the internet presentation of an information structure for\nmedical caregivers and laymen according to disease, treatment,aftercare (2003 and 2004) \n\u0083 First publication of results in public and scientific media (2003 and 2004). \nC.4 Networking  \n1. With the coordination and management group (project A) of the competence \nnetwork for part [2] of the project I.   Establishment of the net presentation of information structure for medical caregivers and laymen according to disease, treatment, aftercare (2003 and 2004) \n2. With Project K for follow-up SOPs concerning second malignancies, with \nAPRO, LESS, GPOH and associated groups for the relapse and after care \nguidelines.   Creation and establishment of SOPs for all diseases, in term of relapse diag-nosis, follow-up and risk of second-malignancies (2003 and 2004).\nPart D- Requested Funding for the Project \nD.1 Salaries (given in \u20ac) \nPosition Post Location  2003 2004 \nAiP D\u00fcsseldorf 20452 20452 \n0,5 BAT Ib D\u00fcsseldorf 31000 31000 Scientific\npersonnel\n0,5 BAT IIa Erlangen 29000 29000 \nData Manager 0,25 BAT IVb D\u00fcsseldorf  7000 7000 \n D\u00fcsseldorf 36500 36500 \n Erlangen  4600 4600 Student\ncoworkers\n W\u00fcrzburg 2300 2300 \nSum    130852 130852 \nScientific personnel\nD\u00fcsseldorf: administration of the project, development of SOPs for vertical net-\nwork, scientific preparations: \u00bd BAT Ib \nCoordination and collection of medical data supervising of partner institution and \nmedical students in respect to complete and quick data transfer: supporting the administrative work, data entry, data checks in the data bank, transfer of data to Erlangen: 1 AiP (Arzt im Praktikum) 175databank, scientific presentations, evaluation of neuropsychological data, data \ntransfer to D\u00fcsseldorf\nNon-scientific personnel\nD\u00fcsseldorf: Data entry of QoL data, scientific evaluations \u00bc data manager\nFor all cooperating institutions support for medical data collection: 4 x 19,5 hours of a medical student/week \nErlangen: Data entry from paper forms: medical student 10 hours a week W\u00fcrzburg: Support of the psychologist in charge of the study in W\u00fcrzburg, data \nentry and evaluation of tapping data: medical student 2,5 hours a week \nD.2 Consumables (given in \u20ac) \nPosition Location  2003 2004 \nAdministrative costs D\u00fcsseldorf 2000 2000 \nBonus system costs D\u00fcsseldorf 1500 1500 \nInstruments Erlangen 6000 6000 MAP analys Berlin 3000 3000 \nSum   12500 12500 \nD\u00fcsseldorf \nAdministrative costs (copies, stamps, prints of QoL measures ) 2000 \u20ac/year \nCosts to pay the bonus system: For improving compliance of patients to have all \n4 evaluation time points a bonus system was implemented: For each evaluation time point they can receive a little present or they can save their points until the whole evaluations are done (2 years) After these system was integrated compli-ance improved and number of patients who refused to be tested again decreased to nearly zero. Therefore in the next two years 1500 \u20ac/year has to be applied for \nto pay this system which would cover the costs for about 50 new patients.\nErlangen\nCosts for neuropsychological measures (added part of VMI): 6000 \u20ac/year Berlin Robert Koch Institute\nSensitivity tests at the end of 2002 and at the end of the project for final definition \nof core set of QoL evaluation 3000 \u20ac/year for MAP analysis.\nD.3 Investments\nNone.\nD.4 Other Costs \nNone.176Section 3 \nMidterm Report of Running Projects and \nApplication for Continued Funding \nTitle Page \nNetwork title :  Second Malignant Neoplasms  \n  after Childhood Cancer (Project K)  \nGrant No. : 01 GI 99 67/3 \nName of scientist-in-charge : Dr. Peter Kaatsch, PhD \nInstitution : German Childhood Cancer Registry \n  (GCCR, Deutsches Kinderkrebsregister) \nAddress : Institute for Medical Biostatistics, \n  Epidemiology and Informatics  \n  (Institut f\u00fcr Medizinische Biometrie,  \n  Epidemiologie und Informatik, IMBEI) \n  55101 Mainz \nPhone : +49 (0) 61 31 \u2013 17 \u2013 31 11 \n  +49 (0) 61 31 \u2013 17 \u2013 67 12 \nFax :  +49 (0) 61 31 \u2013 17 \u2013 29 68 \nE-mail : kaatsch@imsd.uni-mainz.de \nProject home page (if different from \nNetwork homepage) : ------------------------------------------------------------------------------------------ 177Part A - General Statements about the Project\nA.1.Subject\nSecond Malignant Neoplasms after Childhood Cancer \nA.2. Co-Investigators\nName of scientists: None.  \nInstitutions:  None.  \nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes: \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 95 0,6 0 1,5 0 97,1 \n2004 99 0,6 0 1,5 0 101,1 \n1(amounts in thousand Euro),\n * should correlate to funds specified in Part D178Part B \u2013 Results from the First Funding Period\nB.1 Summary \nThe goal of the project is estimating incidence rates and risk ratios for secondary \nmalignant neoplasms (SMN) after childhood malignancies and determining which risk factors might cause SMN. \nIn cooperation with the GPOH, its therapy optimization trials (clinical trials), and \nthe treating hospitals, the German Childhood Cancer Registry (GCCR) has es-tablished an integrated information flow. This allows systematic documentation of SMN after childhood cancer and makes various clinical parameters (e.g. therapy, previous diseases) available. It is the basis for analyzing potential risk factors for developing SMN.\nWith the help of the principal investigators of the clinical trials we have validated \nall already known cases with SMN; furthermore we developed a uniform proce-dure to prospectively validate new SMN cases. We are progressively optimizing our long-term follow-up for 25000 individuals with cancer in childhood docu-mented as living at the GCCR, supported by a computerized managing system. Nearly full coverage of SMN cases is thus ensured. \nBased on the currently 373 SMN cases fulfilling our inclusion criteria we calcu-\nlated a preliminary 15-fold risk for developing SMN until age 30 compared to the general population. \nWe are preparing a case-control study assessing potential risk factors.\nB.2 Original aims of the project \nThe original aims were,\n\u0083 quantifying incidence rates and risk ratios of developing a secondary malig-\nnancy for children with a malignancy, \n\u0083 investigating to what extent elements of the primary therapy and/or genetic \nfactors influence the risk for developing a secondary malignancy, \n\u0083 giving input for conceptualizing programs for post-treatment care and sugges-\ntions for modifying primary therapy.\nB.3 Scientific results \nDuring the first funding period the following results have been achieved so far:\n(a) The infrastructure and uniform procedures for documenting and validating all \nSMN cases after childhood cancer and for performing an optimized long-term follow-up were established: \nRegistration and processing of newly reported SMN cases were integrated into \nthe routines of the GCCR. \nTo ensure high data quality, we had all SMN cases known to us until 12/1999 \nvalidated in close cooperation with the principal investigators of the relevant ther-apy optimization trials. All cases reported since 2000 are immediately validated 179prospectively together with the relevant clinical trials. \nTo ensure completeness we are basically organizing a life-long long-term follow-\nup. It is intended to ensure full coverage of SMN, including adult SMN. We devel-oped computerized managing routines for requesting information from hospitals, clinical trials, and families, as well as an automated reminder system. The basis for this is complete information (such as the address) at the primary registration. With the help of the managing system the following routines were implemented so far: \n\u0083 The hospitals are reminded of missing information 3 times a year shortly after \nthe primary report. \n\u0083 The further follow-up is included in the managing system. A status report of \nthe patients is requested annually \u2013 in the first years after diagnosis from the clinical trials and later from the hospitals. In 2000 about 4500 children were included when addressing the hospitals. We were able to obtain follow-up in-formation more completely than before (e.g. follow-up of osteosarcoma cases has improved: in 2000 20% more patients have follow-up data than in 1999). \n\u0083 We personally contact patients, who have reached or exceeded their 16th \nbirthday asking them to renew the consent to document their data, which had previously been given by their parents. We plan to repeat this annually for in-dividuals who reach their 16th birthday, because adult patients without in-formed consent have to make anonymous. In January 2002 we addressed about 3500 families. 900 had moved with unknown address, which means that - in an additional step \u2013 the project group will have to research their ad-dresses with the help of the municipal offices for the registration of residents. More than 55% of those who were reached by mail (about 1400 patients) sent their consent without a reminder. Only 44 families have so far explicitly re-fused their consent to further documentation. The remaining families are be-ing reminded. \nAdditionally we already made agreements with a number of general German \ncancer registries to match their data on cancer in adulthood with our data to en-sure complete registration of SMN. \n(b) Incidence rates and risk ratios for developing an SMN until age 30 were calcu-\nlated in Germany for the first time : \nIn order to estimate risk rates for developing SMN until age 30, the base risk in \nthe general population was determined using data of the GCCR (until age 15)and - from age 15 - of the Saarland cancer registry and the cancer registry of the former GDR. Currently this is the only data available in Germany with full cover-age of the respective region. Based on currently 373 SMN cases fulfilling our in-clusion criteria (SMN diagnosed since 1980, residence in Germany, primary ma-lignancy diagnosed at age less than 15 years) a 15-fold risk for developing SMN until age 30 compared to the general population was calculated. \nThe cumulative risk of SMN after a childhood malignancy in a defined period (e.g. \n10 years) is usually estimated using the Kaplan-Meier-estimator. We recommend using the Aalen-Johanson estimator instead, because this method considers death as a competing risk instead of a censoring event. The cumulative risk of developing SMN within 10 years after the primary neoplasm is 1.8%. \n(c) Establishing procedures for the documentation of therapy data and other clini-180cal data of SMN cases; preparing a case-control study of potential risk factors: \nIn accordance with the application we started preparing a case-control study of \nSMN risk factors. A comprehensive (still preliminary) protocol was set up for this study. The controls will be sampled from the registry. The study required revising the questionnaires for obtaining the specific data needed in the study; this step is finished. Next we needed an infrastructure, by which the clinical trials can pass their data (mainly therapy data of the first malignancy) on to us. A survey among the clinical trials found that electronic documentation was not generally possible. Many clinical trials have stored only some of the data in electronic form. Espe-cially for patients treated long ago and for patients treated outside of protocol data are not available in electronic form. Because of this, we still send paper forms to the clinical trials, where they are filled in by hand. Some clinical trials may require researching data locally by GCCR personnel. Data entry masks for the documentation forms are being prepared. The managing system is set up to \naccommodate the special needs of the case-control study.\n(d) An increasing number of requests regarding disease specific frequencies of \nSMN were answered promptly: \nThe importance of our database is also emphasized by frequent requests from \nhospitals and clinical trials regarding specific combinations of SMN, relative fre-quency of SMN or requests for risk estimates for specific constellations. Since the beginning of the funding period we were able to address about 20 such requests quickly and competently. This has an added value for the Pediatric Oncology as a whole.\nInternational state-of-the-art compared to our project\nWe are certain that data quality, completeness, and total number of SMN cases \navailable in our database are up to, or possibly above the current international standard (see e.g. Neglia et al. J Nat Cancer Inst 2001, 93: 618-629). We con-sider this to be due to the well-established intense cooperation of the GCCR with the GPOH and its clinical trials. \nThe risk estimates will become increasingly more reliable as the number of cases \nand the follow-up increase with time. So far the time period covered by the GCCR (which started in 1980) is not long enough to calculate realistic risk rates for can-cers occurring as a second malignancy after a long latency period. Therefore, the risks calculated at present are underestimated. Scandinavian cancer registries presumably have better calculations regarding this type of SMN. \nPopulation-based studies on risk factors for SMN have been published rarely. \n(Hawkins et al., Br J Cancer 1987, 56:339-347; Sankila et al., J Clin Oncol 1996, 14:1442-1446; Garwicz et al. Int J Cancer 2000, 88:672-678; Neglia et al., J Nat Cancer Inst 2001, 93: 618-629). We expect to make a major contribution to this issue internationally when we publish the results of our case-control study. \nMilestones as defined in the initial proposal\nThe results obtained so far correspond to the work plan of the initial proposal. \nThe milestones were accomplished, with one exception: the case-control study will start with a delay, as the discussion on the main hypotheses needed more time than expected; the delay is about 9 months.181B.4 Publications and patents \nL\u00f6ning L., Zimmermann M., Reiter A., Kaatsch P., Henze G., Riehm H., Schrap-\npe M.  Secondary neoplasms subsequent to Berlin-Frankfurt-M\u00fcnster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 95: 2770-2775, 2000. \nKaatsch P, Rickert CH, K\u00fchl J, Sch\u00fcz J, Michaelis J. Population-based epidemi-\nological data on brain tumors in German children. Cancer 92: 3155-3164, 2001. \nWibbing R, Kaatsch P, Kaletsch U, Michaelis J. Epidemiologische Untersuchun-\ngen von Sekund\u00e4rmalignomen nach Krebserkrankungen im Kindesalter. Mo-natsschr Kinderheilkunde 147: 982, 1999. \nKaatsch P, Spix C, Michaelis J. Second malignancies after childhood cancer. 20 \nYears German Childhood Cancer Registry \u2013 Annual Report (www.kinderkrebsregister.de) 64-5, 1999. \nPatents\nNone planned. \nB.5 Networking \nWe are contributing considerably to the improvement and consolidation of the \nintegrated information flow between hospitals, clinical trials and GCCR with our pro\nject. We were able to observe a general attentiveness to documenting each \ncase with SMN, and notifications are made timelier than before. Information on newly diagnosed SMN cases is being exchanged between the contributing insti-tutions more rapidly than before. The increasing number of requests regarding frequencies of SMN, which we were able to respond to promptly, also demon-strates the added value of the project for the paediatric oncology as a whole. \nBy optimizing the long-term follow-up we are not only improving the complete-\nness of registered SMN cases, but also the data quality of other follow-up infor-mation (such as long-term survival probabilities or late effects). This will benefit the network as a whole. The direct personal contact of the GCCR with the pa-tients helps to obtain further valuable data. The oldest individuals registered at the GCCR are meanwhile 35 years old. This opens perspectives for further inves-tigations, e.g. regarding fertility or descendants of former patients.  \nThis leads to an especially strong synergy with the project \u201eLate Effects, Quality \nof Life and Vertical Network\u201c of the Network (project I). Furthermore the SMN pro-ject provides important information for optimizing post-treatment care: such as frequency of SMN, latency periods, or risk estimates for specific entities. \nWe established a cooperation with the P\u00e4diatrischen Register f\u00fcr Stammzell-\ntransplantation (Pediatric stem-cell transplantation registry, PRST) during the funding period. It is important for obtaining therapy data for children, who re-ceived stem-cell transplantation (SCT) and developed a SMN later. The GCCR in turn provides the PRST with the information, which children developed a SMN. If the PRST does not have the therapy data itself, it addresses the treating clinic. The PRST is not part of the competence network, but this cooperation does nev-ertheless improve the networking within Pediatric Oncology. 182The increase in data quality may generally lead to better quality in research. This \nmay lead to improvements in diagnostics and therapy, a decrease in late effects, and a better quality of life for the patients. 183Part C \u2013 Follow-Up Proposal \nC.1 Aims\nThe research objectives of the second funding period are in principle the same \nas in the first phase. It is the consequent continuation of the work plan, which from the beginning covered a first and second funding period. \nThe emphasis of the second period lies on the investigation of potential risk fac-\ntors for SMN and on the continuation of the documentation of SMN cases, the therapy data of the primary malignancy, genetically caused prior diseases and previous malignancies or genetic dispositions of the parents and sibling. \nThis requires further extension of the long-term follow-up. The workload this cre-\nates increases continuously as the number of cases and survivors increases with time (currently there are 25,000 living cases in the registry). The cooperation with the German general cancer registries (usually one per German state) in or-der to match their patients and the pati ents at the GCCR will have to be consoli-\ndated.\nTo investigate to what extent elements of the primary therapy and genetic factors \ninfluence the risk for developing a secondary malignancy, we are now carrying out the case-control study on risk factors for SMN. The start of the study will be later than originally intended, as the discussion, which hypotheses are the most suitable ones and the general preparation for conducting the study took longer. \nOne of the aims defined at the beginning of the first funding period was deriving \nrecommendations for the post-treatment care of former patients. The results ofthe case-control study and the risk estimates are intended to contribute to this. Meanwhile we have realized that the translation of scientific results into specific rulings for patients and physicians requires more medical expertise and time than we have available. The channeling of such results into the practical work is possible only in close cooperation with the GPOH and the clinical trials. We ex-pect finishing this will not be possible within the funding period. Nevertheless,our results will certainly initiate such changes. \nScientific publications and the final repor t will also be important parts of the fur-\nther project.\nC.2 Methodological approach \nAt the beginning of the project, we had not decided what kind of study we would \nperform to investigate potential risk factors for SMN. After internal discussions and consulting external experts, we decided to use a matched case-control study as the most appropriate type of study for our purpose. \nMeanwhile we have found that assessing therapeutic as well as genetic risk fac-\ntors exceeds the framework of our time, personnel, and also the case-control study as a method. We were recommended to focus on fewer specific questions. We therefore will focus on therapeutic risk factors. However, potential genetic risk factors remain a relevant aspect of the project. \nWe are still looking for a cooperation partner regarding the genetic aspects. We \nhad first consultations with the newly established genetic institute of the univer-sity clinic in Mainz, as well as with an interested group at the National Cancer Institute in the USA. It may be necessary to interview the families in question di-rectly. In case this were recommended by the experts, it would go beyond the 184original scope of the study. \nWe document the therapy data and some aspects of the genetic predisposition \nof the patient and his relatives in close cooperation with the clinical trials and the hospitals. The GPOH named a board of consultants (principal investigators of a number of clinical trials) who helped generating specific working-hypotheses and provided advice regarding the practical aspects of obtaining data. Through this we understood that we might need to travel to research data locally (at the clini-cal trial or clinic) by ourselves, as some of them do not have the personnel re-quired for this. \nThe application and possibly further extension of biometric methods for risk as-\nsessment will continue to be relevant in the second funding period .\nC.3 Work plan \nThe attached table shows the work plan and the intended time periods for the \nitems for the period spring 2002 up until the end of the funding period in Decem-ber 2004. (The year 2002 is part of the first funding period.) \nMilestones are: \n\u0083 The case-control study starts in spring 2002 after extensive preparations \n\u0083 Consultations regarding genetic aspects in spring 2002 \n\u0083 End of the field phase of the case-control study in fall/winter 2003 \n\u0083 Establishing a regular data matching with the  \nstate cancer registries until fall/winter 2003 \n\u0083 Evaluation of the case-control study in spring 2004 \n\u0083 Publication of results in summer 2004. \nC.4 Networking  \nThe networking presented under B.5 is relevant also for the second funding pe-\nriod, as it consists of a continuous exchange of information. Synergy is achieved by providing important data, such as the frequency of SMN, latency periods, and disease combinations. \nIn order to obtain complete data for the case-control study we need a close co-\noperation with the clinical trials and the hospitals. The results of the case-control study and the continuing efforts for high quality data will benefit the patient and patient care in the long run; specifically therapy optimization, reduction of late effects, and the quality of life of the patients. In the long run the patient is meant to profit. 185Part D- Requested Funding for the Project \nD.1 Salaries\nThere are no changes compared to the previous application. The sums are \nadapted to the actual employees.  \nOne scientific employee: \n\u0083 conceptualizing and coordinating of the case-control study \n\u0083 calculation of risk estimates \n\u0083 contact with clinical trials and consultants \n\u0083 preparation of meetings \n\u0083 writing the final report \n\u0083 publishing results in international scientific publications \n\u00bd medical documentarist: \n\u0083 assisting in the practical working of the case-control study (produces serial \nletters, codes data, enters data, etc.) \n\u0083 study documentation \n\u0083 assists the statistical evaluation \n\u0083 technical assistance for the final report and publications.  \n Costs (in \u20ac) \n2003\nScientific employee 69000 \nMedical documentarist 26000 \n2004\nScientific employee 72000 \nMedical documentarist 27000 186D.2 Consumables\n\u0083 Literature: buying recent publications on SMN or statistical methods \n\u0083 For the case-control study: mailing costs, letters, envelopes, telephone costs, \nprinter\n\u0083 For evaluating the case-control study and the risk estimates: updates of PC-\nprograms, such as statistical software.\n Costs (in \u20ac) \n2003\nLiterature 200 \nMailing costs etc. 150 Software 200 \n2004\nLiterature 200 \nMailing costs etc. 150 Software 200 \nD.3 Investments\nNo change compared to the original application. Per year we estimate about \n1,500 \u20ac of travel costs. Travel to scientific conventions, travel to cooperation partners (e.g. regarding the genetic aspects), travel to clinical trials to obtain data, travel of consultants and the expert group named by the GPOH.\nD.4 Other Costs \nNone.187Section 4 \nNew Projects \nApplication for the Second Funding Period \nTitle Page \nNetwork title :  TOPP (Telemedicine in palliative\n  Pediatric Oncology) (Project T) \nGrant No. : N/A \nName of scientist-in-charge : Dr. med. Boris Zernikow \nInstitution : Universit\u00e4t M\u00fcnster, Universit\u00e4tsklinikum, \n  Klinik und Poliklinik f\u00fcr Kinderheilkunde,\n  P\u00e4diatrische H\u00e4matologie/Onkologie \nAddress : Albert-Schweitzer Str. 33 \n  48149 M\u00fcnster \nPhone : +49 (0) 25 1 \u2013 83 4 \u2013 77 83  \nFax : +49 (0) 25 1 \u2013 83 4 \u2013 82 42  \nFrom 01.10.2002 on :\nInstitution : Vestische Kinderklinik Datteln  \n  Witten/Herdecke University  \nAddress : Dr.-Friedrich-Steiner-Str. 5 \n  45711 Datteln \nPhone : +49 (0) 23 63 \u2013 97 50  \nFax : +49 (0) 23 63 \u2013 64 21 1  \nE-mail : boris.zernikow@t-online.de  \nProject home page (if different from \nNetwork homepage) : 188Part A - General Statements about the Project\nA.1.Subject\nTOPP \u2013 Telemedicine in palliative Pediatric Oncology \nA.2. Co-Investigators\n\u0083 Dr. med. Stefan Friedrichsdorf, Vestische Kinderklinik Datteln, Wit-\nten/Herdecke University \nA.3. Research with Human Subjects/Animals/Gene Therapy \nThis project includes:    \n(a) examination of human subjects  yes  no (b) clinical trials   yes  no \n(c) animal models             yes           no (d) gene therapy   yes           no \nA.4 Requested Funds for the Second Funding Period* \nFiscal \nyearPersonnel1Consumables1Investments1Travel1Other1\n*Amount1\nRequested \n2003 60 20 18,2 5 7,5 110,7 \n2004 78 10 0 5 7,5 100,5 \n1(amounts in thousand Euro), \n * should correlate to funds specified in Part D189Part C- Proposal for a New project\nC.1 Summary \nIn Germany each year about 540 children and adolescents die of malignant dis-\nease. Although several German oncology departments developed their individual model of care for dying children, during their palliative period most children with cancer have no access to home care. The local pediatrician or the general practi-tioner, who usually has not been involved during therapy at the pediatric cancer ward, suddenly might become the primary care giver once a child is in palliative care in the home care setting. TOPP is aiming to introduce a close relationship between the local pediatrician (general practitioner) and the pediatric oncologist by means of telemedicine in order to improve palliative care for children with can-cer.\nC.2 State-of-the-Art and Own Previous Work \nIntroduction\nIn Germany coordination of medical, nursing and psychosocial care for the pedi-\natric cancer patient during his or her end-of-life period is organized on an individ-ual \u201efrom case to case\u201d basis. Apart from the physician of the oncology ward or the outpatient clinic the general pediatric practitioner has a major role in coordi-nating care for a palliative child. He is not only responsible for medical treatment but for all aspects of palliative care (nursing and psychosocial care as well as support of parents, siblings and other family members). \nThe Network of Care\nProfessionals from various medical or psychosocial disciplines as well as indi-\nviduals from school, nursery, kindergarten, religious and spiritual groups or self-help groups are involved in the care for the dying child. Each care team is indi-vidually composed for an individual family. Preferably the care team should be of moderate size. Typically the team might consist of:  \n\u0083 General practitioner, local pediatricians or pediatric hematologist/oncologist \n\u0083 Nurses or pediatric nurses based in a hospital or outpatient clinic, from home \ncare centers or from hospices \n\u0083 Pediatric psychiatrist, pediatric psychologist \n\u0083 Physiotherapist, ergo therapist, music therapist or nutritional special-\nist/dietician\n\u0083 Pharmacist \n\u0083 Social worker \n\u0083 School teacher or clinic-based teacher \n\u0083 Pastor  \n\u0083 Voluntary staff, neighbors \nThe local pediatrician (general practitioner)\nWhen a pediatric malignancy is diagnosed, the child will usually be referred by \nthe local practitioner or pediatric clinician to a pediatric cancer centre. During the 190sophisticated therapy at the cancer centre the local pediatrician (or general prac-\ntitioner) is hardly involved in the child\u2019s treatment. If the disease turns out to be incurable and if it is the wish of the child and his or her family to return home, quite suddenly \u2013 from the local pediatricians\u2019 point of view it may be too sudden -the practitioner becomes the main coordinator of treatment and the family\u2019s main counterpart. His task comprises both medical care and \u2013 functioning as the main coordinator \u2013 multi-professional palliative care. However, in a practitioners\u2019 daily routine the care for a dying child is rather exceptional. Thus most practitioners will be glad to tightly cooperate with a pediatric oncologist/hematologist experienced in palliative medicine. It could be demonstrated that there was a significant im-provement in palliative care if practitioner and pediatric oncologist are involved simultaneously (Wolfe et al. 2000).\nPresent infrastructure of German palliative care\nAn investigation performed by the German Cancer Society (Deutsche Krebsge-\nsellschaft) in the year 1998 stated that \u201etoday\u2019s German palliative medicine is wretched, miserable, and extremely bad. The doctors\u2019 level of specific knowledge is moderate at best. The general public is totally ignorant with respect to those issues \u2013 there is nobody to teach them. There is not only the lack of those more organizational prerequisites. What is more alarming is that even the idea of pallia-tive care is but faintly present in academic life\u201d (R\u00f6glin 1998). \nThroughout Germany there is not a single institutional network providing pediatric \npalliative care. Prospective investigations are missing. There is no nationwide database installed covering therapy or adverse effects during the end-of-life pe-riod. There are no curricula on pediatric palliative medicine for medical profes-sionals. The literature on symptom control, on adverse effects or psychosocial care of dying children is very limited. Practically all books or journals covering palliative care are written in English, but even an English textbook on pediatric palliative care is missing. Guidelines covering pediatric palliative care in oncol-ogy/hematology are missing, too.  \nAlthough several German oncology departments developed their local model of \ncare for dying children, during their palliative period still most children with cancer lack access to home care.\nKey References \nCook DJ, Dolittle GC, Whitten PS. Administrator and provider perceptions of the \nfactors relating to programme effectiveness in implementing telemedicine to pro-vide end-of-life care. J Telemed Telecare 2001;7 Suppl 2:17-9 \nCurrell R, Urquhart C, Wainwright P, Lewis R. Telemedicine versus face to face \npatient care: effects on professional practice and health care outcomes (Coch-rane Review). In: The Cochrane Library, 1, 2002.\nGraf N, Paulussen M, Huf T, Ganslandt T, Stahl J, J\u00fcrgens H. Telemedizin in der \nP\u00e4diatrischen Onkologie - Ergebnisse einer Fragebogenaktion des Kompetenz-netzes P\u00e4diatrische Onkologie. Klin P\u00e4diatr 2002;214:8-19 \nLeggett P, Graham L, Steele K, et al. Telerheumatology \u2013 diagnostic accuracy \nand acceptability to patient, specialist and general practitioner. BJGP 2001:51;749-52191R\u00f6glin H-C. Menschenw\u00fcrdiger Umgang mit dem Sterben aus Sicht praktizieren-\nder Onkologen. Forum DKG 1998;13:244-52 \nWolfe J, Grier HE, Klar N et al. Symptoms and suffering at the end of life in chil-\ndren with cancer. N Engl J Med 2000;342:326-33 \nOwn previous work: The PATE project\nOn June 1, 2001, a project of the German Pediatric Oncology and Hematology \nSociety (GPOH \u2013 Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie) called \u201ePATE\u201c (in English: \u201egodfather\u201d) (Palliative Care, Therapy and its Evalua-tion; in German: Palliativmedizin und -therapie sowie ihre Evaluation in der P\u00e4diatrischen H\u00e4matologie/Onkologie) supported by the German Childhood Can-cer Foundation (Deutsche Kinderkrebsstiftung) was initiated.\nThe aims of PATE are\n1. to analyze the structure and the content in Germany of \n today\u2019s pediatric palliative care in oncology \n2. to disseminate recommendations with respect to symptom control and\npsychosocial care, and to provide those information on a teaching basis \n3. to work on proposals with respect to organization  \nand financing of local palliative care \n4. to collect data reflecting the need in pediatric palliative care in oncology and \nhematology, in order to deliver arguments to support care givers in the dis-cussion with health insurance companies and politicians on how and where to establish programs for palliative home care  \n5. to provide an infrastructure for the investigation of  \nquality of life in the end-of-life period \nPATE is financially supported by the German Pediatric Cancer Society (Deutsche \nKinderkrebsstiftung, covering 1/2 a doctor\u2019s post and 1 pediatric nurse\u2019s post.\nAd 1: On Dec 12, 2001 the first invitational conference was held in Reckling-\nhausen, Germany, on pediatric palliative care. More than 100 pediatricians, pedi-atric nurses and psychosocial professionals from 30 German Pediatric Oncologydepartments attended the meeting. The meeting\u2019s aim was to document the status-quo of care of children with cancer during their end-of-life period. The dis-tinctive departments presented details on their individual practice of pediatric pal-liative care. Based on these data an investigation of the infrastructure of palliative care of German Pediatric Oncology wards is currently under way. \nAd 2: As a first step to provide German-speaking information the World Health \nOrganisation (WHO)-guidelines \u201eCancer Relief and Palliative Care in Children\u201cwere translated (in German: \u201eSchmerztherapie und palliative Versorgung krebskranker Kinder\u201d). Printing of the brochure was financially supported by the German ministry of health (Bundesministerium f\u00fcr Gesundheit). During the con-ference mentioned above a board of experts was constituted. Its task is to work on German guidelines on palliative care for children with cancer. \nAd 3 and 4: International cooperation and the visits of numerous institutions pro-\nviding palliative care in Germany or abroad have led to the establishment of rec-ommendations on how to organize and finance domestic palliative care for chil-192dren with cancer. \nAd 5: PATE is working on a tool for the documentation of therapies and adverse \neffects during pediatric palliative care similar to the one already established in German adult palliative care \nTelemedicine \nWhat is the experience with telemedicine today? A metaanalysis done by the \nCochrane Library 2 years ago comprising 7 clinical studies with a total of 800 pa-tients (all studies except one had but small case numbers) failed to show any significant superiority of telemedicine to standard care. However, the tele-medicine technique was feasible and reliable. Telemedicine was well accepted by the patients. Since the publication of the Cochrane Library more than 1400 stud-ies on the issue have been published. The next metaanalysis is eagerly awaited. \nA recently performed Irish study on 100 patients with rheumatoid arthritis could \nshow that visiting the doctor \u201eby television\u201c was reliable at reasonable costs (Leggett et al. 2001). Image-based patient-doctor interactions were more effec-tive than contacts merely done by phone. After video conferencing just 6 percent of the patients had to visit their doctor in person versus 75 percent after tele-phone contact. The 97 percent diagnostic accuracy after television contact com-pared favorably with the 71 percent diagnostic accuracy after telephone contact. \nOften the health assessment of children during their palliative phase of life is very \ndifficult to perform for a general pediatrician who is not especially trained in that field. Our own experience shows that it is not uncommon that children are as-sessed as \u201eprefinal\u201d who in fact are well under the circumstances and lived for another several months. On the other hand major symptoms go unreported, for instance complete paraplegia/paralysis. To clear up misunderstandings is one of the main issues this project TOPP was designed for.  \nSeveral model projects of palliative care us ing telemedicine are already working \nsuccessfully, for instance in the U.S.A (Cook et al. 2001) and at the Milano Insti-tuti Tumori, Italy. A close cooperation with the latter institution has already been established.\nA German nationwide survey was able to show that most German pediatric on-\ncologists are confident that the introduction of telemedicine will improve the qual-ity of care of children with cancer (Graf et al. 2002).\nC.3 Aims\nThe aim of the model project TOPP is to evaluate the potential of telemedicine \nwith respect to home care for children with cancer during their end-of-life period. At first the quantity and quality of infrastructure (hard- and software) needed and its handling will be evaluated at a level three hospital, i.e. the University Chil-dren\u2019s Hospital M\u00fcnster, Germany (UKM).  \nThe resulting know-how will be transferred to a medium-sized Pediatric Oncology\n(Vestische Kinderklinik Datteln, Witten/Herdecke University; Germany). Datteln has been chosen for reasons of its proximity to and an already established tight cooperation with M\u00fcnster. In M\u00fcnster regularly 10 patients at a time are in pallia-tive care. Each year 30-40 children with cancer die. In Datteln there are 2 to 4 patients in palliative care at a time. 193C.4 Methodological approach \nEach patient\u2019s family will be provided with a notebook computer, web cam, and \nISDN internet connection. The University Children\u2019s Hospital M\u00fcnster and the Vestische Kinderklinik Datteln are either already provided with sufficient internet technology (see telemedicine project of Prof. J\u00fcrgens and Dr. Paulussen), or the technique will be provided in the near future. By this means the pediatric patient and his parents as well as the local pediatrician or general practitioner involved and the nursing home care team are able to contact the pediatric oncologist if they feel the necessity to do so. The primary care providers may even establish regular screen-based visitations during the visitation in the patients\u2019 home. \nTelemedicine will be used in order to establish communication lines and to reach \nits\u2019 aims by the following means: \nCommunication Partners Aim(s) \nPediatric\noncologistFamily \u0083 Direct assessment of the health status in-\ndependent of a third party\u2019s judgement (e.g. effectiveness of analgesia; fatigue; level of activity; adverse effects of therapy; advance of disease) \n\u0083 Regular assessment of family needs \n\u0083 Improved security by regular health reports\n\u0083 Help in the assessment of acute events  \n\u0083 Teaching and supervising (e.g. change of \ndressing)\nPediatric\noncologistLocal pediatri-\ncian or home care team member while visiting the pa-tient\u0083 Discussion of treatment details under direct \nvisualization of the patient (e.g. decubitus, shortness of breath, obstructions of any kind, vigilance, mood, etc.)\n\u0083 Teaching and supervising (e.g. change of \ndrainage devices, change of patient-controlled-analgesia (PCA) medication, change of PCA parameters, or other prob-lem solving) \nLocal pe-\ndiatrician or nursingteam mem-berTOPP Team \u0083 Providing of documentation tools, address \nfiles, proposals on symptom control and control of adverse effects, etc. \n\u0083 Discussion of difficult matters 194C.5 Work plan \nThe data of all patients cared for by TOPP will be collected by a standardized \ndocumentation system developed in their own projects. Pediatricians who are actively involved in palliative care are under the impression that during the end-of-life period children have a great need of analgesics, anticonvulsants, or neuroleptic drugs, exceeding by far all recommendations given in textbooks. The documentation system will help in the prospective evaluation of therapies and adverse effects. On the long run the aim is to improve the care of dying children. \nScientific project evaluation\nIn cooperation with Dr Joanne Wolfe (Harvard Medical School, Boston) we are \ncurrently performing a survey with bereaved parents who lost their child to cancer. Using a validated interview we are collecting data on symptoms, adverse effects of therapy, availability of care, satisfaction with the medical and psychosocial team, and circumstances of death (historical control). The same interview schedule will be used to evaluate the telemedicine setting, using the same historical control (for details of the interview see Wolfe et al. 2000).\nAt the end of the project, all participating local pediatricians and general practitio-\nners will be asked to participate in a survey by standardized questionnaire on the quality of the patient care, telemedicine technique, cooperation quality, etc. This questionnaire will be developed and validated during the TOPP project phase to improve construct validity. \nC.6 Networking \nTOPP is a network of competence which coordinates the horizontal scientific net-\nwork and the vertical network of investigation and care.\nHorizontal scientific network\nResults from other pediatric palliative projects will be transferred to the physicians \nof the TOPP project. Technical know how from the other telemedicine project of Prof. J\u00fcrgens (see above) should help to fasten the development of a functioning video conferencing between patient and TOPP team.\nVertical network of investigation and care\nDocumentation sheets, guidelines etc. recently developed will directly influence \npatient care. In two model institutions (M\u00fcnster and Datteln) TOPP will coordinate and network local pediatricians and members of the home care team with their corresponding cancer wards, outpatient hospitals and day care centers. There-fore, an aim of TOPP is to evaluate the feasibility of vertically connecting experts in Pediatric Oncology/palliative care with the home care physician.195Part D- Requested Funding for the Project \nD.1 Salaries\n\u0083 1/2 Pediatrician post (M\u00fcnster) BAT IIa for 2 years: \n 2003: 30.000 \u20ac  2004: 31.000 \u20ac \n\u0083 1/4 Pediatrician post (Datteln) BAT IIa for 1 year:  \n 2004: 16.000 \u20ac \n\u0083 1/2 Post of a medical informatics technician for 2 years: \n 2003: 30.000 \u20ac  2004: 31.000 \u20ac  \nTasks\nIn the first year development and support of the telemedicine technique in M\u00fcn-\nster. In the second year transfer of the system to Datteln, system support in Dat-teln and M\u00fcnster. Thus, identical workload during both the years 2003, and 2004.\nD.2 Consumables\nServer costs, maintenance, service, internet costs (2 years):  30000 \u20ac \nD.3 Investments\n8 laptops suitable for telemedicine application (2270 \u20ac each): 18160 \u20ac \nCooperations with Deutsche Telekom and Siemens AG are planed in order to \nreduce the costs of technical devices. First very promising contacts with these companies are already established. \nLaptop\nIn order to allow for mobility of the computer work place there is need for a note-\nbook computer (as opposed to a tower model). \nType of processor and size of memory: Internet data rate is the technical bottle \nneck of life cam data transfer. Using a 56k modem or ISDN technology a proces-sor speed of 300 MHz and a RAM size of 64 MB are sufficient. Using DSL tech-nology a 700 MHz processor is recommended. Hence, a today\u2019s standard laptop would meet requirements. \nGraphic board: With modern laptops the choice of the graphic board is of no im-\nportance for the discussed purpose. The cameras\u2019 maximum resolution and frame rate are of interest only for the local work place. The H.323 standard de-fines CIF (common interface format) as the standard video format for video con-ferences. This format is incompatible with common graphic board accelerators. CIF resolution is 352 x 288 pixels, a resolution that is processed by nearly every modern graphic board without any loss in speed or quality.\nSound board: Minimal requirement is Duplex mode (transceiving simultaneously). \nFor an acceptable quality of sound the full Duplex sampling rate should be higher 196than 8 kHz. Any modern sound board matches these requirements. \nNetwork abilities: In order to establish the communication link with the patient and \nthe Pediatric Oncology hospitals, there is need for at least a 56k modem and ISDN ability. In order to allow for DSL networking, a network card should be pro-vided.\nData storage: During each session, all video data will be recorded on hard disk. \nLater, data will be transferred to CD-ROM by means of an internal CD-Rom burner.\nWeb Cam\nThere are huge quality differences in the Web Cams on the market. High sensitiv-\nity and high contrast are the paramount parameters for network applications in the proposed project. The mode of camera fixation to the laptop is critical. Most camera models are not provided with a laptop-compatible fixation device. The Kodak DVC325 Digital seems to be a suitable choice. \nInternet gate\nUsing hardware as described above, internet connection is uncritical. Each pri-\nvate internet gate should be suitable as should be even one of those internet-by-call gates free of a monthly basis charge (connection via modem or ISDN). \nSoftware\nOperating system: Most laptops are delivered with a preinstalled operating sys-\ntem. For the sake of hardware and software compatibility and feasibility our choice is Windows ME or XP (Microsoft Inc., U.S.A.). \nVideo conferencing software: Netmeeting (Microsoft Inc, U.S.A.) is recommended \nfor video conferencing. It is provided free of charge. \nBackup software: For backup purposes special software is needed which is ca-\npable to backup, and restore, whole hard disc partitions. In case of accidental data or program corruption even an ignorant user must be able to easily recon-figure the laptop from CD-ROM. Our choice is Drive Image rel. 5. \nCosts of a single work place (computer hard- and software)\nTechnique estimated cost \nWeb Cam (Kodak DVC325 Digital): 90 \u20ac \nLaptop (Fujitsu-Siemens Lifebook C-6387): 2000 \u20ac \nISDN adapter for PCMCIA-slot:  110 \u20ac Backup software (Drive Image): 70 \u20ac \nTotal 2270 \u20ac \nNot included are the costs for the installation of the internet gateway and for cen-\ntralized service and support (see below).  197D.4 Other Costs \nScientific interchange with a similar Italian project in adults\nThe Milano Instituti Tumori in Milano, Italy, has successfully established a tele-\nmedicine project in adult palliative care. To prepare the implementation of TOPP, members of our team (including Dr. med. Christine Wamsler, qualified Italian in-terpreter) will exchange ideas and participate in the Italian telemedicine project. The aim is to learn from the Italian experiences and study the technical and hu-man resources necessary for such a project.\nTravel expenses will be 10000 \u20ac.\nFurther material\nOffice equipment etc.: 5000 \u20ac. Courses / Conferences\nCosts of courses and conferences on Pediatric Palliative Care in order to improve \nthe medical knowledge and skills of the TOPP team members comprising fees, accommodation and travel expenses: 10000 \u20ac.\n(End of the Midterm Report. Annex follows.)BMBF COMPETENCE NETWORKS \nAnnex\nto the \nSpeaker\u2019s Midterm Report on the  \nCompetence Network\nPediatric Oncology and Hematology 1Contents \u2013 Overview \nThis annex comprises additional data and original material, which complement \nspecific questions and answers of the Speakers\u2019 Midterm Report (MR) section 1.  \nMR Title Page\nA.1 c Full index of network-related English papers in reviewed journals (published or in press)  2 \nA.2 b Patents applied for within the network 8 \nB.4 c \nC.12 h Statutes of the tumor bank \u201cEmbryonal/rare tumors\u201d 9 \nB.4 c \nC.9 c List of cooperative multicenter GPOH clinical trials 12 \nB.5 b Basic data set, revision 2.0 (excerpt) 13 \nC.7 Matrix of cooperation within the network and with external partners  20 \nC.9 b List of clinical multi-center studies performed in the network 22 \nC.10 International partners of the competence network's projects 23 D.14 Presentations of this network and its projects to the public  24 \nD.15 Media coverage \u2013 collection of media reports on this network  31 \nE.20 List of Guidelines in Pediatric Oncology and Hematology and internet start page (AWMF) 33  Report on the questioning of clinical trial centers 35 \n List of network and/or GPOH working groups (excerpt) 42 \n* Project work plans and milestones (A, B/1, C, D, K) 43 \n Internet representation of the PRST and description of data flow  49 \n Mission profile of the assistants in clinical research and quality control (FSA) and temporary \ninternet representation of the coordination and management group  52\n Summary of the interview with the FSA 54 \n Example check lists for practical trial organizing produced by FSA  55  Information brochure on Pediatric Oncology and Hematology (draft) 57 \n \u201cErfolg der Behandlung von Kindern mit Krebserkrankungen durch einheitliche und konse-\nquente Diagnostik und Therapie in Therapieoptimierungsstudien w\u00e4hrend der letzten 20 Jahre\u201d (submitted) 61\nB.4** Abstracts of publications of network projects (published, in press or submitted) 75 \nInternet form for requesting a patient identification number (pseudonymisation/PID service) 85\n \u201cKostenangebot Marketing KPOH 2. Phase\u201d (drescher konzept grafik design) 86 \n \u201cAngebot zur Evaluation und Proze\u00dfbegleitung des Kompetenznetzes\u201d (WIAD/Prognos) 89 \n Annex 1 Project I \u2013 Neuropsychological results 97 \n Annex 2 Project I \u2013 Graphical overview of QoL results 102 \n Annex 3 Project I \u2013 \u201eBandvergleich\u201c  104 \n Annex 4 Project I \u2013 Correspondence, practicability and economical considerations 105  Annex 5 Project I \u2013 Multitrait-multitemanalysis of the PEDQOL instrument 107 \n Annex 7 Project I \u2013 Examples of flow sheets for follow-up of patients 109 \n* Referring to section 3, part C.3 of project proposals.  \n** Referring to section 3, part B.4 of project proposals.  2A.1 c) Full index of network-related English papers in reviewed journals (published or in press) \nColumns of the table:  \n# Number of the reference \na) Publication represents joint activities of two or more network  \ngroups (referring to section 3, B.4 in the Midterm Report).  \nb) Publication involved at least three network partners fr om different universities or non-university  \n research institutions (referring to label \u201c b\u201d of section 1, question A.1 in the Midterm Report). \nc) Publications together with (an) international partner(s) (referring to  \n label \u201c c\u201d of section 1, question A.1 in the Midterm Report).  \nP Project(s) affiliation \n#P Number of reference within project \n# a) b) c) P #P Reference \n1 X X  A \nI1 Langer T, Henze G, Beck J.D. Basic methods and the developing structure of a late \neffects surveillance system (LESS) in the long-term follow-up of pediatric cancer \npatients in Germany. Med Pediatri c Oncology 34: 348-351, 2000 \n2 X X  A \nK2 L\u00f6ning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, Schrappe M. \nSecondary neoplasms subsequent to Berlin-Frankfurt-M\u00fcnster therapy of acute lym-\nphoblastic leukemia in childhood: significan tly lower risk without cranial radiotherapy. \nBlood 95: 2770-2775, 2000 \n3    B/1 1 Knaup P, Harkener S, Ells\u00e4sser K.-H, Haux R, Wiedemann T. On the necessity of \nsystematically planning clinical tumor documentation. Meth. Inform. Med 2001;40, 90-98 \n4    B/1 2 Merzweiler A, Knaup P, Creutzig U, Ehlerding H, Haux R, Mludek V, Schilling FH, \nWeber R, Wiedemann T. (2000). Requirements and Design Aspects of a Data Model \nfor a Data Dictionary in Paediatric Oncology. In: Hasman, A, Blobel, B, Dudeck, J. et \nal. (Hrsg.). Medical Infobahn for Europe, 696-700. Amsterdam: IOS Press. \n5 X X  B/1 3 Knaup P, Mludek V, Wiedemann T, Bauer J, Haux R, Kim L, Schilling FH, Selle B. \n(2000). Integrating Specialized Application Systems into Hospital Information Sys-\ntems -Obstacles and Factors for Success. In:Hasman, A, Blobel, B, Dudeck, J. et al. \n(Hrsg.). Medical Infobahn for Europe, 890-894. Amsterdam: IOS Press. \n6    B/1 4 Merzweiler A, Knaup P, Weber R, Ehlerding H, Haux R, Wiedemann, T. (2001). \nRecording clinical data - from a general set of record items to case report forms (crf) \nfor clinics. In: Patel, V, Rogers, R, Haux, R. (Hrsg.). MEDINFO 2001. Proceedings of \nthe 10th World Congress on Medical Informatics, 653-657. Amsterdam: IOS. \n7 X X  B/1 5 Weber R, Knaup P, Knietig R, Haux R, Merzweiler A, Mludek V, Schilling FH, Wie-\ndemann T. (2001). Object-oriented business process analysis of the Cooperative \nSoft Tissue Sarcoma Trial of the German Society for Paediatric Oncology and Hae-\nmatology (GPOH). In: Patel, V, Rogers, R, Haux, R. (Hrsg.). MEDINFO 2001. Pro-\nceedings of the 10th World Congress on Medical Informatics, 58-62. Amsterdam: \nIOS.\n8 X   D 1 Strau\u00df G, Osen W, Debatin K-M. Clin. Exp. Induction of apoptosis and modulation of \nactivation and effector function in T cells by immunosuppressive drugs. Immun. 200, \nIn Press\n9 X   D 2 Wuchter C, Ruppert V, Schrappe M, Dorken B, Ludwig WD, Karawajew L. In vitro \nsusceptibility to dexamethasone- and do xorubicin-induced apoptotic cell death in \ncontext of  maturation stage, responsivenes s to IL-7 and early cytoreduction in vivo \nin childhood T-ALL. Blood 2002, in press  \n10 X   D 3 Stahnke K, Fulda S, Friesen C, Strauss G, Debatin KM Activation of apoptosis \npathways in peripheral blood lymphocytes by in vivo chemotherapy Blood \n2001,98:3066-7330 \n11 X   D 4 Herr I, Debatin K-M . Cellular stress response and apoptosis in cancer therapy. \nBlood 2001,98: 2603-2614 3# a) b) c) P #P Reference \n12 X   D 5 Wuchter C, Krappmann D, Cai Z, Rup-pert V, Scheidereit C, Dorken B, Ludwig WD, \nKarawajew L. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia \ncells in the context of TRAIL receptor ge ne ex-pression and constitutive NF-kappa B \nactivity. Leukemia  2001,15:921-8 \n13 X   D 6 Cai Z, Lin M, Wuchter C, Ruppert V, Dorken B, Ludwig WD, Karawajew L. Apoptotic \nresponse to homoharring-tonine in human wt  p53 leukemic cells is independent of \nreactive oxygen spe-cies g eneration and implicates Bax translocation, mitochondrial \ncytochrome c release and caspase activation.  Leukemia  2001;15:567-74  \n14 X   D 7 Wuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, Dorken B, \nLudwig WD. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 func-\ntion and spontaneous apoptosis in vitro do not predict the response to induction che-\nmotherapy and relapse rate in child-hood acute lymphoblastic leukaemia. Br J Hae-\nmatol 2000;110:154-60 \n15 X   D 8 Karawajew L, Ruppert V, Wuchter C, Kosser A, Schrappe M, Dorken B, Ludwig WD. \nInhibition of in vitro spontaneous apop-tosis by IL-7 correlates with bcl-2 up-\nregulation, cortical/mature immunophe-notype, and better early cytoreduction of \nchildhood T-cell acute lymphoblastic leukemia. Blood 2000;96:297-306  \n16 X   D 9 Fulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-\ninduced apoptosis by down-regulating Fas-associated death domain-like interleukin \n1-converting enzyme inhibitory protein expression. Cancer Res  2000;60:3947-56  \n17 X   D 10 Beltinger C, Fulda S, Kammertoens T, Uckert W, Debatin KM. Mitochondrial amplifi-\ncation of death signals determines thymidine kinase/ganciclovir-triggered activation \nof apoptosis. Cancer Res  2000;60:3212-7 \n18    E 1 Tschan CA, Pilz C, Zeidler C, Welte K, Germeshausen M. Time course of increasing \nnumbers of mutations in the granulocyte colony-stimulating factor receptor gene in a \npatient with congenital neutropenia who developed leukemia. Blood 97: 1882-84, \n2001. \n19  X  E 2 Germeshausen M, Ballmaier M, Schulze H, Welte K, Flohr T, Beiske K, Storm-\nMathisen I, Abrahamsen TG. Granulocyte colony-stimulating factor receptor muta-\ntions in a patient with acute lymphoblastic leukemia secondary to severe congenital \nneutropenia. Blood 97: 829-830, 2001. \n20    E 3 Germeshausen M, Ballmaier M, Welte K. Implications of mutations in hematopoietic \ngrowth factor receptor genes in congen ital cytopenias. Ann NY Acad Sci 938: 305-\n21, 2001. \n21    E 4 Jung A, Ruckert S, Frank P, Brabletz T, Kirchner T. 7-deaza-2`-deoxyguanosine \nallows PCR and sequencing from CpG islands. Mol Path 55, 55-57, 2001. \n22    E 5 Rischewski J, Schneppenheim R. Screening strategies for a highly polymorphic \ngene: DHPLC analysis of the Fanconi anemia group A gene. J Biochem Biophys \nMethods 30;47:53-64, 2001. \n23   X E 6 Hasle H, Niemeyer CM. Myelodysplastic syndrome and juvenile myelomonocytic \nleukemia in children. In: Trends in Molecular Medicine (formerly: Molecular Medicine \nToday) 2: 468-457, 2002 \n24    F 1 Eckert C, Landt O, Taube T, Seeger K, Beyermann B, Proba J, Henze G. Potential of \nLightCycler technology for quantification of minimal residual disease in childhood \nacute lymphoblastic leukemia. Leukemia 2000;14:316-323 \n25   X F 2 Eckert C, Biondi A, Seeger K, Ca zzaniga G, Hartmann R, Beyermann B, Pogodda M, \nProba J, Henze G. Prognostic value of minimal residual disease in relapsed child-\nhood acute lymphoblastic leukaemia. Lancet 2001;358:1239-1241 \n26    F 3 Nakao M, Janssen JW, Bartram CR. Duplex PCR facilitates the identification of im-\nmunoglobulin kappa (IGK) gene rearrangements in acute lymphoblastic leukemia. \nLeukemia 2000;14:218-219 \n27    F 4 Nakao M, Janssen JW, Flohr T, Bartram CR. Rapid and reliable quantification of \nminimal residual disease in acute lymphoblastic leukemia using rearranged immu-\nnoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res \n2000;60:3281-3289 \n28    F 5 Seeger K, Buchwald D, Peter A, Taube T, von Stackelberg A, Schmitt G, Henze G. \nTEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia. Blood \n1999;94:374-376 4# a) b) c) P #P Reference \n29    F 6 Seeger K, Buchwald D, Taube T, Peter A, von Stackelberg A, Schmitt G, Kochling J, \nHenze G. TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leu-\nkemia in childhood. Berlin-Frankfurt-M unster Study Group. Leukemia 1999;13:1469-\n1470 \n30    F 7 Seeger K, Kreuzer KA, Lass U, Taube T, Buchwald D, Eckert C, Korner G, Schmidt \nCA, Henze G. Molecular quantification of response to therapy and remission status in \nTEL-AML1-positive childhood ALL by real-time reverse transcription polymerase \nchain reaction. Cancer Res 2001;61:2517-2522 \n31    F 8 Seeger K, Taube T, Eckert C, Hanel C, Pogodda M, Henze G. Unusual T-cell recep-\ntor-delta gene rearrangement patterns revealed by screening of a large series of \nchildhood acute lymphoblastic leukaemia by multiplex polymerase chain reaction. Br \nJ Haematol 2001;113:318-322 \n32 X X X F 9 Seeger K, Viehmann S, Buchwald D, Harbott J, Schrappe M, Stary J, Henze G, Trka \nJ. Treatment response and residual-disease monitoring in initial and relapsed TEL-\nAML1 positive childhood ALL. Leukemia 2001;15:280-282 \n33 X X  F 10 zur Stadt U, Harms DO, Schluter S, Schrappe M, Goebel U, Spaar H, Janka G, \nKabisch H. MRD at the end of induction therapy in childhood acute lymphoblastic \nleukemia: outcome prediction strongly depends on the therapeutic regimen. Leuke-\nmia 2001;15:283-285 \n34    F 11 zur Stadt U, Rischewski J, Schneppenheim R, Kabisch H. Denaturing HPLC for \nidentification of clonal T-cell receptor gamma rearrangements in newly diagnosed \nacute lymphoblastic leukemia. Clin Chem 2001;47:2003-2011 \n35    G 1 Otano-Joos M, Mechtersheimer G, Ohi 2, Wilgenbus KK, Scheurlen W, Lehnert T, \nWilleke F, Otto HF, Lichter P, Joos S. Detection of chromosomal imbalances in leio-\nmyosarcoma by comparative genomic hybridization and interphase cytogenetics. \nCytogenet Cell Genet 2000; 90:86-92 \n36    G 2 Granzow M, Popp S, Weber S, Hager HD, Boschert J, Scheurlen W, Jauch A. Multi-\nplex-FISH classifies chromosome rearrangements in a child with intracranial ependy-\nmoma. Cancer Genet. Cytogenet (in press) \n37   X G 3 Schulz S, Becker KF, Braungart E, Reichmuth C, Klamt B, Atkinson M, Gessler M, \nHofler H. Molecular analysis of E-cadherin-11 in Wilm\u2019s tumours. J Pathol 2000; \n191:162-169 \n38  X  G 4 Hartmann W, Waha A, Koch A, Albrecht S, von Schweinitz D, Pietsch T. p57-KIP2 is \nnot mutated in hepatoblastoma but shows increased transcriptional activity - a com-\nparative analysis of three imprinted genes p57-KIP2, IGF2 and H19. Am J Pathol \n2000; 157:1393-403 \n39  X  G 5 Weber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of chromosomal \nimbalances in hepatoblastomas: a role for gains on 8q and 20 as predictors of out-\ncome. Am J Pathol 2000; 157:571-578 \n40    G 6 B\u00fchren J, Christoph AHA, Buslei R, Albrecht S, Wiestler OD, Pietsch T. Expression \nof the neurotrophin receptor p75-NTR in medulloblastomas is correlated to distinct \nhistological and clinical features: Evidence for a medulloblastoma subtype derived \nfrom the external granule cell layer. J Neuropathol Exp Neurol 2000; 59:229-40 \n41    G 7 Herms J, Neidt I, L\u00fcscher B, Sommer A, Sch\u00fcrmann P, Schr\u00f6der T, Bergmann M, \nWilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, \nKretzschmar HA. c-myc expression in medulloblastoma and its prognostic value. Int \nJ Cancer 2000; 89:395-402. \n42  X  G 8 Koch A, Waha A, Tonn JC, S\u00f6rensen N, Berthold F, Hartmann W, Friedl W, Reifen-\nberger G, Wiestler OD, Pietsch T. Mutations of components of the wingless/WNT \nsignaling pathway in sporadic primitive ne uroectodermal tumors. Int J Cancer 2000; \n93:445-9. \n43   X G 9 Kraus JA, de Millas W, S\u00f6rensen N, Herbold C, Schichor C, Tonn JC, Wiestler OD, \nvon Deimling A, Pietsch T. Evidence for a tumor suppressor gene at 22q11-q12 \ninvolved in the pathogenesis of human epe ndymomas and distinct form hSNF5/INI1. \nActa Neuropathol 2001; 102:69-74. \n44    G  S\u00f6ling A, Schurr P, Berthold F. Expression and clinical relevance on NY-ESO1, \nMAGE-1 and MAGE-3 in neuroblstoma. Anticancer Res 1999; 19:2205-09. \n45    G 10 M\u00fcller S, van den Boom D, Zirkel D, K\u00f6ster H, Berthold F, Schwab M, Westphal M, \nZumkeller W. Retention of imprinting of the human apoptosis-related gene TSSC2 in \nhuman brain tumors. Hum Mol Gen 2000; 9:757-763. 5# a) b) c) P #P Reference \n46  X  G 11 Poremba CH, Hero B, Heine B, Scheel CH, Schaefer KL, Christiansen H, Berthold F, \nKneif S, Stein H, Juergens H, Boecker W, Dockhorn-Dworniczak B. Telomerase is a \nstrong indicator for assessing the proneness to progression in neuroblastomas. Med \nPediat Oncol 2000; 35:651-655. \n47  X X G 12 Poremba C, Scheel C, Hero B, Christiansen H, Schaefer K, Nakayama J, Berthold F, \nJuergens H, Boecker W, Dockhorn-Dworniczak B. Telomerase activity and telomera-\nse subunits gene expression patterns in ne uroblastoma: A molecular an immunhisto-\nchemical study establishing prognostic tools for fresh-frozen and paraffin-embedded \ntissue. J Clin Oncol 2000; 18:2582-2592. \n48  X X G 13 Ladenstein R, Ambros IM, Poetschger U, Amann G, Urban C, Fink FM, Schmitt K, \nJones R, Slociak M, Schilling F, Ritter J, Berthold F, Gadner H Ambros PF. Progno-\nstic significanes of DNA Di-tetraploidy in neuroblastoma. Med Pediat Oncol 2001; \n36:83-92. \n49  X  G 14 Theobald M, Christiansen H, Schmidt A, Malekian B, Wolkewitz N, Christiansen N, \nBrinkschmidt C, Berthold F, Lampert F. Sublocalization of putative tumor suppressor \ngene loci on chromosome arm 14q in neuroblastoma. Genes, Chromosomes & Can-\ncer 1999; 26:40-46. \n50   X G 15 Bown N, Cotterill S, Lastowska M, O\u00b4Neill S, Pearson ADJ, Plantaz D, Meddeb M, \nDanglot G, Brinkschmidt C, Christiansen H, Laureys G, Spelemann F. Gain of chro-\nmosome arm 17q and adverse outcome in patients with neuroblastoma. N Eng J \nMed 1999; 340:1951-1962. \n51  X  G 16 Poremba C, Willenbring H, Hero B, Christiansen H, Sch\u00e4fer KL, Brinkschmidt C, \nJ\u00fcrgens H, B\u00f6cker W, Dockhorn-Dworniczak B. Telomerase activity distinguishes \nbetween neuroblastomas with good and poor prognostic. Ann Oncol 1999; 10:1-7. \n52    G 17 D\u00f6tsch J, Harmjanz A, Christiansen H, H\u00e4nze J, Lampert F, Rascher W. Gene ex-\npression of neuronal nitric oxide synthase and adrenomedullin in human neuroblas-\ntoma using real-time PCR. Int J Cancer 2000; 88:172-175. \n53    G 18 Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, B\u00f6cker W, Dock-\nhorn-Dworniczak B. Distal chromosome 17 gains in neuroblastomas detected by \ncomparative genomic hybridisation (CGH) are associated with a poor clinical out-\ncome. Med Pediat Oncol 2001; 36:11-13. \n54   X G 19 Vandesompele J, Speleman F, van Roy N, Laureys G, Brinkschmidt C, Christiansen \nH, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret \nV, Delattre O, Feuerstin BG, Plantaz D. Multicentre analysis of patterns of DNA gains \nand losses in 204 neuroblastoma tumors: How many genetic subgroups are there. \nMed Pediat Oncol 2001; 36:5-10. \n55    G 20 Bergmann E, Wanzel M, Weber A, Shin I, Christiansen H, Eilers M. Expression of \np27Kip1 is prognostic and independent of MYCN amplification in human neuroblas-\ntoma. Int J Cancer 2001; 95:176-183. \n56    G 21 D\u00f6tsch J, Repp R, Rascher W, Christiansen H. Diagnostic and scientific applications \nof TaqMan real-time PCR in neuroblastomas. Expert Rev Mol Diagn 2001; 1:233-\n238.\n57   X G 22 O\u2019Neill S, Estrom L, Lastoska M, Robets P, Brodeur GM, Kees UR, Schwab M, Bown \nN. MYCN Amplification and 17q in neuroblastoma: Evidence for structural associa-\ntion. Genes, Chromosomes & Cancer 2001, 30:87 . \n58   X G 23 Boon K, Caron HN, van Asperen R, Velantijn L, Hermus MC, van Sluis P, Roobeek I, \nWeis I, Voute PA, Schwab M, Versteeg R. N-myc enhance the expression of a large \nset of genes functioning in ribosome biogenesis and protein synthesis. EMBO \nJournal 2001; 20:1-11. \n59    G 24 Savelyeva L, Schwab M. Amplification of oncogenes revisited: From expression \nprofiling to clinical application. Cancer Letters 2001; 167:115-123. \n60  X X G 25 Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab \nM, Antonescu CR, Peterson C, Meltzer PS. Classification and diagnostic prediction \nof cancers using gene expression profiling and artificial neural networks. Nature \nMedicine 2001; 7:673-679. \n61  X  G 26 Bauer A, Savelyeva L, Claas A, Praml C, Berthold F, Schwab M. Smallest region of \noverlapping deletion in 1p36 human neuroblastoma: A 1-Mbp cosmid and PAC con-\ntig. Genes, Chromosomes & Cancer 2001; 31:228-239. \n62   X G 27 Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholoson J, Grundy P, Grundy \nR, Gessler M, Shipley J, Pritchard-Jones K. Gain of 1q is associated with adverse \noutcome in favourable histology Wilm\u00b4s tumors. Am J Pathol 2001; 158:393-8. 6# a) b) c) P #P Reference \n63  X  G 28 Przkora R, Meyer-Puttlitz B, Schmitt O, Berthold F, N\u00f6then M, Krauss J, Tonn JC, \nvon Deimling A, Wiestler OD, Pietsch T. Analysis of the TSC2 gene in human medul-\nloblastoma. Acta Neuropathol 2001; 102:380-4. \n64  X  G 29 Dahmen RP, Koch A, Denkhaus D, Tonn JC, S\u00f6rensen N, Berthold F, Behrens J, \nBirchmeier W, Wiestler OD, Pietsch T. Deletions of AXIN1, a component of the WNT/ \nwingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61:7039-43. \n65  X  H 1 Bader P, Stoll K, Huber S, Geiselhart A, Handgretinger R, Niemeyer C, Einsele H, \nSchlegel PG, Niethammer D, Beck J, Klingebiel T:  Characterization of line-age-\nspecific chimaerism in patients with acute leukaemia and myelodysplastic syndrome \nafter allogeneic stem cell transplantation before and after relapse. Br J Haematol \n108:761, 2000 \n66    H 2 Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, Nurnberg P, \nHenze G: Childhood all blasts retain phenotypic and genotypic characteristics upon \nlong-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol 17:635, 2000 \n67  X  H 3 Bornhauser M, Theuser C, Soucek S, Holig K, Klingebiel T, Blau W, Fauser A, \nRunde V, Schwinger W, Rutt C, Ehninger G: Allogeneic transplantation of G-CSF \nmobilized peripheral blood stem cells from  unrelated donors: a retrospective analy-\nsis. Haematologica 85:839, 2000 \n68  X  H 4 Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D, Pape H, Dunst J, \nKahn T, Willers R, Engel B, Dirksen U, Kramm C, Nurnberger W, Heyll A, Ladenstein \nR, Gadner H, Jurgens H, Goebel U: Allogeneic and autologous stem-cell transplanta-\ntion in advanced Ewing tumors. An update after long-term follow-up from two centers \nof the European Intergroup study EICESS. Stem-Cell Trans-plant Programs at Dus-\nseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Aus-\ntria. Ann Oncol 11:1451, 2000 \n69   X H 5 Burdach S, Baersch G, Hansen G: Immunogenetherapy with IL-2 or IL-7 trans-fected \nEwing tumor cells in NOD/SCID mice. Med Ped Onc 37(3):178 2001 \n70   X H 6 Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S, Ramsay N, Territo M, \nKhan SP, Pamphilon D, Leis JF, Burdach S, Anasetti C, Hackman R, Storer B, Muel-\nler B: Marrow transplants from unrelated donors for patients with aplastic anemia: \nminimum effective dose of total body irradiation. Biol Blood Marrow Transplant 7:208, \n2001 \n71   X H 7 Felzmann T, Buchberger M, Jechling er M, Kircheis R, Wagner E, Gadner H: Xeno-\ngenization by tetanus toxoid loading into lymphoblastoid cell lines and pri-mary hu-\nman tumor cells mediated by polycations and liposomes. Cancer Lett 161:241, 2000 \n72   X H 8 Felzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner H, \nHolter W: Functional maturation of dendritic cells by exposure to CD40L trans-genic \ntumor cells, fibroblasts or keratinocytes. Cancer Lett 168:145, 2001 \n73   X H 9 Fisch P, Moris A, Rammensee HG, Handgretinger R: Inhibitory MHC class I re-\nceptors on gammadelta T cells in tumour immunity and autoimmunity. Immunol To-\nday 21:187, 2000 \n74    H 10 Hattenhorst U, Glynne R, Murray R, Burdach S: Differential gene expression analysis \nin pediatric c-ALL versus normal pre-B-cells and bone marrow DNA-microarrays. \nBlood 96(11):107a, 2000 \n75   X H 11 Heinsohn S, Scholz RB, Weber B, Wittenstein B, Werner M, Delling G, Kempf-\nBielack B, Setlak P, Bielack S, Kabisch H: SV40 sequences in human osteosar-coma \nof German origin. Anticancer Res 20:4539, 2000 \n76    H 12 Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab \nM, Antonescu CR, Peterson C, Meltzer PS: Classification and diagnostic prediction \nof cancers using gene expression profiling and artificial neural net-works. Nat Med \n7:673, 2001 \n77    H 13 Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Durken M, Graf von Finken-\nstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Loliger C, Zander AR: \nAnti-thymocyte-globulin as part of the preparative regimen prevents graft failure and \nsevere graft versus host disease (GvHD) in allogeneic stem cell transplanta-tion from \nunrelated donors. Ann Hematol 80:209, 2001 \n78    H 14 Kurre P, Burdach S: A potential role for leukemia inhibitory factor in the increased \nclonogenicity of human fetal progenitor cells. Blood 96:1199, 2000 7# a) b) c) P #P Reference \n79    H 15 Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, \nMcComb JG, Cogen PH, Vezina G, Kapcala LP: Treatment of progressive or re-\ncurrent pediatric malignant supratentorial brain tumors with herpes simplex virus \nthymidine kinase gene vector-producer cells followed by intravenous ganciclovir \nadministration. J Neurosurg 92:249, 2000  \n80    H 16 Ottinger HD, Muller C, Schmitz N, Kubanek B, Arnold R, Ebell W, Eberhard HP, \nEhninger G, Fronz U, Goldmann S, Grosse-Wilde H, Havers W, Klingebiel T, Kolb \nHJ, Seeber S, Schaefer UW, Baldomero H, Gratwohl A: Transplant activities in Ger-\nmany in 1998--a survey facilitated by the National Registry for Hemopoietic Stem \nCell Transplantation. Ann Hematol 79:437, 2000Schilbach KE, Geiselhart A, Wessels \nJT, Niethammer D, Handgretinger R: Human gammadelta T lympho-cytes exert \nnatural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immu-nother 23:536, \n2000 \n81   X H 17 Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, \nMcComb JG, Cogen PH, Vezina G, Kapcala LP: Treatment of progressive or re-\ncurrent pediatric malignant supratentorial brain tumors with herpes simplex virus \nthymidine kinase gene vector-producer cells followed by intravenous ganciclovir \nadministration. J Neurosurg 92:249, 2000Schilbach K, Geiselhart A, Handgret-inger \nR: Induction of proliferation and augmented cytotoxicity of gammadelta T lympho-\ncytes by bisphosphonate clod ronate. Blood 97:2917, 2001 \n82   X H 18 Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F, Cornish J, Ortega \nJ, Bekasi A, Souillet G, Stary J, Niethammer D: Statement of current ma-jority prac-\ntices in graft-versus-host disease prophylaxis and treatment in children. Bone Mar-row Transplant 26:405, 2000Schlegel PG, Eyrich M, Bader P, Handgretinger R, Lang \nP, Niethammer D, Klingebiel T: OKT-3-based  recondition-ing regimen for early graft \nfailure in HLA-non-identical stem cell transplants. Br J Haematol 111:668, 2000 \n83    H 19 Rischewski J, Bismarck P, Kabisch H, Janka-Schaub G, Obser T, Schneppen-heim \nR: The common deletion 657del5 in the Nibrin gene is not a major risk fac-tor for B or \nT cell non-Hodgkin lymphoma in a pediatric population. Leukemia 14:1528, \n2000Schwinger W, Urban C, Lackner H, Kerbl R, Benesch M, Dorn-busch HJ, So-\nvinz P, Schauenstein K, Schumm M, Handgret inger R: Unrelated peripheral blood \nstem cell transplantation with 'megadoses' of purified CD34+ cells in three children \nwith refractory severe aplastic anemia. Bone Marrow Transplant 25:513, 2000 \n84  X  I 1 Marx M, Beck JD, Grabenbauer GG, D\u00f6rr HG. Spontaneous nocturnal growth hor-\nmone secretion in children after medulloblastoma therapy. Med Pediatr Oncol 36:494 \nWd\nhlg. X  I \nA2 Langer T, Henze G, Beck JD. Basic methods and the developing structure of a late \neffects surveillance system (LESS) in the long-term follow-up of pediatric cancer \npatients in Germany. For the German Late Effects Study Group in the German So-\nciety Pediatric Oncology and Hematology (GPOH). Med Pediatr Oncol;34:348-51, \n2000 \n85  X  I 3 Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W. CNS late-\neffects after ALL-therapy in childhood Part III: Neuropsychological performance in \nlong-term survivors of childhood ALL. Impairments of distractibility, attention and \nmemory and its interferences to CNS morphology. Med Pediatr Oncol. In Press \n86    K 2 Kaatsch P, Rickert CH, K\u00fchl J, Sch\u00fcz J, Michaelis J. Population-based epidemiologi-\ncal data on brain tumors in German children. Cancer 92: 3155-3164, 2001. \nWd\nhlg.X X  K \nA1 L\u00f6ning L., Zimmermann M., Reiter A., Kaatsch P., Henze G., Riehm H., Schrappe M. \nSecondary neoplasms subsequent to Berlin-Frankfurt-M\u00fcnster therapy of acute \nlymphoblastic leukemia in childhood: signific antly lower risk without cranial radiothe-\nrapy. Blood 95: 2770-2775, 2000. 8A.2 b) Patents applied for within the network \nTitle Prospective \nPatent\nHolderMedical Research \nNetwork Project  Implications and planned \nusage Patent Status \nTumor Box  F. Berthold G \u2013 Embryonal Tumors General use for safe trans-\nport of frozen and non-\nfrozen fresh tissue sam-\nples.Application submitted on \n25.06.2001, Application \nnumber A2 10131828.6 \nMethod of detecting \nrelease of sub-\nstances from cell \norganells by means \nstatuteof flow cy-\ntometry K.-M. Debatin D \u2013 Apoptosis and Drug \nResistence Applications submitted \non 13.11.2001,  \n(1) US Application num-\nber US-09-987,206 \n(2) German Application \nNumber 10155518.0 Statut des Aufsichtsrates\nf\u00fcr die P\u00e4diatrische Tumorgewebebank \"Embryonale Tumoren\"\nZweck\nZiel der P\u00e4diatrischen Tumorgewebebank f\u00fcr embryonalen Tumoren ist es, Tumorgewebe in\nhoher Qualit\u00e4t zu sammeln, zu lagern und f\u00fcr Forschungsprojekte zur Verf\u00fcgung zu stellen.Dadurch sollen besonders biologische, immunologische und molekulargenetische Erkennt-nisse zur Verbesserung des Krankheitsverst\u00e4ndnisses, der Diagnostik und der Behandlungs-m\u00f6glichkeiten gewonnen werden.\nRahmen\nDie dezentralen Tumorbanken werden im Rahmen des Kompetenznetzes P\u00e4diatrische On-\nkologie und H\u00e4matologie Teilprojekt G \"Klinische Relevanz molekularbiologischer Marker beiembryonalen Tumoren\" etabliert und gef\u00f6rdert.\nDerzeitige Standorte:\nNeuroblastom, seltene Tumoren: Universit\u00e4tskinderklinik, K\u00f6lnNephroblastom:\nInstitut f\u00fcr physiologische Chemie der Universit\u00e4t W\u00fcrzburg\nHepatoblastom, Hirntumoren: Institut f\u00fcr Neuropathologie der Universit\u00e4t, Bonn \nVerteilung des Tumorgewebes\n1. Automatische Verteilung: \nGewebeproben f\u00fcr patientenrelevante Untersuchungen im Rahmen laufender Therapie-studien werden automatisch nach vorgegebenem Zeittakt (z. B. 1x /Woche) an die koope-rierenden Labors weitergegeben bzw. von den sammelnden Einrichtungen selbst bearbei-tet. Die einsendenden Kliniken k\u00f6nnen auf dem Einsendeschein Priorit\u00e4ten des Laborsfestlegen.Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie\nVorsitzender Prof. Dr. G. Henze Univ.-Kinderklinik,  Charit\u00e9  CVK, Augustenburger Platz 1,  13353  Berlin,  Tel. (030)  450-66032\nGPOH - Sekretariat Tel. (030)  450-66342,   Fax  (030)  450-66906 / email: gpoh@charite.de\n1. Stellv. Vorsitzende Priv.-Doz. Dr. Charlotte Niemeyer Univ.-Kinderklinik,  Mathildenstr. 1,  79106  Freiburg\n2. Stellv. Vorsitzender Prof. Dr. A. Reiter U niv.-Kinderklinik, Feulgenstr.12, 35385 Gie\u00dfen\n3. Stellv. Vorsitzender Prof. Dr. H. J\u00fcrgens Univ.-Kinde rklinik,  Albert-Schweitzer-Str. 33,  48129  M\u00fcnster\nSchatzmeister Prof. Dr. F. Berthold Univ.-Kinde rklinik,  Joseph-Stelzmann-Str. 9,  50924  K\u00f6ln\nSchriftf\u00fchrer Dr. W. D\u00f6rffel, Berlin Klinikum Berlin-Buch, II. Kinderklinik,  Wiltbergstr. 50,  13122  BerlinGesch\u00e4ftsf\u00fchrung Prof. Dr. Ursula Creutzig Thea-B\u00e4hnisch-Weg 12,  30657  Hannover,  Tel. (0511)  604 66 77,  Fax  (0511)  604 64 04\nVorstandsmitglieder\nProf. Dr. J. Boos,  M\u00fcnster - Prof. Dr. H. Gadner,  Wien - Prof.  Dr. D. Harms,  Kiel - Prof. Dr. D. von Schweinitz,  Basel\nProf. Dr. T. Klingebiel,  T\u00fcbingen - Dr. K. Siegler,  Frankfur t - Prof. Dr. K. Welte,  Hannover - Prof. Dr. N. Willich,  M\u00fcnste r\nBankverbindung  Konto Nr. 0951779000  bei  der  Dresdner  Bank  AG  K\u00f6ln   (BLZ 370 800 40)-2-\nEinrichtungen mit automatischer Belieferung sind z. Zt. \nNeuroblastom:\nDKFZ Heidelberg (Prof. Schwab)\nUniversit\u00e4tskinderklinik Marburg (PD Christiansen)Universit\u00e4tskinderklinik K\u00f6ln (Prof. Berthold)\nHepatoblastom:\nInstitut f\u00fcr Neuropathologie der Universit\u00e4t Bonn ( Prof. Wiestler)\nHirntumoren:\nInstitut f\u00fcr Neuropathologie der Universit\u00e4t Bonn (PD Pietsch)\nUniversit\u00e4tskinderklinik Mannheim (PD Scheurlen)\nNephroblastom:\nInstitut f\u00fcr physiologische Chemie Universit\u00e4t W\u00fcrzburg (Prof. Gessler)\nDer Aufsichtsrat legt die Institutionen mit automatischer Zusendung alle zwei Jahre fest.2. Verteilung auf Antrag:\nAntr\u00e4ge auf Tumorgewebe werden an die zust\u00e4ndige Tumorbank gerichtet und mit einem\nVermerk der zust\u00e4ndigen Tumorbank \u00fcber die Verf\u00fcgbarkeit des Materials an den Auf-\nsichtsrat weitergeleitet.\nDer Aufsichtsrat bewertet die Antr\u00e4ge, bestimmt \u00fcber Ablehnung oder Bewilligung und\nlegt Priorit\u00e4ten fest. \nDer jeweilige Studienleiter sollte einen Kommentar zu den beantragten Projekten bzw.\nMaterial abgeben, er hat jedoch kein Entscheidungsrecht. \nVorgegebene allgemeine Priorit\u00e4ten sind:\n1. Priorit\u00e4t\nWissenschaftlich begutachtete Forscher mit bewilligter F\u00f6rderung\n2. Priorit\u00e4t\nneue Forscher oder Forscher bei der Entwicklung neuer Forschungsgebiete\n3. Priorit\u00e4t \nandere Forscher.\n4. Priorit\u00e4t\nAntr\u00e4ge von Forschern aus dem Ausland k\u00f6nnen im Rahmen von Kooperationen\nmit deutschen Gruppen gestellt werden. -3-\nDie Forscher, die Material bzw. Tumorproben erhalten haben, sollen einen Ergebnisbericht\n\u00fcber das Projekt verfassen.\nZusammensetzung und Bestellung des Aufsichtsrates\nmindestens 5, maximal 7 Mitglieder\ndavon a) 2-3 p\u00e4diatrische Onkologen mit Interesse an experimenteller Forschung\nb) 2-3 Grundlagenforscher mit Interesse an p\u00e4diatrisch-onkologischer Forschung c) 1 Tumorbankbetreiber\nDerzeitige Vorschl\u00e4ge f\u00fcr\na) Prof. Treuner, Stuttgart\nProf. Mittler, MagdeburgPD Schweigerer, Essen\nb) Prof. Schmidt, Mannheim\nProf. Bartram, Heidelberg\nProf. Lichter, Heidelberg\nc) Prof. Berthold, K\u00f6lnDie Mitglieder des Aufsichtsrates werden f\u00fcr drei Jahre vom GPOH-Vorstand bestellt. Je-\nweils 40-50% des Aufsichtsrates werden nach Abschlu\u00df einer Wahlperiode durch neue Mit-\nglieder ersetzt. Welche Mitglieder des Aufsichtsrates nach der ersten Wahlperiode ausschei-den, wird durch das Losverfahren bestimmt. \nVorgaben f\u00fcr die Arbeit des Aufsichtsrates\n- Vergabe des Tumorgewebes nach Kriterien der Wissenschaftlichkeit und der klinischen Re-\nlevanz\n- Entscheidungen je nach Bedarf, mindestens aber 2 x j\u00e4hrlich- Koordination der Arbeit des Aufsichtsrates durch einen Tumorbankbetreiber\n- Der Aufsichtsrat ist rechenschaftspflichtig gegen\u00fcber der Leitgruppe \"Kompetenznetz P\u00e4-\ndiatrische Onkologie und H\u00e4matologie\" und dem GPOH-Vorstand\n\u00c4nderungen des Statuts werden vom GPOH-Vorstand beschlossen.Berlin, den ..................................................\n GPOH-Vorsitzender12B.4 c), C.9 c) Clinical Trials of the Society of Pediatric Oncology and Hematology e.V. (GPOH) \nThe following table lists co-operative multicentric clinical trials which are conducted with the approval of the \nGPOH, were initiated by the investigators, are funded completely independent from industry, succeeded to \ninclude almost all eligible patients suffering from the disease entity listed, provide comprehensive medical \ncounselling, and constitute the state-of-the-art of diagnosis and therapy (\u201cTherapieoptimierungsstudie\u201d).  \nThese trials are not financially supported by the competence network, but are listed here to explain the existing \nstructures of medical quality assurance.  \n# Short  \nTitle Disease  \nEntity  Principle  \nInvestigator City of  \nTrial Office\n1 SIOP 93-01/GPOH Nephroblastoms (Wilm\u2019s-Tumor)  Prof. Dr. Graf Homburg/Saar \n2 COSS 96 Osteosarcoma Prof. Dr. Bielack M\u00fcnster \n3 EURO-E.W.I.N.G. - 99 Ewing tumur  Prof. Dr. J\u00fcrgens M\u00fcnster \n4 CWS-96 Soft tissue sarcoma Prof. Dr. Treuner Stuttgart \n5 HB 94 Hepatoblastoma Prof. Dr. von Schweinitz Basel \n6 SIOP CNS GCT 96 Intracranial germ cell tumors Prof. Dr. G\u00f6bel \nDr. Calaminus D\u00fcsseldorf\n7 MAKEI 96 Malignant Germ cell tumors Prof. Dr. G\u00f6bel \nDr .Calaminus D\u00fcsseldorf\n8 NB 97 Neuroblastoma Prof. Dr. Berthold K\u00f6ln \n9 HIT 2000 Primitive neuro ectodermal tumors of \nthe CNS and Ependymomas PD Dr. K\u00fchl W\u00fcrzburg \n10 HIT-ENDO Kraniopharyngeoma PD Dr. M\u00fcller Oldenburg \n11 HIT-GBM: Glioblastoma  Prof. Dr. Wolff Regensburg \n12 HIT-LGG Low grade glioma Dr. Gnekow Augsburg \n13 GPOH HD-95 Morbus Hodgkin N/A since 2002  \n14 AML-BFM 98 Acute myeloblastic leukemia Prof. Dr. Creutzig M\u00fcnster \n15 ALL-BFM 2000 Acute lymphoblastic leuekemia Prof. Dr. Schrappe Hannover \n16 COALL-06-97 Acute lymphoblastic leuekemia Prof. Dr. Janka-Schaub Hamburg \n17 NHL-BFM 95 Non-Hodgkin Lymphome Prof. Dr. Reiter Gie\u00dfen  \n18 ALL-REZ BFM 96 Acute lymphoblastic leukemia - Re-\nlapse Prof. Dr. Henze Berlin \n19 LCH-II Langerhans cell histiocytosis  Prof. Dr. Gadner Wien \n20 CML-p\u00e4d 95/96 Chronic myeloblastic leukemia  PD Dr. Suttorp Dresden \n21 EWOG-MDS 98 Myelodysplastic Syndrome Prof. Dr. Niemeyer Freiburg \n22 MET 97 Malignant endocrine tumors Prof. Dr. Bucsky L\u00fcbeck \n23 SAA 94 Severe aplastic anemia Dr. F\u00fchrer M\u00fcnchen \n24 Carcinoma of the nasophar-\nynx Carcinoma of the nasopharynx Dr. Mertens Aachen \n    Sum \nThe total annual incidence of the diseases listed is approximately 1800, according to the German Children\u2019s \nCancer Registry 2000. The relative frequency of clinical trial patients among all registered patients is 92%.  \nThere are more clinical trials conducted in pediatric oncology and hematology. These address special scientific \ndiagnostic and therapeutic questions and thus include only subsets of patients.  1/17\nMerkmale des Basisdatensatzes der GPOH\nVersion 2.0\nStand: 02/2002\nHinweise zur Verwendung dieses Dokuments\nDieses Dokument enth\u00e4lt die Auflistung der Merkmale des Basisdatensatzes der GPOH. Datenbankrelevant sind\nder angegebene Datentyp, die L\u00e4nge des entsprechenden Datenfeldes und die Codeziffern zur Verschl\u00fcsselung.Die Tabellenanordnung stellt jedoch keine Abbildung eines Datenbankschemas dar.\nKursiv gedruckte  Begriffe sind im Glossar definiert.\nErkl\u00e4rung der Spalteninhalte\nKontext(e): In der Spalte \"Kontext\" stehen ein oder mehrere Kontexte. Mehrere Kontexte sind\ndurch Spiegelstriche getrennt.Unter \"Kontext\" wird ein Gliederungsbereich auf einem Erhebungsformular\nverstanden. Inhaltlich zusammengeh\u00f6rige Merkmale stehen in einem Kontext.\nMehrere durch Spiegelstriche getrennte Kontexte bilden verschachtelte Kontexte(eine Kontexthierarchie), wobei ein Kontext den nachfolgenden Kontext enth\u00e4lt.Um eine gute \u00dcbersichtlichkeit zu erreichen, wurde hier nicht die vollst\u00e4ndigeKontexthierarchie widergegeben.\nMerkmalsart: Die Spalte \"Merkmalsart\" enth\u00e4lt die Bezeichnung des Merkmals auf einem\nErhebungsformular. Zusammen mit der Kontexthierarchie, in der das Merkmal steht,wird der Inhalt des Merkmals eindeutig.\nTyp: Datentyp und Feldl\u00e4nge\nDatentypen:\nA (): alphanumerisch (Anzahl Zeichen)\nD (): Datum (Anzahl Zeichen)I (): numerisch Integer (Anzahl Ziffern)R (): numerisch Real (Anzahl Vorkommastellen, Nachkommastellen)\nVerschl\u00fcsselung/Optionen: Verschl\u00fcsselung (Codierung) der ausw\u00e4hlbaren Optionen bei Optionsmerkmalen.\nBei Schl\u00fcsseln mit vielen Optionsauspr\u00e4gungen dient der unterstricheneSchl\u00fcsselname als Verweis auf die Verschl\u00fcsselungstabellen.\nIn der Regel kann immer nur eine Option gew\u00e4hlt werden, es sei denn, der Zusatz\"(mehrfach)\" zeigt an, dass beliebig viele Optionen gew\u00e4hlt werden k\u00f6nnen.Abk\u00fcrzungen:\nk.A.: keine Angaben.s./n.e.: nicht sinnvoll/nicht erhebbar\nDatumsformat/Einheit: Genauigkeit des Datums oder Einheit.\nDatumsformate:\nTT: Tag, 2stellig\nMM: Monat, 2stelligJJJJ: Jahr, 4ste llig\nss Stunde, 2stellig\nmm Minute, 2stellig\nlfd. Nr. Nummerierung der Merkmale in diesem Dokument.Basisdatensatz, Version 2.0\n2/17Gliederung\n1 Stammdaten des Patienten ___________________________________________4\n1.1 Angaben zur Person ______________________________________________________________4\n1.1.1 Identifikationszahlen _____________________________________________________________4\n1.2 G\u00fcltige Privatadresse _____________________________________________________________4\n1.3 Versicherung ____________________________________________________________________5\n1.3.1 Krankenkasse __________________________________________________________________5\n1.4 Versorgungsamt _________________________________________________________________5\n2 Aktuelles Prim\u00e4rmalignom ___________________________________________6\n2.1 Stammdaten der behandelnden Klinik _______________________________________________6\n2.2 Aufnahme in behandelnde Klinik ___________________________________________________62.3 Behandelnde \u00c4rzte _______________________________________________________________6\n2.3.1 Institution des Arztes _____________________________________________________________7\n2.4 Familienanamnese _______________________________________________________________7\n2.4.1 Vorerkrankungen der Familie ______________________________________________________7\n2.5 Anamnese des Patienten und Diagnostik des aktuellen Prim\u00e4rmalignoms _________________7\n2.5.1 Aktuelle Anamnese ______________________________________________________________7\n2.5.2 Allgemeinzustand bei Diagnosestellung ______________________________________________72.5.3 Vorerkrankungen des Patienten ____________________________________________________82.5.4 Genetische Untersuchungen (vorl\u00e4ufig) ______________________________________________82.5.4.1 Untersuchungen mittels Cytogenetik/CGH (vorl\u00e4ufig)__________________________________82.5.4.2 Untersuchung auf bestimmte genetische Ver\u00e4nderung (vorl\u00e4ufig) ________________________8\n2.6 Hauptdiagnose des aktuellen Prim\u00e4rmalignoms_______________________________________9\n2.7 Nebendiagnosen des aktuellen Prim\u00e4rmalignoms _____________________________________92.8 Teilnahme an Studie ______________________________________________________________9\n2.8.1 Diagnose, die zur Teilnahme an der Studie gef\u00fchrt hat __________________________________9\n2.8.1.1 Diagnosebest\u00e4tigung durch Referenzeinrichtung ____________________________________102.8.2 Studie _______________________________________________________________________10\n2.8.3 Stammdaten des Patienten in der Studie ____________________________________________10\n2.8.4 Stratifizierung __________________________________________________________________10\n2.8.5 Therapiearmzuordnung __________________________________________________________11\n3 Therapie des aktuellen Prim\u00e4rmalignoms ______________________________11\n3.1 Vortherapie  des aktuellen Prim\u00e4rmalignoms_________________________________________11\n3.2 Therapie nach Beginn einer Protokolltherapie _______________________________________11\n3.2.1 Angewendete Therapiemethoden __________________________________________________11\n3.2.2 Protokolltherapie _______________________________________________________________12\n3.2.2.1 In Studienprotokoll definierter Therapieblock _______________________________________12\n3.2.2.1.1 Toxizit\u00e4ten _______________________________________________________________123.2.2.1.2 K\u00f6rperliche Untersuchung bei Blockbeginn ______________________________________123.2.3 Chemotherapie ________________________________________________________________123.2.3.1 Soll-Chemotherapieblock_______________________________________________________123.2.3.1.1 Chemotherapeutika- ationen im Soll-Chemotherapieblock __________________________133.2.3.2 Ist-Chemotherapieblock________________________________________________________133.2.3.2.1 Chemotherapeutika-Applikationen im Ist-Chemotherapieblock _______________________133.2.4 Operation_____________________________________________________________________133.2.4.1 Durchgef\u00fchrte Operation _______________________________________________________133.2.5 Radiotherapie _________________________________________________________________133.2.5.1 Durchgef\u00fchrter Radiotherapieblock _______________________________________________133.2.5.1.1 Bestrahlungen eines Feldes__________________________________________________143.2.6 Stammzelltransplantation ________________________________________________________143.2.6.1 Konditionierung ______________________________________________________________14Basisdatensatz, Version 2.0\n4/171 Stammdaten des Patienten\n1.1 Angaben zur Person\nKontext(e) Merkmalsart Typ Verschl\u00fcsselung/Optionen/Datumsformat/Einheit lfd. Nr.\nName A 50 1\nVorname A 50 2\nGeburtsname A 50 3\nGeschlecht I 1 -1 = k.A.\n1 = m\u00e4nnlich\n2 = weiblich4\nGeburtsdatum D 8 TTMM JJJJ 5\nGeburtsland I 2 Geburtsland 6Stammdaten der Person\nGeburtsort A 50 243\n1.1.1 Identifikationszahlen\nKontext(e) Merkmalsart Typ Verschl\u00fcsselung/Optionen/Datumsformat/Einheit lfd. Nr.\nG\u00fcltiger PID der GPOH ID A 8 7\nAktuelles Prim\u00e4rmalignom \u2013\nG\u00fcltige Identifikationszahl vom\nIMBEIsiehe Kapitel 2, Merkmal 33\nAktuelles Sekund\u00e4rmalignom \u2013\nG\u00fcltige Identifikationszahl vom\nIMBEIsiehe Kapitel 5, Merkmal 215\nIdentifikationszahl von der Klink siehe Kapitel 2.2, Merkmal 42\nIdentifikationszahl von der Studie siehe Kapitel 2.8.3, Merkmal 126\n1.2 G\u00fcltige Privatadresse\nKontext(e) Merkmalsart Typ Verschl\u00fcsselung/Optionen/Datumsformat/Einheit lfd. Nr.\nStra\u00dfe A 50 8\nPLZ A 10 9\nOrt A 50 10G\u00fcltige Privatadresse\nLand A 50 11\nNummer A 25 12 Telefonanschluss\nHinweis: Es k\u00f6nnen beliebig viele\nNummern erfasst werden.Art I 1 -1 = k.A.\n1 = Festnetz\n2 = Fax\n3 = Mobil244Glossar zum Basisdatensatz der GPOH, Version 2.0\n4/10Begriffsordnungssystem\nSynonyme Bezeichn.: Begriffssystem\nUnterbegriffe: ICD-10, Version 2.0, ICD-O-3 international , OPS-301, Version 2.1 , Toxizit\u00e4tskriterien der\nGPOH, Version 2.0\nDefinition: Als Begriffsordnungssystem werden im Basisdatensatz Klassifikationen, Nomenklaturen\nund sonstige Verschl\u00fcsselungssysteme bezeichnet, die bestimmten Begriffen oderKlassen Codierungen (oder Scores) zuweisen.\nICD-10, Version 2.0\nSynonyme Bezeichn.: Internationale Klassifikation der Krankheiten, 10. Revision, Version 2.0, ICD-10-SGB-V,Version 2.0\n\u00dcberbegriffe: Begriffsordnungssystem\nDefinition: Internationale Klassifikation der Krankheiten, 10. Revision in der deutschen SGB-V-\nFassung, Version 2.0.\nICD-O-3 international\nSynonyme Bezeichn.: International Classification of Diseases for Oncology, third edition\n\u00dcberbegriffe: Begriffsordnungssystem\nDefinition: Mit \"ICD-O-3 international\" wird im Basisdatensatz die englischsprachige Originalfassung\nder Internationalen Klassifikation der Krankheiten f\u00fcr die Onkologie in der 3. Auflage\nbezeichnet. Die deutsche Ausgabe (ICD-O-DA) soll im Basisdatensatz nicht verwendetwerden.\nOPS-301, Version 2.1\nSynonyme Bezeichn.: Operationenschl\u00fcssel nach Paragraph 301 SGB V\n\u00dcberbegriffe: Begriffsordnungssystem\nDefinition: Operationenschl\u00fcssel nach Paragraph 301 SGB V, erstellt vom Deutschen Institut f\u00fcr\nMedizinische Dokumentation und Information (DIMDI) in der Version 2.0.\nToxizit\u00e4tskriterien der GPOH, Version 2.0\nSynonyme Bezeichn.: Toxizit\u00e4tsscores der GPOH, Version 2.0, Toxizit\u00e4tsskalen der GPOH, Version 2.0\n\u00dcberbegriffe: Begriffsordnungssystem\nDefinition: Die Toxizit\u00e4tskriterien der GPOH, Version 2.0 umfassen die Toxizit\u00e4sscores\n(einschliesslich der Skala f\u00fcr den Allgemeinzustand), die im Basisdatensatz, Version 2.0\n(Februar 2002), enthalten sind. Diese Toxizit\u00e4tskriterien sind an die Common ToxicityCriteria (CTC), Version 2.0 des NCI angelehnt, jedoch nicht immer mit Ihnen identisch.\nBereitschaft der Eltern bzw. des Patienten zur Studienteilnahme\nSynonyme Bezeichn.: Einverst\u00e4ndnis der Eltern bzw. des Patienten zur Studienteilnahme, Einwilligung der\nEltern bzw. des Patienten zur Studienteilnahme\nDefinition: Die Bereitschaft der Eltern bzw. des Patienten zur Studienteilnahme ist gegeben, wenndie Eltern, bzw., bei ausreichender Einsichtsf\u00e4higkeit, der Patient selbst ihr/sein\nschriftliches Einverst\u00e4ndnis zur Studienteilnahme gegeben haben/hat.Verschl\u00fcsselungstabellen zum Basisdatensatz, Version 2.0\n8/10Toxizit\u00e4tskriterien der GPOH, Version 2.0\n(153)\nAngelehnt an die Common Toxicity Criteria (CTC), Version 2.0 des NCI\nAbk\u00fcrzungen:\nN: Altersnorm\nEF: ejection fraction, Auswurffraktion\nSF-LV: shortening fraction, linksventrikul\u00e4re Verk\u00fcrzungsfraktion\nAllgemeinzustand (modifizierter Karnofski-Index)\n(75, 152)\nCode Klartext\n-1 k.A.\n1 Normale Aktivit\u00e4t, keine Beeintr\u00e4chtigung\n2 Geringe Beeintr\u00e4chtigung der Aktivit\u00e4t, jedoch keine zus\u00e4tzliche Hilfe erforderlich\n3 Altersentsprechende Aktivit\u00e4t stark eingeschr\u00e4nkt (z.B. kein regelm\u00e4\u00dfiger Kindergarten- bzw. Schulbesuch m\u00f6glich)\n4 Bettl\u00e4gerig, pflegebed\u00fcrftig\n5 Intensive Behandlung notwendig, schwerstkrank, moribund\nToxizit\u00e4tsscores Gastrointestinaltrakt\nGrad 0 1 2 3 4\n\u00dcbelkeit keine ausreichende\nNahrungsaufnahmekann essen, aber\ndeutl. verminderte\nAufnahmepraktisch keine\nNahrungsaufnahmeTPN erforderlich\nErbrechen [Anzahl\nEpisoden in 24 h]0 1 2 \u2013 5 6 \u2013 10 > 10\noder TPN erforderlich\nStomatitis keine schmerzlose Ulzera,\nErythemschmerzendes\nErythem oder\nUlzerationen, kann\naber essenschmerzendes\nErythem oder\nUlzerationen, kann\nnichts mehr essenTPN wegen\nStomatitis\nerforderlich\nDiarrhoe\n[Stuhlfrequenz/Tag]keine 2 \u2013 3 4 \u2013 6 oder n\u00e4chtl.\nStuhl oder leichte\nBauchkr\u00e4mpfe7 \u2013 9 oder\nInkontinenz oder\nstarke Bauchkr\u00e4mpfe>= 10 oder blutiger\nDurchfall oder TPN\nerforderlich\nToxizit\u00e4tsscores H\u00e4matologie\nGrad 0 1 2 3 4\nH\u00e4moglobin [g/dl] Altersnorm (N) 10.0 \u2013 < N 8.0 \u2013 < 10.0 6.5 \u2013 < 8.0 < 6.5\nLeukozyten [g/l] >= 4.0 3.0 \u2013 < 4.0 2.0 \u2013 < 3.0 1.0 \u2013 < 2.0 < 1.0\nGranulozyten [g/l] >= 2.0 1.5 \u2013 < 2.0 1.0 \u2013 < 1.5 0.5 \u2013 < 1.0 < 0.5\nThrombozyten [g/l] >= 100 75 \u2013 < 100 50 \u2013 < 75 10 \u2013 < 50 < 10\nToxizit\u00e4tsscores Haut\nGrad 0 1 2 3 4\nHautver\u00e4nderungen keine Erythem trockene\nDesquamation,\nVaskulitis, Pruritusfeuchte\nDesquamationen,\nUlzerationenExfoliative\nDermatitis, NekrosenVerschl\u00fcsselungstabellen zum Basisdatensatz, Version 2.0\n9/10Toxizit\u00e4tsscores Herz\nGrad 0 1 2 3 4\nArrhythmie keine Asympt., keine\nTherapierekurr./persist.\nkeine TherapieTherapie erforderlich Hypotension,\nventr. Arrhyt.,\nDefibrillation\nHerzfunktion Normal asymptomat. EF \u2193\n(Ruhe) >= 10% aber\n< 20% vom\nAusgangswertasymptomat. aber\nEF\u2193 (Ruhe) unter\ndem unteren\nNormwert f\u00fcr EF\n(Arbeit) oder\nEF\u2193 >= 20% vom\nAusgangswertMilde CHF,\ntherapeutisch\nkompensiertSchwere / refrakt\u00e4re\nCHF oder\nNotwendigkeit der\nIntubation\nEchocardio: LV-SF\n(%)>= 30 >= 24 \u2013 < 30 >= 20 \u2013 < 24 > 15 \u2013 < 20 <= 15\nToxizit\u00e4tsscores Infektion\nGrad 0 1 2 3 4\nInfektion keine leicht m\u00e4\u00dfig; ohne\nErregernachweis;\ni.v.-Antibiotikaschwer; mit Erreger-\nnachweis; i.v.-ATBlebensbedrohlich, mit\nHypotonie\nFieber [\u00b0C] < 38 38 \u2013 39 > 39 \u2013 40 > 40 f\u00fcr < 24 Std. > 40 f\u00fcr >= 24 Std.\nToxizit\u00e4tsscores Leber\nGrad 0 1 2 3 4\nBilirubin Altersnorm (N) > N \u2013 1.5 x N > 1.5 \u2013 3.0 x N > 3.0 \u2013 10.0 x N > 10.0 x N\nS-GOT/S-GPT Altersnorm (N) > N \u2013 2.5 x N > 2.5 \u2013 5.0 x N > 5.0 \u2013 20.0 x N > 20 x N\nToxizit\u00e4tsscores Nieren\nGrad 0 1 2 3 4\nCreatinin Altersnorm (N) > N \u2013 1.5 x N > 1.5 \u2013 3.0 x N > 3.0 \u2013 6.0 x N > 6.0 x N\nProteinurie [g/l] keine < 3 3 \u2013 10.0 > 10.0 Nephrot. Syndrom\nH\u00e4maturie keine mikroskopisch makroskop. ohne\nKoagelmakroskop. mit\nKoagelTransfusion\nerforderlich\nCreatinin-Clearence\n[ml/Min./1,73m\u00b2]>= 90 60 \u2013 89 40 \u2013 59 20 \u2013 39 <= 19\nToxizit\u00e4tsscores Neurologie\nGrad 0 1 2 3 4\nZentrale\nNeurotoxizit\u00e4tkeine vor\u00fcbergehende\nLethargieSomnolenz < 50%\nder Zeit; m\u00e4\u00dfige\nDesorientierungSomnolenz \u2265 50%\nder Zeit, erhebl.\nDesorientierung,\nHalluzination.Koma,\nKr\u00e4mpfe\nPeriphere\nNeurotoxizit\u00e4tkeine Par\u00e4sthesien schwere\nPar\u00e4sthesien\nund/oder milde\nSchw\u00e4cheunertr\u00e4gliche\nPar\u00e4sthesien, deutl.\nmotorische VerlusteParalyse20C.7 Matrix of cooperation within the network and with external partners \nCategory Project Name A B/1 B/2 C D E F G H I K T \nA \u2013 coord./man. group  X X X X X X X X X  X \nB/1 \u2013 \"DOSPO\"  X X    X   X  This net-\nwork\u2019s \nprojects \nB/2 \u2013 IT-Security  X    X   X X \n C \u2013 Telemedicine         X  \n D \u2013 Molec. Apotsosis     X    \n E \u2013 Preleukemic dis.   X X   X  \n F \u2013 MRD        \n G \u2013 Embryon. tumors  X    \n H \u2013 Imm./gene ther.     \n I \u2013 QoL, vert. netwk.    \n K \u2013 Sec. malig. neopl. \n T \u2013 Tele palliat. ped. \n  A B/1 B/2 C D E F G H I K T \nKKR  X  X  X  X     Central  \nInstitutionsKTR        X     \n PRST X    X X     X  \n ALL-Bank     X  X X     \n Reference labs for \nimmunophenotyping     X X X X     \n Clinical Pharmacol-\nogy, PedNet Modul  X        X    \n LESS        X  X   \nHospitals (participating in trials) X X X X X X X X X X X X \nALL-BFM  X X  X X X   X   Clinical \nTrials CoALL  X   X X X   X   \n ALL-REZ  X    X X  X    \n AML  X   X X X      \n NHL       X      \n NB (Neuroblastoma)        X     \n WT (Wilm's tumor)  X  X    X     \n HIT MED    X    X  X   \n EURO-E.W.I.N.G.    X         \n CWS             \n COSS             \n MAKEI              \n HB        X     \n SAA/FA      X     X  \nOther DKKS (DLFH) 2           X \n Deutsche Krebshilfe        4     \n Telematics P. (TMF) 1  3 X    X     \n Other competence \nnetworks  X  X   X X      \n Research groups        5     21Legend  \nX: Cooperation without separate/special funding.  \n1: BMBF-grant \u201cTelemedizinische Infrastuktur (TMI)\u201d (cooperation with the TMF and three other networks) \n2: \u201cPublikation strukturierter Dokumente zur Patienten- und Angeh\u00f6rigeninformation bei onkologischen \n und h\u00e4matologischen Erkrankungen\u201d (planned DKKS/KPOH cooperative project)  \n3:  BMBF-grants \u201eEinrichtung eines Pseudonymisierungsdienstes\u201c and \u201eSicherheitsinfrastruktur (PKI)\u201c \n4: Deutsche Krebshilfe grant \"SAGE analysis in neuroblastoma\"  \n5: Five DFG-grants: \"CGH in Wilm's tumors\", \"LOH in Wilm's tumors\", \"Components of the patched  \n signalling pathway\", \"Molecular genetics of ptc+/- mouse tumors\", \"IGF in hepatoblastoma\"  \n (cooperations with the University of Bonn)  22C.9 b) List of clinical multi-center studies performed in the network \n## # Short Title Project classification+ Network  \nmembers  \ninvolved New substantial \ncooperations \nwith New study groups \n1 D Drug Resis-\ntanceBasic science study accompa-\nnying CoALL and ALL-BFM \nstudies+Ludwig  \nJanka-Schaub MDC Berlin, AG \nExperimental  \nPharmacology, \nI. Fichtner \u2013\n2 E Pre-\nLeukemic \nBone Mar-\nrow Disor-dersBasic science study accompa-\nnying SAA, SCN, FA, AML \nstudies+Welte \nBender-G\u00f6tze \nEbell \nHarbottSchneppenheim\nBaumann \nSchmitt-Gr\u00e4f\nKaatsch\nCreutzig \u2013 \"Congenital bone \nmarrow failure disor-\nders\"\n\"Acquired aplastic \nanemia\"  \n(subprojects of the \ncompetence network \nprogram \"Rare dis-\neases\")\n3 F Minimal \nresidual \ndisease Applied biomedical science \nstudy accompanying CoALL, \nAML, ALL-REZ BFM, ALL-\nBFM and NHL-BFM studies+Kabisch Reinhardt \nSeeger \nReiter\nSchrappe \nBartram\nGriesinger European Project \nfor standardiza-\ntion of RQ-PCR \nEuropeanMRD \ntask force project European Group for \nMRD in ALL by phe-\nnotyping \n4 G Embryonal \ntumorsBasic science and applied \nbiomedical science study ac-\ncompanying NB, HB, HIT MED \nand Nephroblastoma studies+Berthold \nChristiansen Multi-center trial \nMAKEI+\nMulti-center trial CWS+\u2013\n5 I \n[1]Late Effects \nand Quality \nof Life Clinical study accompanying \nALL BFM and HIT MED stud-\nies+K\u00fchl\nOttensmeier\nBeck\nRavens-\nSieberer \nCreutzig APRO (Arbeits-\ngemeinschaft \nP\u00e4diatrische \nRadioonkologie) Prospective evalua-\ntion of neuropsy-\nchology and QoL in \ncraniopharyngeoma \nCross-sectional\nevaluation of QoL in \nAML patients in \nGemany and Spain \n* Newly initiated since the network exists. \n+ As explained in the following table.  23C.10 International Partners performing together with network projects  \n# Subproject International Partner(s)  City, Country \nA Education program pediatric \noncology and hematology  JR Mann, SIOPE/ESPHI  Birmingham, UK \nE Classifications of myelodys-\nplastic syndromes H. Hasle, G. Kerndrup, Skejby Hospital  \nJ.M. Bennett, University of Rochester \nJ. Chessells, Camelia Botnar Laboratories \nD. Head, Department of Pathology, Vanderbilt University  Aarhus, Denmark \nRochester, NY, USA \nLondon, Great Britain  \nNashville, USA \nF MRD in AML M. Dworzak, St. Anna Kinderspital \nO. Hrusak, Charles University Wien, Austria \nPrag, Czech Republic \nG Embryonal and rare tumors Institute of Cancer Research  \nEuropean Wilm\u2019s tumors trial\nUniversity of Queensland  \nNational Cancer Institute  \nKarolinska Institute\nNational Cancer Institute Sutton, UK \nAmsterdam, NL \nAustralia\nBethesda, USA \nStockholm, Sweden \nBethesda, USA \nI Late effects  \nQuality of life Jankovicz, ELTEC group \nHealth act, Dr. Jeanne Landgraf, Boston \nQoL unit EORTC Brussels  \nDr. Colin Kennedy, University of Southhampton \nProf, Ortega, University of Barcelona \nProf. Str\u00f6mberg, University of G\u00f6teborg  \nDr. Perilongo, University of Padova  Monza, Italy \nBoston, USA \nBrussels, Belgium \nSouthhampton, UK  \nBarcelona, Spain \nG\u00f6teborg, Sweden \nPadova, Italy  \nT Exchange on adult palliative \ncare telemedicine  Milano Instituti Tumori Milano, Italy \nLegend:  \n# Project of the competence network Pediatric Oncology and Hematology.  \nThe projects mentioned above involve at least three network partners from different universities.  \nIn the table, only the additional international partners/groups involved are listed.  24D.14 Presentations of this network and its projects to the public (sorted by month, meeting, and year) \nD.14 Presentations of the network  \nMo-\nnthMeeting Year Title of presentation  Type of presen-\ntationScientist (pro-\nject)\n01 Telekom-Workshop \"Si-\ncherheitsinfrastruktur\" 2000 Kompetenznetz f\u00fcr die P\u00e4diatri-\nsche Onkologie und H\u00e4matologie. Oral Presentation  Pommerening K \n03 Annual status meeting of \nthe Society for Pediatric \nOncology and Hematology \n(GPOH)2000 \n2001 \n2002 News and recent advances \u2013 \nstatus report about the compe-\ntence network to the society  Oral presenta-\ntionsCreutzig U \n05 Semi-annual scientific \nmeeting of the GPOH 2000 \n2001 \n2002 News and recent advances \u2013 \nstatus report about the compe-\ntence network to the society Oral presenta-\ntionsHenze G,  \nCreutzig U \n03 Deutscher  \nKrebskongress  \n(Berlin)2002 Personal attendance, poster dis-\nplay \u201eP\u00e4diatrische Onkologie und \nH\u00e4matologie, \u201aIhr Kind hat Krebs.\u2019 \n\u2013 diese Nachricht trifft j\u00e4hrlich \n2000 Eltern. Aus Angst und Hoff-\nnung wird Heilung \u2013 immer mehr.\u201c Exhibition (three \ndays) Herold R \n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4matolo-\ngie und Onkologie (DGHO)  2001 Das Kompetenznetz P\u00e4diatrische \nOnkologie und H\u00e4matologie Oral presentation Henze G \n10 Science Street  \nG\u00fcrzenich k\u00f6ln2001 Personal attendance, poster dis-\nplay, alternately representation of \nall medical competence networks  Exhibition (one \nday) Herold R \n11 Semi-annual scientific \nmeeting of the GPOH  2001 News and recent advances \u2013 \nstatus report about the compe-\ntence network to the society Oral presentation Henze G,  \nCreutzig U \n12 Management-Symposium \nDarmstadt,  Kompetenz-\nnetztreffen2001 Kompetenznetz P\u00e4diatrische \nOnkologie und H\u00e4matologie Oral presentation Creutzig U \nPresentation of this network\u2019s projects \nMo-\nnthMeeting Year Title of Presentation  Type of Presen-\ntationScientist (pro-\nject)\n02 4. Kongre\u00df des Tumorzent-\nrums (Freiburg) 2000 Myelodysplastische Syndrome im \nKindes- und Jugendalter Oral presentation Niemeyer CM \n02 Kongress der Gesellschaft \nf\u00fcr Arbeitswissenschaft 2002 Prozessorientierte Arbeitsorgani-\nsation im Krankenhaus  Oral presentation Dickhoff A, Fri-\nesdorf W, Herold \nR, Henze G et al. \n03 Annual Meeting of the \nEuropean Group for Blood \nand Marrow Transplanta-\ntion2001 Stem cell transplantation for chil-\ndren with Juvenile Myelomonocytic \nLeukemia (JMML): interim analysis \nof a multicenter study of the Euro-\npean Working Group of MDS in \nchildhood (EWOG-MDS) and the \nEBMT Oral presentation Niemeyer C et \nal.\n03 Annual Meeting of the \nEuropean Group for Blood \nand Marrow Transplanta-\ntion2001 Busulfan, cyclophosphamide and \nmelphalan as preparative regimen \nto allogeneic stem cell transplanta-\ntion in childhood MDS: results of \nthe second interim analysis of the \nEBMT/EWOG-MDS study Oral presentation Locatelli F, Nie-\nmeyer C et al. 25Mo-\nnthMeeting Year Title of Presentation  Type of Presen-\ntationScientist (pro-\nject)\n03 Annual Meeting of the \nEuropean Group for Blood \nand Marrow Transplanta-\ntion2001 Relapse after allogeneic stem cell \ntransplantation for juvenile myelo-\nmonocytic leukemia: are there still \noptions? Oral presentation Bierings M, Nie-\nmeyer C et al. \n03 Deutscher Krebskongress \n(Berlin)2000 Sekund\u00e4re maligne Neoplasien \nnach Krebserkrankungen im Kin-\ndesalter Oral presentation Klein G, Kaatsch \nP Michaelis J \n03 Deutscher Krebskongress \n(Berlin)2002 Assistants in Clinical Research \nand Quality Assurance Invited oral Pres-\nentation  Herold R \n03 Deutscher Krebskongress \n(Berlin)2002 Minimal residual disease Oral presentation HarbottJ \n03 Deutscher Krebskongress \n(Berlin)2002 Health-related quality of life and \nthe network for follow-up Oral presentation Calaminus G \n03 Deutscher Krebskongress \n(Berlin)2002 Embryonal tumors  Oral presentation Berthold F \n03 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nHumangenetik (L\u00fcbeck) 2000 Discrepancy between cytogenetic \nfindings and the result of a cell-\ncycle analysis in a patient with \nFanconi Anemia, secondary ma-\nlignancy and clonal disease Oral presentation Rischewski J \n03 Semi-annual meeting of the \nnetwork members  2002 Qualifizierung von Kliniken; Quali-\nt\u00e4tsindikatoren, M\u00f6glichkeiten des Auditings von Kliniken; Datenquali-\nt\u00e4t und M\u00f6glichkeiten, die Doku-\nmentationsmenge zu reduzieren Oral presentation Creutzig U \n03 Semi-annual meeting of the \nnetwork members 2002 \u00d6ffentlichkeitsarbeit und Internet-\nportal \u201ckinderkrebsinfo.de\u201d Oral presentation Herold R \n03 Semi-annual meeting of the \nnetwork members 2002 Vertikale Vernetzung Oral presentation Calaminus G \n03 Semi-annual meeting of the \nnetwork members 2002 Erleichterung/Verbesserung der \nStudiendokumentation durch Ko-\nordination der Aktenf\u00fchrung Oral presentation Laupert A \n03 Semi-annual meeting of the \nnetwork members 2002 Telemedizin \u2013 Vernetzung vor Ort: \npraktische Erfahrungen Oral presentation Graf N \n03 TMF-Workshop 2002 PID-Dienst und PKI im Kompe-\ntenznetz POH Oral presentation Pommerening K \n04 DNA 2000 Symposium \n(Boston)2000 Screening strategies for a highly \npolymorphic gene: DHPLC-\nanalysis of  the Fanconi Anemia \nGroup A Gene Oral presentation Rischewski J, \nSchneppenheim \nR\n04 TMF-AG Datenschutz  \nund -sicherheit 2001 \"Aufbau einer Sicherheitsinfra-\nstruktur f\u00fcr die TMF\" and  \n\"PID-Erzeugung (Pseudonymisie-\nrungsdienst)\"  Oral presentation Pommerening K \n05 2nd International Sym-\nposium on Myelodys-plastic \nSyndromes in Childhood \n(Funen DK) 2000 Cytogenetic evaluation of children \nwith MDS and juvenile myelo-\nmonocytic leukemia (JMML) - \nResults of the European Working \nof Childhood MDS (EWOG-MDS) Oral presentation Harbott J, Zim-\nmermann M, \nNiemeyer C et \nal.\n05 2nd International Sym-\nposium on Myelodys-plastic \nSyndromes in Childhood \n(Funen DK) 2000 Detection of monosomy 7 and \ntrisomy 8 in childhood MDS and \nJMML by fluorescence in situ hy-\nbridization (FISH) Oral presentation Pils S, Roitzheim \nB, Niemeyer C, \nHarbott J \n05 2nd International Sym-\nposium on Myelodys-plastic \nSyndromes in Childhood \n(Funen DK) 2000 Acquired chromosomal aberrations \nin children with Down syndrome \nand myelodysplatic syndrome \n(MDS) or acute myeloid leukemia (AML)Oral presentation Teigler-Schlegel \nA, Baumann M, \nCreutzig U, Nie-\nmeyer C, Harbott J26Mo-\nnthMeeting Year Title of Presentation  Type of Presen-\ntationScientist (pro-\nject)\n05 2nd International Sympo-\nsium on Myelodysplastic \nSyndromes in Childhood \n(Funen DK) 2000 Morphological and histopathologi-\ncal features in childhod MD and \nJMML: Experience of the EWOG-\nMDS Morphology board Oral presentation Baumann I, \nNiemeyer CM et \nal.\n05 I-BFM (International BFM-\nStudy group) 2002 Presentation of results on MRD (F) Oral presentation Harbott J \n05 International Symposium on \nMyelodysplastic Syndromes \nin Childhood) 2000 Refractory anemia in childhood: a \nstudy of the European Working \nGroup of MDS in Childhood \n(EWOG-MDS) Oral presentation Kardos G, Nie-\nmeyer C, Zim-\nmermann M et \nal.\n05 International Symposium on \nMyelodysplastic Syndromes \nin Childhood) 2000 International prognostic scoring \nsystem for childhood MDS and \nJMMLOral presentation Hasle H, Harbott \nJ, N\u00f6llke P, Nie-\nmeyer CM et al. \n05 International Symposium on \nMyelodysplastic Syndromes \nin Childhood) 2001 Primary MDS in childhood: AML-\nlike chemotherapy prior to stem \ncell transplantation (SCT) does not \nimprove event-free survival Oral presentation Niemeyer CM, \nLocatelli F, N\u00f6l-\nlke P \n05 International Symposium on \nMyelodysplastic Syndromes \nin Childhood) 2001 Juvenile myelomonocytic leukemia \n(JMML) in the presence of other \ncongenital abnormalities Oral presentation B\u00fcchner J, Nie-\nmeyer CM et al. \n05 International Symposium on \nMyelodysplastic Syndromes in Childhood) 2001 MDS in Childhood and Adoles-\ncence: When to treat and how to treatOral presentation Niemeyer C \n05 Kinder\u00e4rztekongre\u00df 2000 Ph\u00e4notyp-Genotyp-Vergleich einer \ndeutschen Patientin mit Fanconi \nAn\u00e4mie (Fanc) der Gruppe C Oral presentation Rischewski J, \nClausen H, Le-\nber V, Suttorp M, \nSchnepenheim R \n05 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche \nOnkologie und H\u00e4matologie \n(GPOH)200! Stammzelltransplantation f\u00fcr mye-\nlodysplastische Syndrome (MDS): \nRisikofaktoren f\u00fcr Rezidiv und \ntoxische Todesf\u00e4lle Oral presentation Niemeyer C, \nFischer A, Har-\nbott J, N\u00f6llke P \n05 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche \nOnkologie und H\u00e4matologie \n(GPOH)2000 Die Behandlung von Kindern und \nJugendlichen mit myelodysplasti-\nschem Syndrom (MDS) \u2013 Zwi-\nschenbericht zur Therapieoptimie-\nrungsstudie EWOG-MDS 98 Oral presentation Niemeyer C, \nRogge T, Fischer \nA, N\u00f6llke P \n05 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche \nOnkologie und H\u00e4matologie \n(GPOH)2000 Charakterisierung hypoplasticsher \nKnochenmarkerkrankungen bei \nKindern und Jugendlichen Oral presentation Baumann I, \nHarbott J, F\u00fchrer \nM, Niemeyer C \n05 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche \nOnkologie und H\u00e4matologie \n(GPOH)2000 Kann eine intensive Chemothera-\npie vor Stammzelltransplantation \n(SZT) bei Kindern und Jugendli-\nchen mit myelodysplastischem \nSyndrom die Heilungsrate verbes-\nsern?Oral presentation Kontny U, Duff-\nner U, N\u00f6llke P, \nNiemeyer C \n05 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche \nOnkologie und H\u00e4matologie \n(GPOH)2000 Falsch negative Fanconi-An\u00e4mie-\nDiagnostik bei gleichzeitigem Vor-\nliegen eines MDS Oral presentation Rischewski J, \nvon Bismarck P, \nJanka G, Schind-\nler D, Schnep-\npenheim R \n05 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche \nOnkologie und H\u00e4matologie \n(GPOH)2000 Indikationen zur allogenen \nStammzelltransplan tation (SZT) \nbei Kindern und Jugendlichen mit \nn\u00e4chtlicher paroxysmaler H\u00e4-\nmoglobinurie (PNH) Oral presentation Strahm B, Kont-\nny U, Duffner U, \nNiemeyer C 27Mo-\nnthMeeting Year Title of Presentation  Type of Presen-\ntationScientist (pro-\nject)\n06 5th Annual Meeting of the \nEuropean Haematology \nAssociation (EHA, Birming-\nham)2000 Children and adollescents with \nprimary myelodysplastic syn-\ndromes (MDS): should they re-\nceive intensive chemotherapy prior \nto stem cell transplantation (SCT)? Oral presentation Niemeyer C, \nDuffner U, Loca-\ntelli LF, Zecca M, \nRogge T, Fischer \nA, N\u00f6llke P \n06 Jahrestagung der Kind-\nPhilipp-Stiftung f\u00fcr Leuk\u00e4-\nmie-Forschung 2000 Fanconi anemia group G muta-\ntions in pediatric patients with \nmyeloid malignancies Oral presentation Lever V., Ri-\nschewski, J., \nNiemeyer, C., \nSchinder, D., \nSchneppenheim, \nR\n06 Jahrestagung der Kind-\nPhilipp-Stiftung f\u00fcr Leuk\u00e4-\nmie-Forschung 2000 Semiautomatized screening for \nFanconi Anemia gene mutations \nusing DHPLC Oral presentation Rischewski J, \nWierzbinski J., \nSchneppenheim \nR\n08 Porzer Gespr\u00e4che \"Ge-\nsundheitstelematik\" \nIGD/DLR2000 Datenschutz und IT-Sicherheit der \nTelematik im Gesundheitswesen Oral presentation Pommerening K \n08 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nMedizinische Informatik, \nBiometrie und Epidemiolo-gie (GMDS) and Internatio-\nnal Congress of the Euro-\npean Federation for Medi-\ncal Informatics 2000 Integrating Specialized Application \nSystems into Hospital Information \nSystems \u2013Obstacles and Factors \nfor SuccessOral presentation Mludek V, Knaup \nP, Wiedemann \nT, Bauer J, Haux \nR, Kim L, Schil-ling FH, Selle, B \n08 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nMedizinische Informatik, \nBiometrie und Epidemiolo-\ngie (GMDS) and Internatio-\nnal Congress of the Euro-\npean Federation for Medi-\ncal Informatics 2000 Data Protection and Security As-\npects in Medical Research Net-\nworks Oral presentation Pommerening K \n09 TMF-Tagung (BMBF \nTelematics Platform) 2000 PGP und SSL in den medizini-\nschen Forschungsnetzen Oral presentation Pommerening K \n09 World Congress on Medical \nInformatics (Medinfo) 2001 Object-oriented business process \nanalysis of the cooperative soft \ntissue sarcoma trial of the german \nsociety for paediatric oncology and \nhaematology (GPOH) Oral presentation Weber R, Knaup \nP, Knietig R, \nHaux R, Merz-\nweiler A, Mludek \nV, Schilling FH, \nWiedemann T \n09 World Congress on Medical \nInformatics (Medinfo) 2001 Recording clinical data - from a \ngeneral set of record items to case \nreport forms (crf) for clinics Oral presentation Weber R, Merz-\nweiler A, Knaup \nP, Ehlerding H, \nHaux R, Wiede-\nmann T \n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nMedizinische Informatik, \nBiometrie und Epidemiolo-\ngie (GMDS)2001 Systematische Remodellierung \neines bundesweiten Dokumentati-\nons- und Therapieplanungssys-\ntems mit UML Poster presentati-\nonGarde S, Knaup \nP, Baumgarten \nB, Haux R, \nMerzweiler A, \nWeber R \n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nMedizinische Informatik, \nBiometrie und Epidemiolo-\ngie (GMDS) 2001 Ein Pseudonymisierungsdienst f\u00fcr \nMedizinische Forschungsnetze Oral presentation Pommerening K \n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nMedizinische Informatik, \nBiometrie und Epidemiolo-\ngie (GMDS) 2001 A reusable pseudonymization \ninterface for epidemiologic re-\nsearchPoster presentati-\nonWagner M 28Mo-\nnthMeeting Year Title of Presentation  Type of Presen-\ntationScientist (pro-\nject)\n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nMedizinische Informatik, \nBiometrie und Epidemiolo-\ngie (GMDS) 2001 Aufbau eines Telemedizinnetzwer-\nkes im Rahmen multizentrischer \nTherapiestudien der p\u00e4diatrischen \nOnkologie Oral presentation Ganslandt T, Huf \nT, Graf N, Pro-\nkosch HU, J\u00fcr-\ngens H, Paulus-\nsen M \n09 European Congress of \nPathology 2001 Clinical Interoperability: Taking \nTelepathology to the Next Level  Oral presentation Ganslandt T, \nKorsching E, \nProkosch HU, \nHerbst H, B\u00f6cker \nW, Senninger N, \nSpiegel HU \n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nKinderheilkunde und Ju-\ngendmedizin 2001 Elektronische Erfassung von Di-\nagnosen und Prozeduren in der \nP\u00e4diatrischen Onkologie \nund H\u00e4matologie Oral presentation Herold R \n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nKinderheilkunde und Ju-\ngendmedizin 2001 Erkennung von Fanconi An\u00e4mie \nMutationen mittels DHPLC als \nhalbautomatisches Screeningver-\nfahrenOral presentation Rischewski J, \nWierzbinski J., \nSchneppenheim \nR\n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nKinderheilkunde und Ju-\ngendmedizin 2001 Paroxysmale n\u00e4chtliche H\u00e4moglo-\nbinurie (PNH): Krankheitsverlauf \nund therapeutische M\u00f6glichkeiten \nanhand von zwei Fallbeispielen Oral presentation Strahm B, Kont-\nny H U, Duffner \nU, Niemeyer CM \n09 Jahrestagung der Deut-\nschen Gesellschaft f\u00fcr \nKinderheilkunde und Ju-\ngendmedizin 2001 Inzidenz und Management von \nZweitmalignomen Oral presentation Niemeyer C \n09 Symposium \"Telemedizin \nund Robotik\" 2001 Telemedizin und Qualit\u00e4tssiche-\nrung in der Onkologie Oral presentation Rube Ch, Graf N \n10 World Congress of High \nTech Medicine 2000 Data Security and Data Protection \nin Medical Research Networks Oral presentation Pommerening K \n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4matolo-\ngie und Onkologie (DGHO)  2001 Minimal residual disease Oral presentation Harbott J \n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4matolo-\ngie und Onkologie (DGHO)  2001 Telemedicine communication in \nthe GPOH Pediatric Oncology \ncompetence net: Evaluation of \nexpectations and infrastructure  Oral presentation Paulussen M \n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4matolo-\ngie und Onkologie (DGHO)  2001 Aufbau eines Wissensservers f\u00fcr \ndie P\u00e4diatrische Onkologie und \nH\u00e4matologie Oral presentation Herold R \n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4matolo-\ngie und Onkologie (DGHO)  2001 Indications for allogeneic stem cell \ntransplantation (SCT) in two ado-\nlescent patient with paroxysmal \nnocturnal hemoglobinuria (PNH) Oral presentation Strahm B, Kont-\nny H U, Duffner \nU, Niemeyer C M \n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4matolo-\ngie und Onkologie (DGHO)  2001 Stem cell transplantation (SCT) in \nchildren and adolescents with \nmyelodysplastic syndromes \n(MDS): Impact of prior chemother-\napy and karyotype Oral presentation Niemeyer CM et \nal.\n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4matolo-\ngie und Onkologie (DGHO)  2001 Activation of p21ras in MDS, AML, \nJMML and other haematopoeitic \nmalignancies measured by a \nquantitative and non-radioactive \nmethodOral presentation Scheele J, Nie-\nmeyer C et al. \n10 Jahrestagung Deutsche \nGesellschaft f\u00fcr H\u00e4ma-tologie und Onkologie \n(DGHO)2000 Prospective study on stem cell \ntransplantation (SCT) for children and adolescents with MDS Oral presentation Niemeyer C et \nal.29Mo-\nnthMeeting Year Title of Presentation  Type of Presen-\ntationScientist (pro-\nject)\n10 Meeting of the International \nSociety of Pediatric Oncol-\nogy (SIOP) 2000 AML-like chemotherapy prior to \nStem cell transplantation does not \nimprove event-free survival in \nchildren\u2019s and adolescents with \nMDSOral presentation Niemeyer CM, \nLocatelli F, N\u00f6l-\nlke P \n10 Meeting of the International \nSociety of Pediatric Oncol-\nogy (SIOP) 2001 The Meta-EICESS Protocol For \nPatients With Primary Multifocal \nAnd Early Relapsed Ewing Tu-\nmors: Results After 5 Years Oral presentation  Burdach St \n10 Meeting of the International \nSociety of Pediatric Oncol-\nogy (SIOP) 2001 Immunogene Therapy with IL2 or \nIL7 transfected Ewing Tumor Cells \nin NOD/SCID Mice Oral presentation Burdach St \n10 Meeting of the International \nSociety of Pediatric Oncol-\nogy (SIOP) 2001 Allogeneic stem cell transplanta-\ntion for juvenile myelomonocytic \nleukaemia Oral presentation Bierings M, Nie-\nmeyer C et al. \n11 Telemed 2001 2001 Automatische Korrektur fehlerhaf-\nter Patientenzuordnungen im \nRahmen von medizinischen For-\nschungsnetzen Oral presentation Pommerening K \n11 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche Onkologie und H\u00e4matologie \n(GPOH, Berlin) 2000 Versorgung von Kindern und Ju-\ngendlichen mit angeborenen Er-\nkrankungen mit Knochenmarkver-\nsagen Oral presentation Niemeyer C, \nEbell W, Welte K \n11 Wissenschaftliche Halb-\njahrestagung der Ge-\nsellschaft f\u00fcr P\u00e4diatri-sche \nOnkologie und H\u00e4matologie \n(GPOH, Berlin) 2001 Telemedizin im Kompetenznetz \nP\u00e4diatrische H\u00e4matologie und \nOnkologie - Ein Zwischenbericht Poster Presenta-\ntionPaulussen M, \nGraf N, Huf Th, \nGanslandt Th \n11 Medica (industrial fair) 2001 Interoperabilit\u00e4t: Telepathologie \nauf dem n\u00e4chsten Level Presentation Ganslandt T, \nKorsching E, \nProkosch HU, \nSpiegel HU \n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2000 Elevated frequency of the mutation \n657del5 within the NBS1 gene in \nchildhood acute lymphoblastic \nleukemia Oral presentation Rischewski J et \nal.\n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2000 Evolution of severe congenital \nneutropenia (CN) to chronic mye-\nlomonocytic leukemia (CMML) \nassociated with expression of a \ntruncated G-CSF receptor in leu-\nkemic blasts and an activating \nNRAS mutation Oral presentation Germeshausen \nM et al. \n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2000 Development of glomerulonephritis \nin patients (pts) with severe \nchronic neutropenia (SCN)  Oral presentation Boxer L, Welte \nK, Dale DC et al. \n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2000 AML-Type intensive chemotherapy \nprior to stem cell transplantation \n(SCT) does not improve survival in \nchildren and adolescents with \nprimary myelodysplastic syn-\ndromes (MDS) Oral presentation Niemeyer C, \nDuffner U, Ben-\nder-G\u00f6tze C, \nDini G, Ebell W \net al. \n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2001 International Prognostic Scoring \nSystem (IPSS) for Childhood \nMyelodysplastic Syndrome (MDS) \nand Juvenile Myelomonocytic Leukemia (JMML) Oral presentation Hasle H, Nie-\nmeyer CM et al. 30Mo-\nnthMeeting Year Title of Presentation  Type of Presen-\ntationScientist (pro-\nject)\n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2001 Allogeneic Stem cell Transplanta-\ntion in Children with Juvenile Mye-\nlomonocytic Leukemia: Results of \na Prospective Study of the EWOG-\nMDS/EBMT Groups Oral presentation Locatelli F, Nie-\nmeyer C et al. \n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2001 The Outcome of Hepatitis-\nAssociated Aplastic Anemia \n(AA)Treated with Immunosuppres-\nsive Therapy (IST) or Bone Mar-\nrow Transplantation (BMT) \u2013 The \nExperience of the Ger-\nman/Austrian Pediatric AA Study \nGroupOral presentation F\u00fchrer M, Rampf \nU, Niemeyer C, \nBender-G\u00f6tze C \n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2001 Clinical outcome in myelokathexis: \nA report of 6 patients enrolled in \nthe Severe Chronic Neutropenia \nInternational Registry Oral presentation Bonilla MA, Wel-\nte K et al. \n12 Annual Meeting of the \nAmerican Society of Hema-\ntology (ASH) 2001 Long term treatment of chronic \nidiopathic neutropenia in women \nwith G-CSF Oral presentation Bolyard AA, \nWelte K, Dale \nDC et al. \n12 Management-Symposium \nDarmstadt \u2013 Kompetenz-netztreffen2001 Vertikale Vernetzung in der \nP\u00e4diatrischen Onkologie  Oral presentation Neubauer M, \nCalaminus G \n12 Management-Symposium \nDarmstadt \u2013 Kompetenz-\nnetztreffen2001 Strategies for the persistance of \nmedical competence networks Chairing work-\nshop, oral presen-\ntationHerold R 31D.15 Media coverage \u2013 collection of media reports on this network \nPaper end electronic press, radio and TV reports \nThe following list includes the media reports featuring our competence network.  \nThe press conference took place on 23.11.2001, immediately before the society\u2019s semi-annual meeting.  \nThirty-three media representatives requested press information.  \n# Date Medium Name \u2013 Format Report Title Author \n1 01.03.2001 Press targetForum Forschung in Deutschland \u2013 Kompetenz \nvernetztC. Vetter \n2 09.03.2001 Electronic \npressBerliNews  Genomforschung an Mikroorganismen: \nBMBF f\u00f6rdert drei Kompetenznetze \n3 22.11.2001 Press AFP Agence France-\nPresseAnnouncement of press conference  \n4 23.11.2001 Press dpa Deutsche Presse-\nAgenturJ\u00e4hrlich sterben in Deutschland 500 Kinder \nan Krebs bb\n5 23.11.2001 Press Neue Ruhr Zeitung J\u00e4hrlich sterben in Deutschland 500 Kinder \nan Krebs \n6 23.11.2001 Press Ostth\u00fcringer Zeitung J\u00e4hr lich sterben in Deut schland 500 Kinder \nan Krebs \n7 23.11.2001 Press Potsdamer Neueste \nNachrichten Ein Netz der Hoffnung. Kliniken organisieren \nsich im Kampf gegen Kinderkrebs \n8 23.11.2001 Electronic \npressPotsdamer Neueste \nNachrichten online Ein Netz der Hoffnung. Kliniken organisieren \nsich im Kampf gegen Kinderkrebs  bas\n9 23.11.2001 Press Th\u00fcringer Allgemeine Zei-\ntungJ\u00e4hrlich sterben in Deutschland 500 Kinder \nan Krebs \n10 23.11.2001 Electronic \npressweb.de J\u00e4hrlich sterben in Deutschland 500 Kinder \nan Krebs \n11 23.11.2001 Radio Radio Hundert, 6 \u2013 Kom-\npakt am Mittag Summary of the press conference and inter-\nview with Prof. Henze (total, 6 minutes, start \n12:40)\n12 23.11.2001 Radio Sender Freies Berlin Stadt-\nradio 88,8 \u2013 Berolina Interview with Prof. Henze (total, 3,5 minutes, \nstart 12:20) \n13 24.11.2001 TV tv.Berlin Interview with Prof. Henze (total, 1,5 minutes, \nstart 19:14) and visit to a pediatric oncology  \nward \n14 27.11.2001 Electronic \npressBertelsmannSpringer Me-\ndizin Online Das Kompetenznetz P\u00e4diatrische Onkologie \nund H\u00e4matologie P. D\u00fcker \n15 26.11.2001 Press Der Tagesspiegel Ein Netz der Hoffnung. Kliniken organisieren \nsich im Kampf gegen Kinderkrebs bas\n16 26.11.2001 Electronic \npressDer Tagesspiegel online Ein Netz der Hoffnung. Kliniken organisieren \nsich im Kampf gegen Kinderkrebs bas\n17 27.11.2001 Electronic \npressbsmedic-Berlin (HOS-\nMultimedica) Das Kompetenznetz P\u00e4diatrische Onkologie \nund H\u00e4matologie \n18 27.11.2001 Press Frankfurter Rundschau Unterst\u00fctzung bei unsicherer Diagnose. Weil \nKrebs bei Kindern selten vorkommt, brau-\nchen nicht nur Laien, sondern auch \u00c4rzte \nRat/Hilfe per Telefon und Internet R. Jung \n19 09.12.2001 TV ZDF 3sat \u2013 Teletipps vom \nHausarzt NewsEcke: Pointers to the competence net-\nwork \n20 07.01.2002 Press Deutsches \u00c4rzteblatt Kompetenznetzwerke: Eine Struktur gewinnt \nallm\u00e4hlich Inhalte V. Zylka-\nMenhorn \n21 09.01.2002 Press Berliner Morgenpost Kr ebs bei Kindern ist anders. Fortschritte in \nder Therapie retten die meisten der kleinen \nPatienten A.\nSchrum3222 09.01.2002 Electronic \npressBerliner Morgenpost online Krebs be i Kindern ist anders. Fortschritte in \nder Therapie retten die meisten der kleinen Patienten A.\nSchrum\n23 13.02.2002 Press Frankfurter Allgemeine \nZeitung Kompetenznetze verbessern Krankenversor-\ngung. Mehr Kommunikation zwischen For-\nschung und Praxis/Effektivere klinische Stu-\ndien H. Kaulen \nInternet links to this network \nOn March 24th, 2002, the search engine http://www.google.de/ searching for \u201ckompetenznetz p\u00e4diatrische on-\nkologie\u201d retrieved 610 documents in the internet that linked to this competence network\u2019s pages. The following \nare links found on endorsed documents:  \nTitle URI \nYahoo! > Gesundheit > Medizin > Kinder-\nheilkunde http://de.dir.yahoo.com/Gesundheit/Medizin/kinderheilkunde/ \nYahoo! > Gesundheit > Krankheiten und Be-\nschwerden > Krebs > Kinder http://de.dir.yahoo.com/Gesundheit/K rankheiten_und_Beschwerden/Kreb\ns/kinder/\nOnkologie Online (DKFZ) http://www.dkfz-heidelberg.de/tzhdma/tzlinks.htm \nDeutsche Zentralbibliothek f\u00fcr Medizin http:// www.zbmed.de/a_digit/disziplin/haem.html \nDeutsche Gesellschaft f\u00fcr Kinderheilkunde \nund Jugendmedizin e.V. http://www.dgkj.de/kammerntext.htm \nINKA \u2013 Das Informationsnetz f\u00fcr Krebspatien-\nten und Angeh\u00f6rige: Krebstherapie: Therapie-\nstudien http://www.inkanet.de/info/krebstherapie/studien.htm\nKompetenznetze.de des BMBF http://www.kompetenznetze.de/ \nInternetRatgeber Gesundheit http://www.amgen.de/internet/tx_irg_kinder.htm \nKlinikbibliothek Schnarrenberg und Daten-\nbankdienste http://www.medizin.uni-tuebi ngen.de/~webbibl/neues.htm \nNordwestdeutsche Gesellschaft f\u00fcr \u00e4rztliche \nFortbildung e.V. http://www.westerland-symposium.de/linksammlung.htm \nCommunity of Knowledge http://www.community-o f-knowledge.de/cp_arti kel.htm?artikel_id=80 \nMedknowledge Suchkatalog f\u00fcr Medizin http://www. medknowledge.de/fach/kinderheilkunde_onkologie.htm \nSelbstfindung TopNews http://www.vkdnet.de/website/news/texte/ps_topn.htm \nWyeth Pharma GmbH Patienteninfo http://www.krebs-webweiser.de/krebs-webweiser1101.pdf 33E.20 List of Guidelines in Pediatric Oncology and Hematology and internet start page (AWMF) \nThe following guidelines are published on the internet (http://www.awmf-leitlinien.de/) under the auspices of the \nAWMF (working group of the scientific medical specialty societies in Germany). The AWMF definition of step 1 \nis: \u201eA representatively composed group of experts of a AWMF Specialty Society informally consents on a guide-\nline which is passed by the society\u2019s board of directors.\u201c  In addition, \u201c+IDA\u201d refers to accomplishment of an \ninterdisciplinary agreement.  \nThe guidelines were also published on paper:  \n\u0083 Leitlinien f\u00fcr die Diagnostik und Therapie in der P\u00e4diatrischen Onkologie, Creutzi U and Henz G (eds.). \nReihe \u201eQualit\u00e4tssicherung in der Onkologie\u201c, Zuckschwerdt Stuttgart 2nd ed. 2001\n\u0083 Leitlinien f\u00fcr die Diagnostik und Therapie in der P\u00e4diatrischen Onkologie, in: Leitlinien Kinderheilkunde \nund Jugendmedizin, Reinhardt D, B\u00f6hles H, Creutzig U, Kies W, Korinthenberg R, Luthard T, Michal D, Poets CF and Ulmer (eds.), Urban&Fischer M\u00fcnchen 2001 \n\u0083 Leitlinien f\u00fcr Diagnostik und Therapie, Informationszentrum f\u00fcr Standards in der Onkologie (ISTO), On-\nkologie/Deutsche Krebsgesellschaft (#4 to #15, also on the internet http://www.krebsgesellschaft.de/) \n#  Guideline  English translation Step \n(see\ntop of \npage) Number of\npersons \nwithin \nthe network \ninvolved  Date of\npublication Last  \nrevision \n1 Grundlagen der Therapie \nvon Tumoren und malignen \nSystemerkrankungen des \nKindes  Basics of the therapy of \ntumors and malignant sys-\ntemic diseases in childhood 1 2 13.01.1997  \n2 Psychosoziale Standards f\u00fcr \ndie P\u00e4diatrische Onkologie  Psychosocical standards in \npediatric oncology 1 2 13.01.1997  \n3 Prinzipien zur Erfassung von \nSp\u00e4tfolgen Priciples of late effect sur-\nveillance  1 2 13.01.1997  \n4 Nephroblastom Nephroblastoma 1+IDA 1 13.01.1997 01.11.1999 \n5 Osteosarkome Osteosarcoma 1+IDA 1 13.01.1997 01.11.1999 \n6 Ewing-Sarkome und PNET Ewing-Tumors and PNET 1+IDA 2 13.01.1997 01.11.1999 \n7 Weichteilsarkome Soft tissue sarcomas 1+IDA 1 13.01.1997 01.11.1999 \n8 Neruoblastoma Neruoblastoma 1+IDA 2 13.01.1997 01.11.1999 \n9 Medulloblastom Medulloblastoma 1+IDA 2 13.01.1997 01.11.1999 \n10 Keimzelltumoren Germ cell tumors 1+IDA 2 13.01.1997 01.04.2000 \n11 Hepatoblastom Hepatoblastoma 1+IDA 2 13.01.1997 01.11.1999 \n12 Morbus Hodgkin Hodgkin\u2019s Disease 1+IDA 2 13.01.1997 01.11.1999 \n13 Non-Hodgkin Lymphome Non-Hodgkin Lymphomas 1+IDA 2 13.01.1997 01.11.1999 \n14 Akute lymphoblastische \u2013 \n(ALL) und akute myeloische \nLeuk\u00e4mie (AML) Acute lymphoblastic and \nmyeloblastic leukemia 1+IDA 2 13.01.1997 01.11.1999 \n15 Langerhanszell-Histiozytose \n(LCH)Langerhans Histocytosis 1+IDA 0 13.01.1997 01.06.2000 \n16 Sichelzellan\u00e4mie Sickle cell disease 1 0 13.01.1997 01.01.2001 \n17 Thalass\u00e4mie Thalassemia 1 2 13.01.1997 01.01.2001 \n18 Heredit\u00e4re Sph\u00e4rozytose Spherocytosis 1 0 13.01.1997 01.01.2001 \n19 Aplastische An\u00e4mie Aplastic Anemia 1 0 13.01.1997 01.01.2001 \n20 Eisenmangelan\u00e4mie Iron-deficit anemia 1 2 01.06.2000  \n21 Lymphknotenvergr\u00f6\u00dferung Enlarged lymph node 1 0 13.01.1997  AWMF online  \nArbeitsgemeinschaft der\nWissenschaftlichen\nMedizinischen\nFachgesellschaften\nLeitlinien f\u00fcr Diagnostik und Therapie\nP\u00e4diatrische Onkologie und H\u00e4matologie\nDie Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie hat im Rahmen der Deutschen Gesellschaft f\u00fcr Kinderheilkunde bzw.\nder Deutschen Krebsgesellschaft Leitlinien f\u00fcr folgende Diagnosetypen im Schwerpunkt Onkologie / H\u00e4matologie erarbeitet:\nEinleitung\nAllgemeine Grundlagen der P\u00e4diatrischen Onkologie:\n1.\n Grundlagen der Therapie von Tumoren und malignen Systemerkrankungen des Kindes\n2.\n Psychosoziale Standards f\u00fcr die P\u00e4diatrische Onkologie\n3.\n Prinzipien zur Erfassung von Sp\u00e4tfolgen\nOnkologische Diagnosen:\n1.\n Nephroblastom (Wilms-Tumor)\n2.\n Osteosarkome\n3.\n Ewing-Sarkome und PNET\n4.\n Weichteilsarkome\n5.\n Neuroblastome\n6.\n Medulloblastom\n7.\n Keimzelltumoren\n8.\n Hepatoblastom\n9.\n Morbus Hodgkin\n10.\n Non-Hodgkin Lymphome\n11.\n Akute lymphoblastische - (ALL) und akute myeloblastische Leuk\u00e4mie (AML)\n12.\n Langerhanszell-Histiozytose (LCH)\nNicht-onkologische h\u00e4matologische Diagnosen:\n1.\n Sichelzellan\u00e4mie\n2.\n Thalass\u00e4mie\n3.\n Heredit\u00e4re Sph\u00e4rozytose\n4.\n Aplastische An\u00e4mie\n5.\n Eisenmangelan\u00e4mie\n6.\n Lymphknotenvergr\u00f6sserung\nVerzeichnis der Abk\u00fcrzungen\nOrganisationsstruktur der P\u00e4diatrischen Onkologie und derzeitiger Stand der Qualit\u00e4tssicherung\n Zur\u00fcck zur Titelseite \"Leitlinien\"\n Zur\u00fcck zur Liste der Leitlinien\n Zur\u00fcck zur AWMF-Leitseite im WWW\nZuletzt aktualisiert am 06.03.01 13:28:40\n\u00a9 awmf@uni-duesseldorf.deAuswertung der Befragung der dokumentierenden \nMitarbeiter in den Kliniken \ndurchgef\u00fchrt im Januar 2001 \nvom Arbeitsprojekt Studienunterst\u00fctzung \nDokumentation der Studiendaten \nHannover, Juli 2001 \nA.U. Diers \nJ. Hannemann \nStudienunterst\u00fctzungAnalyse der Dokumentation in den Kliniken \n- 1 - \n1. Ziel und Zweck der Befragung der Dokumentierenden in den Kliniken \nDas Arbeitsprojekt Studienunterst\u00fctzung f\u00fchrte im Januar 2001 eine Befragung unter den \ndokumentierenden Mitarbeitern in den Studienkliniken durch. Vorausgegangen war eine Befragung der Mitarbeiter in den Studienzentralen im Herbst 2000, bei der als Haupt-probleme die Kommunikation mit unterschiedlichen Mitarbeitern in den Kliniken und die qualitativ heterogene Dokumentation in den Kliniken herausgestellt wurden. \nUm einen genaueren \u00dcberblick \u00fcber den aktuellen Zustand und \u00fcber bestehende Probleme \nder Dokumentation in der Klinik zu bekommen, wurde der neue Fragebogen (s. Anhang) konzipiert. Ein weiteres Ziel war es, Probleme in der Dokumentation und Kommunikation aus Kliniksicht aufzuzeigen, bei deren L\u00f6sung das Arbeitsprojekt Studienunterst\u00fctzung helfend eingreifen kann.\nAktuell ist geplant, L\u00f6sungsvorschl\u00e4ge zu erarbeiten, um Strukturen und Prozesse im \nDokumentationsablauf zu verbessern. \n2. Zusammenfassung\nVon 54 angeschriebenen Kliniken erhielten wir 42 Frageb\u00f6gen zur\u00fcck. Insgesamt f\u00e4llt auf, da\u00df 20 Befragte (48%) eine Vereinheitlichung der Studien erwarten. Dies bezieht sich sowohl auf eine einheitliche Verwendung von Begriffen als auch auf die Vereinheitlichung der Protokolle und Erhebungsb\u00f6gen. F\u00fcr eine Reduktion von Merkmalen sprechen sich immerhin 12 (29%) der Antwortenden aus. Sieben (17%) bem\u00e4ngeln, da\u00df Protokolle zum Teil nur in englischer Sprache vorliegen, was immer wieder zu Verst\u00e4ndnisschwierigkeiten f\u00fchrt. \nDurch die Art der Fragen und der Fragestellung wurde versucht, auf m\u00f6gliche Schwierig-\nkeiten genauer einzugehen. Es zeigte sich aber, da\u00df der Spielraum der bewu\u00dft allgemein gehaltenen Fragen leider zu wenig genutzt wurde, um eigene Vorstellungen zu vermitteln und konkrete Hinweise zu geben. \nF\u00fcr das Arbeitsprojekt ergeben sich trotz der Allgemeinheit der Aussagen durchaus \nKonsequenzen zur Unterst\u00fctzung der Studien. Es ist geplant, Protokolle und Erhebungs-b\u00f6gen, die besonders positiv oder negativ bewertet wurden, noch einmal gesondert von ausgew\u00e4hlten Dokumentaren und \u00c4rzten beurteilen zu lassen. Aus diesen Bewertungen soll dann ein Empfehlungskatalog zusammengestellt werden, der auff\u00fchrt, was bei der Neuerstellung von Protokollen besonders zu beachten ist. Weiterhin wird sich das Arbeitsprojekt Studienunterst\u00fctzung mit der Erstellung von \u201estrukturierten Arbeitsanweisungen\u201c sog. Standard Operating Procedures (SOP) zur Bearbeitung von Dokumentationsb\u00f6gen besch\u00e4ftigen. Analyse der Dokumentation in den Kliniken \n- 10 - \nAcht Befragte (19%) hielten keine generellen Verbesserungen an den Erhebungsb\u00f6gen f\u00fcr \nnotwendig; 16 (38%) machten zu dieser Frage keine Angaben. \nAbbildung 3: Verbesserungsvorschl\u00e4ge zu den Erhebungsb\u00f6gen (Zahl Nennungen: 34, Mehrfach-   \nnennungen m\u00f6glich) \nFrage 21 \nAuf welche Weise haben Sie Zugang zu den Protokollen? \nInsgesamt verf\u00fcgten 29 (69%) aller Befragten \u00fcber eigene Exemplare, wobei sich folgende \nVerteilung ergab: 13 (65%) \u00c4rzte, sechs (60%) Dokumentare und sieben (88%) FSA. 27 Befragte (64%) hatten Zugang zu Protokollen in einem Arztzimmer. Sechs Personen gaben unter \u201esonstiges\u201c an, da\u00df Protokolle im Stationszimmer f\u00fcr jeden zug\u00e4nglich sind oder, da\u00df Protokolle als Datei im Computer zur Verf\u00fcgung stehen.  Dreimal wurden zu dieser Frage keine Angaben gemacht. \nFrage 22 \nHaben Sie Verst\u00e4ndnisschwierigkeiten in bezug auf die Protokolle? \nVon 20 Dokumentierenden (48%) l\u00f6sten jeweils neun ihre Verst\u00e4ndnisprobleme bei \nProtokollen durch Anrufe in der Studienzentrale bzw. durch Nachfragen bei den \u00c4rzten in der Klinik. Probleme gab es vielfach bei Protokollen, die ausschlie\u00dflich in englischer Sprache vorliegen und bei Verwendung einer uneinheitlichen Nomenklatur (z.B. gleiche Abk\u00fcrzung mit unterschiedlichen Bedeutungen in den verschiedenen Protokollen). Informationen sind teilweise nur verstreut im Protokoll zu finden.  18 Befragte (43%) hatten keine Probleme mit dem Verst\u00e4ndnis der Protokolle. Was sollte generell an den B\u00f6gen verbessert werden?\n02468 1 0 1 2sonstige Verbesserungenkeine Verbesserungen n\u00f6tigVereinheitlichungDesign/\u00dcbersichtlichkeitDatenreduktiondeutsche Sprache\nAnzahl NennungenAnalyse der Dokumentation in den Kliniken \n- 11 - \nFrage 23 \nIst die Uneinheitlichkeit der Protokolle der Therapieoptimierungsstudien ein Problem f\u00fcr Sie? \nAuf diese Frage antworteten 22 Befragte (52%) mit \u201eja\u201c, 17 stellten besondere Probleme mit \nden Protokollen fest. Haupts\u00e4chlich wurden die unterschiedlichen Empfehlungen zu Chemotherapie und Supportivtherapie kritisiert. Es fielen die Nennungen f\u00fcr unterschiedliche Applikationsvorschriften, Dosismodifikationen und L\u00f6sungsmittel (n=8) auf. Hier wurde eine einheitliche Handhabung gew\u00fcnscht. 17 Dokumentierende (41%) hatten mit der Uneinheitlichkeit der Protokolle keine Probleme. \nDie Fragen 22 und 23 wurden im folgenden zusammen ausgewertet, um feststellen zu \nk\u00f6nnen, ob die Verst\u00e4ndnisprobleme in bezug auf die Protokolle in einem Zusammenhang mit deren Uneinheitlichkeit stehen. Bei 40% der Mitarbeiter bestand sowohl ein Problem mit dem Verst\u00e4ndnis als auch mit der Uneinheitlichkeit (z.B. bez\u00fcglich Aufbau, Gestaltung, \nSprache) der Protokolle (Tabelle 3). 29% gaben an, weder Verst\u00e4ndnisprobleme noch Probleme mit der Uneinheitlichkeit der verschiedenen Protokolle zu haben.  \nUneinheitlichkeit\nja nein Gesamt \nn 15 5 20\nja% 40 13 53\nn 7 11 18Verst\u00e4ndnis-\nprobleme\nnein% 18 29 47\n n 22 16 38 Gesamt\n% 58 42 100 \nTabelle 3: Verst\u00e4ndnisprobleme und Uneinheitlichkeit der Protokolle (k.A.=4) \nFrage 24 \nWas k\u00f6nnte an den Protokollen verbessert werden? \nDie im folgenden angesprochenen Verbesserungsvorschl\u00e4ge sind in einigen Studien-\nprotokollen bereits seit einiger Zeit realisiert. \nVon 24 Mitarbeitern in den Kliniken (57%) wurden folgende Vorschl\u00e4ge unterbreitet: \n\u2022Einheitliche Gliederung f\u00fcr alle Studienprotokolle  (n=14) \n\u2022Einheitliches Stichwort- und Abk\u00fcrzungsverzeichnis im Anhang  (n=  5) \n\u2022Dokumentationsanleitungen zu verschiedenen B\u00f6gen   (n=  4) \n angelehnt an Standard Operating Procedures (SOP) \nweitere interessante Vorschl\u00e4ge :\n\u2022Dokumentationsb\u00f6gen als abtrennbare Kopiervorlage im Anhang  \n\u2022Therapiepl\u00e4ne auf der Umschlagseite der Protokolle  \n\u2022\u00dcbersichtliche Erkl\u00e4rung und Definition der Stadieneinteilung\n\u2022Updates nicht als lose \u201eZettelsammlung\u201c (oder zumindest durchnumerieren) Analyse der Dokumentation in den Kliniken \n- 12 - \nF\u00fcr vier Personen (10%) waren keinerlei Verbesserungen an den Protokollen notwendig; 14 \n(33%) machten zu dieser Frage keine Angaben. \nFrage 25 \nWelche Hilfsmittel im Umgang mit den Protokollen w\u00fcnschen Sie sich? \n29 Befragte (69%) machten diesbez\u00fcglich verschiedene Vorschl\u00e4ge (Mehrfachnennungen): \n\u2022Ablaufpl\u00e4ne zur Dokumentation: (n=17) \n\u2022Vorgaben zum Ausf\u00fcllen der B\u00f6gen (SOP): (n=13) \n\u2022\u00dcbersichten: (n=11) \nweitere Hilfsmittel: \n\u2022Weiterbildung \u00fcber die Inhalte der Protokolle \n\u2022Ablaufschemata f\u00fcr Infusionen \n\u2022Protokoll: Register, Abk\u00fcrzungsverzeichnis, Extraseite f\u00fcr Kritik und Verbesserungen \n\u2022aktualisierte Software \nVier (10%) der Dokumentierenden gaben an, da\u00df keine zus\u00e4tzlichen Hilfsmittel gew\u00fcnscht \nwerden; neun (21%) haben zu dieser Frage keine Angaben gemacht. \nFrage 26 \nWelche Verbesserungsvorschl\u00e4ge haben Sie bez\u00fcglich Art und Vorgehen f\u00fcr Follow-up-Anfragen?\nBei der Anfrage von Daten f\u00fcr das Follow-up w\u00e4hlen die Studienzentralen unterschiedliche \nMethoden. Die wichtigsten Anregungen von 15 Dokumentierenden (36%) bezogen sich auf die folgenden Bereiche: \n\u2022Angabe des Datums der letzten Information vom Patienten auf der Follow-up-Anfrage \n\u2022keine doppelten Anfragen (Mainz, Studienzentrale, LESS) \n\u2022Anfrage weniger, relevanter Daten \n\u2022durch das Lesen der Arztbriefe er\u00fcbrigen sich manche Anfragen \n\u2022Auflistung aller Ereignisse des Patienten (Rezidiv, Metastase, Zweitmalignom, Sp\u00e4tfolgen) jeweils mit Datum  \n\u2022eindeutige Vorgabe von Nachsorgeuntersuchungen in Zeit und Umfang (\u201eNachsorgeprogramm\u201c)\n10 (24%) aller Antwortenden hatten keine Verbesserungsvorschl\u00e4ge; 17 (40%) machten \nkeine Angaben. Analyse der Dokumentation in den Kliniken \n- 13 - \nFrage 27 \nSollten Follow-up Anfragen besser \u00fcber das Jahr verteilt oder gesammelt in einem bestimmten Zeitraum gestellt werden? \nDie Antworten auf diese Frage f\u00fchrten zu keiner \u00dcbereinstimmung zwischen \u00c4rzten, \nDokumentaren und FSA. Die H\u00e4lfte aller Antwortenden w\u00fcnschte sich, da\u00df die Follow-up-Anfragen \u00fcber das Jahr verteilt erfolgen, ebenso viele sprachen sich f\u00fcr gesammelte Anfragen zu bestimmten Zeitpunkten aus (Tabelle 4). Dabei war die berufsgruppen-spezifische Verteilung interessant: Bei den \u00c4rzten waren 47% f\u00fcr eine verteilte und 53% f\u00fcr eine gesammelte Follow-up-Anfrage. 60% der als \u201eDokumentare\u201c gruppierten Mitarbeiter sprachen sich f\u00fcr gesammelte Follow-up-Anfragen aus, w\u00e4hrend 71% der FSA \u00fcber das Jahr verteilte Anfragen bevor-zugen.\nZeitpunkt Follow-up  \nverteilt gesammelt Gesamt \nn 8 9 17Arzt\n% 47 53 100\nn 4 6 10Dokumentar\n% 40 60 100\nn 5 2 7FSA\n% 71 29 100\nn 2 2 4andere\n% 50 50 100\nn 19 19 38 Gesamt\n% 50 50 100 \nTabelle 4: Aufgabe in der Klinik und gew\u00fcnschter Zeitpunkt zu Follow-up-Anfragen (k.A.=4) \nFragen 28/29 \n28.) Bearbeiten Sie die Verlaufsdokumentation (auch Therapie und Toxizit\u00e4t) selbst\u00e4ndig? 29.) Werden ihre Angaben noch einmal vom zust\u00e4ndigen Arzt \u00fcberpr\u00fcft? \nDie Fragen 28 und 29 richteten sich an die Dokumentationskr\u00e4fte. F\u00fcr die Auswertung \nwurden daher nur deren Angaben bewertet. Sieben (39%) der Dokumentare und FSA gaben an, die Dokumentation der Verlaufsdaten selbst\u00e4ndig durchzuf\u00fchren, wobei eine nachtr\u00e4gliche \u00dcberpr\u00fcfung durch einen Arzt erfolgt. Die H\u00e4lfte (n=9) der Gruppe bearbeitete die Verlaufsdokumentation und Therapie selbst\u00e4ndig ohne nochmalige \u00dcberpr\u00fcfung durch einen Arzt, z.T. allerdings mit Ausnahme der Toxizit\u00e4tsdaten. Zwei f\u00fchrten die Dokumentation nicht selbst\u00e4ndig durch. Analyse der Dokumentation in den Kliniken \n- 15 - \nAbbildung 5: Zufriedenheit mit der Gestaltung der Erhebungsb\u00f6gen der Ersterhebung, Therapie- und \nToxizit\u00e4tsdokumentation; H\u00e4ufigkeiten prozentual und absolut\n4. Fazit \nDie Befragung unter den dokumentierenden Mitarbeitern in den Studienkliniken hat wertvolle \nAnregungen gebracht, wie die Arbeit in den Kliniken vereinfacht werden k\u00f6nnte. Es zeigte sich, da\u00df nicht nur seitens der Studienzentralen Verbesserungen n\u00f6tig sind, sondern ebenfalls in den Kliniken Bedarf f\u00fcr Ver\u00e4nderungen besteht. Dies betrifft in erster Linie die Zusammenarbeit zwischen \u00c4rzten und Dokumentaren sowie die Dokumentation der Patientenakten. Die Befragung bot die M\u00f6glichkeit, gerade in bezug auf Protokolle und Erhebungsb\u00f6gen, \u00c4rgernisse zu nennen und so auf die Erstellung neuer Protokolle positiv einzuwirken. Leider wurde die Chance, Anregungen und Verbesserungsvorschl\u00e4ge an die Studienzentralen zu geben, nur von wenigen genutzt. \nZu guter Letzt m\u00f6chten wir uns ganz herzlich bei allen bedanken, die mit viel Engagement \nund Zeit ihre Ideen eingebracht haben. \nU. Creutzig \nA. U. Diers J. Hannemann M. Zimmermann Hannover, 07/2001 Wie zufrieden sind Sie mit der Gestaltun g der Erhebun gsb\u00f6gen\nder einzelnen Studien?\n6877 892202292141359682\n7 8 62243 36\n0%20%40%60%80%100%\nErsterhebung (n=453) Therapie (n=451) Toxizit\u00e4t (n=428)\nvoll und ganz \u00fcberwiegend teilweise weniger gar nichtAnalyse der Dokumentation in den Kliniken \n- 14 - \nFrage 30 \nF\u00fcr welche Studien haben Sie bisher die Dokumentation bearbeitet und  a) Welche Studien sch\u00e4tzen Sie als besonders aufwendig/zeitintensiv in bezug auf die \nDaten der Ersterhebung, der Therapie und der Toxizit\u00e4t ein? \nEtwa 40% der Studien wurden als (sehr) aufwendig eingesch\u00e4tzt (vgl. Abbildung 4). Ein \ngeringer bis sehr geringer Aufwand traf lediglich auf 25% der Studien (Toxizit\u00e4t=18%) zu. Bei dieser Frage gab es sehr unterschiedliche Einsch\u00e4tzungen, was die einzelnen Studien angeht. Allerdings wurden einige Studien auch nur sehr selten genannt (s. studien-spezifischer Anhang). \nAbbildung 4: Zeitaufwand f\u00fcr die Datenerhebung \u00fcber alle Therapieoptimierungsstudien; H\u00e4ufigkeiten \nprozentual und absolut \nb) Wie zufrieden sind Sie generell mit der Gestaltung (unter den Aspekten der Handhabung, \nVerst\u00e4ndlichkeit) der Ersterhebungsb\u00f6gen sowie der B\u00f6gen zur Therapie- und Toxizit\u00e4ts-dokumentation der einzelnen Studien? \nDie Befragten waren mit 30% der Ersterhebungsb\u00f6gen und ca. 20% der Therapie- und \nToxizit\u00e4tsdokumentation \u201evoll zufrieden\u201c (vgl. Abbildung 5). Etwa die H\u00e4lfte aller Erhebungs-b\u00f6gen wurde mit \u201e\u00fcberwiegend zufrieden\u201c bewertet. Lediglich knapp 10% aller Nennungen entfielen auf \u201eweniger\u201c bis \u201egar nicht\u201c zufrieden. Wie sch\u00e4tzen Sie den Zeitaufwand f\u00fcr die Datenerhebung ein?\n73\n30 39129\n146166182199190123 117785 9 5\n0%20%40%60%80%100%\nErsterhebung (n=512) Therapie (n=501) Toxizit\u00e4t (n=478)Anzahl Nennungen\nsehr gering gering mittel hoch sehr hoch42List of network and/or GPOH working groups (excerpt)  \n# Working group Name  Subject Number of Members  \n(Network members) Affiliation with the \nnetwork \n4 AG DRG Classification, documentation of \nmedical and psychosocial diagno-\nses and procedures 10 (4) Network provides \nwork force, exchange \nwith other groups \n5 GPOH-Beratungsgremium f\u00fcr \nTeilprojekt K Medizinisches Ratgebergremium 5 (2) Network provides \nTopic (Secondary \nMalignancies)  \n6 Standardisierungsgruppe Erstellung und Verabschiedung \ndes Basisdatensatzes der GPOH 8 (6) Support of B/1 \n1 DOSPO Task Force Controlling the DOSPO develop-\nment10 (8) Support of B/1, prob-\nlem solution introdu-\nced by A \n2 AK Medizinische Informatik \nder GPOH und der GMDS General discussion of IT usage \nfor Pediatric Oncology 12 (6) Exchange with A, B/1, \nB/2, C 43C.3  Project work plans and milestones (referring to section 3, part C.3 of project proposals) \nProject A: Coordination and management group \n  2002 2003 2004 \nTask   3 4 1 2 3 4 1 2 3 4 \nNetwork organisation            \nAnnual status meeting of the GPOH and  \nthe network members   X    X    \nAnual scientific meeting of the network members   X    X    X \nMeetings of all medical documentarists in  \nPediatric Oncology and Hhematology    X    X   \nAnnual meetings of clinical trial offices\u2019 staff  X    X    X  \nM a n a g e m e n t           \nRequest and process status reports of network projects  X  X  X  X  X  \nConduct workshop on project management, transfer of  \nresearch results and marketing/PR employment    X        \nVisibility            \nInternet portal launched and relauchend  X      X      \nNumber of diseases and clinical trials included in the infor-\nmation server    10    18   \nPress conferences, preceding press releases       X    X   \nExposition of the network at fairs and science meetings  X   X    X   \nNews letter \u201cD IE MITTEILUNGEN \u201c           \nInformationbrochure revised and distributed        X      \nTransfer into health care            \nTraining meetings of FSA   X   X   X   X \nLocal auditing of FSAs, site visits  x x x x x x x x x x \nCertification concept completed and agreed upon with mem-\nbers of relevant other bodies and organizations     X        \nCertification of FSA        X X X  \nEvaluation            \nQuestionings          X    \nInterviews     X    X   \nInternal decision report   X    X   X  \nFinal report on the project A           X  \nSustainability \u2013 Quality control system           \nFinal, management and implementation concept completed  X           \nQuality criteria agreed among the specialist society anf the \nnetwork, including piloting in one institution   X         \nPilotinvestigation TOPICS completed and reported   X          \nProposal submission to BMG      X        \nInclusion of a first trial into this system        X      \nParticipation of hospitals    2    5    1 2    \nProject B/1: Computer-based application systems \nPlease, see the following pages.  1 Integration in hospital information systems\n2 Developing HL7-Interface for Patient data + Piloting in 3 hospitals3 Developing HL7-Interface for Diagnoses and Procedures + Piloting in 3\nhospitals\n4 Rollout HL7-Interface (Patient data / Diagnoses + Procedures)\n5 Change to routine operation6 Documentation of diagnoses and procedures\n7 Adapting documentation of diagnoses and procedures to new legal\nrequirements and supporting introduction (without interfaces)\n8 Rollout documentation of diagnoses and procedures in combination with the\nHL7-Interfaces\n9 Change to routine operation\n10 Therapy Planning\n11 Supporting clinics in the current therapy planning module12 Realizing improvements of the protocol definition and therapy planning\nmodules in close cooperation with pilot clinics\n13 Piloting of the modules in the pilot clinics\n14 Rollout improved therapy planning15 Change to routine operation16 Miscellaneous functionality (report writing, scheduling, analysis, ...)\n17  continuous maintenance of the modules and supporting their introduction18 Integrating the revised basic data set\n19 Interface to the Childhood Cancer Registry\n20 Realizing computer-based workflow-support (electronic signature of the\nclinician, automatic sending, checking for completeness, ...)\n21 Piloting in 2 user clinics and the Childhood Cancer Registry\n22 Comprehensive introduction of electronic reporting to the Childhood Cancer\nRegistry\n23 Change to routine operation\n24 Setting up routine operation\n25 Setting up technical and organizational requirements26 Routine hotline-support\nQ4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q12002 2003 2004 20Appendix: DOSPO Work PlanNr.\n1 Extending the terminology server: integrity constraints\n2 Extending and adapting the data model3 Specifiying extended functionality of the application system4 Devolping extendend functionality5 Inputting integrity constraints of already covered items6 Extending the terminology server: versioning management\n7 Extending and adapting the data model8 Specifiying extended functionality of the application system9 Devolping extendend functionality\n10 Inputting versioning information of already covered items11 Evaluating terminology server using the SIOP 2001-trial\n12 Modelling terminology of SIOP 200113 Inputting trial into terminology server14 Gathering suggestions for improvement15 Specifiying improved functionality of the application system16 Developing improved functionality17 Evaluating improvement of degree of standardization18 Modelling and inputting terminology of further trials\n19 Modelling terminology20 Inputting terminology\nQ4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q12002 2003 2004 20Appendix: Terminology Server - Work Plan\nSeite 144Project C: Evaluation of Telemedicine  \nRespon 2002 2003 2004 \n Deliverables sibility 3 4 1 2 3 4 1 2 3 4 \n Point-to-point telemedicine applications  \nI Installation and test of teleradiology systems  \nin 5 participating institutions X X X X X      \n1  Installation of test systems all  X  X          \n2  Technical tests all X X X        \n3  Practical tests in clinic routine all X X X X X      \n4  Feasibility report, implementation suggestions  MS     X  X      \n Central electronic image clearing institution concept  II Evaluation of acceptance;  \norganizational co-ordination X X X X X X X    \n1  Definition of expectations, tasks and structure  MS X X X X       \n2  Co-ordination with telematic-platform  B   X X X X X    \n3  Co-ordination with DOSPO (project B)  HO   X X X X X    \n4  Co-ordination with network co-ordination centre \nand research assistant project (\u201eForschungs-und \nStudienassistenten\u201c, project A)  B\n  X X X X X    \n5  Co-ordination with telemedicine projects of other \ncompetence networks BX X X X X X X    \n6  Acceptance report, suggestions for implementa-\ntionMS     X  X     \nIII Analysis of technical requirements for set-up and \nmaintenance X X X X       \n1  Information technology (hardware, software, data \nflow, backup, network security, data security and \nconfidentiality, ...)  MS\nX X X X       \n2  Staff  MS X X X X       \n3  Finances MS   X  X        \n4  Technical feasibility report, suggestions for im-\nplementation MS    X       \nIV Test installation of central electronic image clearing \ninstitution functionality for a limited number of partici-\npants    X X X X X X \n1  Technical set-up (server, software,  \nconnectivity, safety) MS    X  X      \n2  Function tests (\u201ephantom data\u201c) all      X  X     \n3  Practical evaluation (\u201ereal medical data\u201c) all       X X X  \n4  Feasibility report, suggestions for implementation MS         X  X  \nV Remote Data Entry (RDE) for GPOH Trials  X X X X X X X X X X \n1  Analysis of available RDE systems HO X  X          \n2  Test implementation of an RDE system for the  \nSIOP2001/GPOH study  HOX X X        \n3  Evaluation of DOSPO (project B) compatibility  HO X X X X       \n4  Evaluation of RDE for SIOP2001/GPOH study HO  X X X X      \n5  Evaluation of RDE for other GPOH trials  HO    X X X X X X  \n6  Feasibility report, suggestions for implementation  HO         X  X  45Project D: Molecular parameters of drug resistance \nTask 2003 2004 \nQuarter of year I II III IV I II III IV \n1 \u2013 Analysis of constitutive apoptosis sensitivity          \nStandardization of chemical stress assay X  X        \nApplication in study laboratories  X X X X X X  \nEstablishment of database for experimental data X X X      \nImplementation of clinical data and analysis       X  X  \nDevelopment of tools for data analysis     X X X X X \n2 \u2013 Analysis of drug sensitivity         \nOptimization casp-3/cyto-c assay for T-ALL/AML X  X        \nApplication in study laboratories   X X X X X X \nImplementation of clinical data and analysis       X  X  \nDevelopment of assay for B precursor ALL X X X X     \nApplication in study laboratories    X X X X X \n3 \u2013 Bax and related genes mutation analysis          \nAnalysis of Bax mutation on RT-PCR level     X X X X  \n4 \u2013 Expression analysis of apoptosis genes         \nValidation of apoptosis gene array X  X        \nModification of procedures with primary samples   X X X    \nStandardization of RNA preparation     X X    \nAquisition of RNA in study laboratories     X X   \nAnalysis of expression in primary leukemia cells     X X X X \nDevelopment of tools for data analysis     X X X X X \nImplementation of clinical data and analysis       X  X  \n5 \u2013 Analysis of apoptosis during chemotherapy         \nStandardization of p53 measurement (FCM)  X  X        \np53 measurement during chemotherapy (HH,UL)   X X X X X X \nDevelopment of assays for apoptosis related changes  X X X X     \nApplication on leukemia cells during chemotherapy    X X X X X \n6 \u2013Drug induced apoptosis in leukemia stem cells         \nEstablishment of hu Leukemia on NOD/SCID X X X X X X   \nAnalysis of engraftment properties upon treatment     X X X X \n7 \u2013 Establishment of central database         Definition of database variables X  X        \nEstablishment of database  X X X     \nData entry experimental data     X X X X X \nImport of clinical data       X  X  46Project K: Second malignant neoplasms after childhood cancer  \nTask Time \nContinuation of the documentation  \nValidation of new cases in cooperation with clinical trials Ongoing \nSending documentation forms for SMN patients to clinical trials or clinics Ongoing \nCoding and data entry of documentation form Ongoing \nConducting the case-control study  \nSending out documentation forms for c ontrols sampled until 1999 Apr 2002 \nCheck data for completeness, coding and data entry for controls May \u2013 Dec 2002 \nSample controls for the 2000 to 2002\u2013cases Apr 2003 \nSending out documentation forms for contr ols sampled for 2000 \u2013 2002 Apr/May 2003 \nCheck data for completeness, coding and data entry for control data May \u2013 Sep 2003 \nIf necessary, sample further controls  Jul 2003 \nProcessing of further controls Aug \u2013 Oct 2003 Data exchange with PRST  \nDocumentation of the therapy data of the SMN cases with SCT we currently know by the PRST \n(about 20) Jan \u2013 May 2002 \nDocumentation of the therapy data of new SMN cases with SCT by the PRST  Ongoing \nDocumentation of the therapy data of controls with SCT by the PRST May 2002 \u2013 Dec 2003 \nCooperations regarding genetic aspects  \nContacting potential cooperation partners Mar \u2013 May 2002 \nResulting activities Jun 2002 \u2013 Oct 2003 \nData processing and evaluation of the study  \nFinalize plausibility checks, consistency checks, correct data errors  Dec 2003 Evaluate study Jan \u2013 May 2004 \nMatching data with state cancer registries\nEstablish regular data exchange with all registries until Dec 2003 \nWorking out recommendations for post tr eatment care for former patients  \nBased on the results of the case-control study (as described, we expect not to be able to do this \nwithin the project period) 2004/2005 \nMeeting the board of consultants one or twice a year  \nDepends on the state of the study to be discussed \nPublications on the case-control study  \nFinal report Jun \u2013 Dec 2004 \nFinal scientific publication Jun \u2013 Dec 2004 Kooperatives\nP\u00e4diatrisches Register f\u00fcr Stammzell Transplantationen\nDeutschland - \u00d6sterreich\nDas PRST erfa\u00dft zeitnah Transplantationen h\u00e4matopoetischer Stammzellen bei Kindern zu Zwecken der Qualit\u00e4tssicherung und F\u00f6rder ung der Wissenschaft im Bereich \nP\u00e4diatrie.\nDer vorgesehene Ablauf der Meldungen an das PRST ist im folgenden beschrieben, dort sind auch die ben\u00f6tigten und bisher vorhand enen Formulare zu finden. \n   \nVerantwortlich:\nLeitung:\nProf. Dr. Thomas Klingebiel     Tel.: +49/(0)69/6301-5094      Fax: +49/(0)69/6301-6700  \n                                               Email: tklingebiel@zki.uni -frankfurt.de\n                                               Anschrift: Klinik f\u00fcr Kinderheilkunde III, Goethe Universit\u00e4t Frankfurt a. Main \n                                               Theodor Stern Kai 7, D-60590 Frankfurt  \n\u00c4rztl. Administrator:\nDr. med. Oliver Basu                Tel: +49/(0)201/723-3350       Fax: +49/(0)201/723-5983  \n                                               Email: o.basu@uni -essen.de\n                                               Anschrift: Universit \u00e4tskinderklinik Essen , Hufelandstr. 55, 45122 Essen  \n   \nMed. Dokumentation:                          \nRolf Zipse                                  Tel.: +49/(0)69/6301-83326     Fax: +49/(0)69/6301-83327  \n                                                Email: rolf.zipse@kgu.de\n                                                          Anschrift: Klinik f\u00fcr Kinderheilkunde III, Goethe Universit\u00e4t Frankfu rt a. Main \n                                                          Theodor Stern Kai 7, D-60590 Frankfurt  \n                                              \nBesucher seit dem 1.1.2000 auf dieser Seite:   \nZur\u00fcck zum Anfang\nDas Copyright liegt beim P.R.S.T. \nDie Information wurden zur Ver\u00f6ffentlichung im Internet  zusammengestellt durch Dr. med. Oliver Basu .\nAlle Angaben jedoch ohne jegliche Gew\u00e4hrleistungen. \nLetzte Aktualisierun g: 18. Oktober 2001. \nP\u00e4diatrisches Register f\u00fcr\nStammzell Transplantationen\nPRST\nStartseite\n Dokumentationsablauf\n Chronol. Liste der \u00c4nderungen\nTeilnehmer |\n Formulare\nGef\u00f6rdert von der Deutschen Krebshilfe\nund dem Kompetenznetz -P\u00e4diatrische Onkologie und H \u00e4matologie\nDokumentationsablauf und Formulare\nStand Dezember 1999 \nDas Meldefax.... \n...wird von den transplantierenden Zentren bei Patientenaufnahme an die entsprechenden Studienleitungen * und an das PRST in Frankfurt \ngeschickt.  \nDie Diagnosedaten,.... \n...Informationen zur Prim\u00e4rerkrankung, werden von den Studienleitungen an die transplantierenden Zentren und an das PRST nach F rankfurt\ngeschickt. \nDie DRST-MED-A-Formulare.... \n...First Report/Follow up werden von den transplantierenden Zentren bei Entlassung/nach Wiedervorstellung der Patienten direkt zum PRST \nnach Frankfurt  geschickt. Von dort werden die Daten an das DRST weitergeleitet. ***neu***\nDie Transplantationsdaten.... \n...(Form 2/3) werden von den transplantierenden Zentren f\u00fcr jeden Patienten am Tag 100 an die entsprechenden Studienleitungen * und in\nKopie (***neu***)  zum PRST nach Frankfurt geschickt \n* Ist der Patient an keiner Therapieoptimierungsstudie beteiligt, werden alle Daten direkt Frankfurt \u00fcbermittelt. \nErfa\u00dft die Studienleitung die Daten mit eigenen B\u00f6gen (z.B. MDS-Studie), m\u00fcssen nur  diese ausgef\u00fcllt werden. \n**Das DRST leitet, falls gew\u00fcnscht, die Daten an EBMT/IBMT-R weiter. Ob und wohin die Daten weitergeleitet werden k\u00f6nnen, wird im\nMeldefax  angegeben. \nAnmerkung: Die Formulare sind !!!Ersatz!!! f\u00fcr EBMT-MED B-Formulare.\nDoppeltes Ausf\u00fcllen erfolgt auf freiwilliger Basis! \nBesucher seit dem 1.1.2000 auf dieser Seite:   \nDas Copyright liegt beim P.R.S.T.-Frankfurt. \nDie Information wurden zur Ver\u00f6ffentlichung im Internet  zusammengestellt durch Dr. med. Oliver Basu .\nAlle Angaben jedoch ohne jegliche Gew\u00e4hrleistungen. \nLetzte Aktualisierun g: 10. Oktober 2001. \nP\u00e4diatrisches Register f\u00fcr\nStammzell Transplantationen\nPRST\nStartseite\n Dokumentationsablauf\n Chronol. Liste der \u00c4nderungen\nTeilnehmer |\n Formulare\nInhaltsverzeichnis:\n Download von Acrobat Reader Vers. 4.0 der Firma Adobe:            \n Download aller o.g. Formulare im PDF-Format:                              PDF-Forms.ZIP\n Um die beiden o.g. Dateien zu \"entzippen\" ben\u00f6tigen Sie ein Dekomprimierprogramm wie z.B. \" Winzip \"\nBesucher seit dem 1.1.2000 auf dieser Seite:  \nDas Copyright liegt beim P.R.S.T.-T\u00fcbingen. \nDie Information wurden zur Ver\u00f6ffentlichung im Internet  zusammengestellt durch Dr. med. Oliver Basu .\nAlle Angaben jedoch ohne jegliche Gew\u00e4hrleistungen. \nLetzte Aktualisierun g: 07. Se ptember 2000. \nP\u00e4diatrisches Register f\u00fcr\nStammzell Transplantationen\nPRST-T\u00fcbingen\nStartseite\n Dokumentationsablauf\n Chronol. Liste der \u00c4nderungen\nTeilnehmer |\n Formulare\nPRST-FORMULARE Dateien im Adobe Acrobat Reader 4.0 Format\nEinverst\u00e4ndniserkl\u00e4rung (Dabei handelt es sich um einen Vorschlag !) Einverst \u00e4ndniserkl \u00e4rung\nForm 1: Meldefax Meldefax\nForm 2: Allograft (TP-Daten) Allograft\nForm 3: Autograft (TP-Daten) Autograft\nForm 4: AML (Diagnosedaten) AML\nForm 5: ALL (Diagnosedaten) ALL\nForm 6: Lymphoma (Diagnosedaten) Lymphoma\nForm 7: Aplastic Anemia (Diagnosedaten) Aplastic Anemia\nForm 8: MDS (Diagnosedaten) MDS\nForm 9: CML (Diagnosedaten) CML\nForm 10: Solid Tumors (Diagnosedaten) Solid Tumors\nForm 11: Haemoglobinopathy (Diagnosedaten) Haemoglobinopathy\nDefinitions and Codes Definitions and Codes\nEBMT Diagnoseschl\u00fcssel EBMT Diagnose Schl \u00fcssel\nDRST-FORMULARE (Stand 10/98)\nDRST-Med-A Form First Report Med-A Form First Report\nDRST-Med-A Form Follow-up Med-A Form Follow -up\nDRST-Verschl\u00fcsselung f\u00fcr Med-A Forms Med-A-Codes\n[ Wissensserver  ]\n[ > B Anwendungssysteme  ]\n[ < K Sekund\u00e4rmalignome  ]Projekt A: Koordinationszentrale und Mantelantrag im\nKompetenznetz P\u00e4diatrische Onkologie und H\u00e4matologie\nKoordinationszentrale\nStartseite\nNeue Informationen\nThemen auf einen \nBlick\nThemenArbeitsprogramm\nDia-Bank\nDie Mitteilungen\nDokumente\nEvaluation\nFSA\nLinks & Mails\nMed. Dokumentation\nMitarbeiter\nPGP\nPresse\nProtokolle\nStudienunterst\u00fctzung\nTermine\nVertikale Vernetzung\nSuche\nGuest\nLog in\nJoinStartseite des Mantelantrags und der Koordinationszentrale \u2013\n- willkommen zum Projekt A  im Kompetenznetz  P\u00e4diatrische\nOnkologie und H\u00e4matologie, Projektleiter Prof. Henze . Das\nForschungsnetz geht von der Gesellschaft f\u00fcr P\u00e4diatrischeOnkologie und H\u00e4matologie (GPOH\n) aus. Das\nBundesministerium f\u00fcr Bildung und Forschung (BMBF ) und der\nProjekttr\u00e4ger Gesundheitsforschung (DLR ) f\u00f6rdern dieses und\nandere Netze .\nZiel und Aufgabe\nIn den zehn Projekten  dieses Kompetenznetzes werden\nKrebskrankheiten und Erkrankungen des blutbildenden Systemsbei Kindern und Jugendlichen spezifisch, mit \u00fcbergreifenden\nAns\u00e4tzen\n und auf der Basis eines intensivierten\nZusammenwirkens der Experten und der Strukturen  untersucht.\nDas Arbeitsprogramm  unseres Projekts A l\u00e4uft vom 01.07.1999\nbis vorerst zum 30.06.2002, u.a. zu Themen  wie \nDatenverbesserung und Informationstransfer: Wie auch inanderen Kompetenznetzen in der Medizin\n sollen klinische und \nGrundlagen- Forschung so effektiv gef\u00f6rdert werden, da\u00df neue\nErgebnisse z\u00fcgig in die klinische Praxis und zum Nutzen derBetroffenen vermittelt werden.\nInformationsaustausch\nAllgemeine Informationen zu den Erkrankungen sind \u00fcber die\nInternet-Seiten auf diesem\n und auf dem Wissensserver  zu \nerhalten. Informationen f\u00fcr \u00c4rzte sind zur Zeit Vortr\u00e4ge  \u00fcber die\nKompetenznetz-Projekte sowie Diavorlagen  zu Krebskrankheiten\nund anderen Erkrankungen des blutbildenden Systems beiKindern und Jugendlichen. \n Zum Ausprobieren: Klicken Sie\nJOIN  zum Einschreiben an, um Nachrichten und Dateien anderen\nbereitzustellen. Die Koordinationszentrale  erweitert Ihre \nZugriffsrechte.\nNachrichten\nAktuelle Veranstaltungen...\nNeue Seiten...\nEine Initiative der\nGef\u00f6rdert vom\nEmail an Webmaster zu dieser Seite  | \n  Seite bearbeiten\n Server-Verbindung: unverschl\u00fcsselt | verschl\u00fcsselt (SSL)  | Browser-Check: Schl\u00fcsselst\u00e4rke  | Zertifikat installierensuche Tex*, Enter[ Wissensserver  ]\n[ > B Anwendungssysteme  ]\n[ < K Sekund\u00e4rmalignome  ]Projekt A: Koordinationszentrale und Mantelantrag im\nKompetenznetz P\u00e4diatrische Onkologie und H\u00e4matologie\nKoordinationszentrale\nStartseite\nNeue Informationen\nThemen auf einen \nBlick\nThemenArbeitsprogramm\nDia-Bank\nDie Mitteilungen\nDokumente\nEvaluation\nFSA\nLinks & Mails\nMed. Dokumentation\nMitarbeiter\nPGP\nPresse\nProtokolle\nStudienunterst\u00fctzung\nTermine\nVertikale Vernetzung\nSuche\nGuest\nLog in\nJoin\n[ Netz  : Koordinationszentrale  : Themen  : FSA  : ]         [ <  > > > > > > > > ]\nFSA: Hintergrund zum T\u00e4tigkeitsprofil.\nDas folgende T\u00e4tigkeitsprofil f\u00fcr Forschungs- und Studienassistenten (FSA) wurde von der\nKoordinationszentrale Ende 1999 zusammen mit der erweiterten Leitgruppe des Kompetenznetzesabgestimmt und verabschiedet. Es ist eine verbindliche Obermenge aller konkreten T\u00e4tigkeiten, die die FSA\nam jeweiligen Einsatzort aus\u00fcben. Das T\u00e4tigkeitsprofil ist Bestandteil der Vereinbarungen zwischen der\nKoordinationszentrale und den \u00f6rtlichen FSA-Verantwortlichen \u00fcber den Einsatz der FSA.\nText des T\u00e4tigkeitsprofils\nDie Mitarbeiter haben im Kompetenznetzwerk ihre zentrale Aufgabe in der praktischen Umsetzung, der\nKoordinierung und der Durchf\u00fchrung der Belange von klinischen Studien und wissenschaftlichen\nTeilprojekten in p\u00e4diatrisch-onkologischen Abteilungen und Zentren. Sie unterst\u00fctzen den verantwortlichenArzt bei der Organisationsplanung und Durchf\u00fchrung von Studien an Patienten oder Patientenmaterialien.\nSie sind Mitarbeiter im interdisziplin\u00e4ren wissenschaftlichen Team.\nDer Aufgabenbereich umfa\u00dft:\nUnterst\u00fctzung bei der Durchf\u00fchrung von klinischen Studien\nRegistrierung von Studienpatienten\nBer\u00fccksichtigung und Dokumentation von Ein- und Ausschlu\u00dfkriterien sowie Steuerungsregeln\nvon Studien, damit konkrete Hilfe bei der Umsetzung verschiedener Studienprotokolle vor Ort\nBer\u00fccksichtigung und Dokumentation des Studienablaufs und Therapieplans\nVorbereitung von verschiedenen lokalen Untersuchungen einschlie\u00dflich bildgebenderVerfahren und lokaler Laboruntersuchungen\nLaborlogistik\nGewinnung, Portionierung/Aliquotierung, Konservierung, Asservierung von Blut, Urin, Liquor,\nKnochenmark, Biopsiematerial etc.\nSelbst\u00e4ndige Durchf\u00fchrung von Blutentnahmen\nSelbst\u00e4ndige \u00dcbernahme der Versandlogistik f\u00fcr die termingerechte Materialbereitstellung undVersendung zur Durchf\u00fchrung von Basis- und weiterf\u00fchrenden Untersuchungen\nNachfragen nach ad\u00e4quatem Eintreffen und Einholen von daraus gewonnenen Befunden\nDokumentation\nSchriftlich und elektronisch mit Hilfe von DOSPO (PC-Programm)\nTermingerechte Bereitstellung und Erhebung der Studiendaten mit Patientenfrageb\u00f6gen,\nAuch f\u00fcr Nachsorge und Lebensqualit\u00e4tsmessung\nSelbst\u00e4ndige telefonische und elektronische Kommunikation in Material- Befund- und\nDokumentationsbelangen zwischen Kliniken, KMT-Zentren, Kindertumorregister, Referenz- und\nForschungslaboratorien\nBegleitende Erstellung einer zu \u00fcberlassenden Dokumentation \u00fcber klinikspezifische,\nstudienspezifische und allgemeine Vorgehensweisen (z.B. im Aktenordnerformat)\nHinweise\nM\u00f6gliche Voraussetzungen hierf\u00fcr sind eine abgeschlossene Ausbildung (z.B. Dokumentar,Krankenpflege, MTA, Arzthelfer) und vorhandene Erfahrungen in onkologischen Arbeitsbereichen.\nFortbildungsseminare sind zun\u00e4chst 3x pro Jahr vorgesehen, mit Erfahrungsaustausch f\u00fcr die\nMitarbeiter.\nEmail an Webmaster zu dieser Seite  | \n  Seite bearbeiten\n Server-Verbindung: unverschl\u00fcsselt | verschl\u00fcsselt (SSL)  | Browser-Check: Schl\u00fcsselst\u00e4rke  | Zertifikat installierensuche Tex*, EnterInterviews of the RAs - Summary \nResearch assistants (RAs) are now employed by hospitals that\noperate within the paediatric oncology and hematology network \nand have a minimum annual caseload of 22 patients. This project\nis intended to improve collaboration between hospitals and central research institutes and should relieve hospital staff from research-\nrelated work that was carried out before on top of the usual \nworkload.\nWe carried out informal 1-hour interviews with four groups, each\nwith between four and eight RAs, to gather information about their working conditions, the type of work and how it is being carried\nout.\nDespite this early phase of the project, RAs were able to comment \non the following aspects of their job:\n\u0083Collaboration with central research institutes has improved \nconsiderably. More data are collected and these are\ntransmitted faster than before, requests from centralresearch institutes could be answered faster and \ninformation is processed in a speedier fashion. \n\u0083Collaboration with reference laboratories has improved and \nhas led to a noticeable reduction in the loss of specimens.\n\u0083Several RAs commented that relieving hospital staff by \ntransferring information processing and data management \ntasks to RAs has meant a higher recognition for this type of work, and the RA position itself \n\u0083The appointment of RAs has led to a clearer definition of \nresponsibilities with an elimination of grey areas in \nresponsibilities. Studies are now coordinated by one \nperson and thus easier to access. The amount of suggestions for improvements on the part of RAs \ndemonstrates the advantage of specifically dedicating \nstudy management to RAs. \nHowever, infrastructure at the hospital sites was, and still is, often\nunfavourable, particularly in the beginning stage of this project.This particularly relates to offices and technical equipment, but \nalso to the not often seemless integration into the day-to-day \noperation of the hospitals and their staff.\nThere is a considerable need to improve the conditions for \nintroducing electronic data management, the inadequacy of which makes tasks, such as double data entry, time-consuming for \nphysicians and study personnel. The double documentation\nrequired initially means additional work for the doctors.\n   Seite 1 \u00a9FSA/Kompetenznetz GPOH 2002 1CWS-96 Checkliste \u2013 Initiale Ma\u00dfnahmen \nName:      Vorname:    Geb.-Datum \nStation\u00e4re Aufnahme:    Diagnose-Datum:    Abteilung:\nDatum/Handzeichen \nLabor- und klinische Diagnostik geplant durchgef\u00fchrt Befund \ngesehen CAVE \n1) Anamnese     \n2) Aufkl\u00e4rungsgespr\u00e4ch     \n3) Einwilligungserkl\u00e4rungen \n(KMP, Stanze, Transfusion, HIV, \nChemothera pie, KKR , Studien )    \n4) Psychosoziale Anamnese     \n5) Klinische Untersuchung     \n6) Blutentnahmen, Urin (Protokoll S. 41)     \n7) Hausintern:     \nBildgebende + appa rative Diagnostik \n(Protokoll S. 40/41) geplant durchgef\u00fchrt Befund \ngesehen CAVE \n1) Tumorregion MRT     \n2) LK-Stationen Sono     \n3) LK-Stationen  MRT/CT (nach Sono-Befund)     \n4) Thorax-R\u00f6ntgen in 2 Ebenen     \n5) Thorax-CT, Spiral-CT (falls verf\u00fcgbar)     \n6) Cerebrales MRT oder CCT     \n7) Skelettszintigraphie     \n8) EKG     \n9) Echokardiographie     \n10) EEG     \n11) LUFU     \n12) Augenhintergrund     \n13) Audiometrie     \n14) Hausintern:     \nInvasive Diagnostik \n(Protokoll S. 119-122) geplant durchgef\u00fchrt Befund \ngesehen CAVE \n1) Initiale OP / Biopsie     \n2) Materialversand extern :\n\u00be Frisches Tumorgewebe in RPMI (Kiel)    \n\u00be EDTA-KM (Kiel, Studienzentrale)     \n\u00be EDTA-Blut + Ausstriche (?)     \n3) Materialversand intern :\n\u00be Frisches Tumorgewebe in RPMI (Patho)    \n\u00be EDTA-KM + Stanze (Patho/Labor)     \n\u00be EDTA-Blut + Ausstriche (Patho/Labor)     \n4) Fakultative Diagnostik (Seite 41)      \n5) Hausintern:     \nDokumentation geplant durchgef\u00fchrt Befund \ngesehen CAVE \nFax-Meldung Studienzentrale:\nVor Beginn Chemotherapie \nincl. OP-Bericht, Histologie, \nReferenzhistologie, MRT-/CT-Befunden     \nMeldung KKR     \nHausintern:     \u00a9FSA/Kompetenznetz GPOH 2002 CWS-Checkliste \u2013 Verlaufsdiagnostik \nName:      Vorname:    Geb.-Datum:\nDatum/Handzeichen \nZeitpunkt Untersuchungen \n(Protokoll S. 42/131/138) geplant durchgef\u00fchrt Befund \ngesehen CAVE \nPrim\u00e4rtumorsitz-Sono     \nEcho     Woche 3* \nDatum\nLabor\nPrim\u00e4rtumorsitz-Sono     \nEcho     Woche 6* \nDatum\nLabor     \nPrim\u00e4rtumorsitz:\nMRT + KM     \nThorax-R\u00f6ntgen in 2 Ebenen     \nAbdomen-/Becken-Sono     \nEKG     \nEcho     Woche 9** \n(Response) \nDatum\nLabor     \nPrim\u00e4rtumorsitz-Sono     \nEcho     Woche 12* \nDatum\nLabor     \nPrim\u00e4rtumorsitz-Sono     \nEcho     Woche 15* \nDatum\nLabor     \nPrim\u00e4rtumorsitz:\nMRT + KM     \nThorax-R\u00f6ntgen in 2 Ebenen     \nAbdomen-/Becken-Sono     \nEKG     \nEcho     Woche 18** \n(CR ?) \nDatum\nLabor     \nAbdomen-/Becken-Sono     \nEcho     Woche 21* \nDatum\nLabor     \nAbdomen-/Becken-Sono     \nEcho     Woche 24* \nDatum\nLabor     \nPrim\u00e4rtumorsitz:\nMRT + KM     \nPrim\u00e4rtumor-Sono     \nCerebrales MRT / CCT     \nThorax-CT     \nThorax-R\u00f6ntgen in 2 Ebenen     \nAbdomen-/Becken-Sono/region\u00e4re \nLK-Stationen (?)     \nSkelettszintigraphie     \nEKG     \nEcho     \nEEG     \nAugenhintergrund     \nAudiometrie     \nKM \u2013 initialer Befall     \nLiquor \u2013 initialer Befall     \nLabor     \nKlinische Untersuchung     Woche 27** \n(Therapieabschlu\u00df) \nDatum\nNeurolog. Untersuchung     \nHausintern    \nErsterhebung     \nTherapiedokumentation     \nTherapieabschlu\u00dfdokumentation     Dokumentation** \nLESS + Nachsorgedokumentation     \n* = Fakultativ / ** = Obligat \u201eIHR KIND HAT KREBS.\u201d\nP\u00e4diatrische Onkologie und H\u00e4matologie \nINFORMATIONEN \u00dcBER KREBSERKRANKUNGEN IM KINDES- UND JUGENDALTER\nwww.kinderkrebsinfo.de\u201eIhr Kind hat Krebs.\u201d Jedes Jahr h\u00f6ren 2.000\nEltern in Deutschland diesen furchtbaren Satz.\nBilder mit tapfer l\u00e4chelnden Gesichtern zwischen\nApparaturen und Schl\u00e4uchen gehen durch denKopf. Bisher sind mehr als 20 Krebsarten bei\nKindern bekannt. Jede hat ihre ganz individuelle\nGestalt, ihr eigenes Gesicht. Eine fr\u00fchzeitigeDiagnose ist der wichtigste Schritt auf dem Wegder Heilung. Bei Kindern kann sich die b\u00f6sartige\nErkrankung hinter einer harmlosen \u201eMaske\u201d ver-stecken. H\u00e4ufig auftretende Kopfschmerzen,\nBl\u00e4sse, Schmerzen in den Knochen oder blaue\nFlecken und Fieber k\u00f6nnen schon erste Anzeichen\neiner Krebserkrankung sein. Doch oft wird dieseDiagnose von Anfang an ausgeschlossen: \u201eKrebs\nwird es schon nicht sein.\u201d Die gemeinschaftliche\nSorge um die Kinder, die der \u00c4rzte und die derEltern, sollte so fr\u00fch wie m\u00f6glich beginnen. \nKinder sind keine \nkleinen Erwachsenen\nIn der Behandlung der Krankheit treten zahlrei-\nche H\u00fcrden auf. Ein Beispiel: Viele der\nMedikamente sind f\u00fcr Kinder gar nicht zugelas-\nsen. Die P\u00e4diatrische Onkologie und H\u00e4matologiemuss bisher auf die Pharmaprodukte der\nErwachsenenmedizin zur\u00fcckgreifen. Doch diese\nMedikamente sind in zahlreichen Studien undForschungsreihen auf die Krankheiten und\nOrganismen der Erwachsenen, nicht auf die von\nKindern abgestimmt. Und mit einer kleinerenDosierung ist es nicht getan. F\u00fcr eine erfolgrei-che Behandlung ist die Frage \u201eWas und wieviel\ngibt man wann?\u201d die alles entscheidende. \nKinder sind dankbare Patienten. Der Umgang mit\nder Krankheit ist direkter als bei Erwachsenen,\nohne Umschweife. Die Belastungsprobe, auf diesie zusammen mit ihren Eltern gestellt werden,ist immens. Geduld ist das oberste Gebot. Diegr\u00f6\u00dfte Sorge der Patienten ist die R\u00fcckkehr der\nErkrankung.DIE KRANKHEIT HINTER DER MASKE\nDer Heilung ein grosses St\u00fcck n\u00e4her\nEntgegen g\u00e4ngiger Meinung spielt das Thema \u201eKrebs beiKindern\u201d nur eine untergeordnete Rolle auf der Agenda dermedizinischen Fachwelt. Dies h\u00e4ngt zum einen mit dergl\u00fccklicherweise relativ geringen Zahl von etwa 2.000Erkrankungsf\u00e4llen pro Jahr zusammen (zum Vergleich:J\u00e4hrlich erkranken \u00fcber 40.000 Frauen an Brustkrebs), zumanderen aber auch mit einem hohen Ma\u00df an Unsicherheitund Unwissenheit. Auch bei \u00c4rzten in Kliniken und Praxen.Zu speziell ist das Wissen, das ben\u00f6tigt wird, um Krebs beiKindern rechtzeitig zu erkennen und vor allem anschlie\u00dfenderfolgreich zu behandeln.\nDabei haben sich in den letzten Jahren und Jahrzehnten ra-\nsante Fortschritte gezeigt. Die \u00dcberlebensraten konnten \u2013 je\nnach Art der Erkrankung \u2013 auf durchschnittlich 75 Prozent\ngesteigert werden. Hinter dieser Zahl stehen viele\nEinzelschicksale, die der Krankheit zun\u00e4chst mit Angst und\nOhnmacht gegen\u00fcberstehen, die den Kampf gegen den Krebs\naber immer h\u00e4ufiger gewinnen. Zu verdanken ist dieser\nErfolg einer stark verbesserten Entwicklung derChemotherapie, der Laborforschung und der KlinischenForschung.\nDer status quo kann nur ein Zwischenschritt sein. Ziel auch\naller k\u00fcnftigen Anstrengungen ist es, die Heilungsrate zu er-\nh\u00f6hen und die Lebensqualit\u00e4t der Betroffenen zu steigern.\nDie Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie\n(GPOH), der alle f\u00fchrenden \u00c4rzte und Kliniken angeh\u00f6ren, die\ndie Kinder und Jugendlichen behandeln, hat in den letzten\nJahren daf\u00fcr gesorgt, dass \u00fcber 90 Prozent aller Betroffenenin Deutschland nach einheitlichen Ablaufpl\u00e4nen untersucht\nund behandelt werden. Die in Deutschland erreichten\nBehandlungsergebnisse bei krebskranken Kindern undJugendlichen z\u00e4hlen zu den besten der Welt.\nUm das Wissen aller Beteiligten \u00fcber die Krankheit optimal\nzu vernetzen, hat die GPOH 1999 das \u201eKompetenznetz\nP\u00e4diatrische Onkologie und H\u00e4matologie\u201d gegr\u00fcndet. Das\nNetzwerk soll f\u00fcr \u201eMehr Wissen, besseres Verstehen und ge-\nzielteres Behandeln\u201d sorgen und einen Qualit\u00e4tsstandard f\u00fcralle Fragen rund um Krebs bei Kindern festlegen. Eltern und\nKinder, \u00c4rzte und Kliniken, Forschung und Pharmaunter-\nnehmen, Presse und \u00d6ffentlichkeit sind in einem Netz. Die elfspezifisch ausgerichteten Aufgabenstellungen schaffen ein\nKnow-how, das nur zusammen generiert werden kann.\nDie Ergebnisse des \u201eKompetenznetz P\u00e4diatrische Onkologie\nund H\u00e4matologie\" kommen den Betroffenen schnell zu Gute.\nDamit aus Angst und Ohnmacht immer mehr Hoffnung undHeilung wird. Denn es gibt nicht das eine Medikament gegen\nden Krebs, sondern umfassende Konzepte zur Behandlung\nvon Krebskrankheiten.\nIm Jahr 2010 wird jeder \n250. junge Erwachsene ein \n\u00dcberlebender einer Krebs-\nkrankheit im Kindesalter sein \u2013\ndie gesundheitsbezogene\nLebensqualit\u00e4t und die\nSp\u00e4tfolgenreduktion werden \nimmer wichtiger.BESSERE ERGEBNISSE DURCH KOOPERATION\nUND KOORDINATION\nProjekt Leitung Telefon\nKoordinationszentrale Prof. Dr. med. Dr. h.c. G\u00fcnter Henze, Berlin +49 (30) 45 05-6 60 32\nRechnerbasierte Anwendungssysteme Dipl.-Inform. Med. Ulrike Kutscha, Heidelberg +49 (62 21) 56-54 81\nDatenschutz/Datensicherheit Prof. Dr. rer. nat. Klaus Pommerening, Mainz +49 (61 31) 17-31 06\nTelemedizin Prof. Dr. med. Norbert Graf, Homburg +49 (68 41) 16-2 83 97\nDr. med. Michael Paulussen, M\u00fcnster +49 (2 51) 8 35-28 01\nMolekulare Parameter \nder Zytostatikaresistenz Prof. Dr. med. Klaus Debatin, Ulm +49 (7 31) 5 02-77 00\nPr\u00e4leuk\u00e4mische Knochenmarkerkrankungen Prof. Dr. med. Charlotte Niemeyer, Freiburg +49 (7 61) 2 70-21 05\nMolekulare Ver\u00e4nderungen\nbei embryonalen Tumoren Prof. Dr. med. Frank Berthold, K\u00f6ln +49 (2 21) 4 78-43 80\nLebensqualit\u00e4t und Sp\u00e4tfolgen Dr. med. Gabriele Calaminus, D\u00fcsseldorf +49 (2 11) 8 11-76 80\nMinimale Resterkrankung Prof. Dr. med. Jochen Harbott, Gie\u00dfen +49 (6 41) 99-4 34 26\nSekund\u00e4rmalignome nach \nKrebserkrankungen im Kindesalter Dr. rer. physiol. Peter Kaatsch, Mainz +49 (61 31) 17-31 11\nImmun- und Gentherapie Prof. Dr. med. Stefan Burdach, Halle +49 (3 45) 5 57-23 88Die folgenden Forschungsschwerpunkte und Projekte werden realisiert im Sprecher\nProf. Dr. med. Dr. h.c. G\u00fcnter Henze\nCharit\u00e9\nAugustenburger Platz 1D-13353 Berlin\nTelefon +49 (30) 45 05-6 68 34\nFax +49 (30) 45 05-6 69 06Gesch\u00e4ftsf\u00fchrerin\nProf. Dr. med. Ursula Creutzig\nThea-B\u00e4hnisch-Weg 12\nD-30657 Hannover\nTelefon +49 (5 11) 6 04 66 77\nFax +49 (5 11) 6 04 64 04Koordinator\nDr. med. Ralf Herold\nCharit\u00e9\nAugustenburger Platz 1D-13353 Berlin\nTelefon +49 (30) 45 05-6 68 34\nFax +49 (30) 45 05-6 69 01\nGROSSE FORTSCHRITTE\nF\u00dcR KLEINE PATIENTEN\nEIN PROJEKT DER GEF\u00d6RDERT VOM\nInternet: www.kompetenznetz-paed-onkologie.de\nE-Mail: koordinationszentrale @kompetenznetz-paed-onkologie.de\nKinderkrebs-Informationsportal: www.kinderkrebsinfo.deDas jahresbezogene Auftreten von Krebserkrankungen im Kindes- und\nJugendlichenalter ist seit 20 Jahren konstant: Es erkranken 14 von 100.000,\ndas waren 1.838 unmittelbar Betroffene im Jahr 2000 (jeweils bezogen auf\nunter 15j\u00e4hrige Kinder und Jugendliche).\n75% der Erkrankten werden in 32 speziellen Kliniken betreut. \nNeu durch das Kompetenznetz P\u00e4diatrische Onkologie und H\u00e4matologie:An den meisten Kliniken schaffen Forschungs- und Studienassistenten eine\nneue Daten- und Materiallogistik.\nHamburg\nBremen\nM\u00fcnster\nGiessen\nHeidelbergHomburg\nStuttgart\nT\u00fcbingen\nUlm Augsburg\nM\u00fcnchenErlangenDresdenHalle\nW\u00fcrzburg\nFreiburgFrankfurt/Main\nMainzEssen\nD\u00fcsseldorf\nK\u00f6ln\nBonnHannover\nBielefeld\nG\u00f6ttingenBerlin\nKrebserkrankungen im Kindes- und Jugendalter weisen eine besondere\nVerteilung und charakteristische Tumorarten auf, die beispielsweise aus\nGeweben entstehen, die krankhafterweise in einem embryonalen Stadium\nverblieben sind. Drei von vier Patienten werden geheilt, aber ungef\u00e4hr 500 Kinder und\nJugendliche sterben jedes Jahr an der Krebserkrankung. Zum Vergleich: In\ndieser Altersgruppe sind nur Unfalltodesf\u00e4lle h\u00e4ufiger.Knochentumoren\nund SarkomeSonstige Leuk\u00e4mien\n31,8 %\n11,7 % 21,2 %15,9 %10,9 %8,5 %\nLymphome HirntumorenEmbryonale\nTumoren 1Erfolg der Behandlung von Kindern mit Krebserkrankungen  \ndurch einheitliche und konsequente Diagnostik und Therapie  \nin Therapieoptimierungsstudien w\u00e4hrend der letzten 20 Jahre \nU. Creutzig 1, G. Henze 2, H. J\u00fcrgens 3\nf\u00fcr die Gesellschaft f\u00fcr P\u00e4diatrische Onkolgie und H\u00e4matologie \nunter Mitarbeit von S. Bielack 4, P. Kaatsch 5, J. Klussmann 6, N. Graf 7, D. Reinhardt 4,\nM. Schrappe 8, M. Zimmermann 8\n1 Gesch\u00e4ftsf\u00fchrerin der GPOH und Leiterin der Koordinationszentrale Kompetenznetz P\u00e4diatrische \nOnkologie und H\u00e4matologie; 2Sprecher des Kompetenznetzes P\u00e4diatrische Onkologie und \nH\u00e4matologie, Berlin; 3Vorsitzender der GPOH, M\u00fcnster; 4P\u00e4diatrische H\u00e4matologie/Onkologie \nUniversit\u00e4ts-Kinderklinik, M\u00fcnster; 5Deutsches Kinderkrebsregister, Mainz; 6Stud. med., G\u00f6ttingen; \n7Universit\u00e4ts-Kinderklinik, Homburg/Saar; 8Kinderklinik der MHH, Hannover \nKorrespondenzadresse:\nProf. Dr. med. Ursula Creutzig \nP\u00e4diatrische H\u00e4matologie/Onkologie  \nUniversit\u00e4ts-Kinderklinik, M\u00fcnster \nAlbert-Schweitzer-Str. 33 48129 M\u00fcnster  \nTel: 0511 / 604 6677 \nFax: 0511 / 604 6404 Email: Ucreutzig@aol.co\nm\nDie Diagnose \u201eKrebs\u201c bedeutete noch bis in die 60er und 70er Jahre auch bei Kindern ein nahezu \nsicheres Todesurteil. Im Folgenden soll die Entstehung und Entwicklung der p\u00e4diatrischen Onkologie \nin Deutschland dargestellt werden, die heute bei etwa 75% aller Kinder mit b\u00f6sartigen Erkrankungen \neine Heilung erm\u00f6glicht.  \nEpidemiologie \nMaligne Erkrankungen sind insgesamt bei Kindern selten. Die altersstandardisierte Inzidenz zwischen \n1991-2000 lag bei 13,7 Neuerkrankungen pro 100.000 unt er 15j\u00e4hrigen Kindern pro Jahr. (1).Wichtig \nf\u00fcr die m\u00f6glichst vollst\u00e4ndige Erfassung aller Erkrankungsf\u00e4lle war die Gr\u00fcndung des \nKinderkrebsregisters am Institut f\u00fcr Medizinische Statistik und Dokumentation in Mainz am 1. Januar \n1980. Das Deutsche Kinderkrebsregister ist heute mit etwa 30 000 erfassten Erkrankungen das gr\u00f6\u00dfte seiner Art. Seit 1991, als mit der Erweiterung der Bundesrepublik die Erfassung ausgedehnt wurde, \nkommen j\u00e4hrlich bei einer Bev\u00f6lkerung von 13,0 Millionen Kindern etwa 1800 Neuerkrankungen pro \nJahr hinzu. \nAbbildung 1 zeigt die relative H\u00e4ufigkeit der l991 bis 2000 gemeldeten Patienten nach den h\u00e4ufigsten \nDiagnosegruppen (nur Patienten unter 15 Jahren) (1). Der Vergleich der relativen H\u00e4ufigkeit b\u00f6sartiger Neubildungen bei Kindern und Erwachsenen zeigt, da\u00df im Kindesalter praktisch \nausschlie\u00dflich Malignome mesodermalen Ursprungs auftreten im Gegensatz zu der Dominanz epi- \nund endodermaler Neoplasien im Erwachsenenalter. Die Leuk\u00e4mien und malignen Lymphome \u00fcberwiegen mit 47%, gefolgt von ZNS-Tumoren, embryonalen Neoplasien und Sarkomen des 2Bindesgewebes und Knochens, w\u00e4hrend Karzinome au\u00dferordentlich selten sind (1%). Damit bestehen \ngrundlegende Unterschiede in der absoluten und relativen H\u00e4ufigkeit der Malignome bei Kindern und \nErwachsenen (> 90% Karzinome). \nEin gro\u00dfer Teil der Tumoren im Kindesalter ist pr\u00e4natal angelegt; sie werden als embryonale Tumoren \nbezeichnet (Neuroblastom, Nephroblastom, Medulloblastom, Retinoblastom, embryonales Rhabdo-myosarkom, Keimzelltumoren, Hepatoblastom). Diese Tumoren werden meist bereits in den ersten \nf\u00fcnf Lebensjahren diagnostiziert. Bei den \u00fcbrigen Malignomen ist die Altersverteilung zum Teil sehr \nunterschiedlich. Die akute lymphoblastische Leuk\u00e4mie (ALL), die h\u00e4ufigste Einzeldiagnose, betrifft \u00fcberwiegend 1 bis 6 Jahre alte Kinder, w\u00e4hrend bei \u00e4lteren Kindern Knochentumoren und Lymphome \neine vergleichsweise hohe Inzidenz aufweisen (1). \nZusammenarbeit in der P\u00e4diatrischen Onkologie im Rahmen von Therapieoptimierungsstudien \nAngesichts der Seltenheit von malignen Erkrankungen im Kindesalter haben sich die P\u00e4diatrischen \nOnkologen schon in den siebziger Jahren zusammengeschlossen, um ausreichende Erfahrung in der Therapie so seltener Erkrankungen zu generieren. \nSechs Jahre nachdem Donald Pinkel 1968 (Memphis/USA) auf einem Vortrag in M\u00fcnchen seine \nHeilungsergebnisse bei Kindern mit ALL vorstellte (s.u.), wurden nahezu gleiche Ergebnisse innerhalb einer ersten gemeinsamen Therapiestudie zur Behandlung der ALL in Deutschland (2) \nerreicht. Die 1976 von H. Riehm gegr\u00fcndete BFM (Berlin, Frankfurt, M\u00fcnster)-Studiengruppe ist \ndurch ihr Behandlungskonzept (s.u.) und die erreichten hohen Heilungsraten bei der ALL international \nbekannt geworden (3). Heute beteiligen sich p\u00e4diatrisch-onkologisch t\u00e4tige \u00c4rzte an \u00fcber 70 \ndeutschen, \u00f6sterreichischen und schweizerischen Kliniken an dieser Kooperation. Am internationalen Standard gemessen sind dadurch beispielgebende Behandlungsergebnisse erzielt worden (s. Abb.2).  \nDie \u201eDeutsche Arbeitsgemeinschaft f\u00fcr Leuk\u00e4mie-Forschung und -Behandlung im Kindesalter (DAL) \nwurde 1966 gegr\u00fcndet, 1973 folgte die Gesellschaft f\u00fcr P\u00e4diatrische Onkologie (GPO) mit dem Ziel, \nauch die Tumorkrankheiten im Kindesalter zu erforschen und gemeinsam zu behandeln. GPO und \nDAL tagten seitdem gemeinsam halbj\u00e4hrlich. Ihre wichtigsten Projekte sind die Durchf\u00fchrung von multizentrischen Therapiestudien, deren \u00dcberwachung, Auswertung und kontinuierliche Aktua-\nlisierung. Beide Arbeitsgemeinschaften wurden 1991 zur Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und \nH\u00e4matologie (GPOH) vereinigt.In Deutschland werden derzeit \u00fcber 90% der an Krebs erkrankten Kinder und Jugendlichen in 23 \naktiven Therapiestudien eingeschlossen und einheitlich behandelt (s. Tab. 1). Nach Angaben des \nDeutschen Kinderkrebsregisters (s.u.) liegt der relative Anteil von Studienpatienten je nach Diagnose zwischen 92% und 100%. Der hohe Anteil der in Therapiestudien erfassten und dokumentierten \nPatienten hat Deutschland im internationalen Vergleich eine herausragende Stellung in der Qualit\u00e4t \nvon klinischer Krebsforschung und Krebsbehandlung im Kindesalter verschafft. Die Spitzenstellung \ngeht zur\u00fcck auf die Behandlungslogistik der P\u00e4diatrischen Onkologie und die weitgehende \nKonzentrierung der Behandlung auf spezialisierte Zentren. So werden ca. 75% der krebskranken Kinder und Jugendlichen an den 30 gr\u00f6\u00dften Zentren in Deutschland behandelt. \nTherapieoptimierungsstudien in der P\u00e4diatrischen Onkologie beinhalten Aspekte der klinischen \nForschung und dienen der Verbesserung der Behandlungsqualit\u00e4t der betroffenen Kinder. Referenzlaboratorien innerhalb der Studien sind ein elementares qualit\u00e4tssicherndes Element. So ist \ndie Etablierung innovativer diagnostischer Methodik nur \u00fcber Referenzlaboratorien m\u00f6glich.  \nZwischen den Studienleitungen und dem Kinderkrebsregister findet ein regelm\u00e4\u00dfiger \nInformationsaustausch \u00fcber Initial- und Verlaufsdaten statt. Dieser Austausch tr\u00e4gt zu einer \ngegenseitigen Qualit\u00e4tssicherung der Daten bei.  \nTherapiekonzepte\nDen Therapikonzepten bei soliden Tumoren liegt die Kombination einer intensivierten, systemisch \nwirkenden Polychemotherapie mit einer stetig weiterentwickelten lokalen operativen und/oder strahlentherapeutischen Behandlung zugrunde. Fast alle malignen Tumoren und h\u00e4matologischen \nSystemerkrankungen im Kindesalter sprechen auf eine Behandlung mit Zytostatika an. Aus diesem 3Grund steht die Chemotherapie, von wenigen Ausnahmen abgesehen, im Mittelpunkt oder sie ist \nwesentlicher Bestandteil der kombinierten Behandlungsstrategie. Mit der Chemotherapie wird bei \nsoliden Tumoren die Zerst\u00f6rung und partielle Devitialisation des Prim\u00e4rtumors und von bereits zum Zeitpunkt der Diagnose vorhandenen Mikrometastasen angestrebt. Die definitive lokale Behandlung \ndes Tumors erfolgt durch Operation und Strahlentherapie.  \nDie Kombination von Chemo- und Strahlentherapie  wird pr\u00e4therapeutisch (neoadjuvant) oder postlokaltherapeutisch (adjuvant) eingesetzt. Chemo- und Strahlentherapie wird auch gleichzeitig \n(synchron) oder hintereinandergeschaltet (sequentiell) durchgef\u00fchrt. \nTherapieerfolge  \nDie 5-Jahres-\u00dcberlebensraten f\u00fcr alle malignen Erkrankungen des Kindesalters sind von weniger als \n10%-20% in den 50er und 60er Jahren heute auf ca. 75% angestiegen (s. Abb. 3). Sie betragen \u00fcber \n90% f\u00fcr den Morbus Hodgkin und das Retinoblastom, 80% f\u00fcr die akute lymphatische Leuk\u00e4mie, das \nNon-Hodgkin-Lymphom, den Wilms-Tumor und Keimzelltumoren, 60% f\u00fcr die Weichteilsarkome \nund 55% f\u00fcr die Erkrankung mit der derzeit noch ung\u00fcnstigsten Prognose im Kindesalter, der akuten myeloischen Leuk\u00e4mie. Bei Hirntumoren liegen die \u00dcberlebensraten bei 67% (s. Tab.2).  \n5-Jahres \u00dcberlebensraten sind angesichts der Tatsache, dass Rezidive b\u00f6sartiger Erkrankungen im \nKindesalter meist innerhalb der ersten zwei bis drei Jahre nach Diagnosestellung eintreten, fast \nidentisch mit Heilungsraten. Nach erfolgreicher Therapie ist ein bei den meisten Kindern weitgehend \nnormal verlaufendes Leben zu erwarten. Die Langzeit\u00fcberwachung ehemaliger krebskranker Kinder und Jugendlicher ist notwendig, auch um Sp\u00e4tfolgen und die Entwicklung m\u00f6glicher Zweittumoren \nerkennen zu k\u00f6nnen. Sie ist angesichts der hohen Heilungsraten und der langen Lebenserwartung nach \ngeheilter Krebserkrankung auch eine Aufgabe, die \u00fcber die Kinderheilkunde hinausgeht und entsprechend zu strukturieren ist.\nAn den st\u00e4ndig angestiegenen \u00dcberlebensraten bei den Krebserkrankungen der Kinder und \nJugendlichen haben die bundesweiten multizentrischen Therapieoptimierungsstudien einen erheb-\nlichen Anteil. Durch sie wurde der Standard f\u00fcr Diagnostik und Therapie definiert und weiter \nentwickelt.\nVergleich der Situation der p\u00e4diatrisch-onkologischen Studien in Deutschland und in anderen \nL\u00e4ndern Europas \nDie Situation in Deutschland unterscheidet sich von den meisten anderen L\u00e4ndern Europas und auch \nden USA dadurch, dass hierzulande grunds\u00e4tzlich fast alle Kinder mit einer Krebserkrankung innerhalb von Therapieoptimierungsstudien einheitlich f\u00fcr die jeweilige Krankheit behandelt werden. \nEs ist davon auszugehen, dass \u00fcber 95% aller Patienten zentral dem Kinderkrebsregister gemeldet \nwerden. Eine landesweite Erfassung erfolgt sonst nur in Skandinavien (Norwegen, Schweden, Finnland, D\u00e4nemark und Island) im Rahmen der NOPHO-Studien. In Gro\u00dfbritannien werden etwa 2/3 \nder p\u00e4diatrischen Patienten innerhalb von Studien behandelt. In Frankreich und Italien nimmt nur eine \nbegrenzte Zahl von Kliniken an den Studien teil (Ausnahme nationale ALL Studie in Italien).\nBedingt durch die landesweite Ausdehnung in Deutschland nehmen auch kleinere Kliniken mit \ngeringeren Patientenzahlen an den Therapieoptimierungsstudien teil. Dadurch wird die gesamte Patientengruppe mit einer bestimmten Krankheit erfa\u00dft und einheitlich behandelt. Damit werden \nSelektionen vermieden, z.B. Begrenzung auf bestimmte Krankheitsstadien oder bestimmte Kliniken \noder Ausschlu\u00df von Patienten mit Begleiterkrankungen.  Die deutschen Studien zeichnen sich zus\u00e4tzlich durch die Beratungsleistung der Studienzentralen aus, \ndie durch die zeitnahe Dokumentation und Information \u00fcber die einzelnen Patienten m\u00f6glich ist.  \nEs ist hinzuzuf\u00fcgen, dass eine zunehmende Internationalisierung in der P\u00e4diatrischen Onkologie zu verzeichnen ist und mehrere internationale Studien von Deutschland ausgehen. Dazu geh\u00f6ren die \nEURO-EWING-, Wilms-Tumor-(SIOP)-, Hepatoblastom- und Keimzelltumor-Studien, sowie die \nStudie zur Behandlung der Low-grade-Gliome und die EWOG-MDS-Studie. Bei den Leuk\u00e4mien und Non-Hodgkin-Lymphomen gibt es einen Verbund der BFM-Studien unter Einschluss von \u00d6sterreich, \nTschechien und einem Teil der Schweiz, bei der ALL-Studie eine direkte Kooperation mit Italien. 4Beispiele  von Therapie- und Prognoseverbesserung bei Leuk\u00e4mien und Tumoren  \nAkute Leuk\u00e4mien\nAkute lymphoblastische Leuk\u00e4mien (ALL) und akute myeloische Leuk\u00e4mien (AML) sind mit etwa \n600 Neuerkrankungen/Jahr in Deutschland die h\u00e4ufigsten b\u00f6sartigen Neuerkrankungen bei Kindern. \nOhne Behandlung f\u00fchren sie innerhalb weniger Monate zum Tod. Heute werden mit modernen Kombinationschemotherapien, bestehend aus Induktions-, Konsolidierungs- und Dauertherapie mit \nZytostatika insgesamt \u00fcber 80% der Kinder mit ALL und \u00fcber 50% der Kinder mit AML geheilt. \nAkute lymphoblastische Leuk\u00e4mie\nIn den 50er Jahren wurden erstmals Medikamente zur Behandlung von Leuk\u00e4mien m\u00edt m\u00e4\u00dfigem \nErfolg eingesetzt. Durch Einf\u00fchrung der Dauertherapie wurde die mittlere Lebensdauer zwischen 1963 \nund 1967 in einer deutschen Studie auf 17 Monate angehoben. Die erste erfolgreiche Leuk\u00e4mie-therapie, mit der \u00dcberlebensraten von 30% im St. Jude Childrens Research Hospital in Memphis \nerreicht wurden (4), bestand neben der Induktionstherapie aus einer pr\u00e4ventiven Behandlung des \nzentralen Nervensystems und aus einer Dauertherapie mit mehreren Zytostatika. Diese Therapiestrategie wurde 1971 von Lampert bundesweit erfolgreich eingef\u00fchrt (2). Etwa parallel dazu \nentwickelte H. Riehm eine intensive Kombinationstherapie, die zun\u00e4chst von 1970 an in einer \nWestberliner Pilotstudie eingesetzt wurde (5). Dieser Therapieplan enthielt alle bis dahin bekannten bei der ALL wirksamen Mittel in einer Zusammensetzung, die bis an die therapeutische \nToleranzgrenze ging und wegen der erh\u00f6hten Toxizit\u00e4t erheblich kritisiert wurde. Nachdem \nverbesserte \u00dcberlebensraten (\u00fcber 50%) erkennbar wurden, schlossen sich weitere Kliniken an \n(Frankfurt und M\u00fcnster). 1976 wurde dann die BFM (Berlin, Frankfurt, M\u00fcnster)-Studiengruppe \ngegr\u00fcndet.Die \u00dcberlebensrate stieg auf 55%, und im weiteren Verlauf wurden die Ergebnisse innerhalb von \nbisher  6 aufeinanderfolgenden Studien, an denen jetzt immer mehr Kinderkliniken in Deutschland \nteilnahmen, weiter gesteigert (Abb. 2). Durch Risikoadaptierung wurde die Therapie f\u00fcr Patienten mit Standardrisiko massvoll gestaltet, w\u00e4hrend sie bei Kindern mit mittleren und hohem Risiko weiter \nintensiviert wurde. In den aufeinanderfolgenden Studien konnte immer mehr die pr\u00e4ventive \nSch\u00e4delbestrahlung durch eine auf das Zentralnervensystem ausgerichtete Chemotherapie ersetzt werden.\nIm Rahmen der Studien wurde der Prognosefaktor Ansprechen auf eine Vorphase mit Prednison \netabliert. Die etwa 10% der Patienten, die unzureichend auf die initiale einw\u00f6chige Prednisontherapie \nansprachen, zeigten ein ereignisfreies \u00dcberleben von unter 40% im Vergleich zu den gut an-\nsprechenden Patienten 65%  (Studie ALL-BFM 83).  Die Hochdosistherapie mit Methotrexat f\u00fchrte in der Studie ALL-BFM 86 zu einer Verbesserung der \n\u00dcberlebensraten bei Kindern mit T-ALL. Zugleich kam es zu deutlich weniger Rezidiven im \nZentralnervensystem. In den 90er Jahren war das Ziel, die Sp\u00e4tfolgen bei Patienten mit einem guten \nAnsprechen auf Prednison zu reduzieren. Die Anthrazyklindosen wurden reduziert und die Strahlen-\ntherapie auf Hochrisikopatienten und T-ALL begrenzt. Heute wird die Therapie auch nach dem Ergebnis der molekularen Untersuchungen zur \u201eminimalen Resterkrankung\u201c (MRD) gesteuert. \nInsgesamt konnte an Erkenntnissen gewonnen werden: \n1. die Reintensivierung der Chemotherapie ist auch bei Patienten mit einem niedrigen Risiko eines \nR\u00fcckfalls ein entscheidender Teil der Behandlung \n2. die Intensit\u00e4t der pr\u00e4ventiven Strahlentherapie des ZNS kann gesenkt oder komplett durch eine \nsystemische und intrathekale Chemotherapie ersetzt werden \n3. eine 24-monatige Erhaltungstherapie verhindert eine h\u00f6here Anzahl von R\u00fcckf\u00e4llen im Vergleich \nzu einer 18- monatigen Behandlung \n4. das fr\u00fche Ansprechen erm\u00f6glicht die Zuordnung zu Risikogruppen.   \nHeute sind die BFM-ALL-Studien weltweit anerkannt. In den USA wurden wesentliche 5Therapieelemente \u00fcbernommen. Die Studie wird heute gemeinsam mit \u00d6sterreich und Italien \ndurchgef\u00fchrt und in weiteren Studiengruppen in Osteuropa, Mittel- und S\u00fcdamerika zum Teil in \nadaptierter Form durchgef\u00fchrt. In der zweiten  in Deutschland laufenden  Studie CoALL wurden \u00e4hnliche Ergebnisse mit einer etwas \nanders gestalteten Intensivphase erzielt. \nAkute myeloische Leuk\u00e4mie  \nAkute myeloische Leuk\u00e4mien (AML) sind bei Kindern deutlich seltener als die ALL (nur 20% aller \nLeuk\u00e4mien im Kindesalter). 1978 wurde in Deutschland die erste kooperative Therapiestudie bei Kindern mit AML durchgef\u00fchrt (6). Die Therapiestrategie war \u00e4hnlich aufgebaut wie die der ALL, \nwobei Substanzen, die bei der AML wirksamer sind, verst\u00e4rkt angewandt wurden. Dazu geh\u00f6ren \ninsbesondere die Medikamente Cytosinarabinosid und die Anthrazykline. Wie bei der ALL wurde auch bei der AML eine pr\u00e4ventive Sch\u00e4delbestrahlung und eine Erhaltungstherapie durchgef\u00fchrt.  \nMit Hilfe der Anfangstherapie (Induktion) erreichten 1978 fast 80% der Patienten eine Remission, und \ndie 5-Jahres-\u00dcberlebensrate konnte von unter 10% auf 40% angehoben werden.  \nIn den weiteren Studien wurde die Therapie deutlich intensiviert und optimiert, so dass heute eine  \n5-Jahres\u00fcberlebensrate von 60% erreicht worden ist. Die schematische Entwicklung in der Struktur der AML-BFM-Studien wird in Abbildung 4 aufgef\u00fchrt.  \nDie Erfahrungen der Vorg\u00e4ngerstudie wurden jeweils zur Optimierung der folgenden Studie genutzt. \nDieses Vorgehen hat entscheidend, zusammen mit der Verbesserung der supportiven Therapie und \ndem Erfahrungsgewinn der Teilnehmer, zu einem Anstieg der \u00dcberlebensraten in den vier aufein-anderfolgenden AML-BFM Therapiestudien gef\u00fchrt. \nOsteosarkome\n3% aller b\u00f6sartigen Neuerkrankungen bei Kindern und Jugendlichen sind Osteosarkome. Damit \ngeh\u00f6ren Osteosarkome zu den h\u00e4ufigsten b\u00f6sartigen Knochentumoren in dieser Altersgruppe. Sie sind \nmeist in den Wachstumsfugen der langen R\u00f6hrenknochen lokalisiert und kommen h\u00e4ufiger bei Jungen \nvor.\nBei etwa 70% der Patienten mit Osteosarkom wird davon ausgegangen, dassMikrometastasen zum \nZeittpunkt der Diagnose vorliegen\u201c. Durch eine pr\u00e4operative Therapie  werden diese Mikrometastasen fr\u00fchzeitig behandelt und der Tumor wird partiell devitalisiert. Bei gutem Ansprechen auf die \nChemotherapie werden oft extremit\u00e4tenerhaltende Operationen m\u00f6glich. Aus dem Ansprechen k\u00f6nnen \nauch Prognose und weiteres Vorgehen abgeleitet werden. Nach der Operation wird die Chemotherapie fortgesetzt (7). Die Bestrahlung spielt in der Lokaltherapie wegen der hohen Resistenz der \nOsteosarkomzellen eine untergeordnete Rolle. \nDie deutsch, \u00f6sterreichisch, schweizerische Studiengruppe COSS f\u00fchrt seit 1977 multizentrische \nStudien zur Behandlung von Osteosarkomen durch. W\u00e4hrend das erste Protokoll COSS-77 auf einer postoperativen adjuvanten Chemotherapie basierte, beinhalteten alle Studienprotokolle nach 1980 eine \nneoadjuvante Chemotherapie. \nDer Zusammenhang zwischen Tumorgr\u00f6\u00dfe, dem Ansprechen auf die Chemotherapie und dem r\u00fcckfallfreien \u00dcberleben wurde in der COSS-80-Studie etabliert.  \nInsgesamt stieg die Wahrscheinlichkeit f\u00fcr ein ereignisfreies \u00dcberleben nach 10 Jahren von 46% in \nder Studie COSS-77 auf 66% in der Studie COSS-86 an (s. Abb. 5). Mit der Studie COSS-96 wird an \ndie guten Ergebnisse der COSS-86-Studie angekn\u00fcpft und gleichzeitig versucht, die Nebenwirkungen \nund Sp\u00e4tfolgen der Therapie zu minimieren.  6Wilms-Tumor (Nephroblastom)  \nDer  Wilms-Tumor (Nephroblastom) geh\u00f6rt zu den embryonalen Tumoren. Assoziationen mit Mi\u00dfbil-\ndungssyndromen (Hemi-hypertrophie, Wiedemann-Beckwith Syndrom, urogenitale Fehlbildungen, Aniridie) sind bekannt. 70% der an Wilms-Tumoren neu erkrankten Kinder sind zwischen 1 und 5 \nJahren alt. S\u00e4uglinge sind zu etwa 15% betroffen. Bei 10% der Patienten wird der Tumor bei einer \nVorsorgeuntersuchung als tastbarer Bauchtumor festgestellt .Die Diagnose  beruht wesentlich auf bildgebenden Untersuchungen (abdominelle Sonographie, CT oder MRT).\nDie Behandlung besteht aus einer Kombination von Operation, Chemotherapie und evtl. Bestrahlung. \nSie wird nach dem Alter, dem Stadium (I bis V)  und dem histologischem Subtyp, einem der wesenlichen Prognosefaktoren beim Wilms-Tumor, stratifiziert. Das Ziel der Operation ist immer eine \nradikale Entfernung des Tumors und dessen Metastasen und eine genaue Bestimmung des Stadiums \n(8).\nDie Durchf\u00fchrung der Chemotherapie und Strahlentherapie wird in Abh\u00e4ngigkeit von \nunterschiedlichen Risikofaktoren stratifiziert. Weltweit sind hier die prospektiven, randomisierten, multizentrischen Studien der NWTSG (National Wilms Tumor Study Group) in den USA und der \nSIOP (International Society of Paediatric Oncology), vorwiegend in Europa, f\u00fchrend. Hauptziele \ndieser Studien sind, durch risikoadaptierte Behandlung hohe Heilungsraten zu erzielen, akut- und Sp\u00e4tfolgen zu reduzieren und die Belastung durch die Therapie zu minimieren.  \nInnerhalb der SIOP wurde insbesondere die Wertigkeit einer pr\u00e4operativen Behandlung analysiert. \nDiese f\u00fchrt zu einer Reduktion des Tumorvolumens und bewirkt ein sogenanntes \"downstaging\" des \nTumors nach Operation. Die operative Entfernung des geschrumpften Tumors wird dadurch erleichtert \nund das Risiko von Tumorrupturen deutlich vermindert. Gleichzeitig werden Mikrometastasen ohne Verz\u00f6gerung behandelt und das Ansprechen auf die pr\u00e4operative Therapie kann gemessen und zur \nStratifizierung der postoperativen Therapie herangezogen werden.\nDie wichtigsten Ergebnisse von insgesamt sechs SIOP-Studien sind: \nxSIOP 2 Studie: Signifikant weniger intraoperative Tumorrupturen bei pr\u00e4operativer Bestrahlung \nund pr\u00e4operativer Therapie mit Actinomycin D im Vergleich zur sofortigen Operation.  \nxSIOP 5 Studie (1977): Kein Unterschied in den \u00dcberlebensraten und im ereignisfreien \u00dcberleben \nmit pr\u00e4operativer Chemotherapie oder Radiotherapie. Seitdem ist die pr\u00e4operative Chemotherapie \n\u00fcber 4 Wochen mit Actinomycin D und Vincristin Standard. \nxSIOP 6 Studie (1980): Eine reduzierte postoperative Behandlung, abh\u00e4ngig vom lokalen Stadium, \nwurde mit der damaligen postoperativen Standardtherapie verglichen um Sp\u00e4tfolgen zu senken. \nDas Ergebnis zeigte f\u00fcr das Stadium I keine Prognoseverschlechterung durch Therapiereduktion, \njedoch in den Stadien II und III. Daraufhin wurde die Behandlung f\u00fcr diese Stadien in der folgenden Studie SIOP 9 intensiviert (\u00dcberlebensraten s. Abb. 6). \nxSIOP 9 Studie: Beim Vergleich einer verl\u00e4ngerten pr\u00e4operativen Chemotherapie (4 gegen 8 \nWochen) ergab sich zwar eine weitere Tumorvolumenreduktion aber keine Erniedrigung des post-operativen Stadiums. Die postoperative Chemotherapie bestand aus Vincristin und Actinomycin D und wurde im Stadium II und III durch Doxorubicin erg\u00e4nzt. Die lokale Radiotherapie wurde auf \nwenige Indikationen reduziert, so dass nur noch 18% aller Patienten bestrahlt wurden. Die \nereignisfreie \u00dcberlebensrate betrug 84% und die \u00dcberlebensrate 90% nach jeweils f\u00fcnf Jahren.\nxSIOP 93 Studie: Eine weitere Therapiereduktion im Stadium I wurde prospektiv randomisiert \ngepr\u00fcft. Vorl\u00e4ufige Ergebnisse zeigen, dass die postoperative Therapie im Stadium I auf 4 \nWochen ohne Prognoseverschlechterung reduziert werden kann. Daf\u00fcr konnte die Prognose bei Hochrisikopatienten mit einem Klarzellensarkom durch eine weitere Intensivierung der Therapie \nverbessert werden. \nIn zuk\u00fcnftigen Studien zum Wilmstumor sollen unter Einbeziehung von molekularbiologischen Untersuchungen weitere Risikofaktoren ermittelt werden, um die Behandlung noch besser dem \njeweiligen Risiko anzupassen.  \nHirntumoren \nDie Tumoren des Zentralnervensystems sind mit ca. 20 % aller Krebserkrankungen im Kindesalter die \ngr\u00f6\u00dfte Diagnosegruppe unter den soliden Tumoren. Dies sind in Deutschland j\u00e4hrlich ca. 380 7neuerkrankte Kinder und Jugendliche. Das mittlere Erkrankungsalter liegt bei 6\u00bd Jahren. Astrozytome \nsind mit ca. 50% aller Hirntumoren die gr\u00f6\u00dfte Gruppe. Es folgen Medulloblastome mit 20%, \nEpendymome mit 10% und  Kraniopharyngeome mit 8%. Zwei Drittel der Tumoren betreffen das \nKleinhirn. Das biologische Verhalten der Tumoren und die Prognose h\u00e4ngt vom feingeweblichen Typ, \naber auch von der Lokalisation und Operabilit\u00e4t des Tumors und dem Alter des Kindes ab. H\u00e4ufig \nf\u00fchren neurologische, intellektuelle, hormonelle und psychosoziale Defizite zu einer Beeintr\u00e4chtigung der Lebensqualit\u00e4t.\nMedulloblastome \nDas Medulloblastom entsteht durch eine St\u00f6rung der normalen Kleinhirnentwicklung. Der Tumor \nkann in angrenzende Strukturen hineinwachsen, z.B. in den Hirnstamm, aber auch in den 4. Ventrikel \nund entlang der Liquorwege.  \nDie Anamnese ist aufgrund der B\u00f6sartigkeit der Medulloblastome meist kurz. Kopfschmerzen und Erbrechen sind typisch, ebenso mentale oder emotionale Ver\u00e4nderungen, Gleichgewichtsprobleme\noder St\u00f6rung der Feinmotorik. Bildgebende Verfahren wie Computertomographie oder Magnet-\nresonanztomographie best\u00e4tigen die Diagnose und erm\u00f6glichen eine genaue Lokalisation des Tumors. \nDie Prognose von Kindern mit einem Medulloblastom war noch in den 80er Jahren schlecht. In \nDeutschland \u00fcberlebten damals die H\u00e4lfte der Kinder f\u00fcnf Jahre und nur 39% zehn Jahre. Die k\u00f6rperliche und geistige Entwicklung sowie das psychosoziale Verhalten der geheilten Kinder wurde \nh\u00e4ufig durch die Tumorerkrankung, aber auch durch die Therapie, insbesondere die Bestrahlung von \nKopf- und Spinalkanal, erheblich beeintr\u00e4chtigt. Das Ziel der bundesweiten HIT( Hirntumor)-Studien \nder GPOH war daher nicht nur die Heilung m\u00f6glichst vieler Kinder, sondern auch die Verringerung \nder therapiebedingten Sp\u00e4tfolgen und damit die Steigerung der Lebensqualit\u00e4t der Lang-zeit\u00fcberlebenden.  \nDurch eine adjuvante Chemotherapie in Erg\u00e4nzung zu Operation und Bestrahlung wurde die Prognose \nvon Kindern mit hohem Rezidivrisiko, d.h. ausgedehntem Tumor, inkompletter Resektion, Metastasen und niedrigem Alter, deutlich verbessert. Die Standardkombination besteht aus Cisplatin, CCNU und \nVincristin. Bei Kindern ohne prim\u00e4re Metastasierung k\u00f6nnen mit kombinierter postoperativer \nStrahlen- und Chemotherapie Heilungsraten von \u00fcber 60% erwartet werden (9). \nDie multizentrische Therapiestudie HIT 2000 verfolgt das Ziel einer m\u00f6glichst individuellen, dem \nR\u00fcckfall- und Sp\u00e4tfolgenrisiko angepassten Therapie. Die Zuordnung zu einer bestimmten Therapiegruppe erfolgt anhand von Risikomerkmalen wie zum Beispiel Alter bei Diagnose und \nStadium der Metastasierung. Mehr als in den vorangegangen Studien sollen die Aspekte der \nSp\u00e4tfolgen sowie der Lebensqualit\u00e4t bearbeitet werden, um so die Grundlage f\u00fcr eine ad\u00e4quate Rehabilitation ehemals an einem Hirntumor erkrankter Kinder zu schaffen.  \nInfrastruktur und F\u00f6rderung von Studien  \nMehr als 90% aller Kinder mit malignen Erkrankungen werden in Deutschland innerhalb von \nTherapieoptimierungsstudien behandelt. Somit stellen die Therapieoptimierungsstudien z.Zt. den Standard in der P\u00e4diatrischen Onkologie und H\u00e4matologie dar. Sie haben erheblich zur Verbesserung \nder \u00dcberlebenschancen von Kindern mit malignen Erkrankungen beigetragen und sind ein positives \nBeispiel f\u00fcr gut funktionierende interdisziplin\u00e4re Zusammenarbeit.  \nIn den Therapieoptimierungsstudien werden neue Therapieans\u00e4tze verfolgt. Bei diesen Studien geht es \nnicht prim\u00e4r um die Zulassung von neuen Medikamenten sondern um die Weiterentwicklung von interdisziplin\u00e4ren multimodalen Therapieans\u00e4tzen. \u00dcberwiegend wird eine modifizierte Therapie mit \neiner Standardbehandlung hinsichtlich Verbesserung der Prognose und Verminderung von \nNebenwirkungen verglichen. Gleichzeitig wird im Rahmen dieser Studien ein erheblicher Beitrag zur Qualit\u00e4tssicherung geleistet (Qualit\u00e4t der Diagnose, Beratung der teilnehmenden \u00c4rzte, \nDokumentation der Prozess- und Ergebnisqualit\u00e4t).  \nInnerhalb dieser Therapieoptimierungsstudien m\u00fcssen oft f\u00fcr das Kindesalter nicht zugelassene Medikamente verabreicht werden. Viele Medikamente bleiben in ihrer Zulassung auf h\u00e4ufige \nIndikationen beschr\u00e4nkt, auch wenn der Stand der medizinischen Wissenschaft den Zulassungsrahmen 8\u00fcberschritten hat.  Auch ist in den seltensten F\u00e4llen das Kindesalter bei der Indikation ber\u00fccksichtigt. \nDie Verwendung au\u00dferhalb der registrierten Indikation bei seltenen Krankheiten und f\u00fcr Kinder als \nAltersgruppe ist somit ein zentrales Problem in der P\u00e4diatrischen Onkologie, dem nur durch die Behandlung innerhalb von Therapieoptimierungsstudien, die sich nach dem internationalen Standard \n\u00e4rztlichen Wissens ausrichten, begegnet werden kann. Nur so ist f\u00fcr alle krebskranken Kinder und \nJugendliche eine qualit\u00e4tsgesicherte Therapie gew\u00e4hrleistet.  Ein erheblicher Kl\u00e4rungsbedarf besteht in Hinblick auf die Stellung solcher Studien im Rahmen des \nArzneimittelgesetzes, auch um den damit verbundenen logistischen \u00dcberbau zu definieren und diese \nStudien durchf\u00fchrbar und finanzierbar zu halten. \nDa Tumorerkrankungen im Kindesalter selten sind, k\u00f6nnen nur bundesweite, teils sogar nur \ninternationale Studienkonzepte die notwendigen Daten und die Evidenz f\u00fcr eine Verbesserung in der Behandlung generieren.  \nKostenanalyse\nDie Absch\u00e4tzung der Behandlungskosten einer malignen Erkrankung im Kindesalter ist komplex, da \nsowohl direkte Kosten wie Medikamenten-, Personal-, Ger\u00e4te- oder Geb\u00e4udekosten ber\u00fccksichtigt \nwerden m\u00fcssen, zum anderen aber auch die indirekten Folgekosten durch Arbeitsunf\u00e4higkeit, Beitragsausf\u00e4lle (Eltern und Kinder). Bislang wurden nur in wenigen Analysen die Kosten f\u00fcr die \nBehandlung maligner Erkrankungen untersucht. \nIn einer finnischen Kostenanalyse im Kuopio University Hospital zwischen 1991 und 1994 wurden die \ndurchschnittlichen direkten Kosten einer ALL-Behandlung bei Kindern auf US $103.250 (US \n$55.196-166.039)  kalkuliert.  Die Patienten wurden vor ihrer Behandlung in drei Gruppen (Standardrisiko SR, mittleres Risiko IR, \nhohes Risiko HR) je nach ihrem R\u00fcckfallrisiko eingeteilt. Nach der Einteilung richtete sich auch die \nBehandlung und dementsprechend waren die Kosten stark von der Risikogruppe abh\u00e4ngig (SR: $74.342, IR:$91.207, HR: $136.973).  \nIn den direkten Kosten sind die \u00fcblichen Krankenhauskosten (Bettkosten, Personalkosten etc.) und die \npatientenspezifischen Kosten enthalten. Zu den patientenspezifischen Kosten z\u00e4hlen alle Kosten, die einem einzelnen Patienten angerechnet werden k\u00f6nnen, wie z.B. Kosten, die das Labor, die Radiologie \nund die Therapie (Chemotherapie, Bestrahlung, Operation, Transfusionen, Antibiotika, Antimykotika \netc.) betreffen. Die indirekten Kosten wie z.B. Verdienstausf\u00e4lle der Eltern und Fahrtkosten sind nicht mit einbezogen.\nIn einer derzeitig dualen Finanzierung sind die mit der p\u00e4diatrischen Onkologie verbundenen \nBehandlungskosten durch die Krankenversicherungstr\u00e4ger gedeckt, der mit den Therapie-\noptimierungsstudien verbundene analytische \u00dcberbau ist fremd finanziert. Der weitaus gr\u00f6\u00dfte Anteil \nentf\u00e4llt dabei auf die Deutsche Krebshilfe, der so der wesentliche und nicht wegdenkbare Verdienst \num die Strukturentwicklung in der P\u00e4diatrischen Onkologie zuzuerkennen ist. F\u00fcr den Konsiliarteil \nund qualit\u00e4tssichernde Aspekte sind jedoch neue Finanzierungsmodelle vordringlich. Angemessen w\u00e4re aus unserer Sicht die Kalkulation von Qualit\u00e4tssicherungsanteilen an den \nTherapieoptimierungsstudien und die \u00dcbernahme von so ermittelten Kosten f\u00fcr Konsiliarleistungen, \nDokumentation und Qualit\u00e4tssicherung und Referenzlaboratorien durch die Krankenversicherungen, die f\u00fcr die Qualit\u00e4tssicherung der medizinisch erforderlichen Behandlung zust\u00e4ndig sind. Ein \nMerkmal der Therapieoptimierungsstudien ist auch, dass diese geradezu exemplarisch eine  \"Evidenz-\nbasierte\" Medizin darstellen. Nach den\u00a7\u00a7 2, 70, 72, 135 SGB Vhat der Patient ein Anrecht auf die Weiterentwicklung der Qualit\u00e4t der Behandlung und die Krankenh\u00e4user sind verpflichtet, sich an \neinrichtungs\u00fcbergreifenden Massnahmen der Qualit\u00e4tssicherung zu beteiligen. F\u00f6rderungsmittel der \nDeutschen Krebshilfe wie auch der Deutschen Kinderkrebsstiftung k\u00f6nnen dann verst\u00e4rkt dem eigentlichen Zweck der F\u00f6rderung von Grundlagenforschung, Transferforschung und Klinischer \nForschung zugef\u00fchrt werden. Nur so kann langfristig eine hoch qualifizierte, Evidenz-basierte, \naktuelle Forschungsergebnisse ber\u00fccksichtigende Medizin in der P\u00e4diatrischen Onkologie in Deutschland gesichert werden. Dies ist auch prim\u00e4res Ziel des F\u00f6rderprogramms \"Kompetenznetze in \nder Medizin\" des Bundesministeriums f\u00fcr Bildung und Forschung (BMBF) und des Kompetenznetzes \nP\u00e4diatrische Onkologie und H\u00e4matologie im Rahmen dieses strukturellen F\u00f6rderprogramms.  9Literatur \n(1) Kaatsch P, Spix C, Michaelis J. German Childhood Cancer Registry - Annual Report \n2000 (Jahresbericht 2000 des Deutschen Kinderkrebsregisters). Deutsches Kinderkrebsregister, editor.  2002. Institut f\u00fcr Medizinische Biometrie, Epidemiologie \nund Informatik.  \n(2) Henze G, Langermann HJ, Lampert F, Neidhardt M, Riehm H. Die Studie zur \nBehandlung der akuten lymphoblastischen Leuk\u00e4mie 1971-1974 der Deutschen Arbeitsgemeinschaft f\u00fcr Leuk\u00e4mie-Forschung und -Behandlung im Kindesalter e.V. Klin P\u00e4diatr 1979; 191(2):114-126. \n (3)  Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, \nOdenwald E, Riehm H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14(12):2205-2222. \n (4)  Pinkel D, Simone J, Omar Hustu H, Aur R.J.A. Nine years experience with \"total \ntherapy\" of childhood acute lymphocytic Leukemia. Pediatrics 1972; 50(2):246-251. \n (5)  Riehm H, Gadner H, Welte K. [The west-berlin therapy study of acute lymphoblastic \nleukemia in childhood--report after 6 years ]. Klin Padiatr 1977; 189(8):89-102. \n (6)  Creutzig U, Ritter J, Riehm H, Langermann H-J, Henze G, Kabisch H, Niethammer D, \nJ\u00fcrgens J, Stollmann B, Lasson U, Kaufmann U, L\u00f6ffler H, Schellong G. Improved treatment results in childhood acute myelogenous leukemia: A report of the German \ncooperative study AML-BFM-78. Blood 1985; 65:298-304. \n (7)  Bielack S, Flege S, Kempf-Bielack B. Behandlungskonzept des Osteosarkoms. \nOnkologe  2000; 6:747-759. \n(8) Gutjahr P. Krebs bei Kindern und Jugendlichen. Alzen G, Bode U, Fleischhack G, \nGraf N, Gummich R, Haas RJ, Hasan C, Henze G, Hertl M, Humpl T, Keber W, \nKontny U, Kovar H, K\u00fchl J, Kutzner J, Lion T, Niemeyer C, Schmid I, Schmitt H-J, \nStachel D, Weinmann G, editors. Klinik und Praxis der P\u00e4diatrischen Onkologie.  24-611. 1999.\n(9) K\u00fchl J, M\u00fcller HL, Berthold F, Kortmann R.D., Deinlein F, Maa\u00df F, Graf N, Gnekow \nA, Scheurlen W, G\u00f6bel U, Wolff J, Bamberg M, Kaatsch P, Kleihues P, Rating D, \nS\u00f6rensen N, Wiestler OD. Pre-radiation chemotherapy of children and young adults \nwith malignant brain tumors: results of the German pilot trial HIT `88/`89. Klin P\u00e4diatr 1998; 210:227-233. \n (10)  Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the \nmanagement of Wilms' tumor. The SIOP studies. International Society of Pediatric \nOncology. Urol Clin North Am 2000; 27(3):443-454. 10Tabelle 1: Studien und Projekte der Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie \nProjekt/Studienbezeichnung Leitung \nStudien\n(1)  Akute lymphoblastische Leuk\u00e4mie \u2013  \nALL-BFM 2000 Prof. Dr. med. M. Schrappe, \nKinderklinik der MHH, Hannover \n(2)  Akute lymphoblastische Leuk\u00e4mie \u2013  \nCOALL-06-97 Frau Prof. Dr. med. G. Janka, \nUniv.-Kinderklinik Hamburg\n(3)  Akute lymphoblastische Leuk\u00e4mie- \nRezidive \nALL-REZ BFM 96 Prof. Dr. med. G. Henze, \nUniv.-Kinderklinik Berlin (Charit\u00e9) \n(4)  Akute Myeloische Leuk\u00e4mie \nAML-BFM 98 Prof. Dr. med. J. Ritter,  \nFrau Prof. Dr. med. U. Creutzig, Univ.-Kinderklinik M\u00fcnster  \n(5)  Schwere Aplastische An\u00e4mie \nSAA94Frau Dr. M. F\u00fchrer,  \nFrau Prof. Dr. med. Ch. Bender-G\u00f6tze, \nUniv.-Kinderklinik M\u00fcnchen  \n(6)  Chronische myeloische Leuk\u00e4mie bei Kindern \nCML-p\u00e4d 95/96 Prof. Dr. med. M. Suttorp, \nUniv.-Kinderklinik Dresden  \n(7)  Ewing-Sarkom \nEUROpean Ewing tumour Working Initiative of \nNational Groups \u2013 EURO-E.W.I.N.G. - 99 Prof. Dr. med. H. J\u00fcrgens, \nUniv.-Kinderklinik M\u00fcnster  \n(8)  Hepatoblastom \nHB 94 Prof. Dr. med. D. von Schweinitz,  \nUniv.-Kinderklinik Basel\n(9)  Hirntumoren Medulloblastome (HIT MED) PD Dr. med. J. K\u00fchl, \nUniv.-Kinderklinik W\u00fcrzburg  \n(10) Kraniopharyngeom (HIT-ENDO) PD Dr. med. Hermann M\u00fcller, \nSt\u00e4dt. Kinderklinik Oldenburg \n(11) Glioblastome hoch maligne (HIT \u2013 GBM) PD Dr. J.E.A. Wolff,  \nKinderklinik. St. Hedwig, Regensburg \n(12) Glioblastome niedrig maligne (HIT-LGG) Frau Dr. Astrid K. Gnekow, \nKinderklinik Augsburg (Zentralklinik) \n(13) Morbus Hodgkin \nTherapiestudie f\u00fcr den Morbus Hodgkin bei \nKindern und Jugendlichen \u2013 \nGPOH HD-2002 in Planung  Z. Zt. nicht besetzt\n(14) Maligne nichttestikul\u00e4re Keimzell-Tumoren  \nMAKEI 96 Prof. Dr. med. U. G\u00f6bel, \nUniv.-Kinderklinik D\u00fcsseldorf  \n(15) Testikul\u00e4re Keimzelltumoren  \nMAHO 98 Prof. Dr. med. U. G\u00f6bel, \nUniv.-Kinderklinik D\u00fcsseldorf \n(16) Maligne endokrine Tumoren \nMET 97 Prof. Dr. med. P. Bucsky, \nUniv.-Kinderklinik L\u00fcbeck  \n(17) Myelodysplastische Syndrome \n(einschl. CMML) \u201398 \nEWOG-MDS 98 Frau Prof. Dr. med. Ch. Niemeyer,  \nUniv.-Kinderklinik Freiburg i. Breisgau 11Projekt/Studienbezeichnung Leitung\nStudien\n(18) Nephroblastom (Wilms-Tumor) \nNephroblastom-Studie  \nSIOP 2002/GPOH Prof. Dr. Norbert Graf, \nUniv.-Kinderklinik Homburg/Saar  \n(19) Non-Hodgkin-Lymphom \nNHL-BFM 95 Prof. Dr. med. A. Reiter,\nUniv.-Kinderklinik Giessen  \n(20) Neuroblastom \nNB 97 Prof. Dr. med. F. Berthold,\nUniv.-Kinderklinik K\u00f6ln\n(21) Osteosarkom \nCOSS 96 PD Dr. med. Stefan Bielack, \nUniv.-Kinderklinik M\u00fcnster  \n(22) Weichteilsarkome  \nCWS-96 Prof. Dr. med. J. Treuner, \nKinderklinik Stuttgart (Olgahospital)  \n(23) Nasopharynx-Karzinom (98) Dr. med. R. Mertens,  \nUniv.-Kinderklinik Aachen \nDeutsches Kinderkrebsregister Prof. Dr. med. J. Michaelis, Dr. P. Kaatsch,  \nUniv. Mainz (IMBEI) \nRechnerunterst\u00fctze Therapieplanung und  \nDokumentation (DOSPO) Frau Dr. U. Kutscha, \nUniv. Heidelberg (Abteilung Medizinische \nInformatik)Zentrale \nEinrich-\ntungen und \nProjekte\nProjekt Sp\u00e4tfolgen (LESS) Prof. Dr. med. J.D. Beck, \nUniv.-Kinderklinik Erlangen\nCooperatives P\u00e4diatrisches  Prof. Dr. med. T. Klingebiel,  \nStammzelltransplantations-Register Univ.-Kinderklinik Frankfurt \nReferenz- Immunph\u00e4notypisierung Charite, RRK Berlin-Buch (Med. Klinik)  \nZentren Zytogenetik/ Molekulargenetik Univ.-Kinderklinik Giessen  \nZentrales Kinder-Tumorregister Univ. Kiel (Pathologie ) \nZentrales Lymphknotenregister Univ. Kiel (Pathologie ) \nHirntumor-Referenzzentrum  Univ. Bonn (Neuropathologie) \n Knochenmark ALL / ALL Rez(BFM)   Univ.-Kinderklinik Hannover / Berlin \n Knochenmark ALL(COALL) Univ.-Kinderklinik Hamburg  \n Knochenmark MDS Univ.-Kinderklinik Freiburg  \n Knochenmark AML / CML Univ.-Kinderklinik M\u00fcnster \n   \n   \nAbk\u00fcrzungen: Univ. Universit\u00e4t, IMBEI: Institut f\u00fcr Medizinische Biometrie, Epidemiologie und \nInformatik12Tabelle 2: 3-, 5-, 10- und 15-Jahres-\u00dcberlebenswahrscheinlichkeit und Wahrscheinlichkeit \nereignisfreien \u00dcberlebens (Sterbetafelverfah ren erg\u00e4nzt nach (1)) f\u00fcr die h\u00e4ufigsten \nDiagnosen (1980-2000) \nDiagnose Patienten Wahrscheinlichkeit \nzahl Ereignisfreie \u00dcberlebensrate \u00dcberlebensrate \n3 Jahre 5 Jahre 10 Jahre 3 Jahre 5 Jahre 10 Jahre \n     \nRetinoblastom 449 94 94 92 97 97 95\nMorbus Hodgkin 1462 87 86 84  97 95 93 \nKeimzelltumore 899 81 78 76 89 87 85\nNephroblastom 1661 80 80 79  87 86 85 \nNon-Hodgkin-Lymphom 1768 80 79 76 84 82 81\nAkute lymphoblastische Leuk\u00e4mie 7945 77 71 68  85 81 76 \nAstrozytom 1855 72 68 61 78 77 74\nNeuroblastom 2423 62 59 57  70 66 63 \nOsteosarkom 763 63 58 54 75 67 62\nRhabdomyosarkom 1004 58 55 53  69 63 60 \nEwing-Sarkom 542 61 55 51 71 64 58\nPeriphere neuroektodermale Tumore 1148 51 46 40  58 52 43 \nAkute myeloische Leuk\u00e4mie 1509 41 39 38 49 45 43\n        \n        \nAlle Erkrankungen  26609 70 66 63 78 74 7013Abbildungen\nKeimzeltumore\n3,5%\nNierentumore\n6,2%Knochentumore\n4,6%\nWeichteilsarkome\n6,4%\nTumore des \nsympatischen Nerven- \nsystem s\n8,7%Andere\n4,1%\nLymphome\n12,7%ZNS Tumore\n20,0%Leuk\u00e4mien\n33,8%\nAbbildung 1:  Relative H\u00e4ufigkei t der gemeldeten Patiente n nach den h\u00e4ufigsten Einzeldiagnosen (1991-\n2000) \nAbbildung 2: Anstieg der Wahrscheinlichkeit des Ereignisfreien \u00dcberlebens von Kindern und \nJugendlichen mit mit akuter lymphoblastischer Leuk\u00e4mieALL-BFM 70: .55, SE=.05 (N=  119,   54 Ereignisse)\nALL-BFM 83: .62, SE=.02 (N=  653, 239 Ereignisse)\nALL-BFM 86: .69, SE=.02 (N=  998, 293 Ereignisse)ALL-BFM 90: .76, SE=.01 (N=2178, 499 Ereignisse)JahreP\n0.00.10.20.30.40.50.60.70.80.91.0\n0123456789 1 0\nDAL 70-74:    .33, SE=.02 (N=  495, 326 Ereignisse)14Abbildung 3: Anstieg der \u00dcberlebensraten von Kindern und Ju gendlichen mit b\u00f6sart igen Erkrankungen \nseit 1940 (es wird nur eine 2 Jahres \u00dcberlebensrate angegeben, da es vor 1970 keine l\u00e4ngeren Verlaufsdaten \ngibt) \nAbbildung 4: Schematische Darstellung von aufeinander folgenden Therapiestudien am Beispiel \nder AML BFM Studien AML Studien: BFM-78/-83/-87/-93\nZNS-RT\nDauertherapie\nDauertherapie\n\u00b1 ZNS-RT / Dauertherapie\nZNS-RT / DauertherapieBFM-78\nBFM-83\nBFM-87\nBFM-93Induktion   /    Konsolidierung\nKonsolidierung Induktion\nInduktion\nInduktion    HAMKonsolidierung\nKonsolidierungIntensivierung\nIntensivierung\nTherapiedauer (Monate)ZNS-RT / DauertherapieBFM-98\nInduktion    HAM Konsolidierung IntensivierungZNS-RT1940 1950 1960 1970 1980 1990 20000102030405060708090100\nJahrZwei-Jahres-\u00dcberlebensraten Morbus Hodgkin\n Wilmstumor\n Akute lymphoblastische Leuk\u00e4mie\n Non-Hodgkin-Lymphom\n Ewingsarkom\n Osteosarkom\n Rhabdomyosarkom\n Maligne Keimzelltumoren\n Neuroblastom\n Hirntumoren\n Akute myeloische Leuk\u00e4mie\nJahr der DiagnoseAnteil \u00dcberlebender nach 2Jahren [%]15\nAbbildung 5: Analyse des metastasenfreien \u00dcberlebens: Vergleich der Studien COSS-77, COSS-80, \nCOSS-82-CPL und COSS-86 \nAbbildung 6: Wahrscheinlichkeit f\u00fcr das Ereignisfreie \u00dcberleben der Studienpatienten mit \nNephroblastomen in Jahren  \n(10)\nB.4 Abstracts of publications of network projects (published, in press or submitted) \nP Reference Abstract  \nA\nICreutzig U, Calaminus G.  \nVertikale Vernetzung in der \nP\u00e4diatrischen Onkologie.  \nOnkologe 6: 814-188, 2000 Die Strukturierung der medizinischen Versorgung bedarf einer Neuorien-\ntierung. Dies findet bereits im Bem\u00fchen der Gesundheitsreformer wie \nauch der Politik darin Ausdruck,Versorgungsnetzwerke zu errichten, die \neine Zusammenf\u00fchrung von Kompetenzen und die F\u00f6rderung des Auf-\nbaus \u00fcbergeordneter Funktionen erm\u00f6glichen. Ziel ist es, sowohl eine \nbessere horizontale Vernetzung der Fachdisziplinen, die in die Behand-\nlung von Patienten involviert sind, zu erhalten, als auch den Informations-\nfluss \u00fcber Erkrankung, Therapie und d en Erfolg der Rehabilitation \u2013 z.B. \nnach einer Krebserkrankung \u2013 f\u00fcr den nachbetreuenden Arzt abrufbar zu \nmachen.Dies betrifft sowohl die Information \u00fcber den individuellen Patien-\nten als auch generell Informationen zum Erkrankungsbild und dem \u201estate \nof art\u201c der Diagnostik und Behand lung. Diese Aspekte werden mit dem \nBegriff der vertikalen Vernetzungumsc hrieben. In der Patientenver-\nsorgung wird hierunter die Verbindung zwischen der spezialisierten \nmedizinischen Versorgung und dem medizinischen Alltag verstanden. \nSpezialwissen soll f\u00fcr die niedergelassenen Fachdisziplinen einfach und \nschnell erh\u00e4ltlich sein. F\u00fcr die P\u00e4diatrische Onkologie und H\u00e4matologie \nist die Bedeutung dieser vertikalen Vernetzung f\u00fcr die Gestaltung der \ngenerellen Patientenversorgung weniger entscheidend als f\u00fcr andere \nspezielle Fachgruppen, bei denen gro\u00dfe Patientenzahlen betroffen sind.  \nB/1 Knaup P, Harkener S, Ells\u00e4sser K.-H, \nHaux R, Wiedemann T.  \nOn the necessity of systematically \nplanning clinical tumor documentation.  \nMeth Inform Med 2001;40, 90-98 Tumor documentation is an important task for both clinical research and \npatient care. Documentation systems de signed for this purpose should be \ngoal-oriented and must be planned systematically. We applied the so-\ncalled 'standardized documentation protocol' method to the systematic \nplanning of two documentation systems in oncology: one for the tumor \ncenter Heidelberg/Mannheim, and the other for a nationwide project in the \nfield of documentation and therapy planning in pediatric oncology. The \nmethod proved to be helpful in both cases, even though the resulting \ndocumentation protocols are completely different and served different \nobjectives. Therefore, the aim of this paper is to help medical informatics \nprofessionals and motivate them to systematically plan other documenta-\ntion systems by using this method.  \nB/1 Merzweiler A, Ehlerding H, Creutzig U, \nGraf N, Hero B, Kaatsch P, Zimmer-\nmann M, Weber R, Knaup P. (2002) \nTerminologiestandardisierung in der \nP\u00e4diatrischen Onkologie - der Basisda-\ntensatz. Klinische P\u00e4diatrie (submitted)  Background: Within the scope of more than 20 therapy-optimizing clinical \nstudies in pediatric oncology, extensive documentation and vast amounts \nof case report forms have been developed within the past 20 to 25 years. \nWithin these studies, information is often captured in different termino-\nlogical ways, making patient documentation in clinics more difficult. \nMethod: The terminology used in therapy-optimizing clinical studies of the \nGerman Society for Pediatric Oncology and Hematology (GPOH) is to be \nstandardized by a central \u201estandards committee\u201c. Result: As a first result, \nthe basic data set of the GPOH was revised and made available via \nhttp://www.dospo.uni-hd.de. Conclusion: The base for a unique documen-\ntation language in pediatric oncology has been made available to German \nspeaking institutions. \nB/1 Merzweiler A, Knaup P, Creutzig U, \nEhlerding H, Haux R, Mludek V, Schil-\nling FH, Weber R, Wiedemann T. \n(2000).  \nRequirements and Design Aspects of a \nData Model for a Data Dictionary in \nPaediatric Oncology.  \nIn: Hasman, A, Blobel, B, Dudeck, J. et \nal. (Hrsg.). Medical Infobahn for Eu-\nrope, 696-700. Amsterdam: IOS Press. German children suffering from cancer are most often treated within the \nframework of multi-centered clinical trials. Extensive information and \nknowledge exchange is important in conducting these trials, which should \nbe based on a standardized documentation. To support this effort, a na-\ntionwide project aims to define a standardized terminology that should be \nused for therapy documentation in clinical trials. In order to support termi-\nnology maintenance, we are currently developing a data dictionary. In this \npaper, we will describe the requirements and design aspects of the data \nmodel used for the data dictionary as first results of our research. Also, \nwe will compare it to other terminology systems. \nB/1 Knaup P, Mludek V, Wiedemann T, \nBauer J, Haux R, Kim L, Schilling FH, \nSelle B. (2000).  \nIntegrating Specialized Application \nSystems into Hospital Information Sys-\ntems -Obstacles and Factors for Suc-\ncess.\nIn:Hasman, A, Blobel, B, Dudeck, J. et \nal. (Hrsg.). Medical Infobahn for Hospital information systems are often huge and heterogeneous systems. \nTo support physicians in their daily clinical work, dedicated application \nsystems are being developed for particular medical fields or tasks. These \nsystems must be integrated into the standing hospital information sys-\ntems. The integration process is quite complicated, because it makes the \ninformation system's infrastructure even more heterogeneous. We have \ndeveloped an application system for documentation and therapy planning \nin pediatric oncology (DOSPO). We have introduced the system in the \nDepartment of Pediatric Oncology of Heidelberg University Hospital. The \nfact that DOSPO has been developed as a universal system for nation-77P Reference Abstract  \nEurope, 890-894. Amsterdam: IOS \nPress.wide use made the integration process more difficult. In any case, the \nintroduction of specialized application systems must be systematically \nplanned in advance. Special, regard must be given the available re-\nsources and established processes of the prevailing information system. \nTo simplify the integration process, comprehensive future electronic pa-\ntient records should be designed in a way that allows easy enhancement \nof new clinical functions. \nB/1 Merzweiler A, Knaup P, Weber R, Eh-\nlerding H, Haux R, Wiedemann, T. \n(2001).  \nRecording clinical data - from a general \nset of record items to case report forms \n(CRF) for clinics.  \nIn: Patel, V, Rogers, R, Haux, R. \n(Hrsg.). MEDINFO 2001. Proceedings \nof the 10th World Congress on Medical \nInformatics, 653-657. Amsterdam: IOS. Standardizing a documentation language only makes sense if it is used \nconsequently for documentation. An example from German pediatric \noncological is the development of a procedure that generates CRFs from \na documentation language. The introduced procedure has proven feasi-\nble in practice. With it, we can support developers of documentation sys-\ntems in creating CRFs. Through guaranteed use of the documentation \nterminology, we further achieve that information recorded with the created \nCRFs can be analyzed statistically across different institutions. \nB/1 Weber R, Knaup P, Knietig R, Haux R, \nMerzweiler A, Mludek V, Schilling FH, \nWiedemann T. (2001).  \nObject-oriented business process \nanalysis of the Cooperative Soft Tissue \nSarcoma Trial of the German Society \nfor Paediatric Oncology and Haematol-\nogy (GPOH).  \nIn: Patel, V, Rogers, R, Haux, R. \n(Hrsg.). MEDINFO 2001. Proceedings \nof the 10th World Congress on Medical \nInformatics, 58-62. Amsterdam: IOS. The German Society for Pediatric Oncology and Hematology (GPOH) \nruns national multi-centered clinical trials to improve the treatment of \nchildren suffering from malignant diseases. Our goal is to provide meth-\nods and tools to support the trial centers in developing study-specific \nmodules for the computer-based DOcumentation System for Paediatric \nOncology (DOSPO). For this purpose, we have carried out an object-\noriented business process analysis of the Cooperative Soft Tissue Sar-\ncoma Trial at the Olga Hospital for Child and Adolescent Medicine, Stutt-\ngart, Germany. A comprehensive business process model resulted con-\nsisting of UML diagrams and use case specifications. We recommend \nobject-oriented business process analysis as a method for defining re-\nquirements of information processing projects in the general field of clini-\ncal trials. Our model could serve as a basis for this purpose, because only \nslight adjustments are required for each type of clinical study. \nB/2 Pommerening K.  \nIT-Sicherheit in medizinischen Netzen -\n- aktuelle Probleme und L\u00f6sungsans\u00e4t-ze.\nZentralbl Gynakol 122: 658-662, 2000. Designers and users of medical networks have to face strong require-\nments for data protection and security. Professional discretion and data \nprotection laws allow the transfer of or access to patient data only in a therapeutic context. These data should also be protected from the net-\nwork provider. Patients should be safe from any harm by faulty data or \nbuggy procedures. On the other hand the security of the most used soft-\nware products gets worse and worse. The use of the internet more and \nmore endangers the integrity of the user's computer. The security re-\nquirements can be met only through strict care in planning, building, and \nconfiguring the infrastructure. Some concrete recommendations and \nguiding principles can immediately be realized. If these recommendations \nare followed, the internet can be of immense value for health care. \nD Stahnke K, Mohr A, Liu J, Schneider M, \nDebatin KM:\nFlowcytometric detection of mitochon-\ndrial cytochrome c release identifies \ndeficient mitochondrial apoptosis sig-\nnaling in leukemia cells Deficient activation of apoptosis sign aling pathways may be responsible \nfor drug resistance and treatment failure of malignant diseases. We de-\nveloped a method for the detection of cytochrome c release in intact cells \nby flow cytometry. In Jurkat T cell leukemia cells mitochondrial cyto-\nchrome c release could be detected in CD95 receptor or cytotoxic drug \ninduced apoptosis. A good correlation was found to results obtained in \nconventional immunoblotting and fl uorescence microscopy. Differential \nrequirement for mitochondrial signaling in CD95 induced apoptosis in \nSKW (type I) and Jurkat (type II) was detected by the method. By simul-\ntaneous measurement of cytochrome c release and active caspase-3 in \nmulticolor flowcytometry, we identified deficient mitochondrial apoptosis \nsignaling in the presence of caspase-3 activation in Jurkat cells overex-\npressing Bcl-2. In addition, we found the method to be applicable for analysis of primary leukemia cells identifying heterogeneous patterns of \nmitochondrial signaling and caspase activation. Flowcytometric analysis \nof mitochondrial cytochrome c release is a valuable tool for the analysis of \nmitochondrial apoptosis resistance mechanisms in leukemia.  \nD Stahnke K, Eckhoff S, Mohr A, Debatin \nKM:\nChemotherapy induces depletion and \napoptosis predominantly in a CD34 \npositive subset of leukemia cells The initial response to induction chemotherapy is one of the major prog-\nnostic factors in acute leukemia. Chemotherapy in vivo eliminates leuke-\nmia cells from bone marrow and peripheral blood possibly by induction of \napoptosis. It has recently been shown that leukemia arises from immature \nleukemia stem cells positive for CD34 and negative for CD38. We there-\nfore analyzed depletion and induction of apoptosis in the subset of CD34 78P Reference Abstract  \npositive in peripheral blood leukemia cells from patients with ALL and \nAML undergoing first cycle chemotherapy. We found expression of CD34 \non leukemic blasts in 23 of 24 cases analyzed. The proportion of leuke-\nmia cells expressing CD34 varied from 0% to 87% in AML and 1.5% to \n74.5% in ALL patients. During induction chemotherapy, CD34+ leukemia \ncells were more rapidly depleted than CD34- cells. Furthermore, in vivo \nchemotherapy induced a significant increase of in vitro apoptosis after \n24hours in this immature subpopulation. Interestingly, without differentiat-\ning mature and immature leukemia cells according to their CD34 status, \nno effect on in vitro apoptosis could be detected during in vivo chemo-\ntherapy. In vitro treatment with cytarabin again resulted in predominant \ninduction of apoptosis in CD34 positive leukemia cells in ALL and AML \nsamples. CD95 expression and sensitivity on both CD34 positive and \nnegative subpopulations remained low during in vivo chemotherapy and \nupon in vitro drug treatment, suggesting induction of apoptosis independ-\nent of the CD95 system. Thus induction of apoptosis by in vivo chemo-\ntherapy targets an immature subpopulation of leukemia cells during re-\nmission induction. Analysis of differential chemosensitivity of leukemia \ncell subpopulations could enhance the predictive value of in vitro drug \ntesting assays for response to treatment.  \nD Wuchter C, Ruppert V, Schrappe M, \nDorken B, Ludwig WD, Karawajew L.  \nIn vitro susceptibility to dexa-\nmethasone- and doxorubicin-induced \napoptotic cell death in context of matu-\nration stage, responsiveness to IL-7 \nand early cytoreduction in vivo in child-\nhood T-ALL.  \nBlood 2002, in press  Within childhood T-ALL, patients with a cortical (CD1a positive) immuno-\nphenotype have been identified as a subgroup with favorable outcome in \nthe ALL-BFM, COALL and POG studies. We investigated in leukemic samples of children with T-ALL (n=81) whether the different in vivo ther-\napy response could be linked to differential in vitro susceptibility to apop-\ntotic cell death. The extent of dexamethasone- as well as doxorubicin-\ninduced apoptosis, detected by annexin V-staining, positively correlated \nwith the expression levels of CD1a (Spearman correlation coefficient, rs = \n0.3 and 0.4, respectively; p<0.01). When compared to cortical T-ALL, \nmature (CD1a negative, surface CD3 positive) T-ALL were significantly \nmore resistant to doxorubicin, and immature, pro-/pre-T-ALL were more \nresistant to both drugs (p<0.05). Apoptosis-related parameters (Bax, Bcl-\n2, CD95 and CD95-induced apoptosis) did not account for differential \nsusceptibility to drug-induced apoptosis. By contrast, an IL-7 induced \nrescue of leukemic cells from spontaneous apoptosis, recently proposed \nto reflect distinct developmental stages and apoptotic programs in T-ALL, \nwas highly associated with susceptibility to dexamethasone- but not \ndoxorubicin-induced apoptosis (p<0.001 vs. p=0.08). Analysis of clinical \ndata showed that in vitro susceptibility to dexamethasone (but not to \ndoxorubicin) closely correlated with early in vivo therapy response char-\nacterized by percentages of blast cells in bone marrow on day 15 (rs = -\n0.46, p=0.001). Taken together, the in vitro assessment of drug-induced \napoptosis revealed maturation-depende nt differences within childhood T-\nALL. The enhanced sensitivity to both drugs in cortical T-ALL might ac-\ncount for the better in vivo treatment response of this prognostically fa-\nvorable T-ALL subgroup. \nD Stahnke K, Fulda S, Friesen C, Strauss \nG, Debatin KM  \nActivation of apoptosis pathways in \nperipheral blood lymphocytes by in vivo \nchemotherapy \nBlood 2001,98:3066-7330 In addition to myelosuppression, anticancer drugs cause rapid and persis-\ntent depletion of lymphocytes, possibly by direct apoptosis induction in \nmature T and B cells. Induction of apoptosis regulators was analyzed in \nperipheral blood lymphocytes from pediatric patients undergoing first-\ncycle chemotherapy for solid tumors. In vivo chemotherapy induced a \nsignificant increase in lymphocyte apoptosis ex vivo. The activation of \ninitiator caspase-8 and effector caspase-3 and the cleavage of caspase \nsubstrates was detected 12 to 48 hours after the onset of therapy. Cas-\npase inhibition by Z-VAD-fmk did not reduce ex vivo lymphocyte apop-\ntosis in all patients, indicating the additional involvement of caspase-\nindependent cell death. No evidence for the involvement of activation-\ninduced cell death was found in the acute phase of lymphocyte depletion \nas analyzed by activation marker expression and sensitivity for CD95 \nsignaling. Lymphocyte apoptosis in vivo appeared to be predominantly \nmediated by the mitochondrial pa thway because a marked decrease of \nmitochondrial membrane potential (DeltaPsi(M)) was detected after 24 to \n72 hours of treatment, preceded by the increased expression of Bax. \nInterestingly, despite the use of DNA-damaging agents, p53 remained \ncompletely undetectable throughout treatment. In contrast, in vitro treat-\nment with cytarabine and etoposide induced p53 protein, CD95 receptor \nexpression, CD95 sensitivity, and CD95 receptor-ligand interaction in \nstimulated cycling lymphocytes, but no such induction was seen in resting \ncells. These data suggest that chemotherapy-induced lymphocyte deple-79P Reference Abstract  \ntion involves distinct mechanisms of apoptosis induction, such as direct \nmitochondrial and caspase-dependent pathways in resting cells and p53-\ndependent pathways in cycling lymphocytes. \nD Wuchter C, Krappmann D, Cai Z, Rup-\npert V, Scheidereit C, Dorken B, \nLudwig WD, Karawajew L  \nIn vitro susceptibility to TRAIL-induced \napoptosis of acute leukemia cells in the \ncontext of TRAIL receptor gene ex-\npression and constitutive NF-kappa B \nactivity.   \nLeukemia  2001,15:921-8 The TNF-related apoptosis-inducing ligand (TRAIL) is currently under \nevaluation as a possible (co-)therapeutic in cancer treatment. We there-\nfore examined 129 cell samples from patients with de novo acute leuke-\nmia as to their constitutive susceptibility to TRAIL-induced apoptosis In \nvitro. Only 21 (16%) cell samples revealed at least 10% TRAIL-\nsusceptible cells/sample as detected by flow cytometric annexinV staining \nafter 24 h culture compared with medium control. Precursor B cell ALL \nsamples (11 (27%) of 41) were more TRAIL-susceptible compared with \nAML (5 (9%) of 54; P < 0.05) but not compared with precursor T cell ALL \n(5 (15%) of 34; P = 0.20). Furthermore, we examined constitutive mRNA \nexpression levels of TRAIL receptors R1-R4 by semi-quantitative RT-\nPCR (n = 58). Expression levels were heterogeneous, however, there \nwas no significant correlation between the expression of the signal-\ntransducing receptors (R1, R2) as well as of the decoy receptors (R3, R4) \nand TRAIL sensitivity in this series. Constitutive NF-kappa B activity has \nbeen shown to influence TRAIL susceptibility of leukemic cells. In 39 \nleukemic cell samples examined, we found a generally high NF-kappa B \nactivity as detected by electrophoretic mobility shift assay which did not \ndiffer between TRAIL-susceptible and TRAIL-resistant cases. Finally, 49 \nacute leukemic cell samples were coin cubated with doxorubicin in vitro. \nDoxorubicin sensitized four of 35 initially TRAIL-resistant samples and \naugmented TRAIL-induced apoptosis in two of 14 TRAIL-susceptible \nsamples. In summary, constitutive TRAIL susceptibility differs between \nleukemia subtypes and does not correlate with mRNA expression levels \nof the TRAIL receptors R1-R4 as well as constitutive NF-kappa B activa-\ntion status. The observed sensitization of leukemic cells to TRAIL by \ndoxorubicin in vitro indicates that TRAIL should be further evaluated as to \nits possible role as an in vivo cotherapeutic in acute leukemia. \nD Cai Z, Lin M, Wuchter C, Ruppert V, \nDorken B, Ludwig WD, Karawajew L \n Apoptotic response to homoharring-\ntonine in human wt p53 leukemic cells \nis independent of reactive oxygen spe-\ncies generation and implicates Bax \ntranslocation, mitochondrial cytochrome \nc release and caspase activation.  \nLeukemia  2001;15:567-74   In the present study, we investigated the in vitro apoptotic response of \nleukemic cells to the cellular stress induced by homoharringtonine (HHT), \na plant alkaloid with antileukemic activity which is currently being tested \nfor treatment of acute and chronic leukemias. A comparison of leukemic \ncell lines with different p53 gene status revealed a considerably higher \nsensitivity to HHT-induced apoptosis in the cells with a wt p53, and apop-\ntotic events in wt p53 leukemia cells (MOLT-3 cell line) were studied in \nmore detail. To this end, we examined components of apoptotic cascades \nincluding Bax expression and its intracellular localization, changes of \nmitochondrial membrane potential (MMP), reactive oxygen species (ROS) \nlevels, cytochrome c release from mitochondria and activation of cas-\npases. Bax protein levels did not increase despite an up-regulation of bax \nat mRNA level. However, Bax translocation from cytosol towards mito-\nchondria was observed. In addition, we observed a release of cytochrome c from the mitochondria, and the localization changes of both Bax and \ncytochrome c were found already at the early, annexin V-negative stage \nof HHT-induced apoptosis. HHT-treated MOLT-3 cells revealed loss of \nMMP as well as activation of caspases demonstrated by DEVD-, IETD- \nand LEHD-tetrapeptide cleavage activity in the cell lysates. ROS levels \nonly slightly increased in HHT-treated cells and antioxidants did not pre-\nvent apoptosis and MMP changes. Therefore, wt p53 leukemic cells re-\nspond to HHT-specific cellular stre ss by induction of ROS-independent \napoptotic pathway characterized by translocation of Bax, mitochondrial \ncytochrome c release and activation of caspases. \nD Wuchter C, Karawajew L, Ruppert V, \nSchrappe M, Harbott J, Ratei R, \nDorken B, Ludwig WD. \nConstitutive expression levels of CD95 \nand Bcl-2 as well as CD95 function and \nspontaneous apoptosis in vitro do not \npredict the response to induction che-\nmotherapy and relapse rate in child-\nhood acute lymphoblastic leukaemia  \nBr J Haematol 2000;110:154-60 CD95 (Fas/APO-1) expression and function and Bcl-2 expression, as well \nas spontaneous apoptosis in vitro, have been shown to be predictive \nmarkers for the in vivo response to chemotherapy in acute myeloid leu-\nkaemia (AML). To determine the clinical significance of apoptosis-\nregulating factors in acute lymphoblastic leukaemia (ALL), we investi-\ngated cell samples of children with ALL who had been included in the \nGerman ALL Berlin-Frankfurt-Munster (BFM) study using flow cytometry \nfor constitutive expression levels of CD95 (n = 110) and Bcl-2 (n = 110). \nFurthermore, we determined the extent of spontaneous apoptosis in vitro \n(n = 102) and susceptibility to anti-CD95-induced apoptosis (CD95-\nsensitivity) (n = 97). We correlated these findings with the functional activ-\nity of the multidrug resistance (MDR)-associated P-glycoprotein (P-gp), as \ndetected by the rhodamine123 efflux  test, immunophenotype, cytogenet-\nics and clinical data of the patients examined. Good responders to initial 80P Reference Abstract  \nprednisone therapy ('prednisone response') revealed significantly higher \nBcl-2 expression levels [5.4 +/- 3.4 relative fluorescence intensity (RFI), n \n= 68] than poor responders (3.7 +/- 2.6 RFI, n = 42; P = 0.002). There \nwas no significant correlation between the other investigated parameters \nand prednisone response. Moreover, neither the CD95 and Bcl-2 expres-\nsion levels nor the extent of spontaneous apoptosis in vitro, CD95 sensi-\ntivity or P-gp function were correlated with the response to induction \nchemotherapy or relapse rate, either for B-cell precursor ALL or T-cell \nALL. No consistent pattern of change in CD95 (n = 10) and Bcl-2 expres-\nsion (n = 9) was noted in cases studied at both initial diagnosis and re-\nlapse. In conclusion, our findings underline the different cell biological \nfeatures of primary AML and ALL cells. \nD Karawajew L, Ruppert V, Wuchter C, \nKosser A, Schrappe M, Dorken B, \nLudwig WD.  \nInhibition of in vitro spontaneous apop-\ntosis by IL-7 correlates with bcl-2 up-\nregulation, cortical/mature immunophe-\nnotype, and better early cytoreduction \nof childhood T-cell acute lymphoblastic \nleukemia.   \nBlood  2000;96:297-306   In normal T-cell development, IL-7 plays a nonredundant role as an an-\ntiapoptic factor by regulating Bcl-2 ex pression in pro-T cells. In the current \nstudy, we addressed the roles of IL-7 and related cytokines as apoptosis-\nmodulating factors in precursor T-cell acute lymphoblastic leukemia (T-\nALL). To this end, leukemic blasts from pediatric patients with T-ALL were \nprospectively investigated as to their responsiveness to IL-7, IL-4, and IL-\n2 (in terms of modulation of spontaneous apoptosis, assessed by flow \ncytometry), cytokine receptor expression profiles, and expression levels \nof Bcl-2 and Bax proteins. IL-7, in contrast to IL-4 and IL-2, was highly \nefficient in apoptosis inhibition, and this effect correlated with the expres-\nsion levels of IL-7Ralpha chain and with the up-regulation of Bcl-2 protein \nexpression (P <.0001). Subclassification of T-ALL samples (n = 130) \naccording to their in vitro IL-7 responses revealed that IL-7 refractory \nsamples were more frequently positive for CD34 (P <.0001) and the mye-\nloid-associated antigen CD33 (P =.01), whereas IL-7 responsiveness was \nassociated with an expression of more mature differentiation-associated \nT-cell antigens (CD1a, surface CD3, CD4/8; P <.05). Furthermore, the \nextent of apoptosis inhibition by IL-7 in vitro quantitatively correlated with \nearly cytoreduction as determined by the prednisone peripheral blood \nresponse on day 8 and cytoreduction in the marrow on day 15 (n = 87; P \n<.05). Multivariate analysis of the apoptosis-related parameters investi-\ngated, including spontaneous apoptosis, its inhibition by IL-7, and expres-\nsion levels of Bcl-2 and Bax, showed that only IL-7 responsiveness has \nan independent impact on early cytore duction (P <. 05), thus indicating a \npotential prognostic relevance of IL-7 sensitivity in T-ALL. \nD Fulda S, Kufer MU, Meyer E, van Valen \nF, Dockhorn-Dworniczak B, Debatin \nKM.\nSensitization for death receptor- or \ndrug-induced apoptosis by re-\nexpression of caspase-8 through de-\nmethylation or gene transfer.  \nOncogene  2001;20:5865-77 Resistance of tumors to treatment with cytotoxic drugs, irradiation or \nimmunotherapy may be due to disrupted apoptosis programs. Here, we \nreport in a variety of different tumor cells including Ewing tumor, neuro-\nblastoma, malignant brain tumors and melanoma that caspase-8 expres-\nsion acts as a key determinant of sensitivity for apoptosis induced by \ndeath-inducing ligands or cytotoxic drugs. In tumor cell lines resistant to \nTRAIL, anti-CD95 or TNFalpha, caspase-8 protein and mRNA expression \nwas decreased or absent without caspase-8 gene loss. Methylation-specific PCR revealed hypermethylation of caspase-8 regulatory se-\nquences in cells with impaired caspase-8 expression. Treatment with the \ndemethylation agent 5-Aza-2'-deoxyc ytidine (5-dAzaC) reversed hyper-\nmethylation of caspase-8 resulting in restoration of caspase-8 expression \nand recruitment and activation of caspase-8 at the CD95 DISC upon \nreceptor cross-linking thereby sensitizing for death receptor-, and impor-\ntantly, also for drug-induced apoptosis. Inhibition of caspase-8 activity \nalso inhibited apoptosis sensitization by 5-dAzaC. Similar to demethyla-\ntion, introduction of caspase-8 by gene transfer sensitized for apoptosis \ninduction. Hypermethylation of caspase-8 was linked to reduced caspase-\n8 expression in different tumor cell lines in vitro and, most importantly, \nalso in primary tumor samples. Thus, these findings indicate that re-\nexpression of caspase-8, e.g. by demethylation or caspase-8 gene trans-\nfer, might be an effective strategy to restore sensitivity for chemotherapy- \nor death receptor-induced apoptosis in various tumors in vivo. \nD Fulda S, Meyer E, Debatin KM.   \nMetabolic inhibitors sensitize for CD95 \n(APO-1/Fas)-induced apoptosis by \ndown-regulating Fas-associated death \ndomain-like interleukin 1-converting \nenzyme inhibitory protein expression.   \nCancer Res  2000;60:3947-56    Protein or RNA synthesis inhibitors are known to sensitize some resistant \ncells for death receptor-induced apoptosis. However, the molecular \nmechanism(s) involved in sensitization have not yet been defined exactly. \nHere, we report that metabolic inhibitors such as cycloheximide (CHX) or \nactinomycin D (ActD) sensitize for CD95-induced apoptosis by strongly \ndown-regulating FLIP and RIP expression. Metabolic labeling studies \nrevealed that CHX or ActD inhibited protein or RNA synthesis at concen-\ntrations required for sensitization. In contrast to Fas-associated death \ndomain (FADD) or caspase-8, FADD-like interleukin 1-converting en-81P Reference Abstract  \nzyme-inhibitory protein (FLIP) and RIP protein levels rapidly decreased \nupon treatment with CHX or ActD, indicating that both molecules have a \nhigh turnover rate. Selective down-regu lation of FLIP expression by FLIP \nantisense oligonucleotides sensitized for CD95-induced apoptosis. Re-\nduction of FLIP levels resulted in undetectable amounts of FLIP at the \nCD95 death-inducing signaling complex (DISC) upon CD95 stimulation, \nthereby enhancing the recruitment of caspase-8 to the DISC and cas-\npase-8 activation. CHX- or ActD-mediated sensitization to CD95-induced \napoptosis was predominantly found in type I cells in which FADD and \ncaspase-8 are recruited to CD95 upon stimulation but not in type II cells \nin which no DISC formation is detected. Pretreatment with CHX or ActD \nsensitized for subsequent CD95 stimulation compared with cells without \npretreatment. CHX or ActD also reduced XIAP expression and similarly \nsensitized for tumor necrosis factor-related apoptosis-inducing ligand- or \ntumor necrosis factor-alpha-induced apoptosis. Because blockade of \ndeath receptor triggering by FLIP overexpression has recently been impli-\ncated in tumorigenesis and treatment resistance in vivo, strategies to \ninhibit FLIP expression, e.g., by metabolic inhibitors, may prove to be a \nuseful complementary tool for the treatment of cancer. \nD Beltinger C, Fulda S, Kammertoens T, \nUckert W, Debatin KM.  \nMitochondrial amplification of death \nsignals determines thymidine \nkinase/ganciclovir-triggered activation \nof apoptosis.  \nCancer Res  2000;60:3212-7  Previous clinical experience shows that the efficacy of suicide gene trans-\nfer in tumor therapy is limited, resulting from inefficient gene transfer or \nalternatively, from intrinsic resistance of the tumor in vivo. Herpes simplex \nvirus thymidine kinase/ganciclovir (TK/GCV), a paradigmatic suicide gene therapy system, has been described to exert its cytotoxic effect, at least in \npart, by inducing apoptosis in target cells. Here, we report that mitochon-\ndria amplify TK/GCV-induced apoptosis by regulating p53 accumulation \nand the effector phase of apoptosis. Treatment with TK/GCV led to mito-\nchondrial perturbations including loss of the mitochondrial membrane \npotential and release of cytochrome c from mitochondria into the cytosol, \ninducing caspase activation and nuc lear fragmentation. Inhibition of \nTK/GCV-induced mitochondrial perturbations by Bcl-2 overexpression or \nby the mitochondrion-specific inhibitor bongkrekic acid also strongly inhib-\nited TK/GCV-induced activation of caspases and apoptosis. TK/GCV-\ninduced mitochondrial perturbations depended on caspase activity possi-\nbly initiated by death receptor signaling. Perturbation of mitochondrial \nfunction mediated accumulation of wild-type p53 protein, since Bcl-2 \noverexpression, bongkrekic acid, or inhibition of mitochondrial protein \nsynthesis with chloramphenicol strongly reduced TK/GCV-induced accu-\nmulation of wild-type p53 protein. These findings suggest that TK/GCV \ntherapy may be less efficient in tumo rs in which the mitochondrial amplifi-\ncation of TK/GCV-induced apoptosis is blocked, e.g., by Bcl-2 overex-\npression. Given the low efficacy of currently used gene therapy systems, \nour data on molecular mechanisms that regulate sensitivity or resistance \ntoward TK/GCV-induced cytotoxicity might have important implications to \nimprove the clinical application of suicide gene therapy. \nE Tschan CA, Pilz C, Zeidler C, Welte K, \nGermeshausen M.\nTime course of increasing numbers of \nmutations in the granulocyte colony-\nstimulating factor receptor gene in a \npatient with congenital neutropenia who \ndeveloped leukemia.  \nBlood 97: 1882-84, 2001  Point mutations in the granulocyte colony-stimulating factor receptor (G-\nCSFR) gene have been linked to the development of secondary leukemia \nin patients with congenital neutropenia (CN). This report presents data on \na now 18-year-old patient with CN who has received G-CSF treatment \nsince 1989 and who developed acute myeloid leukemia (AML) in 1998. \nTo evaluate whether there is an association between the occurrence of \npoint mutations of the G-CSFR gene and development of secondary \nAML, DNA/messenger RNA of neutrophils and mononuclear cells from \nthis patient were analyzed at different time points by polymerase chain \nreaction and subsequent cloning by DNA sequencing of representative \nnumbers of individual clones. Findings suggest an increasing instability of \nthe G-CSFR gene in time as judged by increasing numbers of mutations \nproposed to be one important step in the development of AML in this \npatient. \nE Germeshausen M, Ballmaier M, Welte \nK.\nImplications of mutations in hematopoi-\netic growth factor receptor genes in \ncongenital cytopenias.  \nAnn NY Acad Sci 938: 305-21, 2001 Mutations in the genes of hematopoietic growth factor receptors as a \ncause of congenital cytopenia, such as congenital amegakaryocytic \nthrombocytopenia (CAMT) or severe congenital neutropenia (CN), are \ndiscussed. There are striking differences in the relevance of receptor \nmutations in these diseases. CAMT is a rare disease characterized by \nsevere hypomegakaryocytic thrombocytopenia during the first years of life \nthat develops into pancytopenia in later childhood. In patients with CAMT, \nwe found inherited mutations in c-mpl, the gene coding for the throm-\nbopoietin receptor, in 8 out of 8 cases. The type of mutation seems to \ncorrelate with the clinical course seen in the patients. Functional studies 82P Reference Abstract  \ndemonstrated defective thrombopoietin (TPO) reactivity in hematopoietic \nprogenitor cells and platelets in CAMT patients. CN is a group of hemato-\npoietic disorders characterized by profound, absolute neutropenia due to \na maturation arrest of myeloid progenitor cells. About 10% of all patients \ndevelop secondary MDS/leukemia. The malignant progression is associ-\nated with acquired nonsense mutations within the G-CSF receptor gene \nthat lead to the truncation of the carboxy-terminal cytoplasmic domain of \nthe receptor protein involved in maturation of myeloid progenitor cells. \nThis seems to be one important step in leukemogenesis in CN patients. \nCAMT is caused by inherited mutations in c-mpl, the gene for the throm-\nbopoietin receptor, which lead to reduc ed or absent reactivity to TPO. In \ncontrast, mutations in the G-CSF receptor in CN are acquired and are \nmost probably connected with progression of the neutropenia into \nMDS/leukemia as a result of a loss of differentiation signaling.  \nE Jung A, Ruckert S, Frank P, Brabletz T, \nKirchner T.  \n7-deaza-2`-deoxyguanosine allows \nPCR and sequencing from CpG is-\nlands.\nMol Path 55, 55-57, 2001  CpG islands are GC-rich sequences which are found in many promoters \nof higher eukaryotes. They contain CG dinucleotides at high frequency \nwhich are substrates for DNA methylases. Methylation leads to transcrip-\ntional silencing of promoters. Due to the high GC content CpG islands \nexhibit strong base-base interactions which lead to super-structures and \nconsequently to regions with higher melting temperatures. Therefore, \nTaq-polymerases and especially sequenases fall of their templates caus-\ning premature termination of PCR or sequencing reactions. The results \nfrom such reactions are thus insufficient for further analysis. We have \ntherefore evaluated the usage of 7-deaza-2\u00b4-deoxyguanosine for PCR \namplification of the human p16INK4A promoter and sequencing of \nHUMARA exon 1 PCR products. Our results show that addition of 7-\ndeaza-2\u00b4-deoxyguanosine significantly improves results particularly when \nsmall amounts of poor quality DNA are available as starting material.  \nE Rischewski J, Schneppenheim R. \nScreening strategies for a highly poly-\nmorphic gene: DHPLC analysis of the \nFanconi anemia group A gene.  \nJ Biochem Biophys Methods 30;47:53-\n64, 2001 Introduction: Patients with Fanconi anemia (Fanc) are at risk to develop \nleukemia. Mutations of the group A gene (FancA) are most common. A \nmultitude of polymorphisms and mutations within the 43 exons of the \ngene are described. To examine the role of heterozygosity as a risk factor \nfor malignancies, a partial automatized screening method to identify aber-\nrations was needed. We report on our experience with DHPLC (WAVE \n(Transgenomic)). Methods: PCR amplification of all 43 exons from one \nindividual is done on one microtiter plate on a gradient thermocycler. \nDHPLC analysis conditions were established via melting curves, predic-\ntion software, and test runs with aberrant samples. PCR-products are \nanalyzed twice: Native, and after adding a WT- PCR product. Retention \npatterns are compared to previously identified polymorphic PCR products \nor mutants. Results and discussion: We defined the mutation screening \nconditions for all 43 exons of FANCA using DHPLC. So far, 40 different \nsequence variations could be detected in more than 100 individuals. The \nnative analysis identifies heterozygous individuals, the second run detects \nhomozygous aberrations. Retention patterns are specific for the underly-ing sequence aberration, thus reducing sequencing demand and costs. \nDHPLC is a valuable tool for reproducible recognition of known sequence \naberrations and screening for unknown mutations in the highly polymor-\nphic FANCA gene \nE Rischewski J, Clausen H, Leber V, \nNiemeyer C, Ritter J, Schindler D, \nSchneppenheim R:  \nA heterozygous frameshift mutation in \nthe Fanconi anemia C gene in familial \nT-ALL and secondary malignancy.  \nKlin Padiatr 212:174-6, 2000  Background: Patients with Fanconi Anemia (FANC) have a well docu-\nmented increased risk to develop malignancies, especially Acute Myeloid \nLeukemia (AML) and Myelodysplastic Syndrome (MDS). The risk for \nheterozygous individuals is not clear, epidemiological data are inconsis-\ntent. If the risk for heterozygous individ uals to develop malignancies was \nincreased, they should be found in groups of patients with AML or MDS at \nhigher proportion than in the normal population. We are currently screen-\ning a pediatric population with hematologic malignancies for mutations in \nthe FANCA, FANCC and FANCG gene, and report here on siblings carry-\ning a heterozygous frameshift mutation in the FANCC Gene. Patients and \nMethods: Using PCR based single strand conformational analysis we \nscreened the DNA from pediatric patients suffering from 1\u00b0 or 2\u00b0 MDS, \nCMML / JMML or AML for mutations in the FANCA (43 exons), FANCC \n(14 exons) and FANCG (14 exons) gene, and included one patient with \nrefractory T-ALL, being the brother of a patient with T-ALL and MDS \ntransforming into AML. Aberrant PCR products were directly sequenced. \nFlowcytometric measurement of mitogen- sensitivity and G2-phase arrest \nis used to evaluate cultured stimulated lymphocytes from individuals \ncarrying FANC- mutations. Results: A novel heterozygous frameshift \nmutation, 377-378delGA in the FANCC gene was found in 2 siblings, both 83P Reference Abstract  \nsuffering from T-ALL with subsequent MDS transforming to AML in one of \nthem. No other mutation was found by direct sequencing of the complete \nFANCC gene. Both patients died under therapy. The parents (first degree \ncousins) and one healthy brother are also carriers. Their lymphocytes \nshow a higher mutagen sensitivity than normal, but do not get blocked in \nG2 phase as being typical for Fanconi Anemia. Conclusion: As the muta-\ntion causes a premature Stopcodon within exon 4 of the FANCC gene it \nhas to be regarded as a causal FANCC gene defect. The findings within \nthis family support the hypothesis of an increased risk to develop malig-\nnancies in heterozygous carriers of FANC- mutations. A systematic \nscreening of further patients is needed, and we are currently examining a \nlarger cohort to get a better estimate of the true risk of heterozygosity. \n Rischewski J, Schindler D, Ziegler K, \nJanka-Schaub G, Schneppenheim R: \nDiscrepancy of diagnostic hallmarks of \nFanconi anemia in a patient with \nmyelodysplastic syndrome.  \nKlin Padiatr. 2002, in press. Abstract: Background: Patients with Fanconi anemia (FA) are well-\ndocumented of facing increased risk for developing malignancies, fore-\nmost acute myelogenous leukemia (AML) that often evolves from preced-\ning myelodysplastic syndrome (MDS). The diagnosis FA is based on the \ngreatly elevated sensitivity of the patient\u00b4s cells to mitomycin C (MMC) \nand diepoxybutan (DEB), conspicuous in the analysis of metaphase \nchromosomes, in reduced cellular survival rates, and in the accumulation \nof live cells in the G2/M phase of the cell cycle. However, the diagnosis \nFA cannot savely be made from blood cells in case of  high-grade so-\nmatic mosaicism of hematopoetic cells or (pre)leukemic conditions, no \nmatter what type of analysis is used. Patient, Methods and Results: An \none year old patient displayed morphological features of FA. The diagno-\nsis was confirmed by high breakage rates of metaphase chromosomes \nusing DEB challenge of peripheral blood lymphocytes (PBL). At age two \nyears, he developed abdominal B-cell non-Hodgkin lymphoma responsive \nto chemotherapy. At age four years, he presented with a medulloblas-\ntoma. At that time, cell cycle analysis failed to show G2/M accumulation in \nmononuclear blood cells, whereas the analysis of metaphase chromo-\nsomes from PBL detected a subset of cells with increased breakage and \nrearrangements typical of FA. Likewise, the diagnosis FA was confirmed \nwith cultured fibroblasts by their oxygen hypersensitivity and dispropor-\ntionately reduced growth rates in the presence of MMC. Six months later, \nbone marrow studies were indicative of MDS type RAEBt, which devel-\noped towards overt leukemia. Another month later, the patient died from \nincreased cranial pressure caused by relapse of the medulloblastoma. \nConclusion: False-negative results of FA testing using chromosome \nanalysis and cell cycle studies with blood have been reported when mo-\nsaicism of hematopoetic cells or (pre)-leukemia was present. In particular, \nFA testing with (pre)-leukemic blood represents a diagnostic pitfall. Im-\nproved statistics by the high number of cells anlyzed with the flow assay \nnormally forms an advantage, but the detection of increased breakage in \na subset of cells at a single cell basis may be helpful in the above condi-\ntions, although this assumption reportedly does not always apply in a \n(pre)-leukemic status. In the present patient, evidence of MDS was \ngained, assumedly responsible for negative testing in cell cycle studies. \nThe diagnosis of FA in patients with di screpant diagnostic results in PBL \nshould be evaluated by a fibroblast MMC challenge, and a bone marrow \naspirate should be performed to exclude the existence of MDS. \nE Hasle H, Niemeyer CM, Baumann I, \nBennett JM, Chessells J, Kerndrup G, \nHead D.  \nProposal for the classification of myelo-\ndysplastic diseases in children.  \nSubmittedAbstract: Myelodysplasia is rare in childhood and there is no widely ac-\ncepted system for its diagnosis and classification. We propose minimal \ndiagnostic criteria and a simple classification scheme which, while based \non accepted morphological features, allows for the special problems of \nmyelodysplastic diseases in childhood. This new classification recognizes \nthree major diagnostic groups: 1) juvenile myelomonocytic leukemia \n(JMML), previously named chronic myelomonocytic leukemia (CMML), or \njuvenile chronic myeloid leukemia (JCML) 2) MDS/AML of Down syn-\ndrome, a disease with distinct clinical and biological features, is referred \nto as myeloid leukemia of Down syndrome 3) MDS occurring both de \nnovo and as a complication of previous therapy or pre-existing bone mar-\nrow disorder (secondary MDS). The main proposed subtypes of MDS are: \nrefractory cytosine (RC) and refractory anemia with excess of blasts \n(RAEB). There remains uncertainty about the value of retaining the sub-\ntype of RAEB-T with 20-30% blasts in the marrow, abolished by the re-\ncent WHO classification. Cytogenetics and serial assessments of the \npatients are essential adjuncts to morphology both in diagnosis and clas-\nsification.84P Reference Abstract  \nE Kardos G, Baumann I, Passmore J, \nLocatelli F, Hasle H, Schulz J, Star\u00fd J, \nSchmitt-Graef A, Fischer A, Harbott J, \nWebb D, Chessels J, Fenu S, Cant\u00fa \nRajnoldi A, Kerndrup G, van Wering E, \nN\u00f6llke P, Niemeyer CM.  \nRefractory cytopenia in childhood. A \nRetrospective analysis of 67 cases.  \nSubmittedAbstract: Refractory cytopenia (RC) is an uncommon diagnosis in child-\nhood. In an attempt to identify prognostic factors influencing outcome we \nanalyzed retrospectively the data of 67 children with RA. Median age at \ndiagnosis was 8.3 years. Only 24% of children had hypercellular bone \nmarrow at diagnosis. Dysplasia of the erythopoetic line was most often \nseen. Of the 66 patients with karyotypic analysis, 32 had monosomy \nseven (- 7). Overall survival at 15 years was 0.48 (\u00b1 0.19). 20 children \nprogressed to advanced form of MDS. Median time to progression was \n1,7 years. The probability of progression was much higher in patients with \nmonosomy 7 as compared to those with other chromosomal abnormali-\nties or a normal karyotype (0.91 at 6 years v. 0.39 and 0.16). 41 children \nwere transplanted, 17 with an HLA compatible family donor (MFD) and 24 \nwith an unrelated donor (MUD). Probability of survival at 10 years was \n0.64 (\u00b1 0.17) with no significant difference between MFD and MUD trans-\nplants. Children transplanted after progression had a significantly worse \nsurvival (0.76 v 0.36). Stem cell  transplantation improved survival signifi-\ncantly in children with -7, but not in the others (0.42 v 0.27 and 0.77 v \n0.64). Relapse after stem cell  transplantation was only seen in patients \nwith monosomy 7 and more advanced MDS at the time of transplantation. \nA high progression rate and a short survival were observed in children \nwith RA and monosomy 7 with conservative therapy. Early bone marrow \ntransplantation before progression seems to be the treatment of choice. Anforderung eines Patienten-Identifikators \n(PID)\nErkl\u00e4rung/Hilfe  [Vor der ersten Verwendung unbedingt lesen!]\nIdentifizierende AngabenWie sicher ist der\nName?sicher unsicher\nNachname: Vorname:\nfr\u00fcherer\nNachname:GeburtsdatumTT:  MM:  JJJJ:\nErg\u00e4nzende Angaben\nGeschlecht:weiblich m\u00e4nnlich\nunbekannt\nPostleitzahl: Wohnort:\nStaat:\nBevor Sie das Formular abschicken, vergewissern Sie sich bitte noch\neinmal, ob alle Eintr\u00e4ge korrekt sind.PID anfordern\nFormular zur\u00fccksetzen\nFalls Sie als Reaktion nicht einen PID oder eine verst\u00e4ndliche Fehlermeldung zur\u00fcck erhalten, wenden Sie sich per\nE-Mail  anwebmaster@gpoh.de .Sehr geehrter Herr Herold,\nvielen Dank f\u00fcr Ihre Anfrage bez\u00fcglich der Fortf\u00fchrung von Marketingma\u00dfnahmen f\u00fcr\ndas \u201eKompetenznetz P\u00e4diatrische Onkologie und H\u00e4matologie\u201d(KPOH, 2. Phase).\nIn der ersten Phase 2001/2002 der Marketingaktivit\u00e4ten f\u00fcr das KPOH wurden \u2013 im\nRahmen des Budgets von netto 35.260,00 \u20ac\u2013 die folgenden Aktivit\u00e4ten durchgef\u00fchrt:\n\u2022 Entwurf und Produktion der Gesch\u00e4ftsausstattung (Briefb\u00f6gen) des KPOH\n\u2022 Konzeption, Entwurf und Produktion einer Infobrosch\u00fcre in Form einer Mappe als\nTr\u00e4ger weiterf\u00fchrender Informationen von thematisch unterschiedlichen Einlegebl\u00e4ttern\n(derzeit in Arbeit)\n\u2022 Marketingkonzept zur professionellen \u00d6ffentlichkeitsarbeit (derzeit in Arbeit)\u2022 Presseaktivit\u00e4ten: Pressekonferenz November 2001, Kontakte zu TV-Stationen\n\u2022 Entwurf, Strukturierung (Sitemap) und programmiertechnische Umsetzung des Internet-\nAuftritts f\u00fcr das Kinderkrebs-Info-Portal\n\u2022 Strukturierung (Sitemap) des Internet-Auftritts f\u00fcr das KPOH\nMit den genannten Aktivit\u00e4ten sind erste Schritte in Richtung eines einheitlichen und pro-\nfessionellen Auftritts in Sachen \u00d6ffentlichkeitsarbeit getan. Dies mit dem Ziel, (a) die \u201eei-\ngenen Reihen\u201d mit professionellem Informationsmaterial auszustatten, (b) die Belangedes KPOH in der \u00d6ffentlichkeit durchzusetzen und um (c) eine Basis f\u00fcr die\nEigenst\u00e4ndigkeit des Netzes ab 2005 zu legen.\nZiel der Aktivit\u00e4ten in der folgenden Phase\nist, das KPOH marketingstrategisch als\nKompetenz-Qualit\u00e4tsmarke gegen\u00fcber Krankenkassen/Krankenh\u00e4usern, Betroffenen\nund der allgemeinen \u00d6ffentlichkeit zu positionieren.\nDas KPOH wird k\u00fcnftig offensiv die Belange der P\u00e4diatrischen Onkologie undH\u00e4matologie in der \u00d6ffentlichkeit thematisieren, um so die wissenschaftliche Arbeit unddie Behandlung der Kranken auf eine stabilere Grundlage zu stellen (Stichworte\n\u201eFinanzierung \u2013 weg von Charity\u201d und \u201eMedikamente f\u00fcr Kinder\u201d).Charit\u00e9 /Campus Virchow-Klinikum\nDr. Ralf Herold \u2022 KoordinatorAugustenburger Platz 1\n13353 Berlin\nKostenangebot Marketing KPOH 2. Phase 09/04/2002\nClaudia Drescher\nAnklamer Stra\u00dfe 38\nD-10115 Berlin\nTel. 030.44 00 85 05\nFax 030.44 00 85 06\nmail@drescherkonzept.de\nwww.drescherkonzept.de\nLeo/Fritz 030.47 37 87 27 \nBerliner Volksbank\nBLZ 100 900 00\nKonto 57 95 077 008 \nkonzeptKONZEPT\nGRAFIKDESIGNdrescherIm Zeitraum 2003-2004 sehen wir daf\u00fcr \u2013 im Rahmen des Budgets von 80.000 \u20ac\u2013 die folgenden Aktivit\u00e4ten:\nKONZEPT:\nIn Fortf\u00fchrung des \u201eMarketingkonzeptes 2002\u201d wird das KPOH zu einer bundesweit bekannten Marke ausgebaut. Dieser\nProzess wird konzeptionell begleitet und st\u00e4ndig auf dem Laufenden gehalten. Als \u201eProdukte\u201d werden wir aktualisiertePowerpoint- (bzw. \u00e4hnlich strukturierte) \u2013 Folien liefern und aktualisieren, die die Mitglieder des KPOH in Vortr\u00e4gen verwen-\nden k\u00f6nnen. Wir stellen uns vor, diese Marketing-Folien im Internet bereitzuhalten, so dass diese jederzeit aktuell z.B. in\nBerlin, Hannover oder M\u00fcnster abgerufen werden k\u00f6nnen.\nZeitgleich wird der Verselbstst\u00e4ndigungsprozess konzeptionell begleitet und ebenfalls durch Folien unterlegt.\nPRINTPRODUKTE:\nTr\u00e4ger der Basisinformationen wird auch in den Jahren 2003 \u2013 2004 die Infobrosch\u00fcre sein. Diese hatten wir so angelegt,\ndass sie jederzeit durch \u201eEinlegebl\u00e4tter\u201d modular erweiterbar ist. Konzeption, Gestaltung, Text und Produktion derEinlegebl\u00e4tter werden wir weiterf\u00fchren.\nDie Infobrosch\u00fcre wird \u2013 allein aus Kostengr\u00fcnden \u2013 kein Massenstreumedium sein k\u00f6nnen. Daher schlagen wir einen Flyer\nvor (in Leporello-Form), der auf Messen oder \u00e4hnlichen \u00f6ffentlichkeitsstarken Versammlungen distribuiert werden kann. DerFlyer wird auch als \u201eT\u00fcr\u201d  zum Web-Auftritt im Internet dienen.\nMit dem Ziel, die Meinungsbildner aktuell \u00fcber das KPOH auf dem Laufenden zu halten (insbesondere im Hinblick auf den\nVerselbstst\u00e4ndigungsprozess), schlagen wir einen 4-seitigen Newsletter vor (empfohlenes Format A4), der im Zeitraum 2003 \u2013 2004 zwei Mal als Print-Version erscheinen soll und selbstverst\u00e4ndlich auch im Internet abgerufen werden kann.Im Jahr 2004 schlagen wir eine konzeptionelle und grafische \u00dcberarbeitung der Infobrosch\u00fcre vor.\nMESSEAUFTRITT:\nIn der Vergangenheit hat sich gezeigt, dass Messeauftritte hervorragende Gelegenheiten sind, um mit der dort versammeltenPresse gezielt in Kontakt zu kommen.Wir werden daher eine f\u00fcr den flexiblen Einsatz geeignete KPOH-Messewand konzeptionell und grafisch vorbereiten und\nproduzieren lassen.\nINTERNET-SEITEN\nDie Gestaltung der KPOH Seiten auf Basis des Corporate Designs der vorhandenen Produkte (Kinderkrebs-Info-Portal, Info-\nMappe, Gesch\u00e4ftsausstattung) sollte in 2003 geschehen.Eine Aktualisierung/\u00dcberarbeitung der Bilddaten und Farbwelt der Seiten KPOH und Info-Portal erfolgt in 2004. \nDie st\u00e4ndige inhaltliche Aktualisierung erfolgt \u00fcber das KPOH und wird konform mit der Grafik umgesetzt.\nPR\nDie Thematisierung der KPOH-Belange in der Presse wird weiter und offensiv fortgesetzt. Wir schlagen hierzu die Erstellungeines PR-Verteilers f\u00fcr ca. 50 Journalisten, die regelm\u00e4\u00dfige Herausgabe von Pressemitteilungen, die Initialisierung von weite-ren TV-Kontakten sowie eine j\u00e4hrliche Pressekonferenz vor. Au\u00dferdem werden die PR-Aktivit\u00e4ten rund um Messeauftritte\nverst\u00e4rkt.\nkonzeptKONZEPT\nGRAFIKDESIGNdrescherDie aufgef\u00fchrten Vorschl\u00e4ge w\u00fcrden wir gern mit Ihnen in einen \u201eMarketing-Fahrplan\u201d einarbeiten. \nIn einem ersten (groben) Schritt stellen wir diese Ma\u00dfnahmen wie folgt dar:\nPrint Konzept Messeauftritt Internetseiten PR \n2003: Einlegebl\u00e4tter Markenkonzept Prod. einer mobilen Gestaltung PR-Verteiler\nImage-Flyer Detailliertes Messewand KPOH-Seiten Pressekonferenz\nNewsletter Nr. 1 Marketingkonzept (Konzeption TV-Auftritte\n(Konzeption Privatisierung + Gestaltg.) Pressemitteilungen\n+ Gestaltg./Druck)\n2004: Newsletter Nr. 2 Fortsetzung  Web-Relaunch Pressekonferenz \n\u00dcberarbeitung der Info-Portal TV-Auftritte\nInfo-Brosch\u00fcre KPOH-Seiten Pressemitteilungen\n(Konzeption\n+ Gestaltg./Druck)\nBudget ca. 25.000 \u20ac ca. 7.500 \u20ac ca. 7.500 \u20ac ca. 10.000 \u20ac ca. 30.000 \u20ac\nDieses Angebot versteht sich zuz\u00fcglich der gesetzlich geltenden Mehrwertsteuer. \nAufwendungen f\u00fcr Bildrechte sowie Illustratorenkosten sind nicht Bestandteil dieses Angebotes. \nDiese werden Ihnen bei Bedarf avisiert.\nF\u00fcr weitere Gespr\u00e4che stehen wir Ihnen gern zur Verf\u00fcgung.\nWir freuen uns auf eine spannende Zusammenarbeit!\nMit besten Gr\u00fc\u00dfen\nClaudia Drescher\nCOPYRIGHT\ndrescher konzept grafik design sichert streng vertrauliche Behandlung aller erhaltenen Angaben zu, wie andererseits der Auftraggeber sich verpflichtet, die ihm von drescher konzept grafik design im Rahmen von Pr\u00e4sentationen bekannt-gewordenen \u00dcberlegungen, Konzeptionen und Ausarbeitungen streng vertraulich zu behandeln, Au\u00dfenstehendennicht bekannt zu geben sowie f\u00fcr eigene Zwecke in keiner Form ohne Zustimmung von drescher konzept grafik design unmittelbar oder abgewandelt zu verwerten. Die in den Ausarbeitungen enthaltenen Layouts sind geistiges Eigentum von drescher konzept grafik design.Jegliche Verwendung sowie Weitergabe an Dritte bedarf der schriftlichen Genehmigung des Design-Unternehmens.\nkonzeptKONZEPT\nGRAFIKDESIGNdrescher/G36/G81/G74/G72/G69/G82/G87/G3/G93/G88/G85\n/G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G3/G88/G81/G71/G3/G51/G85/G82/G93/G72/G86/G86/G69/G72/G74/G79/G72/G76/G87/G88/G81/G74\n/G71/G72/G86/G3/G46._/G82/G80/G83/G72/G87/G72/G81/G93/G81/G72/G87/G93/G72/G86\n/G51/G108/G71/G76/G68/G87/G85/G76/G86/G70/G75/G72/G3/G50/G81/G78/G82/G79/G82/G74/G76/G72/G3/G88/G81/G71/G3/G43/G108/G80/G68/G87/G82/G79/G82/G74/G76/G72\n/G21/G17/G3/G51/G75/G68/G86/G72/G29/G3/G21/G19/G19/G19/G3/G16/G3/G21/G19/G19/G23\n/G36/G81/G86/G83/G85/G72/G70/G75/G83/G68/G85/G87/G81/G72/G85\n/G58/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G79/G76/G70/G75/G72/G86/G3/G44/G81/G86/G87/G76/G87/G88/G87/G3/G71/G72/G85/G3/G98/G85/G93/G87/G72\n/G39/G72/G88/G87/G86/G70/G75/G79/G68/G81/G71/G86/G3/G11/G58/G44/G36/G39/G12/G3/G74/G72/G80/G17/G3/G72/G17/G57/G17/G42/G82/G71/G72/G86/G69/G72/G85/G74/G72/G85/G3/G36/G79/G79/G72/G72/G3/G24/G23/G24/G22/G20/G26/G24/G3/G37/G82/G81/G81\n/G39/G85/G17/G3/G47/G82/G87/G75/G68/G85/G3/G46._/G79/G68/G72/G86\n/G53/G68/G79/G73/G3/G53/G72/G76/G70/G75/G72/G55/G72/G79/G72/G73/G82/G81/G29 /G11/G19/G21/G21/G27/G12/G3/G27/G20/G3/G19/G23/G16/G20/G26/G21\n/G55/G72/G79/G72/G73/G68/G91/G29 /G11/G19/G21/G21/G27/G12/G3/G27/G20/G3/G19/G23/G16/G20/G24/G24\n/G40/G80/G68/G76/G79/G29/G3 /G90/G76/G68/G71/G35/G90/G76/G68/G71/G17/G71/G72\n/G51/G85/G82/G74/G81/G82/G86/G3/G36/G42\n/G56/G81/G87/G72/G85/G3/G54/G68/G70/G75/G86/G72/G81/G75/G68/G88/G86/G72/G81/G3/G22/G26\n/G24/G19/G25/G25/G26/G3/G46._/G124/G79/G81\n/G39/G85/G17/G3/G58/G82/G79/G73/G74/G68/G81/G74/G3/G53/G76/G72/G71/G72/G79\n/G45/G68/G78/G82/G69/G3/G48/G68/G72/G87/G93/G72/G79/G55/G72/G79/G72/G73/G82/G81/G29 /G11/G19/G21/G21/G20/G12/G3/G20/G3/G25/G19/G3/G21/G26/G16/G19\n/G55/G72/G79/G72/G73/G68/G91/G29 /G11/G19/G21/G21/G20/G12/G3/G20/G22/G3/G22/G27/G3/G21/G21\n/G40/G80/G68/G76/G79/G29 /G83/G85/G82/G74/G81/G82/G86/G17/G78/G82/G72/G79/G81/G35/G87/G16/G82/G81/G79/G76/G81/G72/G17/G71/G72/G20\n/G20/G17/G3 /G57/G82/G85/G69/G72/G80/G72/G85/G78/G88/G81/G74\n/G58/G44/G36/G39/G3/G88/G81/G71/G3/G51/G85/G82/G74/G81/G82/G86/G3/G75/G68/G69/G72/G81/G3/G76/G81/G3/G71/G72/G85/G3/G72/G85/G86/G87/G72/G81/G3/G51/G75/G68/G86/G72/G3/G71/G72/G85/G3/G90/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G79/G76/G70/G75/G72/G81/G3/G37/G72/G74/G79/G72/G76/G87/G88/G81/G74/G3/G71/G72/G86/G3/G46._/G82/G80/G83/G72/G16\n/G87/G72/G81/G93/G81/G72/G87/G93/G72/G86/G3/G72/G76/G81/G72/G3/G5/G37/G72/G86/G87/G68/G81/G71/G86/G68/G88/G73/G81/G68/G75/G80/G72/G3/G71/G72/G85/G3/G57/G72/G85/G81/G72/G87/G93/G88/G81/G74/G3/G76/G81/G3/G71/G72/G85/G3/G51/G108/G71/G76/G68/G87/G85/G76/G86/G70/G75/G72/G81/G3/G50/G81/G78/G82/G79/G82/G74/G76/G72/G3/G88/G81/G71/G3/G43/G108/G16/G80/G68/G87/G82/G79/G82/G74/G76/G72/G5/G3/G71/G88/G85/G70/G75/G74/G72/G73/G129/G75/G85/G87/G15/G3/G71/G72/G85/G72/G81/G3/G40/G85/G74/G72/G69/G81/G76/G86/G86/G72/G3/G80/G76/G87/G3/G72/G76/G81/G72/G80/G3/G36/G69/G86/G70/G75/G79/G88/G86/G86/G69/G72/G85/G76/G70/G75/G87/G3/G76/G80/G3/G45/G88/G81/G76/G3/G21/G19/G19/G19/G3/G89/G82/G85/G74/G72/G79/G72/G74/G87/G90/G88/G85/G71/G72/G81/G17/G3/G39/G76/G72/G86/G72/G3/G37/G72/G86/G87/G68/G81/G71/G68/G88/G73/G81/G68/G75/G80/G72/G3/G69/G76/G79/G71/G72/G87/G3/G71/G76/G72/G3/G42/G85/G88/G81/G71/G79/G68/G74/G72/G3/G73/G129/G85/G3/G71/G76/G72/G3/G41/G82/G85/G87/G86/G72/G87/G93/G88/G81/G74/G3/G88/G81/G71/G3/G40/G85/G90/G72/G76/G87/G72/G85/G88/G81/G74/G3/G71/G72/G85/G51/G85/G82/G93/G72/G86/G86/G69/G72/G74/G79/G72/G76/G87/G88/G81/G74/G3/G88/G81/G71/G3/G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G3/G76/G81/G3/G71/G72/G85/G3/G21/G17/G3/G51/G75/G68/G86/G72/G3/G76/G81/G3/G71/G72/G81/G3/G45/G68/G75/G85/G72/G81/G3/G21/G19/G19/G19/G3/G69/G76/G86/G3/G21/G19/G19/G23/G15/G3/G73/G129/G85/G3/G71/G76/G72/G3/G75/G76/G72/G85/G80/G76/G87/G72/G76/G81/G3/G36/G81/G74/G72/G69/G82/G87/G3/G88/G81/G87/G72/G85/G69/G85/G72/G76/G87/G72/G87/G3/G90/G76/G85/G71/G17\n/G44/G81/G3/G71/G76/G72/G86/G72/G3/G21/G17/G3/G51/G75/G68/G86/G72/G3/G87/G85/G72/G87/G72/G81/G3/G81/G72/G69/G72/G81/G3/G71/G76/G72/G3/G36/G88/G73/G74/G68/G69/G72/G81/G3/G71/G72/G85/G3/G90/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G79/G76/G70/G75/G72/G81/G3/G37/G72/G74/G79/G72/G76/G87/G88/G81/G74/G3/G76/G80/G3/G72/G81/G74/G72/G85/G72/G81\n/G54/G76/G81/G81/G72/G3/G68/G88/G70/G75\n/G156/G3 /G71/G76/G72/G3/G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G3/G69/G72/G76/G3/G71/G72/G85/G3/G54/G87/G72/G88/G72/G85/G88/G81/G74/G3/G71/G72/G86/G3/G42/G72/G86/G68/G80/G87/G89/G82/G85/G75/G68/G69/G72/G81/G86/G3/G88/G81/G71/G3/G71/G72/G85/G3/G55/G72/G76/G79/G83/G85/G82/G77/G72/G78/G87/G72/G15\n/G156/G3 /G71/G76/G72/G3/G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G3/G69/G72/G76/G3/G71/G72/G85/G3/G103/G73/G73/G72/G81/G87/G79/G76/G70/G75/G78/G72/G76/G87/G86/G68/G85/G69/G72/G76/G87/G3/G88/G81/G71/G3/G40/G85/G74/G72/G69/G81/G76/G86/G89/G72/G85/G90/G72/G85/G87/G88/G81/G74/G3/G86/G82/G90/G76/G72\n/G156/G3 /G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G86/G16/G3/G88/G81/G71/G3/G48/G72/G87/G75/G82/G71/G72/G81/G69/G72/G85/G68/G87/G88/G81/G74/G15\n/G36/G88/G73/G74/G68/G69/G72/G81/G15/G3/G71/G76/G72/G3/G76/G80/G3/G90/G72/G86/G72/G81/G87/G79/G76/G70/G75/G72/G81/G3/G76/G80/G3/G53/G68/G75/G80/G72/G81/G3/G89/G82/G81/G3/G55/G68/G74/G88/G81/G74/G72/G81/G3/G69/G93/G90/G17/G3/G58/G82/G85/G78/G86/G75/G82/G83/G86/G3/G68/G69/G93/G88/G79/G72/G76/G86/G87/G72/G81/G3/G86/G76/G81/G71/G17\n/G44/G81/G3/G71/G72/G85/G3/G81/G68/G70/G75/G86/G87/G72/G75/G72/G81/G71/G72/G81/G3/G47/G72/G76/G86/G87/G88/G81/G74/G86/G69/G72/G86/G70/G75/G85/G72/G76/G69/G88/G81/G74/G3/G90/G72/G85/G71/G72/G81/G3/G71/G76/G72/G3/G68/G81/G86/G87/G72/G75/G72/G81/G71/G72/G81/G3/G36/G88/G73/G74/G68/G69/G72/G81/G83/G68/G78/G72/G87/G72/G3/G80/G82/G16\n/G71/G88/G79/G68/G85/G87/G76/G74/G3/G71/G68/G85/G74/G72/G86/G87/G72/G79/G79/G87/G17/G21\n/G21/G17/G3 /G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G86/G71/G72/G86/G76/G74/G81/G3/G88/G81/G71/G3/G48/G72/G87/G75/G82/G71/G72/G81\n/G36/G85/G69/G72/G76/G87/G86/G80/G82/G71/G88/G79/G3/G20/G29/G3/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G3/G71/G72/G85/G3/G46._/G82/G82/G83/G72/G85/G68/G87/G76/G82/G81/G86/G16/G3/G88/G81/G71/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G86/G87/G85/G88/G78/G87/G88/G85/G72/G81/G3/G93/G90/G76/G86/G70/G75/G72/G81\n/G54/G87/G88/G71/G76/G72/G81/G93/G72/G81/G87/G85/G68/G79/G72/G81/G15/G3/G53/G72/G73/G72/G85/G72/G81/G93/G79/G68/G69/G82/G85/G68/G87/G82/G85/G76/G72/G81/G3/G88/G81/G71/G3/G46._/G79/G76/G81/G76/G78/G72/G81\n/G36/G85/G69/G72/G76/G87/G86/G80/G82/G71/G88/G79/G3/G20/G3/G78/G81/G129/G83/G73/G87/G3/G68/G81/G3/G71/G76/G72/G3/G129/G69/G72/G85/G74/G72/G82/G85/G71/G81/G72/G87/G72/G3/G61/G76/G72/G79/G86/G72/G87/G93/G88/G81/G74/G3/G71/G72/G86/G3/G46._/G82/G80/G83/G72/G87/G72/G81/G93/G81/G72/G87/G93/G72/G86/G3/G51/G108/G71/G76/G68/G87/G85/G76/G86/G70/G75/G72\n/G50/G81/G78/G82/G79/G82/G74/G76/G72/G3/G68/G81/G15/G3/G81/G108/G80/G79/G76/G70/G75/G3/G71/G72/G81/G3/G36/G88/G73/G69/G68/G88/G3/G72/G76/G81/G72/G85/G3/G72/G73/G73/G76/G93/G76/G72/G81/G87/G72/G81/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G78/G82/G82/G83/G72/G85/G68/G87/G76/G82/G81/G3/G71/G88/G85/G70/G75/G3/G57/G72/G85/G69/G76/G81/G71/G88/G81/G74/G89/G82/G81/G3/G46._/G79/G76/G81/G76/G78/G15/G3/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3/G40/G76/G81/G85/G76/G70/G75/G87/G88/G81/G74/G72/G81/G3/G88/G81/G71/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G79/G68/G69/G82/G85/G68/G87/G82/G85/G76/G72/G81/G17/G3/G42/G72/G83/G79/G68/G81/G87/G3/G76/G86/G87/G3/G76/G81/G3/G71/G76/G72/G86/G72/G80/G3/G46._/G82/G81/G87/G72/G91/G87/G71/G76/G72/G3/G40/G87/G68/G69/G79/G76/G72/G85/G88/G81/G74/G3/G81/G72/G88/G72/G85/G15/G3/G81/G72/G87/G93/G90/G72/G85/G78/G129/G69/G72/G85/G74/G85/G72/G76/G73/G72/G81/G71/G72/G85/G3/G54/G87/G85/G88/G78/G87/G88/G85/G72/G81/G3/G93/G88/G85/G3/G57/G72/G85/G69/G72/G86/G86/G72/G85/G88/G81/G74/G3/G71/G72/G86/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G16\n/G73/G79/G88/G86/G86/G72/G86/G15/G3/G71/G72/G85/G3/G46._/G82/G82/G83/G72/G85/G68/G87/G76/G82/G81/G3/G88/G81/G71/G3/G71/G72/G85/G3/G44/G81/G87/G72/G85/G68/G78/G87/G76/G82/G81/G3/G93/G90/G76/G86/G70/G75/G72/G81/G3/G71/G72/G81/G3/G51/G68/G85/G87/G81/G72/G85/G81/G3/G68/G88/G86/G3/G46._/G79/G76/G81/G76/G78/G3/G88/G81/G71/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G15\n/G90/G76/G72/G3/G93/G88/G80/G3/G37/G72/G76/G86/G83/G76/G72/G79/G29\n/G156/G3 /G72/G76/G81/G72/G3/G93/G72/G81/G87/G85/G68/G79/G72/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G78/G82/G82/G85/G71/G76/G81/G68/G87/G76/G82/G81/G15\n/G156/G3 /G71/G76/G72/G3/G73/G79/G108/G70/G75/G72/G81/G71/G72/G70/G78/G72/G81/G71/G72/G3/G40/G76/G81/G73/G129/G75/G85/G88/G81/G74/G3/G89/G82/G81/G3/G85/G72/G70/G75/G81/G72/G85/G69/G68/G86/G76/G72/G85/G87/G72/G81/G3/G36/G81/G90/G72/G81/G71/G88/G81/G74/G86/G86/G92/G86/G87/G72/G80/G72/G81/G3/G88/G81/G71/G3/G87/G72/G79/G72/G80/G72/G16\n/G71/G76/G93/G76/G81/G76/G86/G70/G75/G72/G81/G3/G57/G72/G85/G73/G68/G75/G85/G72/G81/G15\n/G156/G3 /G71/G76/G72/G3/G50/G83/G87/G76/G80/G76/G72/G85/G88/G81/G74/G3/G71/G72/G85/G3/G47/G82/G74/G76/G86/G87/G76/G78/G3/G73/G129/G85/G3/G71/G72/G81/G3/G48/G68/G87/G72/G85/G76/G68/G79/G89/G72/G85/G86/G68/G81/G71/G3/G88/G81/G71\n/G156/G3 /G71/G76/G72/G3/G37/G72/G85/G72/G76/G87/G86/G87/G72/G79/G79/G88/G81/G74/G3/G89/G82/G81/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G72/G81/G3/G88/G81/G71/G3/G58/G76/G86/G86/G72/G81/G3/G93/G88/G85/G3/G53/G72/G68/G79/G76/G86/G76/G72/G85/G88/G81/G74/G3/G71/G72/G85/G3/G89/G72/G85/G87/G76/G78/G68/G79/G72/G81/G3/G57/G72/G85/G81/G72/G87/G16\n/G93/G88/G81/G74/G17\n/G39/G76/G72/G3/G90/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G79/G76/G70/G75/G72/G3/G37/G72/G74/G79/G72/G76/G87/G88/G81/G74/G3/G71/G72/G85/G3/G81/G72/G88/G72/G81/G3/G46._/G82/G82/G83/G72/G85/G68/G87/G76/G82/G81/G86/G16/G3/G88/G81/G71/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G86/G87/G85/G88/G78/G87/G88/G85/G72/G81/G3/G90/G76/G85/G71/G3/G86/G76/G70/G75\n/G75/G68/G88/G83/G87/G86/G108/G70/G75/G79/G76/G70/G75/G3/G68/G81/G3/G71/G72/G81/G3/G73/G82/G79/G74/G72/G81/G71/G72/G81/G3/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G72/G81/G3/G69/G93/G90/G17/G3/G47/G72/G76/G87/G73/G85/G68/G74/G72/G81/G3/G82/G85/G76/G72/G81/G87/G76/G72/G85/G72/G81/G29\n/G156/G3/G58/G76/G86/G86/G72/G81/G86/G87/G85/G68/G81/G86/G73/G72/G85/G3 /G76/G81/G81/G72/G85/G75/G68/G79/G69/G3 /G71/G72/G85/G3 /G51/G108/G71/G76/G68/G87 /G85/G76/G86/G70/G75/G72/G81/G3 /G50/G81/G78/G82/G79/G82/G74/G76/G72/G3 /G88/G81/G71/G3 /G43/G108/G80/G68/G87/G82/G79/G82/G74/G76/G72/G3 /G11/G56/G81/G87/G72/G85/G86/G88/G16\n/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G3/G20/G12/G58/G72/G79/G70/G75/G72/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G84/G88/G72/G79/G79/G72/G81/G3/G90/G72/G85/G71/G72/G81/G3/G93/G88/G80/G3/G58/G76/G86/G86/G72/G81/G86/G72/G85/G90/G72/G85/G69/G18/G16/G87/G85/G68/G81/G86/G73/G72/G85/G3/G74/G72/G81/G88/G87/G93/G87/G34\n/G58/G76/G72/G3/G90/G72/G85/G71/G72/G81/G3/G71/G76/G72/G86/G72/G3/G52/G88/G72/G79/G79/G72/G81/G3/G75/G76/G81/G86/G76/G70/G75/G87/G79/G76/G70/G75/G3/G36/G81/G90/G72/G81/G71/G88/G81/G74/G3/G88/G81/G71/G3/G53/G72/G79/G72/G89/G68/G81/G93/G3/G89/G82/G81/G3/G71/G72/G81/G3/G37/G72/G87/G72/G76/G79/G76/G74/G87/G72/G81/G3/G69/G72/G16\n/G90/G72/G85/G87/G72/G87/G34/G58/G76/G72/G3/G78/G68/G81/G81/G3/G71/G72/G85/G3/G58/G76/G86/G86/G72/G81/G86/G87/G85/G68/G81/G86/G73/G72/G85/G3/G82/G83/G87/G76/G80/G76/G72/G85/G87/G3/G90/G72/G85/G71/G72/G81/G34/G58/G76/G72/G3/G78/G68/G81/G81/G3/G71/G72/G85/G3/G58/G76/G86/G86/G72/G81/G86/G86/G72/G85/G89/G72/G85/G3/G71/G72/G86/G3/G46._/G82/G80/G83/G72/G87/G72/G81/G93/G81/G72/G87/G93/G72/G86/G3/G76/G81/G3/G71/G72/G81/G3/G55/G85/G68/G81/G86/G73/G72/G85/G3/G72/G76/G81/G74/G72/G69/G88/G81/G71/G72/G81/G3/G90/G72/G85/G71/G72/G81/G34\n/G156/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G79/G76/G72/G73/G72/G85/G88/G81/G74/G3/G71/G72/G85/G3/G46._/G79/G76/G81/G76/G78/G72/G81/G3/G68/G81/G3/G71/G76/G72/G3/G54/G87/G88/G71/G76/G72/G81/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3/G69/G93/G90/G17/G3/G53/G72/G73/G72/G85/G72/G81/G93/G79/G68/G69/G82/G85/G68/G87/G82/G85/G76/G72/G81\n/G11/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G3/G21/G12/G58/G76/G72/G3/G75/G82/G70/G75/G3/G76/G86/G87/G3/G71/G72/G85/G3/G36/G88/G73/G90/G68/G81/G71/G3/G71/G72/G85/G3/G46._/G79/G76/G81/G76/G78/G72/G81/G3/G73/G129/G85/G3/G71/G76/G72/G3/G47/G76/G72/G73/G72/G85/G88/G81/G74/G3/G89/G82/G81/G3/G48/G68/G87/G72/G85/G76/G68/G79/G3/G88/G81/G71/G3/G39/G68/G87/G72/G81/G3/G68/G81/G3/G71/G76/G72/G3/G54/G87/G88/G16/G71/G76/G72/G81/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3/G69/G93/G90/G17/G3/G53/G72/G73/G72/G85/G72/G81/G93/G79/G68/G69/G82/G85/G68/G87/G82/G85/G76/G72/G81/G34/G58/G76/G72/G3/G90/G76/G85/G71/G3/G71/G72/G85/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G68/G88/G86/G87/G68/G88/G86/G70/G75/G3/G89/G82/G81/G3/G71/G72/G81/G3/G37/G72/G87/G72/G76/G79/G76/G74/G87/G72/G81/G3/G69/G72/G90/G72/G85/G87/G72/G87/G34/G42/G76/G69/G87/G3/G72/G86/G3/G50/G83/G87/G76/G80/G76/G72/G85/G88/G81/G74/G86/G80/G124/G74/G79/G76/G70/G75/G78/G72/G76/G87/G72/G81/G3/G69/G72/G76/G3/G48/G68/G87/G72/G85/G76/G68/G79/G68/G86/G86/G72/G85/G89/G76/G72/G85/G88/G81/G74/G3/G88/G81/G71/G3/G16/G89/G72/G85/G86/G68/G81/G71/G34\n/G58/G72/G79/G70/G75/G72/G3/G81/G72/G88/G72/G81/G3/G39/G82/G78/G88/G80/G72/G81/G87/G68/G87/G76/G82/G81/G86/G80/G72/G71/G76/G72/G81/G3/G78/G82/G80/G80/G72/G81/G3/G93/G88/G80/G3/G40/G76/G81/G86/G68/G87/G93/G34\n/G156/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G72/G80/G83/G73/G68/G81/G74/G3/G71/G72/G85/G3/G46._/G79/G76/G81/G76/G78/G72/G81/G3/G89/G82/G81/G3/G71/G72/G81/G3/G54/G87/G88/G71/G76/G72/G81/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3/G69/G93/G90/G17/G3/G53/G72/G73/G72/G85/G72/G81/G93/G79/G68/G69/G82/G85/G68/G87/G82/G16\n/G85/G76/G72/G81/G3 /G11/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G3/G22/G12\n/G44/G81/G3/G90/G72/G79/G70/G75/G72/G85/G3/G41/G82/G85/G80/G3/G72/G80/G83/G73/G68/G81/G74/G72/G81/G3/G71/G76/G72/G3/G46._/G79/G76/G81/G76/G78/G72/G81/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G72/G81/G3/G89/G82/G81/G3/G71/G72/G81/G3/G54/G87/G88/G71/G76/G72/G81/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3/G69/G93/G90/G17/G3/G53/G72/G16/G73/G72/G85/G72/G81/G93/G79/G68/G69/G82/G85/G68/G87/G82/G85/G76/G72/G81/G3/G11/G54/G87/G88/G71/G76/G72/G81/G83/G85/G82/G87/G82/G78/G82/G79/G79/G72/G15/G3/G37/G72/G85/G68/G87/G88/G81/G74/G72/G81/G3/G72/G87/G70/G17/G12/G34/G58/G76/G72/G3/G90/G72/G85/G71/G72/G81/G3/G71/G76/G72/G86/G72/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G84/G88/G72/G79/G79/G72/G81/G3/G69/G72/G90/G72/G85/G87/G72/G87/G3/G88/G81/G71/G3/G90/G82/G3/G86/G76/G81/G71/G3/G50/G83/G87/G76/G80/G76/G72/G85/G88/G81/G74/G86/G83/G82/G87/G72/G81/G87/G76/G68/G79/G72/G34/G22\n/G156/G3/G40/G76/G81/G86/G68/G87/G93/G3/G71/G72/G85/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3 /G11/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G3/G23/G12\n/G58/G72/G79/G70/G75/G72/G3/G46._/G72/G81/G81/G87/G81/G76/G86/G86/G72/G3/G88/G81/G71/G3/G41/G108/G75/G76/G74/G78/G72/G76/G87/G72/G81/G3/G90/G72/G85/G71/G72/G81/G3/G89/G82/G81/G3/G71/G72/G81/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G72/G85/G90/G68/G85/G87/G72/G87/G34/G58/G72/G79/G70/G75/G72/G3/G57/G72/G85/G69/G72/G86/G86/G72/G85/G88/G81/G74/G72/G81/G3/G76/G81/G3/G71/G72/G85/G3/G61/G88/G86/G68/G80/G80/G72/G81/G68/G85/G69/G72/G76/G87/G3/G80/G76/G87/G3/G71/G72/G81/G3/G54/G87/G88/G71/G76/G72/G81/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3/G90/G72/G85/G71/G72/G81/G3/G71/G88/G85/G70/G75/G71/G72/G81/G3/G40/G76/G81/G86/G68/G87/G93/G3/G89/G82/G81/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G72/G85/G90/G68/G85/G87/G72/G87/G34/G58/G72/G79/G70/G75/G72/G3/G57/G72/G85/G69/G72/G86/G86/G72/G85/G88/G81/G74/G72/G81/G3/G90/G88/G85/G71/G72/G81/G3/G72/G85/G93/G76/G72/G79/G87/G34/G58/G76/G72/G3/G74/G72/G86/G87/G68/G79/G87/G72/G87/G3/G86/G76/G70/G75/G3/G71/G68/G86/G3/G36/G88/G73/G74/G68/G69/G72/G81/G86/G83/G72/G78/G87/G85/G88/G80/G3/G71/G72/G85/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G34\n/G61/G88/G85/G3/G37/G72/G68/G85/G69/G72/G76/G87/G88/G81/G74/G3/G71/G72/G85/G3/G74/G72/G81/G68/G81/G81/G87/G72/G81/G3/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G72/G3/G86/G76/G81/G71/G3/G93/G90/G72/G76/G3/G86/G70/G75/G85/G76/G73/G87/G79/G76/G70/G75/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G72/G81/G3/G89/G82/G81\n/G46._/G79/G76/G81/G76/G78/G108/G85/G93/G87/G72/G81/G3/G74/G72/G83/G79/G68/G81/G87/G29\n/G156/G3 /G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G20/G3/G72/G85/G86/G87/G85/G72/G70/G78/G87/G3/G86/G76/G70/G75/G3/G68/G88/G73/G3/G71/G76/G72/G3/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G72/G3/G20/G3/G69/G76/G86/G3/G22/G17/G3/G44/G81/G3/G71/G76/G72/G86/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G86/G82/G79/G16\n/G79/G72/G81/G3/G68/G79/G79/G72/G3/G71/G76/G72/G77/G72/G81/G76/G74/G72/G81/G3/G46._/G76/G81/G71/G72/G85/G78/G79/G76/G81/G76/G78/G72/G81/G3/G72/G76/G81/G69/G72/G93/G82/G74/G72/G81/G3/G90/G72/G85/G71/G72/G81/G15/G3/G71/G76/G72/G3/G83/G85/G82/G3/G45/G68/G75/G85/G3/G80/G72/G75/G85/G3/G68/G79/G86/G3/G93/G72/G75/G81/G3/G82/G81/G78/G82/G79/G82/G74/G76/G16\n/G86/G70/G75/G72/G3/G69/G93/G90/G17/G3/G75/G108/G80/G68/G87/G82/G79/G82/G74/G76/G86/G70/G75/G72/G3/G49/G72/G88/G72/G85/G78/G85/G68/G81/G78/G88/G81/G74/G72/G81/G3/G69/G72/G75/G68/G81/G71/G72/G79/G81/G17/G3/G43/G76/G72/G85/G93/G88/G3/G93/G108/G75/G79/G72/G81/G3/G74/G72/G74/G72/G81/G90/G108/G85/G87/G76/G74/G3/G72/G87/G90/G68\n/G24/G19/G3/G46._/G79/G76/G81/G76/G78/G72/G81/G17\n/G156/G3 /G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G21/G3/G72/G85/G86/G87/G85/G72/G70/G78/G87/G3/G86/G76/G70/G75/G3/G68/G88/G73/G3/G71/G72/G81/G3/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G86/G69/G72/G85/G72/G76/G70/G75/G3/G23/G17/G3/G41/G129/G85/G3/G71/G76/G72/G86/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G78/G82/G80/G80/G72/G81\n/G68/G79/G79/G72/G3/G71/G76/G72/G77/G72/G81/G76/G74/G72/G81/G3/G46._/G76/G81/G71/G72/G85/G78/G79/G76/G81/G76/G78/G72/G81/G3/G76/G81/G3/G37/G72/G87/G85/G68/G70/G75/G87/G15/G3/G71/G76/G72/G3/G72/G76/G81/G72/G81/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G69/G72/G86/G70/G75/G108/G73/G87/G76/G74/G72/G81/G17/G3/G43/G76/G72/G85/G93/G88/G3/G93/G108/G75/G79/G72/G81/G3/G74/G72/G74/G72/G81/G90/G108/G85/G87/G76/G74/G3/G72/G87/G90/G68/G3/G22/G19/G3/G46._/G79/G76/G81/G76/G78/G72/G81/G3/G80/G76/G87/G3/G77/G72/G90/G72/G76/G79/G86/G3/G80/G72/G75/G85/G3/G68/G79/G86/G3/G21/G24/G3/G49/G72/G88/G72/G85/G16/G78/G85/G68/G81/G78/G88/G81/G74/G72/G81/G17\n/G37/G72/G76/G71/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G72/G81/G3/G90/G88/G85/G71/G72/G81/G3/G69/G72/G85/G72/G76/G87/G86/G3/G72/G76/G81/G80/G68/G79/G3/G76/G80/G3/G45/G68/G75/G85/G72/G3/G20/G28/G28/G28/G3/G71/G88/G85/G70/G75/G74/G72/G73/G129/G75/G85/G87/G17/G3/G54/G76/G72/G3/G86/G82/G79/G79/G72/G81/G3/G90/G108/G75/G85/G72/G81/G71/G3/G71/G72/G86\n/G41/G124/G85/G71/G72/G85/G93/G72/G76/G87/G85/G68/G88/G80/G86/G3/G81/G82/G70/G75/G3/G93/G90/G72/G76/G80/G68/G79/G3/G71/G88/G85/G70/G75/G74/G72/G73/G129/G75/G85/G87/G3/G90/G72/G85/G71/G72/G81/G15/G3/G88/G80/G3/G71/G76/G72/G3/G57/G72/G85/G81/G72/G87/G93/G88/G81/G74/G86/G73/G82/G85/G87/G86/G70/G75/G85/G76/G87/G87/G72/G3/G68/G81/G74/G72/G80/G72/G86/G16/G86/G72/G81/G3/G72/G89/G68/G79/G88/G76/G72/G85/G72/G81/G3/G93/G88/G3/G78/G124/G81/G81/G72/G81/G17\n/G36/G85/G69/G72/G76/G87/G86/G80/G82/G71/G88/G79/G3/G21/G29/G3/G57/G72/G85/G87/G76/G72/G73/G72/G81/G71/G72/G3/G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G3/G71/G72/G86/G3/G40/G76/G81/G86/G68/G87/G93/G72/G86/G3/G71/G72/G85/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G16\n/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81\n/G61/G88/G85/G3/G58/G72/G76/G87/G72/G85/G72/G81/G87/G90/G76/G70/G78/G79/G88/G81/G74/G3/G71/G72/G85/G3/G57/G72/G85/G81/G72/G87/G93/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G46._/G82/G82/G83/G72/G85/G68/G87/G76/G82/G81/G86/G86/G87/G85/G88/G78/G87/G88/G85/G72/G81/G3/G93/G90/G76/G86/G70/G75/G72/G81/G3/G46._/G79/G76/G81/G76/G78/G72/G81/G15/G3/G54/G87/G88/G71/G76/G16\n/G72/G81/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3 /G88/G81/G71/G3 /G53/G72/G73/G72/G85/G72/G81/G93/G79/G68/G69/G82/G85/G68/G87/G82/G85/G76/G72/G81/G3 /G73/G124/G85/G71/G72/G85/G87/G3 /G71/G68/G86/G3 /G37/G88/G81/G71/G72/G86/G80/G76/G81/G76/G86/G87/G72/G85/G76/G88/G80/G3 /G73/G129/G85/G3 /G37/G76/G79/G71/G88/G81/G74/G3 /G88/G81/G71/G3 /G41/G82/G85/G16\n/G86/G70/G75/G88/G81/G74/G3 /G71/G76/G72/G3 /G37/G72/G86/G70/G75/G108/G73/G87/G76/G74/G88/G81/G74/G3 /G86/G82/G74/G17/G3 /G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3 /G88/G81/G71/G3 /G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G17/G3 /G44/G75/G85/G72/G3 /G36/G88/G73/G74/G68/G69/G72/G81/G3 /G79/G76/G72/G74/G72/G81/G86/G70/G75/G90/G72/G85/G83/G88/G81/G78/G87/G80/G108/G137/G76/G74/G3/G76/G81/G3/G71/G72/G81/G3/G81/G68/G70/G75/G86/G87/G72/G75/G72/G81/G71/G72/G81/G3/G37/G72/G85/G72/G76/G70/G75/G72/G81/G29\n/G156/G3 /G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G3/G71/G72/G85/G3/G89/G72/G85/G68/G81/G87/G90/G82/G85/G87/G79/G76/G70/G75/G72/G81/G3/G98/G85/G93/G87/G72/G3/G69/G72/G76/G3/G71/G72/G85/G3/G50/G85/G74/G68/G81/G76/G86/G68/G87/G76/G82/G81/G3/G88/G81/G71/G3/G39/G88/G85/G70/G75/G73/G129/G75/G85/G88/G81/G74/G3/G89/G82/G81/G3/G78/G79/G76/G81/G76/G16\n/G86/G70/G75/G72/G81/G3/G54/G87/G88/G71/G76/G72/G81\n/G156/G3 /G40/G81/G87/G81/G68/G75/G80/G72/G15/G3/G36/G88/G73/G69/G72/G85/G72/G76/G87/G88/G81/G74/G3/G88/G81/G71/G3/G57/G72/G85/G86/G68/G81/G71/G3/G89/G82/G81/G3/G51/G68/G87/G76/G72/G81/G87/G72/G81/G80/G68/G87/G72/G85/G76/G68/G79/G76/G72/G81/G18/G47/G68/G69/G82/G85/G79/G82/G74/G76/G86/G87/G76/G78\n/G156/G3 /G39/G82/G78/G88/G80/G72/G81/G87/G68/G87/G76/G82/G81/G3/G88/G81/G71/G3/G46._/G82/G80/G80/G88/G81/G76/G78/G68/G87/G76/G82/G81/G3/G80/G76/G87/G3/G68/G81/G71/G72/G85/G72/G81/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G72/G76/G81/G85/G76/G70/G75/G87/G88/G81/G74/G72/G81\n/G39/G76/G72/G3/G36/G85/G69/G72/G76/G87/G86/G73/G72/G79/G71/G72/G85/G3/G88/G81/G71/G3/G71/G68/G86/G3/G55/G108/G87/G76/G74/G78/G72/G76/G87/G86/G86/G83/G72/G78/G87/G85/G88/G80/G3/G71/G72/G85/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G86/G82/G79/G79/G72/G81\n/G72/G76/G81/G72/G85/G3/G74/G72/G86/G82/G81/G71/G72/G85/G87/G72/G81/G3/G37/G72/G87/G85/G68/G70/G75/G87/G88/G81/G74/G3/G88/G81/G87/G72/G85/G93/G82/G74/G72/G81/G3/G90/G72/G85/G71/G72/G81/G17/G3/G44/G80/G3/G57/G82/G85/G71/G72/G85/G74/G85/G88/G81/G71/G3/G86/G87/G72/G75/G72/G81/G3/G75/G76/G72/G85/G69/G72/G76/G3/G71/G76/G72/G3/G73/G82/G79/G74/G72/G81/G16\n/G71/G72/G81/G3/G41/G85/G68/G74/G72/G81/G29\n/G156/G3 /G58/G72/G79/G70/G75/G72/G3/G88/G81/G87/G72/G85/G86/G70/G75/G76/G72/G71/G79/G76/G70/G75/G72/G81/G3/G36/G88/G73/G74/G68/G69/G72/G81/G18/G55/G108/G87/G76/G74/G78/G72/G76/G87/G72/G81/G3/G90/G72/G85/G71/G72/G81/G3/G89/G82/G81/G3/G71/G72/G81/G3/G81/G72/G88/G72/G81/G3/G48/G76/G87/G68/G85/G69/G72/G76/G87/G72/G85/G81/G3/G90/G68/G75/G85/G16\n/G74/G72/G81/G82/G80/G80/G72/G81/G34\n/G156/G3 /G48/G76/G87/G3/G90/G72/G79/G70/G75/G72/G81/G3/G61/G72/G76/G87/G68/G81/G87/G72/G76/G79/G72/G81/G3/G90/G72/G85/G71/G72/G81/G3/G71/G76/G72/G86/G72/G3/G36/G88/G73/G74/G68/G69/G72/G81/G18/G55/G108/G87/G76/G74/G78/G72/G76/G87/G72/G81/G3/G90/G68/G75/G85/G74/G72/G81/G82/G80/G80/G72/G81/G34/G23\n/G156/G3 /G58/G72/G79/G70/G75/G72/G3/G68/G81/G71/G72/G85/G72/G81/G3/G46._/G79/G76/G81/G76/G78/G80/G76/G87/G68/G85/G69/G72/G76/G87/G72/G85/G3/G90/G72/G85/G71/G72/G81/G3/G71/G88/G85/G70/G75/G3/G71/G72/G81/G3/G40/G76/G81/G86/G68/G87/G93/G3/G71/G72/G85/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G16\n/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G76/G81/G3/G90/G72/G79/G70/G75/G72/G80/G3/G56/G80/G73/G68/G81/G74/G3/G72/G81/G87/G79/G68/G86/G87/G72/G87/G34\n/G156/G3 /G58/G76/G72/G3/G86/G76/G81/G71/G3/G71/G76/G72/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G76/G81/G3/G71/G76/G72/G3/G36/G88/G73/G69/G68/G88/G16/G3/G88/G81/G71/G3/G36/G69/G79/G68/G88/G73/G82/G85/G74/G68/G81/G76/G86/G68/G87/G76/G82/G81/G3/G71/G72/G85\n/G46._/G79/G76/G81/G76/G78/G72/G81/G3/G72/G76/G81/G74/G72/G69/G88/G81/G71/G72/G81/G34\n/G156/G3 /G48/G76/G87/G3/G90/G72/G80/G3/G78/G82/G80/G80/G88/G81/G76/G93/G76/G72/G85/G72/G81/G3/G71/G76/G72/G3/G81/G72/G88/G72/G81/G3/G48/G76/G87/G68/G85/G69/G72/G76/G87/G72/G85/G3/G11/G76/G81/G87/G72/G85/G81/G3/G88/G81/G71/G3/G72/G91/G87/G72/G85/G81/G12/G34/G3/G58/G68/G86/G3/G86/G76/G81/G71/G3/G71/G76/G72/G3/G43/G68/G88/G83/G87/G74/G72/G16\n/G74/G72/G81/G86/G87/G108/G81/G71/G72/G3/G71/G72/G85/G3/G46._/G82/G80/G80/G88/G81/G76/G78/G68/G87/G76/G82/G81/G15/G3/G90/G68/G86/G3/G71/G76/G72/G3/G46._/G82/G80/G80/G88/G81/G76/G78/G68/G87/G76/G82/G81/G86/G80/G72/G71/G76/G72/G81/G34\n/G156/G3 /G58/G72/G79/G70/G75/G72/G3/G41/G108/G75/G76/G74/G78/G72/G76/G87/G72/G81/G15/G3/G46._/G72/G81/G81/G87/G81/G76/G86/G86/G72/G3/G88/G81/G71/G3/G73/G82/G85/G80/G68/G79/G72/G81/G3/G52/G88/G68/G79/G76/G73/G76/G78/G68/G87/G76/G82/G81/G72/G81/G3/G69/G72/G86/G76/G87/G93/G72/G81/G3/G71/G76/G72/G3/G72/G76/G81/G74/G72/G86/G87/G72/G79/G79/G87/G72/G81\n/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G34\n/G156/G3 /G58/G72/G79/G70/G75/G72/G3/G57/G72/G85/G108/G81/G71/G72/G85/G88/G81/G74/G72/G81/G3/G79/G68/G86/G86/G72/G81/G3/G86/G76/G70/G75/G3/G76/G81/G3/G71/G72/G81/G3/G37/G72/G85/G72/G76/G70/G75/G72/G81/G3/G196/G39/G88/G85/G70/G75/G73/G129/G75/G85/G88/G81/G74/G3/G89/G82/G81/G3/G54/G87/G88/G71/G76/G72/G81/G179/G15/G3/G196/G47/G68/G69/G82/G85/G16\n/G79/G82/G74/G76/G86/G87/G76/G78/G179/G3/G88/G81/G71/G3/G196/G39/G82/G78/G88/G80/G72/G81/G87/G68/G87/G76/G82/G81/G179/G3/G90/G108/G75/G85/G72/G81/G71/G3/G71/G72/G86/G3/G41/G124/G85/G71/G72/G85/G93/G72/G76/G87/G85/G68/G88/G80/G86/G3/G81/G68/G70/G75/G90/G72/G76/G86/G72/G81/G34\n/G61/G88/G85/G3/G37/G72/G68/G81/G87/G90/G82/G85/G87/G88/G81/G74/G3/G71/G76/G72/G86/G72/G85/G3/G41/G85/G68/G74/G72/G86/G87/G72/G79/G79/G88/G81/G74/G72/G81/G3/G76/G86/G87/G3/G72/G76/G81/G3/G93/G90/G72/G76/G74/G79/G72/G76/G86/G76/G74/G72/G85/G3/G44/G81/G86/G87/G85/G88/G80/G72/G81/G87/G72/G81/G72/G76/G81/G86/G68/G87/G93/G3/G74/G72/G83/G79/G68/G81/G87/G29\n/G156/G3 /G54/G70/G75/G85/G76/G73/G87/G79/G76/G70/G75/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G72/G81/G3/G71/G72/G85/G3/G70/G68/G17/G3/G22/G19/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G86/G76/G81/G71/G3/G76/G81/G3/G71/G72/G81/G3/G45/G68/G75/G85/G72/G81\n/G21/G19/G19/G20/G3/G86/G82/G90/G76/G72/G3/G21/G19/G19/G23/G3/G89/G82/G85/G74/G72/G86/G72/G75/G72/G81/G17\n/G156/G3 /G48/G129/G81/G71/G79/G76/G70/G75/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G72/G81/G3/G71/G72/G85/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G86/G76/G81/G71/G3/G76/G81/G3/G71/G72/G81/G3/G45/G68/G75/G85/G72/G81/G3/G21/G19/G19/G19/G15\n/G21/G19/G19/G21/G3/G88/G81/G71/G3/G21/G19/G19/G23/G3/G89/G82/G85/G74/G72/G86/G72/G75/G72/G81/G17/G3/G43/G76/G72/G85/G93/G88/G3/G86/G82/G79/G79/G72/G81/G3/G71/G76/G72/G3/G85/G72/G74/G72/G79/G80/G108/G137/G76/G74/G3/G86/G87/G68/G87/G87/G73/G76/G81/G71/G72/G81/G71/G72/G81/G3/G42/G85/G88/G83/G83/G72/G81/G87/G85/G72/G73/G73/G72/G81/G71/G76/G72/G86/G72/G85/G3/G48/G76/G87/G68/G85/G69/G72/G76/G87/G72/G85/G3/G74/G72/G81/G88/G87/G93/G87/G3/G90/G72/G85/G71/G72/G81/G17/G3/G36/G81/G79/G108/G137/G79/G76/G70/G75/G3/G71/G76/G72/G86/G72/G85/G3/G42/G85/G88/G83/G83/G72/G81/G87/G85/G72/G73/G73/G72/G81/G3/G86/G76/G81/G71/G3/G68/G79/G87/G72/G85/G81/G68/G87/G76/G89/G3/G68/G88/G70/G75/G3/G39/G76/G86/G16/G78/G88/G86/G86/G76/G82/G81/G72/G81/G3/G80/G76/G87/G3/G72/G76/G81/G72/G80/G3/G74/G85/G124/G137/G72/G85/G72/G81/G3/G46._/G85/G72/G76/G86/G3/G89/G82/G81/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G80/G124/G74/G79/G76/G70/G75/G17\n/G36/G85/G69/G72/G76/G87/G86/G80/G82/G71/G88/G79/G3/G22/G29/G3/G39/G82/G78/G88/G80/G72/G81/G87/G68/G87/G76/G82/G81/G3/G88/G81/G71/G3/G51/G85/G108/G86/G72/G81/G87/G68/G87/G76/G82/G81/G3/G71/G72/G85/G3/G40/G85/G74/G72/G69/G81/G76/G86/G86/G72\n/G39/G76/G72/G3/G39/G82/G78/G88/G80/G72/G81/G87/G68/G87/G76/G82/G81/G3/G71/G72/G85/G3/G40/G85/G74/G72/G69/G81/G76/G86/G86/G72/G3/G72/G85/G73/G82/G79/G74/G87/G3/G74/G72/G80/G72/G76/G81/G86/G68/G80/G3/G80/G76/G87/G3/G71/G72/G85/G3/G46._/G82/G82/G85/G71/G76/G81/G68/G87/G76/G82/G81/G86/G93/G72/G81/G87/G85/G68/G79/G72/G3/G71/G72/G86/G3/G46._/G82/G80/G16\n/G83/G72/G87/G72/G81/G93/G81/G72/G87/G93/G72/G86/G17/G3/G44/G81/G86/G74/G72/G86/G68/G80/G87/G3/G86/G76/G81/G71/G3/G72/G76/G81/G3/G61/G90/G76/G86/G70/G75/G72/G81/G69/G72/G85/G76/G70/G75/G87/G3/G76/G80/G3/G45/G68/G75/G85/G72/G3/G21/G19/G19/G20/G3/G81/G68/G70/G75/G3/G39/G88/G85/G70/G75/G73/G129/G75/G85/G88/G81/G74/G3/G88/G81/G71/G3/G36/G88/G86/G16\n/G90/G72/G85/G87/G88/G81/G74/G3/G71/G72/G85/G3/G72/G85/G86/G87/G72/G81/G3/G40/G85/G75/G72/G69/G88/G81/G74/G86/G90/G72/G79/G79/G72/G3/G86/G82/G90/G76/G72/G3/G72/G76/G81/G3/G68/G69/G86/G70/G75/G79/G76/G72/G137/G72/G81/G71/G72/G85/G3/G37/G72/G85/G76/G70/G75/G87/G3/G93/G88/G80/G3/G40/G81/G71/G72/G3/G71/G72/G86/G3/G45/G68/G75/G85/G72/G86\n/G21/G19/G19/G23/G3/G74/G72/G83/G79/G68/G81/G87/G17\n/G39/G76/G72/G3/G40/G85/G74/G72/G69/G81/G76/G86/G86/G72/G3/G86/G82/G90/G82/G75/G79/G3/G71/G72/G86/G3/G61/G90/G76/G86/G70/G75/G72/G81/G16/G3/G68/G79/G86/G3/G68/G88/G70/G75/G3/G71/G72/G86/G3/G40/G81/G71/G69/G72/G85/G76/G70/G75/G87/G72/G86/G3/G90/G72/G85/G71/G72/G81/G3/G72/G76/G81/G72/G80/G3/G89/G82/G80/G3/G36/G88/G73/G87/G85/G68/G74/G16\n/G74/G72/G69/G72/G85/G3/G93/G88/G3/G69/G72/G86/G87/G76/G80/G80/G72/G81/G71/G72/G81/G3/G46._/G85/G72/G76/G86/G3/G82/G71/G72/G85/G3/G42/G85/G72/G80/G76/G88/G80/G3/G83/G85/G108/G86/G72/G81/G87/G76/G72/G85/G87/G3/G88/G81/G71/G3/G93/G88/G85/G3/G39/G76/G86/G78/G88/G86/G86/G76/G82/G81/G3/G74/G72/G86/G87/G72/G79/G79/G87/G17\n/G36/G85/G69/G72/G76/G87/G86/G80/G82/G71/G88/G79/G72/G3/G23/G16/G25/G29/G3/G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G37/G72/G85/G68/G87/G88/G81/G74/G86/G79/G72/G76/G86/G87/G88/G81/G74/G72/G81\n/G41/G129/G85/G3/G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G37/G72/G85/G68/G87/G88/G81/G74/G86/G79/G72/G76/G86/G87/G88/G81/G74/G72/G81/G3/G76/G80/G3/G53/G68/G75/G80/G72/G81/G3/G71/G72/G85/G3/G48/G82/G71/G88/G79/G72/G3/G23/G3/G69/G76/G86/G3/G25/G3/G78/G68/G81/G81/G3/G71/G72/G85/G3/G36/G88/G73/G87/G85/G68/G74/G16\n/G74/G72/G69/G72/G85/G3/G77/G108/G75/G85/G79/G76/G70/G75/G3/G68/G88/G73/G3/G20/G19/G3/G69/G76/G86/G3/G20/G24/G3/G51/G72/G85/G86/G82/G81/G72/G81/G87/G68/G74/G72/G3/G93/G88/G85/G129/G70/G78/G74/G85/G72/G76/G73/G72/G81/G17/G3/G39/G76/G72/G3/G47/G72/G76/G86/G87/G88/G81/G74/G72/G81/G3/G78/G124/G81/G81/G72/G81/G3/G86/G76/G70/G75/G3/G68/G88/G73/G3/G71/G76/G72\n/G81/G68/G70/G75/G86/G87/G72/G75/G72/G81/G71/G3/G74/G72/G81/G68/G81/G81/G87/G72/G81/G3/G41/G72/G79/G71/G72/G85/G3/G72/G85/G86/G87/G85/G72/G70/G78/G72/G81/G29\n/G156/G3/G51/G85/G82/G77/G72/G78/G87/G80/G68/G81/G68/G74/G72/G80/G72/G81/G87\n/G39/G68/G86/G3/G46._/G82/G80/G83/G72/G87/G72/G81/G93/G81/G72/G87/G93/G3/G51/G108/G71/G76/G68/G87/G85/G76/G86/G70/G75/G72/G3/G50/G81/G78/G82/G79/G82/G74/G76/G72/G3/G86/G87/G72/G79/G79/G87/G3/G72/G76/G81/G3/G51/G85/G82/G77/G72/G78/G87/G3/G71/G68/G85/G15/G3/G71/G68/G86/G3/G76/G81/G81/G72/G85/G75/G68/G79/G69/G3/G69/G72/G86/G87/G72/G75/G72/G81/G16\n/G71/G72/G85/G3/G50/G85/G74/G68/G81/G76/G86/G68/G87/G76/G82/G81/G86/G86/G87/G85/G88/G78/G87/G88/G85/G72/G81/G3/G83/G68/G85/G68/G79/G79/G72/G79/G3/G93/G88/G80/G3/G80/G72/G71/G76/G93/G76/G81/G76/G86/G70/G75/G72/G81/G3/G53/G82/G88/G87/G76/G81/G72/G69/G72/G87/G85/G76/G72/G69/G3/G93/G88/G3/G69/G72/G90/G108/G79/G87/G76/G74/G72/G81/G3/G76/G86/G87/G17\n/G40/G86/G3/G90/G72/G76/G86/G87/G3/G72/G76/G81/G72/G3/G53/G72/G76/G75/G72/G3/G89/G82/G81/G3/G48/G72/G85/G78/G80/G68/G79/G72/G81/G3/G68/G88/G73/G15/G3/G71/G76/G72/G3/G71/G76/G72/G3/G54/G87/G72/G88/G72/G85/G88/G81/G74/G3/G81/G76/G70/G75/G87/G3/G72/G76/G81/G73/G68/G70/G75/G3/G80/G68/G70/G75/G72/G81/G3/G88/G81/G71/G3/G71/G68/G86/G48/G68/G81/G68/G74/G72/G80/G72/G81/G87/G3/G89/G82/G85/G3/G69/G72/G86/G82/G81/G71/G72/G85/G72/G3/G43/G72/G85/G68/G88/G86/G73/G82/G85/G71/G72/G85/G88/G81/G74/G72/G81/G3/G86/G87/G72/G79/G79/G72/G81/G17/G3/G61/G88/G3/G81/G72/G81/G81/G72/G81/G3/G76/G86/G87/G3/G76/G81/G3/G71/G76/G72/G86/G72/G80/G3/G61/G88/G86/G68/G80/G16/G80/G72/G81/G75/G68/G81/G74/G3/G71/G76/G72/G3/G57/G76/G72/G79/G93/G68/G75/G79/G3/G72/G91/G87/G72/G85/G81/G72/G85/G3/G37/G72/G87/G72/G76/G79/G76/G74/G87/G72/G85/G3/G68/G88/G73/G74/G85/G88/G81/G71/G3/G71/G72/G85/G3/G40/G76/G81/G69/G76/G81/G71/G88/G81/G74/G3/G76/G81/G3/G129/G69/G72/G85/G74/G72/G82/G85/G71/G81/G72/G87/G72/G3/G51/G85/G82/G16/G74/G85/G68/G80/G80/G86/G87/G85/G88/G78/G87/G88/G85/G72/G81/G3/G11/G37/G88/G81/G71/G72/G86/G80/G76/G81/G76/G86/G87/G72/G85/G76/G88/G80/G3/G68/G79/G86/G3/G41/G124/G85/G71/G72/G85/G72/G85/G15/G3/G51/G85/G82/G77/G72/G78/G87/G87/G85/G108/G74/G72/G85/G15/G3/G68/G70/G75/G87/G3/G90/G72/G76/G87/G72/G85/G72/G3/G46._/G82/G80/G83/G72/G87/G72/G81/G93/G16/G81/G72/G87/G93/G72/G15/G3/G93/G68/G75/G79/G85/G72/G76/G70/G75/G72/G3/G129/G69/G72/G85/G74/G72/G82/G85/G71/G81/G72/G87/G72/G3/G42/G85/G72/G80/G76/G72/G81/G3/G88/G81/G71/G3/G51/G85/G82/G77/G72/G78/G87/G72/G12/G17/G3/G61/G88/G3/G81/G72/G81/G81/G72/G81/G3/G86/G76/G81/G71/G3/G71/G72/G86/G3/G90/G72/G76/G87/G72/G85/G72/G81/G3/G71/G76/G72/G24\n/G57/G76/G72/G79/G93/G68/G75/G79/G3/G76/G81/G87/G72/G85/G81/G72/G85/G3/G37/G72/G87/G72/G76/G79/G76/G74/G87/G72/G85/G3/G68/G88/G73/G74/G85/G88/G81/G71/G3/G89/G82/G81/G3/G81/G72/G88/G81/G3/G56/G81/G87/G72/G85/G83/G85/G82/G77/G72/G78/G87/G72/G81/G3/G88/G81/G71/G3/G71/G76/G72/G3/G75/G82/G75/G72/G3/G40/G76/G74/G72/G81/G86/G87/G108/G81/G71/G76/G74/G16\n/G78/G72/G76/G87/G3/G71/G72/G85/G3/G56/G81/G87/G72/G85/G83/G85/G82/G77/G72/G78/G87/G72/G3/G80/G76/G87/G3/G93/G88/G80/G3/G55/G72/G76/G79/G3/G75/G72/G87/G72/G85/G82/G74/G72/G81/G72/G81/G3/G61/G76/G72/G79/G86/G72/G87/G93/G88/G81/G74/G72/G81/G3/G88/G81/G71/G3/G54/G72/G79/G69/G86/G87/G72/G89/G68/G79/G88/G68/G87/G76/G82/G81/G17\n/G48/G68/G81/G68/G74/G72/G80/G72/G81/G87/G68/G88/G73/G74/G68/G69/G72/G81/G3/G86/G87/G72/G79/G79/G72/G81/G3/G86/G76/G70/G75/G3/G86/G82/G90/G82/G75/G79/G3/G68/G88/G73/G3/G71/G72/G85/G3/G40/G69/G72/G81/G72/G3/G71/G72/G85/G3/G72/G76/G81/G93/G72/G79/G81/G72/G81/G3/G55/G72/G76/G79/G83/G85/G82/G77/G72/G78/G87/G72/G3/G68/G79/G86\n/G68/G88/G70/G75/G3/G68/G88/G73/G3/G71/G72/G85/G3/G40/G69/G72/G81/G72/G3/G71/G72/G85/G3/G61/G88/G86/G68/G80/G80/G72/G81/G73/G129/G75/G85/G88/G81/G74/G3/G71/G72/G85/G3/G55/G72/G76/G79/G83/G85/G82/G77/G72/G78/G87/G72/G3/G93/G88/G80/G3/G74/G72/G80/G72/G76/G81/G86/G68/G80/G72/G81/G3/G46._/G82/G80/G83/G72/G16\n/G87/G72/G81/G93/G81/G72/G87/G93/G3/G51/G108/G71/G76/G68/G87/G85/G76/G86/G70/G75/G72/G3/G50/G81/G78/G82/G79/G82/G74/G76/G72/G17/G3/G39/G76/G72/G3/G68/G81/G74/G72/G69/G82/G87/G72/G81/G72/G81/G3/G37/G72/G85/G68/G87/G88/G81/G74/G86/G79/G72/G76/G86/G87/G88/G81/G74/G72/G81/G3/G78/G124/G81/G81/G72/G81/G3/G86/G76/G70/G75/G3/G76/G81/G3/G71/G76/G72/G16/G86/G72/G80/G3/G46._/G82/G81/G87/G72/G91/G87/G3/G68/G88/G73/G3/G68/G79/G79/G72/G3/G55/G72/G76/G79/G69/G72/G85/G72/G76/G70/G75/G72/G3/G71/G72/G86/G3/G78/G79/G68/G86/G86/G76/G86/G70/G75/G72/G81/G3/G51/G85/G82/G77/G72/G78/G87/G80/G68/G81/G68/G74/G72/G80/G72/G81/G87/G86/G3/G72/G85/G86/G87/G85/G72/G70/G78/G72/G81/G29/G3/G68/G88/G73/G3/G71/G76/G72/G51/G85/G82/G77/G72/G78/G87/G83/G79/G68/G81/G88/G81/G74/G3/G88/G81/G71/G3/G16/G82/G85/G74/G68/G81/G76/G86/G68/G87/G76/G82/G81/G15/G3/G68/G88/G73/G3/G71/G68/G86/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G80/G68/G81/G68/G74/G72/G80/G72/G81/G87/G3/G88/G81/G71/G3/G71/G76/G72/G3/G51/G85/G82/G77/G72/G78/G87/G71/G82/G78/G88/G16\n/G80/G72/G81/G87/G68/G87/G76/G82/G81/G3/G86/G82/G90/G76/G72/G3/G68/G88/G73/G3/G71/G76/G72/G3/G51/G85/G82/G77/G72/G78/G87/G86/G87/G72/G88/G72/G85/G88/G81/G74/G3/G88/G81/G71/G3/G16/G78/G82/G81/G87/G85/G82/G79/G79/G72/G17/G3/G41/G129/G85/G3/G71/G72/G81/G3/G46._/G81/G82/G90/G16/G75/G82/G90/G16/G55/G85/G68/G81/G86/G73/G72/G85/G3/G86/G76/G81/G71\n/G89/G72/G85/G86/G70/G75/G76/G72/G71/G72/G81/G72/G3/G58/G72/G74/G72/G3/G71/G72/G81/G78/G69/G68/G85/G29/G3/G85/G72/G74/G72/G79/G80/G108/G137/G76/G74/G72/G3/G36/G85/G69/G72/G76/G87/G86/G86/G76/G87/G93/G88/G81/G74/G72/G81/G3/G80/G76/G87/G3/G71/G72/G81/G3/G51/G85/G82/G77/G72/G78/G87/G89/G72/G85/G68/G81/G87/G90/G82/G85/G87/G79/G76/G16/G70/G75/G72/G81/G15/G3/G58/G72/G76/G87/G72/G85/G74/G68/G69/G72/G3/G89/G82/G81/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G72/G81/G3/G93/G88/G80/G3/G55/G75/G72/G80/G68/G3/G51/G85/G82/G77/G72/G78/G87/G80/G68/G81/G68/G74/G72/G80/G72/G81/G87/G3/G129/G69/G72/G85/G3/G71/G68/G86/G3/G44/G81/G87/G85/G68/G81/G72/G87/G3/G71/G72/G86/G46._/G82/G80/G83/G72/G87/G72/G81/G93/G81/G72/G87/G93/G72/G86/G15/G3/G40/G85/G68/G85/G69/G72/G76/G87/G88/G81/G74/G3/G89/G82/G81/G3/G51/G85/G82/G77/G72/G78/G87/G83/G79/G108/G81/G72/G81/G15/G3/G36/G69/G79/G68/G88/G73/G71/G76/G68/G74/G85/G68/G80/G80/G72/G81/G15/G3/G51/G73/G79/G76/G70/G75/G87/G72/G81/G75/G72/G73/G87/G72/G81/G3/G72/G87/G70/G17/G74/G72/G80/G72/G76/G81/G86/G68/G80/G3/G80/G76/G87/G3/G71/G72/G81/G3/G51/G85/G82/G77/G72/G78/G87/G89/G72/G85/G68/G81/G87/G90/G82/G85/G87/G79/G76/G70/G75/G72/G81/G17\n/G156/G3/G40/G89/G68/G79/G88/G68/G87/G76/G82/G81\n/G44/G86/G87/G3/G90/G76/G72/G3/G76/G80/G3/G89/G82/G85/G79/G76/G72/G74/G72/G81/G71/G72/G81/G3/G41/G68/G79/G79/G3/G72/G76/G81/G72/G3/G76/G81/G87/G72/G85/G81/G72/G3/G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G3/G89/G82/G85/G74/G72/G86/G72/G75/G72/G81/G15/G3/G80/G88/G137/G3/G71/G76/G72/G86/G72/G3/G76/G81/G3/G71/G76/G72/G3/G51/G79/G68/G81/G88/G81/G74/G15/G71/G68/G86/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G80/G68/G81/G68/G74/G72/G80/G72/G81/G87/G3/G88/G81/G71/G3/G71/G76/G72/G3/G54/G87/G72/G88/G72/G85/G88/G81/G74/G3/G71/G72/G86/G3/G51/G85/G82/G77/G72/G78/G87/G72/G86/G3/G80/G76/G87/G3/G72/G76/G81/G69/G72/G93/G82/G74/G72/G81/G3/G90/G72/G85/G71/G72/G81/G17/G41/G72/G86/G87/G93/G88/G79/G72/G74/G72/G81/G3/G86/G76/G81/G71/G3/G76/G81/G86/G69/G72/G86/G82/G81/G71/G72/G85/G72/G3/G71/G76/G72/G3/G61/G76/G72/G79/G72/G3/G71/G72/G85/G3/G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G15/G3/G71/G76/G72/G3/G93/G88/G80/G3/G40/G76/G81/G86/G68/G87/G93/G3/G78/G82/G80/G80/G72/G81/G71/G72/G81/G3/G48/G72/G16/G87/G75/G82/G71/G72/G81/G3/G88/G81/G71/G3/G40/G85/G75/G72/G69/G88/G81/G74/G86/G76/G81/G86/G87/G85/G88/G80/G72/G81/G87/G72/G15/G3/G71/G76/G72/G3/G36/G88/G73/G69/G68/G88/G82/G85/G74/G68/G81/G76/G86/G68/G87/G76/G82/G81/G15/G3/G71/G17/G3/G75/G17/G3/G90/G72/G85/G3/G73/G129/G85/G3/G90/G72/G79/G70/G75/G72/G3/G36/G88/G73/G74/G68/G69/G72/G81/G76/G80/G3/G53/G68/G75/G80/G72/G81/G3/G71/G72/G85/G3/G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G3/G89/G72/G85/G68/G81/G87/G90/G82/G85/G87/G79/G76/G70/G75/G3/G76/G86/G87/G15/G3/G71/G72/G85/G3/G93/G72/G76/G87/G79/G76/G70/G75/G72/G3/G53/G68/G75/G80/G72/G81/G3/G86/G82/G90/G76/G72/G3/G71/G76/G72/G3/G41/G82/G85/G80/G3/G71/G72/G85/G3/G39/G82/G16/G78/G88/G80/G72/G81/G87/G68/G87/G76/G82/G81/G3/G71/G72/G85/G3/G40/G85/G74/G72/G69/G81/G76/G86/G86/G72/G17\n/G39/G76/G72/G3/G68/G81/G74/G72/G69/G82/G87/G72/G81/G72/G81/G3/G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G86/G79/G72/G76/G86/G87/G88/G81/G74/G72/G81/G3/G78/G124/G81/G81/G87/G72/G81/G3/G86/G76/G70/G75/G3/G75/G76/G72/G85/G69/G72/G76/G3/G76/G81/G86/G69/G72/G86/G82/G81/G71/G72/G85/G72/G3/G68/G88/G73/G3/G71/G76/G72/G3/G48/G72/G16\n/G87/G75/G82/G71/G72/G81/G90/G68/G75/G79/G3/G88/G81/G71/G3/G71/G76/G72/G3/G44/G81/G86/G87/G85/G88/G80/G72/G81/G87/G72/G81/G72/G81/G87/G90/G76/G70/G78/G79/G88/G81/G74/G3/G69/G72/G93/G76/G72/G75/G72/G81/G17/G3/G46._/G81/G82/G90/G16/G75/G82/G90/G3/G86/G87/G72/G75/G87/G3/G76/G81/G3/G71/G72/G81/G3/G37/G72/G85/G72/G76/G70/G75/G72/G81\n/G72/G80/G83/G76/G85/G76/G86/G70/G75/G72/G3/G54/G82/G93/G76/G68/G79/G90/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G72/G81/G15/G3/G40/G83/G76/G71/G72/G80/G76/G82/G79/G82/G74/G76/G72/G15/G3/G37/G76/G82/G86/G87/G68/G87/G76/G86/G87/G76/G78/G3/G88/G81/G71/G3/G42/G72/G86/G88/G81/G71/G75/G72/G76/G87/G86/G124/G78/G82/G81/G82/G80/G76/G72/G3/G93/G88/G85/G57/G72/G85/G73/G129/G74/G88/G81/G74/G17/G3/G36/G88/G70/G75/G3/G76/G80/G3/G53/G68/G75/G80/G72/G81/G3/G71/G72/G85/G3/G36/G88/G73/G69/G72/G85/G72/G76/G87/G88/G81/G74/G3/G88/G81/G71/G3/G39/G68/G85/G86/G87/G72/G79/G79/G88/G81/G74/G3/G89/G82/G81/G3/G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G86/G72/G85/G74/G72/G69/G81/G76/G86/G86/G72/G81/G86/G76/G81/G71/G3/G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G86/G79/G72/G76/G86/G87/G88/G81/G74/G72/G81/G3/G71/G72/G81/G78/G69/G68/G85/G3/G11/G86/G76/G72/G75/G72/G3/G75/G76/G72/G85/G93/G88/G3/G68/G88/G70/G75 /G3/G103/G73/G73/G72/G81/G87/G79/G76/G70/G75/G78/G72/G76/G87/G86/G68/G85/G69/G72/G76/G87/G3/G88/G81/G71/G3/G40/G85/G74/G72/G69/G16\n/G81/G76/G86/G89/G72/G85/G90/G72/G85/G87/G88/G81/G74/G12/G17\n/G156/G3/G103/G73/G73/G72/G81/G87/G79/G76/G70/G75/G78/G72/G76/G87/G86/G68/G85/G69/G72/G76/G87/G3/G88/G81/G71/G3/G40/G85/G74/G72/G69/G81/G76/G86/G89/G72/G85/G90/G72/G85/G87/G88/G81/G74\n/G40/G79/G72/G80/G72/G81/G87/G68/G85/G72/G85/G3/G37/G72/G86/G87/G68/G81/G71/G87/G72/G76/G79/G3/G71/G72/G86/G3/G41/G124/G85/G71/G72/G85/G78/G82/G81/G93/G72/G83/G87/G86/G3/G71/G72/G85/G3/G48/G72/G71/G76/G93/G76/G81/G76/G86/G70/G75/G72/G81/G3/G46._/G82/G80/G83/G72/G87/G72/G81/G93/G81/G72/G87/G93/G72/G3/G76/G86/G87/G3/G68/G88/G70/G75\n/G71/G76/G72/G3/G57/G72/G85/G80/G76/G87/G87/G79/G88/G81/G74/G3/G71/G72/G85/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G15/G3/G90/G68/G86/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G3/G79/G72/G76/G86/G87/G72/G87/G3/G88/G81/G71/G3/G73/G129/G85/G3/G90/G72/G81/G17/G3/G54/G82/G3/G76/G86/G87/G3/G72/G76/G81/G72/G86/G3/G71/G72/G85/G3/G47/G72/G76/G87/G16\n/G93/G76/G72/G79/G72/G3/G71/G76/G72/G3/G54/G70/G75/G68/G73/G73/G88/G81/G74/G3/G72/G76/G81/G72/G85/G3/G86/G82/G90/G82/G75/G79/G3/G73/G129/G85/G3/G71/G76/G72/G3/G41/G68/G70/G75/G90/G72/G79/G87/G3/G68/G79/G86/G3/G68/G88/G70/G75/G3/G76/G81/G3/G69/G72/G86/G82/G81/G71/G72/G85/G72/G80/G3/G48/G68/G137/G72/G3/G73/G129/G85/G3/G71/G76/G72/G3/G103/G73/G16/G73/G72/G81/G87/G79/G76/G70/G75/G78/G72/G76/G87/G3 /G72/G85/G78/G72/G81/G81/G69/G68/G85/G72/G81/G3 /G46._/G82/G80/G83/G72/G87/G72/G81/G93/G17/G3 /G40/G91/G87/G72/G85/G81/G72/G3 /G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G86/G16/G3 /G88/G81/G71/G3 /G37/G72/G85/G68/G87/G88/G81/G74/G86/G79/G72/G76/G86/G87/G88/G81/G74/G72/G81/G78/G124/G81/G81/G87/G72/G81/G3/G76/G81/G3/G71/G76/G72/G86/G72/G80/G3/G46._/G82/G81/G87/G72/G91/G87/G3/G71/G76/G72/G3/G40/G85/G68/G85/G69/G72/G76/G87/G88/G81/G74/G3/G72/G76/G81/G72/G86/G3/G46._/G82/G81/G93/G72/G83/G87/G72/G86/G3/G73/G129/G85/G3/G71/G76/G72/G3/G103/G73/G73/G72/G81/G87/G79/G76/G70/G75/G78/G72/G76/G87/G86/G68/G85/G69/G72/G76/G87/G3/G86/G82/G16/G90/G76/G72/G3/G71/G76/G72/G3/G80/G72/G71/G76/G72/G81/G74/G72/G85/G72/G70/G75/G87/G72/G3/G36/G88/G73/G69/G72/G85/G72/G76/G87/G88/G81/G74/G3/G89/G82/G81/G3/G40/G85/G74/G72/G69/G81/G76/G86/G86/G72/G81/G3/G73/G129/G85/G3/G71/G72/G81/G3/G55/G85/G68/G81/G86/G73/G72/G85/G3/G76/G81/G3/G71/G76/G72/G3/G103/G73/G73/G72/G81/G87/G79/G76/G70/G75/G78/G72/G76/G87/G88/G80/G73/G68/G86/G86/G72/G81/G17/G25\n/G22/G17/G3 /G3/G36/G85/G69/G72/G76/G87/G86/G16/G3/G88/G81/G71/G3/G61/G72/G76/G87/G83/G79/G68/G81\n/G39/G76/G72/G3/G47/G72/G76/G86/G87/G88/G81/G74/G86/G69/G72/G86/G70/G75/G85/G72/G76/G69/G88/G81/G74/G3/G90/G76/G85/G71/G3/G76/G81/G3/G41/G82/G85/G80/G3/G72/G76/G81/G72/G86/G3/G36/G85/G69/G72/G76/G87/G86/G16/G3/G88/G81/G71/G3/G61/G72/G76/G87/G83/G79/G68/G81/G86/G3/G89/G82/G85/G74/G72/G79/G72/G74/G87/G15/G3/G76/G81/G3/G71/G72/G80/G3/G71/G72/G81\n/G72/G76/G81/G93/G72/G79/G81/G72/G81/G3/G36/G85/G69/G72/G76/G87/G86/G80/G82/G71/G88/G79/G72/G81/G3/G71/G76/G72/G3/G77/G72/G90/G72/G76/G79/G76/G74/G72/G81/G3/G47/G72/G76/G86/G87/G88/G81/G74/G72/G81/G3/G69/G93/G90/G17/G3/G44/G81/G86/G87/G85/G88/G80/G72/G81/G87/G72/G3/G73/G129/G85/G3/G71/G72/G81/G3/G42/G72/G86/G68/G80/G87/G93/G72/G76/G87/G85/G68/G88/G80/G21/G19/G19/G19/G3/G69/G76/G86/G3/G21/G19/G19/G23/G3/G93/G88/G74/G72/G82/G85/G71/G81/G72/G87/G3/G86/G76/G81/G71/G17/G3/G61/G88/G86/G108/G87/G93/G79/G76/G70/G75/G3/G76/G86/G87/G3/G71/G72/G85/G3/G47/G72/G76/G86/G87/G88/G81/G74/G86/G68/G88/G73/G90/G68/G81/G71/G3/G73/G129/G85/G3/G71/G76/G72/G3/G72/G76/G81/G93/G72/G79/G81/G72/G81/G3/G36/G85/G69/G72/G76/G87/G86/G16/G86/G70/G75/G85/G76/G87/G87/G72/G3/G76/G81/G3/G55/G68/G74/G72/G81/G3/G68/G88/G86/G74/G72/G90/G76/G72/G86/G72/G81/G17\n/G36/G85/G69/G72/G76/G87/G86/G16/G3/G88/G81/G71/G3/G61/G72/G76/G87/G83/G79/G68/G81\n/G36/G85/G69/G72/G76/G87/G86/G80/G82/G71/G88/G79/G72\n/c21/c19/c19/c19 /c21/c19/c19/c20 /c21/c19/c19/c21 /c21/c19/c19/c22 /c21/c19/c19/c23/c58 /c76/c86/c86/c72/c81 /c16\n/c86/c70 /c75/c68/c73 /c87/c79/c72/c85 /c16\n/c55/c68 /c74/c72\n/G11/G20/G12 /G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G3/G71/G72/G85/G3/G46._/G82/G82/G83/G72/G85/G68/G87/G76/G82/G81/G86/G16/G3/G88/G81/G71/G3/G44/G81/G16\n/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G86/G87/G85/G88/G78/G87/G88/G85/G72/G81/G3/G11/G93/G17/G37/G17/G3/G49/G88/G87/G93/G88/G81/G74/G3/G71/G72/G86\n/G58/G76/G86/G86/G72/G81/G86/G86/G72/G85/G89/G72/G85/G86/G15/G3/G44/G81/G73/G82/G85/G80/G68/G87/G76/G82/G81/G86/G79/G76/G72/G73/G72/G85/G88/G81/G74/G3/G88/G81/G71\n/G177/G72/G80/G83/G73/G68/G81/G74/G15/G3/G40/G76/G81/G69/G76/G81/G71/G88/G81/G74/G3/G88/G81/G71/G3/G57/G72/G85/G81/G72/G87/G93/G88/G81/G74/G86/G16\n/G69/G72/G76/G87/G85/G68/G74/G3/G71/G72/G85/G3/G41/G82/G85/G86/G70/G75/G88/G81/G74/G86/G16/G3/G88/G81/G71/G3/G54/G87/G88/G71/G76/G72/G81/G68/G86/G16\n/G86/G76/G86/G87/G72/G81/G87/G72/G81/G3/G11/G41/G54/G36/G12/G15/G3/G40/G81/G87/G90/G76/G70/G78/G79/G88/G81/G74/G3/G71/G72/G85/G3/G57/G72/G85/G81/G72/G87/G16\n/G93/G88/G81/G74/G12\n/G20/G17/G20 /G54/G70/G75/G85/G76/G73/G87/G79/G76/G70/G75/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G71/G72/G85/G3/G54/G87/G88/G71/G76/G72/G81/G16 /G24/G24\n/G93/G72/G81/G87/G85/G68/G79/G72/G81/G3/G88/G81/G71/G3/G53/G72/G73/G72/G85/G72/G81/G93/G79/G68/G69/G82/G85/G68/G87/G82/G85/G76/G72/G81\n/G11/G81/G3/G32/G3/G70/G68/G17/G3/G22/G19/G12\n/G20/G17/G21/G3 /G54/G70/G75/G85/G76/G73/G87/G79/G76/G70/G75/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G79/G72/G76/G87/G72/G81/G71/G72/G85/G3/G46._/G79/G76/G16 /G24/G19\n/G81/G76/G78/G108/G85/G93/G87/G72/G3/G11/G81/G3/G32/G3/G70/G68/G17/G3/G24/G19/G12\n/G11/G21/G12 /G56/G81/G87/G72/G85/G86/G88/G70/G75/G88/G81/G74/G3/G71/G72/G85/G3/G36/G85/G69/G72/G76/G87/G86/G73/G72/G79/G71/G72/G85/G3/G88/G81/G71/G3/G71/G72/G85\n/G40/G76/G81/G69/G72/G93/G76/G72/G75/G88/G81/G74/G3/G71/G72/G85/G3/G41/G54/G36/G3/G76/G81/G3/G71/G76/G72/G3/G36/G88/G73/G69/G68/G88/G16/G3/G88/G81/G71\n/G36/G69/G79/G68/G88/G73/G82/G85/G74/G68/G81/G76/G86/G68/G87/G76/G82/G81/G3/G86/G82/G90/G76/G72/G3/G71/G72/G85/G3/G40/G73/G73/G72/G78/G87/G76/G89/G76/G87/G108/G87\n/G71/G72/G85/G3/G41/G54/G36\n/G21/G17/G20 /G54/G70/G75/G85/G76/G73/G87/G79/G76/G70/G75/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G71/G72/G85/G3/G41/G54/G36 /G24/G24\n/G11/G81/G3/G32/G3/G70/G68/G17/G3/G22/G19/G12\n/G21/G17/G21 /G48/G129/G81/G71/G79/G76/G70/G75/G72/G3/G37/G72/G73/G85/G68/G74/G88/G81/G74/G3/G71/G72/G85/G3/G41/G54/G36 /G23/G24\n/G11/G81/G3/G32/G3/G70/G68/G17/G3/G22/G19/G12/G3/G76/G80/G3/G53/G68/G75/G80/G72/G81/G3/G89/G82/G81\n/G42/G85/G88/G83/G83/G72/G81/G87/G85/G72/G73/G73/G72/G81\n/G11/G22/G12 /G37/G72/G85/G76/G70/G75/G87/G72/G85/G86/G87/G68/G87/G87/G88/G81/G74/G3/G74/G72/G80/G72/G76/G81/G86/G68/G80/G3/G80/G76/G87/G3/G71/G72/G85/G3/G46._/G82/G82/G85/G16\n/G71/G76/G81/G68/G87/G76/G82/G81/G86/G93/G72/G81/G87/G85/G68/G79/G72/G3/G11 /G117/G12/G15/G3/G51/G85/G82/G77/G72/G78/G87/G68/G69/G86/G87/G76/G80/G80/G88/G81/G74/G15/G117 /G117/G27/G24\n/G39/G76/G86/G78/G88/G86/G86/G76/G82/G81/G3/G88/G81/G71/G3/G51/G85/G108/G86/G72/G81/G87/G68/G87/G76/G82/G81/G3/G71/G72/G85/G3/G40/G85/G74/G72/G69/G81/G76/G86/G16\n/G86/G72\n/G11/G23/G12 /G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G3/G69/G72/G76/G3/G71/G72/G85/G3/G54/G87/G72/G88/G72/G85/G88/G81/G74/G3/G71/G72/G86/G3/G42/G72/G16\n/G86/G68/G80/G87/G89/G82/G85/G75/G68/G69/G72/G81/G86/G3/G88/G81/G71/G3/G71/G72/G85/G3/G55/G72/G76/G79/G83/G85/G82/G77/G72/G78/G87/G72\n/G11/G24/G12 /G40/G89/G68/G79/G88/G68/G87/G76/G82/G81/G86/G16/G3/G88/G81/G71/G3/G48/G72/G87/G75/G82/G71/G72/G81/G69/G72/G85/G68/G87/G88/G81/G74 /G25/G24\n/G11/G25/G12 /G56/G81/G87/G72/G85/G86/G87/G129/G87/G93/G88/G81/G74/G3/G69/G72/G76/G3/G103/G73/G73/G72/G81/G87/G79/G76/G70/G75/G78/G72/G76/G87/G86/G68/G85/G69/G72/G76/G87/G3/G88/G81/G71\n/G40/G85/G74/G72/G69/G81/G76/G86/G89/G72/G85/G90/G72/G85/G87/G88/G81/G74\n/c21/c19/c19/c19 /c21/c19/c19/c20 /c21/c19/c19/c21 /c21/c19/c19/c22 /c21/c19/c19/c23/G26\n/G39/G76/G72/G3/G58/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G79/G72/G85/G16/G55/G68/G74/G72/G3/G89/G72/G85/G87/G72/G76/G79/G72/G81/G3/G86/G76/G70/G75/G3/G90/G76/G72/G3/G73/G82/G79/G74/G87/G3/G68/G88/G73/G3/G71/G76/G72/G3/G78/G68/G79/G78/G88/G79/G76/G72/G85/G87/G72/G81/G3/G48/G82/G71/G88/G79/G72/G3/G88/G81/G71/G3/G45/G68/G75/G85/G72/G17/G3/G39/G76/G72/G86/G72\n/G47/G72/G76/G86/G87/G88/G81/G74/G86/G80/G72/G81/G74/G72/G81/G3/G89/G72/G85/G87/G72/G76/G79/G72/G81/G3/G86/G76/G70/G75/G3/G93/G88/G3/G74/G79/G72/G76/G70/G75/G72/G81/G3/G55/G72/G76/G79/G72/G81/G3/G68/G88/G73/G3/G69/G72/G76/G71/G72/G3/G36/G81/G69/G76/G72/G87/G72/G85/G17\n/G48/G82/G71/G88/G79/G72 /G21/G19/G19/G19 /G21/G19/G19/G20 /G21/G19/G19/G21 /G21/G19/G19/G22 /G21/G19/G19/G23 /G42/G72/G86/G68/G80/G87\n/G20/G17/G20 /G16/G22 /G19 /G16 /G16/G21 /G24 /G24/G24\n/G20/G17/G21 /G16/G21 /G24 /G16 /G16/G21 /G24 /G24/G19\n/G21/G17/G20 /G16/G22 /G19 /G16 /G16/G21 /G24 /G24/G24\n/G21/G17/G21 /G20/G24 /G16 /G20/G24 /G16 /G20/G24 /G23/G24\n/G22/G17 /G20/G19 /G21/G19 /G20/G19 /G20/G19 /G21/G24 /G26/G24\n/G3/G3/G3/G23/G17/G3/G177/G3/G25/G17 /G20/G19 /G20/G24 /G20/G24 /G20/G24 /G20/G19 /G25/G24\n/G42/G72/G86/G68/G80/G87 /G22/G24 /G20/G21/G19 /G23/G19 /G21/G24 /G20/G21/G24 /G22/G23/G24\n/G23/G17/G3 /G46._/G68/G79/G78/G88/G79/G68/G87/G76/G82/G81\n/G39/G72/G85/G3/G46._/G68/G79/G78/G88/G79/G68/G87/G76/G82/G81/G3/G79/G76/G72/G74/G87/G3/G72/G76/G81/G3/G58/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G79/G72/G85/G16/G55/G68/G74/G72/G86/G86/G68/G87/G93/G3/G89/G82/G81/G3/G39/G48/G3/G20/G17/G22/G19/G19/G15/G16/G3/G76/G80/G3/G45/G68/G75/G85/G72/G3/G21/G19/G19/G19/G3/G93/G88/G74/G85/G88/G81/G71/G72/G15\n/G71/G72/G85/G3/G88/G80/G3/G77/G108/G75/G85/G79/G76/G70/G75/G3/G39/G48/G3/G24/G19/G15/G16/G3/G72/G85/G75/G124/G75/G87/G3/G90/G76/G85/G71/G17/G3/G39/G76/G72/G3/G129/G69/G85/G76/G74/G72/G81/G3/G46._/G82/G86/G87/G72/G81/G3/G90/G72/G85/G71/G72/G81/G3/G93/G88/G3/G78/G82/G81/G86/G87/G68/G81/G87/G72/G81/G3/G51/G85/G72/G76/G86/G72/G81/G3/G78/G68/G79/G78/G88/G16/G79/G76/G72/G85/G87/G17/G3/G43/G76/G72/G85/G81/G68/G70/G75/G3/G72/G85/G74/G72/G69/G72/G81/G3/G86/G76/G70/G75/G3/G73/G82/G79/G74/G72/G81/G71/G72/G3/G46._/G82/G86/G87/G72/G81/G15/G3/G71/G76/G72/G3/G81/G72/G87/G87/G82/G3/G75/G108/G79/G73/G87/G76/G74/G3/G68/G88/G73/G3/G69/G72/G76/G71/G72/G3/G36/G81/G69/G76/G72/G87/G72/G85/G3/G72/G81/G87/G73/G68/G79/G79/G72/G81/G17\n/G46._/G82/G86/G87/G72/G81/G83/G79/G68/G81/G3/G58/G44/G36/G39/G3/G88/G81/G71/G3/G51/G85/G82/G74/G81/G82/G86 /G21/G19/G19/G19 /G21/G19/G19/G20 /G21/G19/G19/G21 /G21/G19/G19/G22 /G21/G19/G19/G23 /G42/G72/G86/G68/G80/G87\n/G11/G36/G12/G3/G43/G82/G81/G82/G85/G68/G85/G72\n/G156/G3/G58/G76/G86/G86/G72/G81/G86/G70/G75/G68/G73/G87/G79/G72/G85 /G23/G24/G17/G24/G19 /G19/G20/G25/G21/G17/G19/G19/G19 /G24/G25/G17/G19/G19 /G19/G22/G25/G17/G21/G24/G19/G20/G27/G26/G17/G24/G19/G19 /G23/G27/G26/G17/G21/G24/G19\n/G156/G3/G51/G85/G82/G77/G72/G78/G87/G68/G86/G86/G76/G86/G87/G72/G81/G93 /G22/G17/G19 /G19/G24/G17/G19/G19/G22/G17/G19/G19/G22/G17/G19/G19/G24/G17/G19/G19 /G20/G28/G17/G19/G19 /G19\n/G156/G3/G54/G72/G78/G85/G72/G87/G68/G85/G76/G68/G87 /G23/G17/G19 /G19/G20/G21/G17/G19/G19/G19 /G25/G17/G19/G19/G25/G17/G19/G19/G20/G24/G17/G19/G19/G19 /G23/G22/G17/G19/G19 /G19\n/G11/G37/G12/G3/G54/G68/G70/G75/G78/G82/G86/G87/G72/G81\n/G156/G3/G53/G72/G76/G86/G72/G78/G82/G86/G87/G72/G81 /G22/G17/G19 /G19/G27/G17/G19/G19/G27/G17/G19/G19/G27/G17/G19/G19/G27/G17/G19/G19 /G22/G24/G17/G19/G19 /G19\n/G156/G3/G86/G82/G81/G86/G87/G76/G74/G72/G3/G54/G68/G70/G75/G78/G82/G86/G87/G72/G81 /G21/G17/G19 /G19/G23/G17/G19/G19/G22/G17/G19/G19/G21/G17/G19/G19/G23/G17/G19/G19 /G20/G24/G17/G19/G19 /G19\n/G46._/G82/G86/G87/G72/G81/G3/G11/G81/G72/G87/G87/G82/G12 /G24/G26/G17/G24/G19 /G19/G20/G28/G20/G17/G19/G19/G19 /G26/G25/G17/G19/G19 /G19 /G24/G24/G17/G21/G24 /G19/G21/G20/G28/G17/G24/G19/G19 /G24/G28/G28/G17/G21/G24/G19\n/G48/G58/G54/G87/G17/G3/G58/G44/G36/G39/G3/G11/G26/G8/G12 /G21/G17/G19 /G25/G17/G25 /G27/G21/G17/G25/G25/G20/G17/G28/G22/G26/G17/G25/G27 /G21/G19/G17/G28/G26 /G24\n/G48/G58/G54/G87/G17/G3/G51/G85/G82/G74/G81/G82/G86/G3/G11/G20/G25/G8/G12 /G23/G17/G25 /G19/G20/G24/G17/G21/G27/G19 /G25/G17/G19/G27/G23/G17/G23/G21/G20/G26/G17/G24/G25/G19 /G23/G26/G17/G28/G23 /G19\n/G42/G72/G86/G68/G80/G87/G78/G82/G86/G87/G72/G81/G3/G11/G69/G85/G88/G87/G87/G82/G12 /G25/G23/G17/G20/G20 /G22/G21/G20/G21/G17/G28/G25/G24 /G27/G23/G17/G26/G23 /G19 /G25/G20/G17/G25/G19 /G23/G21/G23/G23/G17/G26/G23/G22 /G25/G25/G27/G17/G20/G25/G24Midtermreportcalaminus3/03/2002 \nANNEX 1:  \nAuswertung der Neuropsychologie \nIn diesem Anhang wird \u00fcber die Auswertung der neuropsychologischen Testverfahren berichtet, sofern die \nvorliegenden Testeregebnisse eine statistische Auswertung (Gr\u00f6\u00dfe der Stichprobe zulie\u00dfen). \nZur \u00dcbersicht zun\u00e4chst einige Informationen zu der Patientenstichprobe: \nH\u00e4ufigkeit Prozen t\nweiblich 44 46,8\nm\u00e4nnlich 50 53,2\nGesam t 94 100,0\nDIAGNOSEGRUPPE\nH\u00e4ufigkeit Prozen t\nALL 62 66,0\nHirntu 32 34,0\nGesam t 94 100,0\nIm folgenden noch einige Erl\u00e4uterungen zu den angewandten Testverfahren als \nHintergrundinformation:\nEingesetzte Testverfahren: \nIntelligenztests\nx Kaufman-Assesment-Battery for Children  (K-ABC) (Altersstufen 2;6 bis 11;11 Jahre), Individualtest zur \nMessung von Intelligenz und Fertigkeiten bei Kindern und Jugendlichen von A. S. Kaufman und N. L. \nKaufman. Deutsche Bearbeitung von U. Melchers, U. Preu\u00df. \nx Kaufman-Adolescent and Adult Intelligence Test  (K-TIM) (Altersstufe \u009512;0 Jahre) Individualtest zur \nMessung von Intelligenz und Fertigkeiten bei Jugendlichen und Erwachsenen von A. S. Kaufman und N. \nL. Kaufman. Deutsche Bearbeitung von U. Melchers, U. Preu\u00df und S. Sch\u00fcmann. Experimentalversion. \nDie K-ABC ist ein Testverfahren, das Intelligenz und Fertigkeiten mi\u00dft. Die Grundlage der K-ABC ist die Definition der Intelligenz als F\u00e4higkeit, Probleme durch geistiges Verarbeiten zu l\u00f6sen. Hierbei steht der \nProze\u00df der L\u00f6sungsfindung im Vordergrund. Die Messung intellektueller F\u00e4higkeiten wird von der Messung \ndes Standes erworbener Fertigkeiten getrennt, um diese unterschiedlichen Bereiche mentaler Leistung einzeln und im Vergleich miteinander erfassen zu k\u00f6nnen. Deshalb ist die K-ABC in vier Skalen gegliedert: \n\u201eSkala einzelheitlichen Denkens\u201c, \u201eSkala ganzheitlichen Denkens\u201c, \u201eFertigkeitenskala\u201c und \u201eSprachfreie \nSkala\u201c. Die K-TIM ist ebenfalls ein Verfahren zur Messung von Intelligenz und Fertigkeiten, jedoch f\u00fcr Jugendliche \nund Erwachsene. Die Skalen werden anders bezeichnet: \u201eSkala kristalliner Intelligenz\u201c und \u201eSkala fluider \nIntelligenz\u201c. Die Skala kristalliner Intelligenz mi\u00dft erworbenes Wissen und ist vom Schul- und Ausbildungsstand abh\u00e4ngig. Dagegen mi\u00dft die \u201eSkala fluider Intelligenz\u201c die F\u00e4higkeit, neue Aufgaben und \nProbleme zu l\u00f6sen. SEX\nweiblich N = 44 (46,8%)\nm\u00e4nnlich N = 50 (53,2%)m\u00e4nnlichweiblich\nDIAGNOSEGRUPPE\nALL N = 62 (66%)\nHirntumor N = 32 (34%)Hirntumor\nALLMidtermreportcalaminus3/03/2002 \nErg\u00e4nzende Neuropsychologische Verfahren \nx Developmental Test of Visual-Motor Integration  (VMI) (Altersstufen: 2;6 bis 18;0 Jahre) von K. E. Beery. \nDer VMI erfa\u00dft die visuomotorische Integrationsleistung. Hierzu sind geometrische Figuren unterschiedlicher \nKomplexit\u00e4t nachzuzeichnen. \nDer Test ist in der Durchf\u00fchrung anwenderfreundlich, die Auswertung bedarf einiger Erfahrung. Aus diesem \nGrund wird der Test zus\u00e4tzlich zentral (Erlangen) nachbewertet, um Einfl\u00fcsse einer subjektiven \nTestleiterbewertung auszuschlie\u00dfen. Der Test wird in allen Altersklassen angewandt und ist f\u00fcr die Testpersonen nicht belastend. Anwendungszeit 10 min, Auswertungszeit 20 min.  \nx Fragmentierter Bildertest\n (FBT) (Altersstufen: 10;0 bis 18;0 Jahre) von J. Kessler, A. Schaaf und R. \nMielke.\nDer Einsatz erfolgt zur Untersuchung der visuellen Informationsverarbeitung und zur \u00dcberpr\u00fcfung von h\u00f6heren integrativen Wahrnehmungsprozessen. Der FBT, ein auf Gollin zur\u00fcckgehendes Verfahren, ist ein \nWahrnehmungs- und Ged\u00e4chtnistest, bei dem die Gestalt von 10 konkreten Figuren sukzessive in 5 Stufen \nvervollst\u00e4ndigt wird. Der Patient wird instruiert, die Figuren anhand der Fragmenteso fr\u00fch wie m\u00f6glich zu identifizieren und zu benennen. \nx Differentieller Leistungstest-KE\n (DL-KE) (Altersstufen: 5;0 bis 6;11 Jahre), Test zur Erfassung des \nLeistungsverhaltens bei konzentrierter T\u00e4t igkeit von E. W. Kleber, G. Kleber und O. Hans. \nx Differentieller Leistungstest-KG  (DL-KG) (Altersstufen: 7;0 bis 8;11 Jahre), Test zur Erfassung des \nLeistungsverhaltens bei konzen trierter T\u00e4tigkeit von E. W. Kleber, G. Kleber und O. Hans. \nBeide Verfahren sind Figurendurchstreichtests, die f\u00fcr die Eingangsstufe der Grundschule bzw. f\u00fcr die \u00fcbrigen Altersgruppen der Grundschule Material auf einem angemessenen Bearbeitungsniveau zur \nVerf\u00fcgung stellen. In der Studie wird in Absprache mit den Testautoren eine reduzierte Itemzahl eingesetzt. \nDies ist aus testtheoretischer Sicht (G\u00fctekriterien) problematisch (Bortz & D\u00f6ring, 1995; Krauth, 1995). Es existieren nur grob differenzierende Normen f\u00fcr beide Testverfahren. \nx Aufmerksamkeits-Belastungstest d2\n (Test d2) (Altersstufen: \u0095 9;0 Jahre), Test zur Erfassung der \nAufmerksamkeits- und Konzentrationsleistung von R. Brickenkamp. \nDer Test d2 ist ein Durchstreichtest. Er mi\u00dft Tempo und Sorgfalt des Arbeitsverhaltens bei der \nUnterscheidung \u00e4hnlicher visueller Reize (Detail-Diskrimination) und erm\u00f6glicht damit die Beurteilung individueller Aufmerksamkeits- und Konzentrationsleistungen. \nx Tapping-/Reaktionszeitverfahren\n (Altersstufen: 4;0 bis 18;0 Jahre) von H. Ottensmeier, N. Galley und G. \nHopmann, 1997. \nBeim Fingertapping wird die Geschwindigkeit einer basalen motorischen Funktion EDV-gest\u00fctzt erfa\u00dft. \nIm Abstand von 10 min werden 2 Untersuchungsg\u00e4nge durchgef\u00fchrt. Dazu mu\u00df der Patient eine Morsetaste mit dem Zeigefinger bei aufliegendem Handgelenk \u00fcber einen Zeitraum von 30 Sekunden so schnell wie \nm\u00f6glich bet\u00e4tigen. Beim Reaktionszeitverfahren (RT) wird die Latenz der o.b. motorischen Reaktion bei \nDarbietung eines visuellen und eines akustischen Reizes gepr\u00fcft. Hierbei ist bei Erscheinen des Reizes der Finger von der gedr\u00fcckten Morsetaste abzuheben. Es werden 30 Reize angeboten. \nDarstellung der Ergebnisse der Neuropsychologie: \nAusgewertet wurden: der K-ABC, der K-TIM, der D2, DL-KG und DL-KE, sowie der VMI \nund der FBT. Nicht auswertbar war Tapping/Reaktionszeit, da dazu nur sehr wenige vollst\u00e4ndige Datens\u00e4tze vorlagen, aus denen kein direktes Testergebnis abzulesen ist. \nK-ABC Skala intellektueller F\u00e4higkeiten\n1 03,4597,1 31 03,5020,34\n98,7015 , 4 215 , 9 1 8,06\n0,0020,0040,0060,0080,00100,00120,00140,00\n     N=33        \nE1 ALL     N=8          \nE1 HiTu     N=10       \nE2  ALL   N=4      E2\nHiTuMittelwert (Standardabweichung)Midtermreportcalaminus3/03/2002 \nAltersbereich 6 bis 11.11 Jahre, bei Hirntumoren 4.00 bis 11.11 Jahre \nAngegeben sind die Mittelwerte und Standardabweichungen der getesteten Studienpatienten. Diese lassen \nsich mit der Normpopulation (durchschnitt 100, Standardabweichung 15) vergleichen. Dabei schneidet die \nGruppe der ALL zum ersten Testzeitpunkt im Durchschnitt etwas besser, die Gruppe der Hirntumorkinder im Durchschnitt etwas schlechter als die Normpopulation ab. Die Standardabweichungen sind vergleichbar. \nZum Zweiten Testzeitpunkt kehrt sich dieses Verh\u00e4ltnis dahingehend um, das im Durchschnitt die ALL \nKinder etwas schlechter als die Normpopulation sind, die Hirntumorkinder jedoch etwas besser. Allerdings finden sich bei beiden Werten eine geringe Anzahl an getesteten Kindern und eine vergleichsweise hohe \nStandardabweichung. \nNormgruppe: Kinder aus dem deutschsprachigen Raum, mehrere Untersuchungen, \nVergleichspopulationen mit Auff\u00e4lligkeiten, 40 Korrelationsstudien zu anderen Testverfahren \nAltersgruppe ab 12 Jahre \nNormpopulation aus dem amerikanischen Sprachbereich, keine deutschsprachige Normpopulation. Durchschnitt 100 Standardabweichung 15. Wert entspricht einem IQ \nDer Durchschnitt der ALL Patienten unserer Studie liegt zu beiden Testzeitpunkten leicht \u00fcber dem \nDurchschnitt der Normpopulation, und steigt vom ersten zum zweiten Zeitpunkt leicht an. Die Hirntumorpatienten liegen im Durchschnitt leicht unter dem der Normpopulation und werden zum zweiten \nTestzeitpunkt noch etwas schlechter, allerdings bei sehr geringer Anzahl und steigender \nStandardabweichung. \nAltersgruppe: ab 6 \nNormpopulation: Durchschnitt 100+/-15 ; 2614 Testpersonen in der Validierung, mehrfach getestet Bei E1 ALL im Durchschnitt etwas besser als Normpopulation, Hirntumoren etwas schlechter, bei E2 beide \nGruppen im Durchschnitt unterhalb der Normpopulation., Hirntumoren noch deutlicher als ALL, aber besser \nals zum Zeitpunkt E1(allerdings h\u00f6here Standardabweichung) K-TIM Gesamt-IQ\n1 06,8296,00 94,2014 , 6 5\n1 09,7817 , 9 2\n14 , 5 634,1 2\n0,0020,0040,0060,0080,00100,00120,00140,00\n     N=11        \nE1 ALL     N=8          \nE1 HiTu     N=9       \nE2  ALL   N=5        E2\nHiTuMittelwert (Standardabweichung)\nVMI Standardwerte\n1 03,78\n88,93 95,1 111, 3 8\n97,1 314 , 7 9\n19 , 8 520,47\n0,0020,0040,0060,0080,00100,00120,00140,00\n     N=45        \nE1 ALL     N=15          \nE1 HiTu     N=15       \nE2  ALL   N=9        E2\nHiTuMittelwert (Standardabweichung)Midtermreportcalaminus3/03/2002 \nAltersgruppe ab10 \nNormgruppe: 19 Personen 10-20 Jahre, Durchschnittsalter 16,66 \nA: 23,73 (3.76), B: 12,42(2.91), A-B: 11,31(2.98) \nErgebnisse unauff\u00e4llig, deutlich erkennbarer Lerneffekt zum E2 Zeitpunkt Summe A: erstes Erkennen der Figur- hohe Werte schlecht \nSumme B: Wiederholung/ Lerneffekt deutlich durch hohes A-B(  kein direkter Vergleich der gelben S\u00e4ulen \nm\u00f6glich, da diese von der H\u00f6he der blauen S\u00e4ule abh\u00e4ngt! \nNormdurchschnitt:3, Alter: ab 9Jahren \n1=deutlich unterdurchschnittlich. 2= unterdurchschnittlich. \n3=durchschnittlich \n4=\u00fcberdurchschnittlich. 5=deutlich \u00fcberdurchschnittlich. \nALL wird von E1 zu E2 besser, Hitumore schon zu E1 schlechter als Durchschnitt, wird zu E2 noch etwas \nschlechter (geringe Personenanzahl!!) Hohe Standardabweichungen in der Population (da ordinalskaliert gibt es keine Standardabweichungen f\u00fcr die Norm )FBT\n0,005,0010,0015,0020,0025,0030,0035,00\n     N=25 \nE1 ALL     N=8  \nE1 HiTu     N=13 \nE2  ALL   N=8    \nE2 HiTuSummenwerteSumme A\nSumme B\nDifferenz A-B\nD2 Mittelwerte\n0,001,002,003,004,005,006,00\n     N=26        \nE1 ALL     N=7          \nE1 HiTu     N=7          \nE2  ALL       N=4           \nE2 HiTuMittelwertzur besseren Vergleichbarkeit werden aus ordinalskalierten Werten Mittelwerte berechnetMidtermreportcalaminus3/03/2002 \nAlter:7-9\nKlassifikation siehe oben \nQuantitativ: Anzahl aller insgesamt bearbeiteten Zeichen \nQualitativ: Anzahl aller richtig bearbeiteten Zeichen \nunauff\u00e4llig\nAuff\u00e4llig: qualitative Schw\u00e4che bei den HiTu Kindern zum E1 Zeitpunkt \nE2 zu wenige Patienten (Gleiche Qualit\u00e4t, geringere Qualit\u00e4t) \nAlter 6-7, minimale Personenzahl, hohe Standardabweichung, Hirntumorpatienten  in beiden Bewertungen \nschlechter als ALL, qualitativ aber deutlich schlechter. DL-KG Mittelwerte\n0,001,002,003,004,005,006,00\nN=5\nquantitativ\nE1  ALLN=5\nqualitativ  \nE1  ALLN=2\nquantitativ\nE1  HiTuN=2\nqualitativ  E1\nHiTuN=4\nquantitativ\nE2 ALLN=4\nqualitativ  \nE2 ALLN=0\nquantitativ\nE2 HiTuN=0\nqualitativ \nE2 HiTuMittelwertezur besseren Vergleichbarkeit werden aus ordinalskalierten Werten Mittelwerte berechnet\nDL-KE Mittelwerte\n0,001,002,003,004,005,006,00\nN=5\nquantitativ\nE1  ALLN=5\nqualitativ  \nE1  ALLN=3\nquantitativ\nE1  HiTuN=3\nqualitativ  E1\nHiTuN=0\nquantitativ\nE2 ALLN=0\nqualitativ  \nE2 ALLN=0\nquantitativ\nE2 HiTuN=0\nqualitativ \nE2 HiTuMittelwertezur besseren Vergleichbarkeit werden aus ordinalskalierten Werten Mittelwerte berechnetMidtermreportcalaminus3/03/2002 \nANNEX 2 \nGraphische Darstellung der Lebensqualit\u00e4tsergebnisse, deskriptive Statistik in % \nE1: neg. Bewertung des Pedqol-Bogens ALL vs Hirntumor\n01020304050\nK AUT E C Fr Fam KB\nPedqol ALL n=50 Pedqol Hirn n=23 Nomsch\u00fcler n=552\nE2: neg. Bewertung des Pedqol-Bogens ALL vs Hirntumor\n01020304050\nKA U TE C F rF a m K B\nPedqol ALL n=23 Pedqol Hirn n=17 Nomsch\u00fcler n=552\nneg. Bewertun g Pedqol Hirn (n=10 ) in E1 vs E2, wenn beide \nB\u00f6gen vorhanden\n01020304050\nK AUT E C Fr Fam KB Pedqol E1 Pedqol E2 Nomsch\u00fcler n=552\nneg. Bewertun g Pedqol ALL (n=17 ) in E1 vs E2, wenn beide \nB\u00f6gen vorhanden\n01020304050\nK AUT E C Fr Fam KB Pedqol E1 Pedqol E2 Nomsch\u00fcler n=552Midtermreportcalaminus3/03/2002 \nK= K\u00f6rperliche Funktion \nAUT= Autonomie \nE= Emotionaler Zustand \nC= Kognition Fr= Soziale Funktion Freunde \nFam: Soziale Funktion Familie \nKB= K\u00f6rperbild E1:Vergleich der LQ-Instrumentarien neg \nBewertung\n020406080100\nK AUT E C Fr Fam KB\nPedqol n=80 CHQ n=88 KindlK n=37 KindlJ n=33\nE2:Vergleich der LQ-Instrumentarien neg \nBewertung\n0102030405060708090100\nK AUT E C Fr Fam KB\nPedqol n=43 CHQ n=52 KindlK n=23 KindlJ n=20Midtermreportcalaminus3/03/2002 \nANNEX 3:\nBandvergleich der psychosozialen, neuropsychologischen und Lebensqualit\u00e4tsdaten\n36%Neuropsychologie Lebensqualit\u00e4t\n40%\n68%\nauff\u00e4lligSozialanamnese\n64% 40%auff\u00e4lligauff\u00e4llig\nunauff\u00e4lligauff\u00e4lligBandvergleich: 55/81 auff\u00e4llige Anamnese,\nNeuropsychologie und Lebensqualit\u00e4tMidtermreportcalaminus3/03/2002 \nANNEX 4: \u00dcbereinstimmungsvalididt\u00e4t der Instrumente, Praktikabilit\u00e4t und Test\u00f6konomie \nNeuropsychologie: \nIm Rahmen des Folgeantrags f\u00fcr das BMBF-Projekt Lebensqualit\u00e4t und Sp\u00e4tfolgen wurden vom \nProjekttr\u00e4ger mit der Weiterf\u00f6rderung des Projektes in der zweiten F\u00f6rderungsphase bestimmte Auflagen verbunden. Diese umfassen vor allem die Anpassung des Basisinstrumentariums in Form einer m\u00f6glichen \nReduktion. \nZur Erf\u00fcllung dieser Auflage wurde in der ersten Phase des Projektes mit den bis 10/2001 vorliegenden \nDaten ein Pr\u00fcfverfahren durchgef\u00fchrt, das verschiedene Schritte umfasste: \nErstellung des neuropsychologischen Basisinstrumentariums\nKonzept\u00fcbersicht\nUmsetzung abgeschlossen: November 2001\nggf. Reduktion\n\u009f        aufgrund         \u009f\nPr\u00fcfschritt 1 - 3\nPr\u00fcfschritt1:\n1) \u00dcbereinstimmungsvalidit\u00e4t (Intertestkorrelationen pro Erhebungszeitraum\no \u00dcberschneidung der Pr\u00fcfbereiche)\na)o ALL-ZNS-Tox.-Studie\nb)o laufende Studie E1 (und E2)\n2) Test\u00f6konomie Absch\u00e4tzung der Kosten / Nutzen \u2013 Relation pro Test\n3) Anwendererfahrung Handhabbarkeit, Motivierbarkeit der Testpersonen\n1Differenzierung nach ALL- / Medulloblastom-Patienteneingesetzte\nPr\u00fcfverfahrenBasisinstrumentarium\nAnwenderfreundlichkeit, Praktikabilit\u00e4t und \u00d6konomie der eingesetzten\nIntelligenztests\nx Kaufman-Assesment-Battery for Children  (K-ABC) (Altersstufen 2;6 bis 11;11 Jahre), Individualtest zur \nMessung von Intelligenz und Fertigkeiten bei Kindern und Jugendlichen von A. S. Kaufman und N. L. \nKaufman. Deutsche Bearbeitung von U. Melchers, U. Preu\u00df. \nx Kaufman-Adolescent and Adult Intelligence Test  (K-TIM) (Altersstufe \u009512;0 Jahre) Individualtest zur \nMessung von Intelligenz und Fertigkeiten bei Jugendlichen und Erwachsenen von A. S. Kaufman und N. \nL. Kaufman. Deutsche Bearbeitung von U. Melchers, U. Preu\u00df und S. Sch\u00fcmann. Experimentalversion. \nBewertung \nDie Normgruppendaten  des K-TIM entstammen der amerikanischen Validierung. Im Originaltest sind \nTestungen vorgesehen, die im Vorgang Gelerntes zu einem sp\u00e4teren Zeitpunkt innerhalb der Testung abfragen. Diese werden in der Studienanwendung nicht durchgef\u00fchrt, da der Test bei wenig belastbaren \nPatienten nicht aufgesplittet werden kann.  \nDie Testdurchf\u00fchrung f\u00fcr K-ABC oder K-TIM betr\u00e4gt rund 120 min., die Auswertungsdauer 45 min.  Eine komplexe Erfassung der Grundintelligenz ist mit beiden Testverfahren m\u00f6glich. Problematisch ist der \nben\u00f6tigte Testmaterialumfang, der vor allem bei Testungen am Patientenbett Umsetzungsprobleme schafft. Midtermreportcalaminus3/03/2002 \nDie K-ABC erweist sich als anwenderfreundlich. Beim K-TIM ist mit Einschr\u00e4nkungen der Testobjektivit\u00e4t \naufgrund fehlerhaften Test- und Auswertungsmaterials zu rechnen. \nHinsichtlich der Attraktivit\u00e4t der Testverfahren zeigen sich die Kinder bei der Durchf\u00fchrung der K-ABC in der \nRegel interessiert und gut motivierbar. Demgegen\u00fcber bestehen bei der K-TIM durch Eint\u00f6nigkeit und Aufgabenl\u00e4nge Probleme. \nAuch liegen Hinweise daf\u00fcr vor, da\u00df im Vergleich zu den Wechslertests (WAIS) beim KAIT (amerikanische \nOrginalversionen der Tests) im Bereich niedrigerer Intelligenz und der Alterspanne 12 bis 16 Jahre eine ungenauere Differenzierung zu beobachten ist (vgl. Vo et al. 1999). \nDer Test ist in der Durchf\u00fchrung anwenderfreundlich, die Auswertung bedarf einiger Erfahrung. Aus diesem \nGrund wird der Test zus\u00e4tzlich zentral (Erlangen) nachbewertet, um Einfl\u00fcsse einer subjektiven Testleiterbewertung auszuschlie\u00dfen \nx Fragmentierter Bildertest\n (FBT) (Altersstufen: 10;0 bis 18;0 Jahre) von J. Kessler, A. Schaaf und R. \nMielke.\nBewertung: \nDer Test ist anwenderfreundlich und dient der Motivationsf\u00f6rderung bei den Kindern.  Nachteil ist die Beinhaltung einer Wiederholungstestung, die bei weniger belastbaren Kindern zum \nTestabbruch und einer Nichtauswertbarkeit des Gesamttestes f\u00fchren kann. Anwendungszeit  2x5 min (plus \n10 Min Pause zwischen den Testungen). Auswertungszeit 5 min. \nx Differentieller Leistungstest-KE\n (DL-KE) (Altersstufen: 5;0 bis 6;11 Jahre), Test zur Erfassung des \nLeistungsverhaltens bei konzentrierter T\u00e4t igkeit von E. W. Kleber, G. Kleber und O. Hans. \nx Differentieller Leistungstest-KG  (DL-KG) (Altersstufen: 7;0 bis 8;11 Jahre), Test zur Erfassung des \nLeistungsverhaltens bei konzen trierter T\u00e4tigkeit von E. W. Kleber, G. Kleber und O. Hans. \nBewertung: \nDer Test ist in der Durchf\u00fchrung recht anwenderfreundlich f\u00fcr den Testleiter, f\u00fcr die Testperson ist der Test monoton und anstrengend und f\u00fchrt teilweise zu Frustrationserlebnissen und -\u00e4u\u00dferungen bzw. Testabbruch \nbei Kindern mit eingeschr\u00e4nkter Belastbarkeit zum Testzeitpunkt. Anwendungszeit 11 min, Auswertungszeit \n45 min. \nx Aufmerksamkeits-Belastungstest d2\n (Test d2) (Altersstufen: \u0095 9;0 Jahre), Test zur Erfassung der \nAufmerksamkeits- und Konzentrationsleistung von R. Brickenkamp. \nBewertung: Durch das h\u00f6here Alter der Testpersonen treten die f\u00fcr dien DL-Tests beschriebenen Probleme hier weniger \nauf. Schwierigkeiten werden in der Gruppe der Hirntumorpatienten in der Durchf\u00fchrbarkeit beobachtet. \nAnwendungszeit 5 min. Auswertungszeit 45 min. \nx Tapping-/Reaktionszeitverfahren\n (Altersstufen: 4;0 bis 18;0 Jahre) von H. Ottensmeier, N. Galley und G. \nHopmann, 1997. \nBewertung Problematisch bei diesem Verfahren ist die Software, die nicht auf g\u00e4ngigen Computern geladen werden \nkann und somit eines besonderen Equipments bedarf (386/486er Computer). Auch Hardwareprobleme \nhaben dazu gef\u00fchrt, da\u00df \u00fcber einen l\u00e4ngeren Zeitraum die teilnehmenden Kliniken keine funktionsf\u00e4higen \nTasten zur Verf\u00fcgung hatten. Die PC-Oberfl\u00e4che des Programms ist f\u00fcr den Testleiter nicht ausreichend \neinfach zu bearbeiten. Die Motivation der Probanden ist sehr unterschiedlich aber insgesamt durch die nicht kindgerechte Pr\u00e4sentation beeinflu\u00dft. Anwendungsdauer 45 min. Auswertung wird zentral in W\u00fcrzburg \ndurchgef\u00fchrt. Auswertungsinformationen sind dem Testleiter nur von dort zug\u00e4nglich.\n\u00dcbereinstimmungsvalidit\u00e4tsuntersuchungen der neuropsychologische \nInstrumentarien\nDatei unter Dateiname \u201c\u00dcbereinstimmungsvalidit\u00e4t der Neuropsychologie\u201d Diese datei kann bei Beadrf \nangefordert werden  \nBewertung: \nDie untersuchten Testverfahren sind nicht redundant. Es zeigen sich keine Korrelationen. Somit ist aus der Berechnung der \u00dcbereinstimmungsvalidit\u00e4t keine Reduktion der Instrumente abzuleiten, sondern nur aus \nden o.genannten Punkten\n.Midtermreportcalaminus3/03/2002 \nANNEX 5 \nMultitrait-Multitemanalyse des PEDQOL und Korrelation zu anderen Instrumenten \nDokumentation zur psychometrischen Analyse des PEDQOL im Projekt \u201eLebensqualit\u00e4t und \nSp\u00e4tfolgen\u201c des Kompetenznetzes P\u00e4diatrische Onkologie \nDatensatz vom 17.01.02, Stand der Auswertung: 13.03.02 \nDie Ergebnistabellen befinden sich in einer Excel-Datei \u201eErgebnisse Psychometrische Analyse Pedqol.xls\u201c, \nder Text dokumentiert die einzelnen Auswertungsschritte. Die Excel Tabellen k\u00f6nnen bei Bedarf angefordert \nwerden.\nAnalyse fehlender Werte \n(Tabellen \u201efehlende Werte E1\u201c und \u201efehlende Werte E2\u201c) \nZu E1 liegen PEDQOL-Daten zu 73 Kindern bzw. Jugendlichen vor. Bei jeder einzelnen Frage fehlen \nAntworten von 0 bis 6 Probanden (0 \u2013 8,2 %). Die meisten fehlenden Werte weisen die Items der Skala \u201eAutonomie\u201c auf, gefolgt von den beiden Zufriedenheits-Items sowie den Items \u201eAngst krank zu werden\u201c und \n\u201elange f\u00fcr Schularbeiten gebraucht\u201c. Die fehlenden Werte auf den beiden letztgenannten Fragen k\u00f6nnten \ndadurch verursacht sein, dass diese Bedingung auf die Befragten nicht zutraf. Bis zu ca. 2,5 % fehlender Werte k\u00f6nnen als akzeptabel angesehen werden. Die Frage ist, warum in den beiden Skalen \u201eAutonomie\u201c \nund \u201eGlobal\u201c durchg\u00e4ngig mehr fehlende Werte auftreten. Dies k\u00f6nnte ein Hinweis darauf sein, dass der \nFragebogen insgesamt zu lang ist. \nZu E2 liegen von 28 Kindern bzw. Jugendlichen PEDQOL-Daten vor. Es fehlen zwischen 0 und 6 Angaben \n(0 \u2013 21,4 %). Besonders viele Angaben fehlen bei Fragen, die sich auf Schule oder auf Aktionen mit \nFreunden beziehen, vermutlich weil dies in der klinischen Situation nicht zutrifft. Die Skalen \u201eAutonomie\u201c und \u201eGlobal\u201c weisen zu E2 nicht mehr fehlende Werte auf als die anderen Skalen. \nPsychometrische Eigenschaften der Einzelitems \n(Tabelle \u201eEinzelitems\u201c) \nDa die Antwortskala von 1 bis 4 geht, k\u00f6nnen die einzelnen Items Mittelwerte zwischen 1 und 4 annehmen. \nErw\u00fcnscht sind eine Ausnutzung aller Antwortkategorien und ein Item-Mittelwert m\u00f6glichst in der Mitte der Skala, hier also etwa zwischen 2 und 3. Items mit zu stark von der Mitte abweichendem Mittelwert \nproduzieren Boden- oder Deckeneffekte und k\u00f6nnen nicht zwischen Personen mit guter und solchen mit \neingeschr\u00e4nkter Lebensqualit\u00e4t differenzieren. Meist ist ihre Streuung auch im Vergleich zu den anderen \nItems reduziert. Den extremsten Mittelwert weist das Item \u201ealleine\u201c aus der Skala \u201eEmotional\u201c auf, gefolgt \nvom Item \u201ewegen Schmerzen aufgewacht\u201c aus der Skala \u201ePhysisch\u201c und \u201egut verstanden mit Eltern\u201c aus der Skala \u201eSozial\u201c. Insgesamt zeigen sich keine besonders ausgepr\u00e4gten Boden- oder Deckeneffekte. Die \nErgebnisse zu E2 \u00e4hneln denen zu E1. \nDie Item-Total-Korrelation gibt an, wie hoch der Zusammenhang jeder einzelnen Frage mit ihrer Subskala, \nbereinigt um diese Frage, ist. Alle Item-Total-Korrelationen innerhalb einer Subskala sollten von mittlerer bis \ngro\u00dfer H\u00f6he (r=.40 bis r=.70) und homogen (d.h. etwa gleich hoch) sein. Es gibt mehrere Items mit niedriger \nbis sehr niedriger Item-Total-Korrelation (in der Tabelle grau markiert). Lediglich die Subskalen \u201eLernf\u00e4hig\u201c und \u201eGlobal\u201c sind davon nicht betroffen. Es w\u00e4re zu pr\u00fcfen, ob die Skalenstruktur des Pedqol durch andere \nSkalenzuordnung einzelner Items oder durch Weglassen derjenigen Items mit besonders niedriger Item-\nTotal-Korrelation verbessert werden kann. \nSkalenqualit\u00e4t, interne Konsistenz \n(Tabelle \u201eSkalen\u201c) \nEin zentrales Kriterium f\u00fcr die psychometrische Qualit\u00e4t einer Skala ist die interne Konsistenz (Cronbach\u2019s \nD). Sie sollte f\u00fcr alle Subskalen \u00fcber 0,70 liegen. Bis auf die Skalen \u201eAutonomie\u201c und \u201eGlobal\u201c erf\u00fcllen dies \nf\u00fcr die Gesamtgruppe alle Skalen. Die interne Konsistenz der Gesamtskala kann mit D=.93 als sehr gut \nbezeichnet werden. Betrachtet man die Werte get rennt f\u00fcr die Diagnose gruppen Leuk\u00e4mie und \nMedulloblastom, ergeben sich kaum relevante Unterschiede, mit Ausnahme einer niedrigeren internen \nKonsistenz der Skala \u201eEmotional\u201c in der Medulloblastom-Gruppe. Eine Interpretation ist nicht zuletzt aufgrund der geringen Fallzahl (n = 10) schwierig. \nDer Skalenfit gibt an, wie gut die einzelnen Items der angenommenen Skalenstruktur des Instruments \nentsprechen und wird in prozentualen Werten angegeben. Ein Wert von 90 % wird angestrebt. Der Skalenfit \nbetr\u00e4gt f\u00fcr die Gesamtskala 79 %, f\u00fcr die Skala \u201ePhysisch\u201c 93 %, f\u00fcr die Skala \u201eEmotional\u201c 80 %, \u201eLernf\u00e4hig\u201c Midtermreportcalaminus3/03/2002 \n96 %, \u201eAutonomie\u201c 68 % und \u201eGlobal\u201c 20 %. Hier ist noch Verbesserungspotenzial zu erkennen, z.B. durch \nNeuzuordnung oder Herausnahme von Fragen mit geringer Item-Total-Korrelation (vgl. oben). \nKonvergente Validierung \n(Tabelle \u201eValidierung\u201c) \nBei der konvergenten Validierung wird gepr\u00fcft, ob der PEDQOL die erwarteten Zusammenh\u00e4nge zu anderen \nLebensqualit\u00e4ts-Messinstrumenten aufweist. Zum einen wird die Korrelation der Gesamt-Summenscores \ngepr\u00fcft, zum anderen die korrespondierender Subskalen. Die Korrelation des PEDQOL mit allen Skalen des \nKINDL und dessen Gesamtscore ist hoch. Dies \u00fcberrascht nicht angesichts \u00e4hnlicher Fragenformulierungen. \nTeilweise bildet sich auch in beiden Instrumenten eine \u00e4hnliche Skalenstruktur ab, allerdings korreliert die Skala \u201eEmotional\u201c des PEDQOL h\u00f6her mit der K\u00f6rper-Skala des KINDL als mit dessen Psyche-Skala. Die \nKorrelation des PEDQOL mit dem CHQ ist insgesamt wesentlich niedriger, vor allem mit dessen \npsychosozialer Summenskala. Noch am h\u00f6chsten korreliert die Skala \u201ePhysisch\u201c des PEDQOL mit der \nPhysischen Summenskala des CHQ. \n\u00c4nderungssensitivit\u00e4t\n(Tabelle \u201c\u00c4nderungssensitivit\u00e4t\u201d) \nBeim Vergleich der beiden Erhebungszeitpunkte zeigt sich, ob die Instrumente stattgefundene \nVer\u00e4nderungen in der Lebensqualit\u00e4t abbilden k\u00f6nnen. Gepr\u00fcft wird, ob der t-Test f\u00fcr \nMittelwertsver\u00e4nderungen von E1 nach E2 signifikant ist (p > .05) und wie gro\u00df der in der Mittelwertdifferenz \nabgebildete Effekt ist. Effektst\u00e4rken von 0 bis r0,3 sind als klein zu betrachten, von r0,4 bis r0,7 als mittel \nund gr\u00f6\u00dfer als r0,8 als gro\u00df. Die einzig signifikante Ver\u00e4nderung, die sich von E1 nach E2 zeigt, ist ein \nAnstieg des PEDQOL-Physischen Skalenwerts mit einer mittleren Effektst\u00e4rke.  \nVer\u00e4nderungen im PEDQOL korrelieren signifikant mit Ver\u00e4nderungen im KINDL und im Ver\u00e4nderungsitem \ndes CHQ. \nZur genaueren Beurteilung der \u00c4nderungssensitivit\u00e4t fehlt ein \u2013 m\u00f6glichst objektives \u2013 Au\u00dfenkriterium, an \ndem die in der Selbst- und Elterneinsch\u00e4tzung beurteilten Ver\u00e4nderungen gemessen werden k\u00f6nnen. Zudem ist die Fallzahl mit n = 23 noch recht klein. \nBewertung: \nDer PEDQOL zeigt sich als reliables, sensitives und valides Me\u00dfinstrument  f\u00fcr die untersuchten \nPatientengruppen. \nDie Instrumente zur Lebensqualit\u00e4t sollten in Ihrer Zusammensetzung weiter angewandt werden. Der \nEinsatz eines PEDQOL Elternfragebogens als Vergleich zum CHQ erscheint sinnvoll.  Midtermreportcalaminus3/03/2002 \nANNEX 7 Beispiele f\u00fcr Flow-sheets zur Nachsorge  \nCoALL-97/AML-BFM 98 follow-up  akute lymphatische Leuk\u00e4mie / akute myeloische Leuk\u00e4mie \nPatient:\nTherapieende nach Therapieende \nDatum \n__.__.20__ 1. Jahr \n20__ 2. Jahr \n20__ 3. Jahr \n20__ 4. Jahr \n20__ 5. Jahr \n20__ - 10. Jahr \n- 20__ \nRezidivdiagnostik \nallgem. k\u00f6rperliche \nUntersuch. + Hoden 1-malig mtl. 3 mtl. 3 mtl. 4 mtl. 6 mtl. j\u00e4hrlich \nneurologische Unters. 1-malig mtl. 3 mtl. 3 mtl. 4 mtl. 6 mtl. j\u00e4hrlich \nBB / Diff.-Blutbild / \nLDH1-malig mtl. 3 mtl. 3 mtl. 4 mtl. 6 mtl. j\u00e4hrlich \nVerlaufs- und Sp\u00e4tfolgendiagnostik \nallgem. Blutentnahme1 1-malig 1-malig - - - - - \nNierenwerte im \nSerum/Urin2 1-malig 4 mtl. 6 mtl. - - - - \nVirusserologie3/\nImpftiter4 1-malig 1-malig - - - - - \nBlutentnahme-\nEndokrinologie 5 1-malig j\u00e4hrlich j\u00e4hrlich j\u00e4hr lich j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich \nPerzentilen61-malig j\u00e4hrlich j\u00e4hrlich j\u00e4hr lich j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich \nTannerstadien/Hodenvol. 1-malig 6 mtl. 6 mtl. j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich \nSpermiogramm bei Auff\u00e4lligkeiten in der Pubert\u00e4tsentwicklung  \nOphthalmol. Unters. 1-malig - - - - 1-malig - \nSonographie-\nSchilddr\u00fcse7 1-malig - - - - 1-malig 1-malig \nEKG / (Stress-) Echo-\nkardiogramm 1-malig - - - - 1-malig - \nKnochendichtemessung 1-malig - 1-malig - - - - \nAudiometrie 1-malig - - - - 1-malig - \nNachsorge \nStrahlentherapie 1 x j\u00e4hrlich enstprechend APRO-Richtlinien \nNeuropsych. Testung \n(Motorik, Koordination, \nKognition) ab 4. Lj. 1-malig - 1-malig - - - 1-malig \nLebensqualit\u00e4t 1-malig - 1-malig - - - 1-malig \nZweitmalignome\nH\u00e4ufigstes Zweitmalignom bei AML: AML und MDS 50% 1.-3. Jahr nach initialer Dx \nH\u00e4ufigstes Zweitmalignom bei ALL: Hirntumoren 6.-10. Jahr nach initialer Dx \n1Blutentnahme:  BB, CRP, BSG, Bili, GOT, GPT, \u0003J-GT, AP, LDH, D-Amylase, Ferritin, Immunglobuline. \n2Nierewerte im Serum: Phosphat, Magnesium, Na, K, Calcium, Kreatinin, Bicarbonat. \nNierewerte im Urin: Urinstatus, Phosphat, Kreatinin, Calcium. \n3 Virusserologie: Virus- und Antik\u00f6rper-Nachweis f\u00fcr HBV, HCV, HIV, CMV, EBV. \n4 Impftiter: 6 Monate nach Ende der Therapie bei Pat. mit abgesc hl. Grundimmunisierung Auffri schungsimpfung mit folgenden \nTotimpfstoffen: Td, HBV, Polio-Salk. Weiterf\u00fchrende Impfungen bei nicht abgesc hl. Grundimmunisierung. \nLebendimpfstoffe gem\u00e4\u00df STIKO-Empfehlungen nach 12 Monaten. \n5 Endokrinologie-Blutentnahme: Sexualhormone: 1-malig oder bei pathol. Befund in  der Pubert\u00e4tsentwicklung o. den \nPerzentilen LH, FSH, Prolaktin, bei Jungen  zus\u00e4tzlich Testosteron, bei M\u00e4dchen  \u00d6stradiol (cave Zyklusabh\u00e4ngigkeit),  \nggf. Stimulationstests. Schilddr\u00fcsenhormone (nach Bestrahlung im Thorax-/Halsbereich j\u00e4hrlich): fT3, fT4, TSH \n6R\u00f6ntgen-Linke-Hand Knochenalterbe stimmung bei bei Auff\u00e4lligkeiten\n7nach Sch\u00e4delbestrahlung Midtermreportcalaminus3/03/2002 \nMAKEI 96 / MAHO 98-follow-up\nextrakranielle Keimzelltumoren / maligne Hodentumoren \nPatient:      \nTherapieende nach Therapieende \nDatum \n__.__.20__ 1. Jahr \n20__ 2. Jahr \n20__ 3. Jahr \n20__ 4. Jahr \n20__ 5. Jahr \n20__ - 10. Jahr \n- 20__ \nRezidivdiagnostik \nallgemeine k\u00f6rperliche \nUnters., Lokalbefund 1-malig mtl. 3 mtl. 3 mtl. 6 mtl. 6 mtl. j\u00e4hrlich \nBlutbild 1-malig mtl. 3 mtl. 3 mtl. 6 mtl. 6 mtl. j\u00e4hrlich \nAFP / E-HCG 1-malig mtl. 3 mtl. 3 mtl. 6 mtl. 6 mtl. j\u00e4hrlich \nR\u00f6ntgen-Thorax1 1-malig - - - - - - \nCT / Sonographie der \nprim. Tumorlokalisaton 1-malig 3 mtl. 6 mtl. j\u00e4hr lich j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich \nVerlaufs- und Sp\u00e4tfolgendiagnostik \nallgem. Blutentnahme2/\nUrinuntersuchung2 1-malig 1-malig - - - - - \nVirusserologie3/\nImpftiter4 1-malig 1-malig - - - - - \nBlutentnahme-\nEndokrinologie5 1-malig bei Auff\u00e4lligkeiten in der Pubert\u00e4tsentwicklung u./o. nach Bestrahlung j\u00e4hrlich \nPerzentilen61-malig j\u00e4hrlich j\u00e4hrlich j\u00e4hr lich j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich \nTannerstadien/Hodenvol. 1-malig 6 mtl. 6 mtl. j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich j\u00e4hrlich \nSpermiogramm bei Auff\u00e4lligkeiten in der Pubert\u00e4tsentwicklung u./o. nach Bestrahlung \nEKG/Echokardiogramm 1-malig - - - - 1-malig - \nLungenfunktion 1-malig j\u00e4hrlich nach Gabe von Bleomycin u./o. nach Bestrahlung \nAudiometrie 1-malig - - - - 1-malig - \nNachsorge \nStrahlentherapie 1x j\u00e4hrlich entsprechend den APRO-Richtlinien \nNeuropsych. Testung \n(Motorik, Koordination, \nKognition) ab 4. Lj. 1-malig - 1-malig  - 1-malig - \nLebensqualit\u00e4t 1-malig - 1-malig - - 1-malig - \nmetachrone Erkrankungen\nzwischen 2. bis 10. Jahr nach  Diagnose (insbesondere Ovar) \nZweitmalignome\nKnochentumoren \nALL, MDS \n1 bei initialen Metastasen \n2allgemeine Blutentnahme:  CRP, BSG, Bili, Harnstoff, Harns\u00e4ure Kreatinin, GOT, GPT, \u0003J-GT, AP, LDH, D-Amylase, Ferritin, \nPhosphat, Magnesium, Na, K, Ca lcium, Kreatinin, Bicarbonat. \nUrinuntersuchung: Urinstatus, Eiwei\u00df, Glucose, Phosphat, Kreatinin, Calcium. \n3 Virusserologie: Virus- und Antik\u00f6rper-Nachweis f\u00fcr HBV, HCV, HIV, CMV, EBV. \n4 Impfungen: 6 Monate nach Ende der Therapie bei Pat. mit a bgeschl. Grundimmunisierung Auffrischungsimpfung mit \nfolgenden Totimpfstoffen: Td, HBV, Polio-Salk. Weiterf\u00fchre nde Impfungen bei nicht abgeschl. Grundimmunisierung. \nLebendimpfstoffe gem\u00e4\u00df STIKO-Empfehlungen nach 12 Monaten. \n5Blutentnahme-Endokrinologie: Sexualhormone: 1-malig oder bei pathol. Befund in  der Pubert\u00e4tsentwicklung o. den \nPerzentilen LH, FSH, Prolaktin, bei Jungen  zus\u00e4tzlich Testosteron, bei M\u00e4dchen  \u00d6stradiol (cave Zyklusabh\u00e4ngigkeit),  \nggf. Stimulationstests. Schilddr\u00fcsenhormone (nach Bestrahlung im Thorax-/Halsbereich j\u00e4hrlich): gT3, fT4, TSH. \n6 incl. Sitzh\u00f6hebestimmung bei bestrahlten Patienten. R\u00f6ntgen-Linke-Hand zur Knochenalterbestimmung bei Auff\u00e4lligkeiten. ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}